<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="confer">
            <roleset id="confer.01" name="" wordnet="2">
                <roles>
                    <role n="0" descr="agent&#x09;&#x09;// mechanism, process, entity(imply to condition or property in that entity) // &#x0A;" />
                    <role n="1" descr="given biological property&#x09;&#x0A;" />
                    <role n="2" descr="entity receiving the biological property&#x09;         // gene product, celll, tissue, etc. //&#x0A;" />
                </roles>
                <example src="EGRAM" no="0">
                    <text>A 0 (no significant change or change in table in the coding sequence or for splice variants) was considered to confer loss of functions.</text>
                    <arg n="1">loss of functions</arg>
                </example>
                <example src="EGRAM" no="1">
                    <text>Elevated AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were considered to be conferred by transfection of AGT to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="2">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that resistance was conferred as a conferred substitutions in Gly156 and Lys165 to 06-BG through distortions of the lumbar spine.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="3">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that substitutions in Gly156 and Lys165 may have the ability to confer resistance to 06-BG through distortions of the lumbar spine.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="4">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that replaceing Gly156 and Lys165 conferred resistance to 06-BG by means of spinal distortions.</text>
                    <arg n="0">replaceing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="5">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that replaceing Gly156 and Lys165 is considered as conferring resistance to 06-BG through spine distortions.</text>
                    <arg n="0">replaceing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="6">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance could be conferred by Gly156 and Lys165 replacement to 06-BG through spine distortions.</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="7">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that replacing Gly156 and Lys165 conferred resistance on 06-BG through distortions of the vertebral column.</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="8">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance is conferred by replacements to Gly156 and Lys165 to 06-BG through distortions of the vertebral column.</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="EGRAM" no="9">
                    <text>In addition, function loss engines could be conferred by discount alterations or frame change in the encoding sequence or by splice variants, genetic screening has revealed a large number of missense codons with less obvious functional consequences.</text>
                    <arg n="0">discount alterations or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="EGRAM" no="10">
                    <text>In addition, function loss engines would be conferred by no sense alterations or frame shifts in the encoding sequence or for splice variants, genetic screening has revealed a large number of codons with less obvious functional consequences.</text>
                    <arg n="0">no sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="EGRAM" no="11">
                    <text>In addition, function loss motion can be conferred by no sense alterations or frame change in the encoding sequence or by splice variants, genetic screening has revealed a large number of codons with less obvious functional consequences.</text>
                    <arg n="0">no sense alterations or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="EGRAM" no="12">
                    <text>In addition, function loss motion can be conferred by no-sense alterations or frame shifts in the encoding sequence or for splice variants, genetic screening has revealed a large number of codons with less obvious functional consequences.</text>
                    <arg n="0">no-sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="EGRAM" no="13">
                    <text>In addition, function loss motion may have been conferred by no sense alterations or frame change in the encoding sequence or for splice variants, genetic screening has revealed a large number of codons with less obvious functional consequences.</text>
                    <arg n="0">no sense alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="EGRAM" no="14">
                    <text>In addition, it is believed that no is conferred by nonsense or frameshift alteration in the coding sequence or by splice variants, gene screening revealed a large number of lost codons with less evident functional consequences.</text>
                    <arg n="0">nonsense or frameshift alteration in the coding sequence or by splice variants</arg>
                    <arg n="M-NEG">no</arg>
                </example>
                <example src="EGRAM" no="15">
                    <text>In addition, it is observed that function loss engines is the no to be conferred by without significant changes or frame deviations in the coding sequence or for splice variants, gene screening revealed a large number of codons with less evident functional consequences.</text>
                    <arg n="0">without significant changes or frame deviations in the coding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                    <arg n="M-NEG">no</arg>
                </example>
                <example src="EGRAM" no="16">
                    <text>In addition, it was believed that changes in function loss was conferred by changes in frame in the coding sequence or by splice variants, genetic screening revealed a large number of wrong-sense codons with less evident functional consequences.</text>
                    <arg n="0">changes in frame in the coding sequence or by splice variants</arg>
                    <arg n="1">changes in function loss</arg>
                </example>
                <example src="EGRAM" no="17">
                    <text>In addition, motors of loss of function would be conferred by no change in meaning or deviation of frame in the coding sequence or for splice variants, gene screening revealed a large number of codons with less evident functional consequences.</text>
                    <arg n="0">no change in meaning or deviation of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="EGRAM" no="18">
                    <text>In addition, movement of loss of function will be conferred by non-sense change or deviation of frame in the coding sequence or for splice variants, gene screening revealed a large number of codons with less evident functional consequences.</text>
                    <arg n="0">non-sense change or deviation of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="EGRAM" no="19">
                    <text>In addition, mutations of loss of functions cannot have been conferred by senseless alteration or frame change in the encoding sequence or by splice variants, gene screening revealed a large number of lost codons with less obvious functional consequences.</text>
                    <arg n="0">senseless alteration or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="EGRAM" no="20">
                    <text>In addition, overexpression of EvgA may not confer resistance in a tolC-deficient strain.</text>
                    <arg n="0">overexpression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="EGRAM" no="21">
                    <text>In addition, overexpression of EvgA may not confer resistance to a tolC deficient strain.</text>
                    <arg n="0">overexpression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="EGRAM" no="22">
                    <text>In itself, the genetic variant will have conferred no a higher risk of diabetes.</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                    <arg n="M-NEG">no</arg>
                </example>
                <example src="EGRAM" no="23">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT transformation can confer resistance to Alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="24">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance have been conferred by transfection of AGT to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="25">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and transformation of AGT were able to confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="26">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and transformation of AGT were observed to confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="27">
                    <text>Increased GAT in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and transformation of GAT was considered to confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of GAT in the treatment resistance.</text>
                    <arg n="0">transformation of GAT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="28">
                    <text>It is believed that the part of TASTs confers specificity to A2 (a MAPK or a MAPK substrate kinase (MAPKAP) has not been confer.</text>
                    <arg n="0">the part of TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="EGRAM" no="29">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistance 06-BG could be conferred for these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="EGRAM" no="30">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistance of 06-BG is thought to be conferred by these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance of 06-BG</arg>
                </example>
                <example src="EGRAM" no="31">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), these mutations confer resistance 06-BG (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="EGRAM" no="32">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), these mutations was able to confer the A1 resistance (06-BG) (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                </example>
                <example src="EGRAM" no="33">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), six mutations was considered to confer resistance 06-BG (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="EGRAM" no="34">
                    <text>Similarly, the introduction of the charge of the mutations Gly160His and Gly160Arg repels the benzyl group (Figure 3B), six mutations is considered to confer the resistance 06-BG (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="EGRAM" no="35">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), resistance 06-BG is conferred by These mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="EGRAM" no="36">
                    <text>The Human 06-alkylguaning-DNA alkyltransferase (AGT) having conferred resistance on alkylation pathways was therefore an active target of anti-drugs.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="EGRAM" no="37">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in Stat1 , since replacing simply the C-terminal with Stat5 has the ability to confer the Stat5 phenotype in the presence of MG132 in Stat1 .</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="EGRAM" no="38">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in State1 , since only the C-terminal substitution for Stat5 was able to confer the Stat5 stability phenotype in the presence of MG132 in State1 .</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="EGRAM" no="39">
                    <text>The increase of CATs in parallel with the acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and GAT transformation was considered to confer resistance to Alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of CAT in resistance.</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="40">
                    <text>The portion of the STATs conferred specificity for either a MAPK or a MAPK kinase substrate (MAPKAP).</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="EGRAM" no="41">
                    <text>The resistance in a tolC deficit strain is conferred by the EvgA overexpression.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="EGRAM" no="42">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was conferred by AGT transformation to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="43">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and AGT transformation has the ability to confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="EGRAM" no="44">
                    <text>genetic variation may not have conferred increasing risk of diabetes.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increasing risk of diabetes</arg>
                </example>
                <example src="EGRAM" no="45">
                    <text>genetic variety might have not conferred increased risk of diabetes.</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="EGRAM" no="46">
                    <text>human 06-alkylguaning-DNA alkyltransferase (AGT) is thought to confer resistance on alkylation pathways was therefore an active target of anti-tank drugs.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="EGRAM" no="47">
                    <text>human 06-alkylguaning-DNA alkyltransferase (AGT), which directly confer endogenous alkylation to 06-position of guanine, confers resistance on alkylation pathways and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="EGRAM" no="48">
                    <text>human 06-alkylguaning-DNA alkyltransferase (AGT), which directly inverts endogenous alkylation to 06-position of the guanine, could confer resistance to alkylation pathways and thus was an active target of anti-cancer drugs.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="EGRAM" no="49">
                    <text>human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at 06-position of the guanine, has the ability to confer resistance to alkylation pathways and is therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="EGRAM" no="50">
                    <text>increasing risk of diabetes will be conferred by genetic variation by not.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increasing risk of diabetes</arg>
                    <arg n="M-NEG">not</arg>
                </example>
                <example src="EGRAM" no="51">
                    <text>nonsense or frameshift alteration of the codiding sequence or by splice variants gave no conferred loss of function mutation.</text>
                    <arg n="0">nonsense or frameshift alteration of the codiding sequence or by splice variants</arg>
                    <arg n="1">loss of function mutation</arg>
                    <arg n="M-NEG">no</arg>
                </example>
                <example src="EGRAM" no="52">
                    <text>resistance can be conferred by alkyltransferase of 06-alkyltransferase of AGT, which directly reverses the endogenous alkylation to the position of 06-guanin, to alkyltransferase chemotherapies.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="EGRAM" no="53">
                    <text>resistance has the ability to confer alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to alkylation chemotherapies.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="54">
                    <text>resistance is able to confer alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to alkylation chemotherapies.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="EGRAM" no="55">
                    <text>resistance may have been conferred by alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at the 06-guanine position, in alkylation pathways.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="EGRAM" no="56">
                    <text>resistance was confer as alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT, which directly reverses the endogenous alkylation to the position of 06-guanin, to alkylation.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="EGRAM" no="57">
                    <text>resistance was conferred by alkyltransferase of 06-alkyltransferase of AGT, which directly reverses the endogenous alkylation to the position of 06-guanin, to alkyltransferase of pathways.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase of pathways</arg>
                </example>
                <example src="EGRAM" no="58">
                    <text>senseless alteration or frame change of the codex sequence or by cutting variants of M-NEG does not confer mutation function miss.</text>
                    <arg n="0">senseless alteration or frame change of the codex sequence or by cutting variants</arg>
                    <arg n="1">mutation function miss</arg>
                </example>
                <example src="EGRAM" no="59">
                    <text>specificity for a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs) (a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by the part of STATs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="EGRAM" no="60">
                    <text>the part of the STATs which confers specificity to A2 (a MAPK substrate or a MAPK kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">the part of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>06-BG in a tolC problem strain has been conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>06-BG in a tolC-deficient strain is conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>06-BG in a tolC-deficient strain may have been conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>06-BG is the not conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>06-BG is thought to be conferred by M-NG (not) for these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>06-BG resistant can be conferred by no by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistant</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>06-BG resistant can be conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistant</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>06-BG resistant in a tolC-deficient strain is conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistant</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>06-BG resistant in a tolC-deficient strain may have been conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistant</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>AGATT transfection (AGT) that can confer resistance to alkylation-sensitive cells was therefore an active target of anti-drugs.</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>AGATT transfection (AGT) that is able to confer resistance to alkylation-sensitive cells was therefore an active target of anti-drugs.</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>AGATT transfection (AGT), which directly inverts endogenous alkylation to 06-position of guanine, is observed to confer resistance to alkylation-sensitive cells and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>AGATT transfection (AGT), which directly inverts endogenous alkylation to 06-position of the guanine, would confer resistance to alkylation-sensitive cells and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>AGATT transfection (AGT), which directly reverses endogenous alkylation at 06-position of guanine, was observed to confer resistance on alkylation-sensitive cells and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>AGATT transfection (AGT), which directly reverses the endogenous alkylation in 06 guanin positions, has the ability to confer resistance to alkylation-sensitive cells and therefore is an active target of antineoplastic drugs.</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>AGATT transfection 06 human (AGT) that conferred resistance over alkylation-sensitive cells was therefore an active target of anti-drugs.</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>AGATT transfection may confer resistance to alkylation-sensitive cells has not been determined.</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>AGT (AGT), which directly inverts endogenous alkylation to 06-position of guanine, is able to confer resistance to alkylation-sensitive cells and is therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>AGT transformation (AGT) which conferring resistance on Alkylation-sensitive cells is therefore an active target of anti-tank drugs.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>AGT transformation (AGT), which directly inverts endogenous alkylation to 06-position of guanine, is able to confer resistance to alkylation-sensitive cells and is therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>AGT transformation (AGT), which directly inverts endogenous alkylation to 06-position of guanine, is thought to confer resistance to Kaina et al., 1991 and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>AGT transformation (AGT), which directly inverts endogenous alkylation to 06-position of the guanine, can confer resistance to Kaina et al., 1991 and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>AGT transformation (AGT), which directly reverses endogenous alkylation at 06-position of guanine, was able to confer resistance to Alkylation-sensitive cells and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>AGT transformation (AGT), which directly reverses the endogenous alkyl to the 6-position of guanin, is observed to confer resistance to Alkylation-sensitive cells and is therefore an active target for anticancer drugs.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="25">
                    <text>AGT transformation (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, was observed to confer resistance to Kaina et al., 1991 and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="26">
                    <text>AGT transformation (AGT), which directly reverses the endogenous alkylation at the position of guanin 6, conferred resistance to alkylation-sensitive cells and is therefore an active target of anticancer drugs.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="27">
                    <text>AGT transformation (AGT), which directly reverses the endogenous alkylation in 06 guanin positions, has the ability to confer resistance to Kaina et al., 1991 and therefore is an active target of antineoplastic drugs.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="28">
                    <text>AGT transformation (AGT), which directly reverses the endogenous alkylation to 06-platinin position, would confer resistance to alkylation-sensitive cells and therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="29">
                    <text>AGT transformation (AGT), which directly reverses the endogenous alkylation to the position 06 of guanin, could confer resistance to Alkylation-sensitive cells and thus was an active target of antineoplastic drugs.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="30">
                    <text>AGT transformation (AGT), which directly reverses the endogenous alkylation to the position 06 of guanin, could confer resistance to alkylation-sensitive cells and thus was an active target of antineoplastic drugs.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="31">
                    <text>AGT transformation (AGT), which directly reverses the endogenous alkylation to the position 06 of guanin, may confer resistance to Kaina et al., 1991 and is therefore an active target of anticancer drugs.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="32">
                    <text>AGT transformation has not been determined to be able to confer resistance to alkylation-sensitive cells.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="33">
                    <text>AGT transition (AGT) is thought to confer resistance on Kaina et al., 1991 was therefore an active target of anti-tank drugs.</text>
                    <arg n="0">AGT transition</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="34">
                    <text>AGT transition (AGT) that conferred resistance over Kaina et al., 1991 was therefore an active target for anti-drugs.</text>
                    <arg n="0">AGT transition</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="35">
                    <text>AGT transition (AGT) that is able to confer resistance to Kaina et al., 1991 was therefore an active target of anti-drugs.</text>
                    <arg n="0">AGT transition</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="36">
                    <text>AGT transition (AGT), which directly reverses endogenous alkylation at 06-position of the guanine, was believed to confer resistance on Kaina et al., 1991 and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">AGT transition</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="37">
                    <text>AGT transition (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, was able to confer resistance to Kaina et al., 1991 and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">AGT transition</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="38">
                    <text>AGT transition (AGT), which directly reverses the endogenous alkylation at the position of guanin 6, conferred resistance to Kaina et al., 1991 and is therefore an active target of anticancer drugs.</text>
                    <arg n="0">AGT transition</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="39">
                    <text>AGT transition (AGT), which directly reverses the endogenous alkylation to the position 06 of guanin, may confer resistance to Kaina et al., 1991 and is therefore an active target of anticancer drugs.</text>
                    <arg n="0">AGT transition</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="40">
                    <text>AGT transition has not been determined to be able to confer resistance to Kaina et al., 1991.</text>
                    <arg n="0">AGT transition</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="41">
                    <text>Elevated AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were considered to be conferred by GAT transformation to Alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="42">
                    <text>Elevated AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were considered to be conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation pathways (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="43">
                    <text>Elevated AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were considered to be conferred by alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="44">
                    <text>Elevated AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were considered to be conferred by alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase to alkylation pathways (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="45">
                    <text>Elevated AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were considered to be conferred by alkylguaning-DNA alkyltransferase to alkylation routes (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="46">
                    <text>Elevated AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were considered to be conferred by alkyltransferase of 06-alkyltransferase-DNA to alkyltransferase chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="47">
                    <text>Elevated AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were considered to be conferred by human alkyl-alkylation-DNA alkyltransferase to alkylation routes (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">human alkyl-alkylation-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="48">
                    <text>Elevated AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were considered to be conferred by transfection of AGATT to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="49">
                    <text>Elevated AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were considered to be conferred by transformation of AGT to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="50">
                    <text>Elevated AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were considered to be conferred by The portion of the STATs to either a MAPK or a MAPK kinase substrate (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="51">
                    <text>Elevated AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were considered to be conferred by The portion of the STATs to either a MAPK or a MAPK substrat kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="52">
                    <text>Elevated AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were considered to be conferred by The portion of the STATs to either a MAPK or a MAPK substratum kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="53">
                    <text>Elevated AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were considered to be conferred by the portion of the STATs to either a MAPK or a MAPK kinase substrate (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="54">
                    <text>Elevated AGT levels in parallel with acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were considered to be conferred by replacing simply the C-terminal with Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="55">
                    <text>EvgA overexpression can be conferred to resistance.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="56">
                    <text>EvgA overexpression was considered to be the one that confers resistance to A2 (a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="57">
                    <text>GAT transformation (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, was able to confer resistance to Alkylation-sensitive cells and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="58">
                    <text>GAT transformation (AGT), which directly reverses the endogenous alkylation to the position 06 of guanin, is able to confer resistance to Alkylation-sensitive cells and therefore is an active target of antineoplastic drugs.</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="59">
                    <text>GAT transformation 06 human (AGT) that conferred resistance over Alkylation-sensitive cells was therefore an active target of anti-drugs.</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="60">
                    <text>GAT transformation has not been determined to be able to confer resistance to Alkylation-sensitive cells.</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="61">
                    <text>Gly156 and Lys165 replacement (AGT), which directly reverses the endogenous alkylation at the position of guanin 6, conferred resistance to 06-BG and is therefore an active target of anticancer drugs.</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="62">
                    <text>Gly156 and Lys165 replacement (AGT), which directly reverses the endogenous alkylation in 06 guanin positions, has the ability to confer resistance to 06-BG and therefore is an active target of antineoplastic drugs.</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="63">
                    <text>Human 06-alkylguaning-DNA alkyltransferase (AGT) that is able to confer resistance to alkylation pathways was therefore an active target of anti-drugs.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="64">
                    <text>Human 06-alkylguaning-DNA alkyltransferase (AGT), which directly inverts endogenous alkylation to 06-position of the guanine, could confer resistance to alkylation pathways and thus was an active target of anti-cancer drugs.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="65">
                    <text>Human 06-alkylguaning-DNA alkyltransferase (AGT), which directly inverts endogenous alkylation to 06-position of the guanine, would confer resistance to alkylation pathways and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="66">
                    <text>Human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, may confer resistance to alkylation pathways and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="67">
                    <text>Human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses the endogenous alkylation to the position 06 of guanin, is able to confer resistance to alkylation pathways and therefore is an active target of antineoplastic drugs.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="68">
                    <text>Human 06-alkylguaning-DNA alkyltransferase may confer resistance to alkylation pathways has not been determined.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="69">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structure suggests the ability of The portion of the STATs to confer specificity to either a MAPK or a MAPK substrat kinase (MAPKAP) through distortions of the lumbar spine.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="70">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structure suggests the ability of alkyguaning-DNA alkyltransferase to confer resistance to alkylation chemotherapies through distortions of the lumbar spine.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="71">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structure suggests the ability of alkylation of human alkyl hydroxyl-DNA alkyltransferase to confer resistance to alkylation routes through distortions of the lumbar spine.</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="72">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structure suggests the ability of alkylguaning-DNA alkyltransferase to confer resistance to alkyl ways through distortions of the lumbar spine.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyl ways</arg>
                </example>
                <example src="PERMUTATE" no="73">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structure suggests the ability of alkyltransferase of 06-alkyltransferase of AGT to confer resistance to alkyltransferase of pathways through distortions of the lumbar spine.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase of pathways</arg>
                </example>
                <example src="PERMUTATE" no="74">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structure suggests the ability of human alkyl-alkylation-DNA alkyltransferase to confer resistance to alkylation routes through distortions of the lumbar spine.</text>
                    <arg n="0">human alkyl-alkylation-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="75">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structure suggests the ability of replaceing Gly156 and Lys165 to confer resistance to 06-BG through distortions of the lumbar spine.</text>
                    <arg n="0">replaceing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="76">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structure suggests the ability of replacing simply the C-terminal with Stat5 to confer stat5 phenotype of stability in the presence of MG132 to Stat1 through distortions of the lumbar spine.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="77">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structure suggests the ability of replacing simply the C-terminal with the Stat5 phenotype to confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 through distortions of the lumbar spine.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="78">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structure suggests the ability of substituting only the C-terminal with Stat5 to confer the Stat5 phenotype in the presence of MG132 to Stat1 through distortions of the lumbar spine.</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="79">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structure suggests the ability of the portion of the STATs to confer specificity to either a MAPK or a MAPK kinase substrate (MAPKAP) through distortions of the lumbar spine.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="80">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that AGATT transfection are able to confer resistance to alkylation-sensitive cells through distortions of the lumbar spine.</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="81">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that AGATT transfection has the ability to confer resistance to alkylation-sensitive cells through distortions of the lumbar spine.</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="82">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that AGT are able to confer resistance to alkylation-sensitive cells through distortions of the lumbar spine.</text>
                    <arg n="0">AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="83">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that AGT has the ability to confer resistance to alkylation-sensitive cells through distortions of the lumbar spine.</text>
                    <arg n="0">AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="84">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that AGT may confer resistance to alkylation-sensitive cells through distortions of the lumbar spine.</text>
                    <arg n="0">AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="85">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that AGT transformation are able to confer resistance to alkylation-sensitive cells through distortions of the lumbar spine.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="86">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that AGT transformation has the ability to confer resistance to Alkylation-sensitive cells through distortions of the lumbar spine.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="87">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that AGT transformation has the ability to confer resistance to alkylation-sensitive cells through distortions of the lumbar spine.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="88">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that AGT transformation may confer resistance to alkylation-sensitive cells through distortions of the lumbar spine.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="89">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that AGT transformation may have conferred resistance to Alkylation-sensitive cells through distortions of the lumbar spine.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="90">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that AGT transformation may have conferred resistance to alkylation-sensitive cells through distortions of the lumbar spine.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="91">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that AGT transformation may have the ability to confer resistance to Alkylation-sensitive cells through distortions of the lumbar spine.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="92">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that AGT transformation was considered to confer resistance to Alkylation-sensitive cells by means of lumbar spine distortions.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="93">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that AGT transformation will confer resistance to Alkylation-sensitive cells through distortions of the lumbar spine.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="94">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that AGT transformation will confer resistance to Kaina et al., 1991 through distortions of the lumbar spine.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="95">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that AGT transition may confer resistance to Kaina et al., 1991 through distortions of the lumbar spine.</text>
                    <arg n="0">AGT transition</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="96">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that GAT transformation are able to confer resistance to Alkylation-sensitive cells through distortions of the lumbar spine.</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="97">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that GAT transformation may confer resistance to Alkylation-sensitive cells through distortions of the lumbar spine.</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="98">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that GAT transformation may have the ability to confer resistance to Alkylation-sensitive cells through distortions of the lumbar spine.</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="99">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that GAT transformation was considered to confer resistance to Alkylation-sensitive cells by means of lumbar spine distortions.</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="100">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that GAT transformation will confer resistance to Alkylation-sensitive cells through distortions of the lumbar spine.</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="101">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that Gly156 and Lys165 replacement are able to confer resistance to 06-BG through distortions of the lumbar spine.</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="102">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that Gly156 and Lys165 replacement has the ability to confer resistance to 06-BG through distortions of the lumbar spine.</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="103">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that Human 06-alkylguaning-DNA alkyltransferase was considered to confer resistance to alkylation pathways by means of lumbar spine distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="104">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that The STAT portion may confer specificity to a MAPK substrate or a MAPK kinase (MAPKAP) through distortions of the lumbar spine.</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="105">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that The portion of the STATs are able to confer specificity to either a MAPK or a MAPK substratum kinase (MAPKAP) through distortions of the lumbar spine.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="106">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that The portion of the STATs are observed to confer specificity to either a MAPK or a MAPK substratum kinase (MAPKAP) by means of lumbar spine distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="107">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that The portion of the STATs may have conferred specificity to either a MAPK or a MAPK substratum kinase (MAPKAP) through distortions of the lumbar spine.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="108">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that alkyguaning-DNA alkyltransferase are able to confer resistance to alkylation chemotherapies through distortions of the lumbar spine.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="109">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that alkyguaning-DNA alkyltransferase are observed to confer resistance to alkylation routes by means of lumbar spine distortions.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="110">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that alkyguaning-DNA alkyltransferase may have conferred resistance to alkylation chemotherapies through distortions of the lumbar spine.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="111">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that alkyguaning-DNA alkyltransferase may have conferred resistance to alkylation routes through distortions of the lumbar spine.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="112">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that alkyguaning-DNA alkyltransferase was considered to confer resistance to alkylation routes by means of lumbar spine distortions.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="113">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that alkyguaning-DNA alkyltransferase will confer resistance to alkylation routes through distortions of the lumbar spine.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="114">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that alkylation of human alkyl hydroxyl-DNA alkyltransferase are able to confer resistance to alkylation routes through distortions of the lumbar spine.</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="115">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase has the ability to confer resistance to alkylation chemotherapies through distortions of the lumbar spine.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="116">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase may have conferred resistance to alkylation chemotherapies through distortions of the lumbar spine.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="117">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase may have the ability to confer resistance to alkylation chemotherapies through distortions of the lumbar spine.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="118">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that alkylguaning-DNA alkyltransferase was considered to confer resistance to alkyl ways by means of lumbar spine distortions.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyl ways</arg>
                </example>
                <example src="PERMUTATE" no="119">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT are able to confer resistance to alkylation through distortions of the lumbar spine.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="120">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT has the ability to confer resistance to alkylation through distortions of the lumbar spine.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="121">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT was considered to confer resistance to alkylation by means of lumbar spine distortions.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="122">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that alkyltransferase of 06-alkyltransferase of AGT has the ability to confer resistance to alkyltransferase of pathways through distortions of the lumbar spine.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase of pathways</arg>
                </example>
                <example src="PERMUTATE" no="123">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that alkyltransferase of 06-alkyltransferase of AGT may confer resistance to alkylation through distortions of the lumbar spine.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="124">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that alkyltransferase of 06-alkyltransferase of AGT may have conferred resistance to alkyltransferase of pathways through distortions of the lumbar spine.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase of pathways</arg>
                </example>
                <example src="PERMUTATE" no="125">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that alkyltransferase of 06-alkyltransferase of AGT may have the ability to confer resistance to alkyltransferase chemotherapies through distortions of the lumbar spine.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="126">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that alkyltransferase of 06-alkyltransferase of AGT will confer resistance to alkyltransferase of pathways through distortions of the lumbar spine.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase of pathways</arg>
                </example>
                <example src="PERMUTATE" no="127">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that alkyltransferase-DNA alkyltransferase has the ability to confer resistance to alkylation chemotherapies through distortions of the lumbar spine.</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="128">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that alkyltransferase-DNA alkyltransferase may confer resistance to alkylation chemotherapies through distortions of the lumbar spine.</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="129">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that alkyltransferase-DNA alkyltransferase may have the ability to confer resistance to alkylation chemotherapies through distortions of the lumbar spine.</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="130">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that human 06-alkylguaning-DNA alkyltransferase are able to confer resistance to alkylation pathways through distortions of the lumbar spine.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="131">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that human 06-alkylguaning-DNA alkyltransferase was considered to confer resistance to alkylation pathways by means of lumbar spine distortions.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="132">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that human alkyl-alkylation-DNA alkyltransferase may confer resistance to alkylation routes through distortions of the lumbar spine.</text>
                    <arg n="0">human alkyl-alkylation-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="133">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that human alkyl-alkylation-DNA alkyltransferase may have the ability to confer resistance to alkylation routes through distortions of the lumbar spine.</text>
                    <arg n="0">human alkyl-alkylation-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="134">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that human alkyl-alkylation-DNA alkyltransferase was considered to confer resistance to alkylation routes by means of lumbar spine distortions.</text>
                    <arg n="0">human alkyl-alkylation-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="135">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that just replacing C-terminus by Stat5 may have the ability to confer the stability phenotype Stat5 in the presence of MG132 to Stat1 through distortions of the lumbar spine.</text>
                    <arg n="0">just replacing C-terminus by Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="136">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that just replacing the C-terminal with the Stat5 phenotype may have the ability to confer the stability Stat5 phenotype in the presence of MG132 to Stat1 through distortions of the lumbar spine.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="137">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that only C-terminal substitution for Stat5 are observed to confer the Stat5 phenotype of stability in the presence of MG132 to State1 by means of lumbar spine distortions.</text>
                    <arg n="0">only C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="138">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that only the C-terminal substitution for Stat5 are able to confer the Stat5 stability phenotype in the presence of MG132 to State1 through distortions of the lumbar spine.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="139">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that only the C-terminal substitution for Stat5 are observed to confer the Stat5 stability phenotype in the presence of MG132 to State1 by means of lumbar spine distortions.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="140">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that replaceing Gly156 and Lys165 are observed to confer resistance to 06-BG by means of lumbar spine distortions.</text>
                    <arg n="0">replaceing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="141">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that replacements in Gly156 and Lys165 are observed to confer resistance to 06-BG by means of lumbar spine distortions.</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="142">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that replacements in Gly156 and Lys165 may have conferred resistance to 06-BG through distortions of the lumbar spine.</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="143">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that replacements to Gly156 and Lys165 are observed to confer resistance to 06-BG by means of lumbar spine distortions.</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="144">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that replacements to Gly156 and Lys165 may confer resistance to 06-BG through distortions of the lumbar spine.</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="145">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that replacements to Gly156 and Lys165 was considered to confer resistance to 06-BG by means of lumbar spine distortions.</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="146">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that replacements to Gly156 and Lys165 will confer resistance to 06-BG through distortions of the lumbar spine.</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="147">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that replacing Gly156 and Lys165 will confer resistance to 06-BG through distortions of the lumbar spine.</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="148">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that replacing simply the C-terminal with Stat5 may confer stat5 phenotype of stability in the presence of MG132 to Stat1 through distortions of the lumbar spine.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="149">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that replacing simply the C-terminal with Stat5 was considered to confer stat5 phenotype of stability in the presence of MG132 to Stat1 by means of lumbar spine distortions.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="150">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that replacing simply the C-terminal with Stat5 was considered to confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 by means of lumbar spine distortions.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="151">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that replacing simply the C-terminal with Stat5 will confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 through distortions of the lumbar spine.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="152">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that replacing simply the C-terminal with the Stat5 phenotype are able to confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 through distortions of the lumbar spine.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="153">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that replacing simply the C-terminal with the Stat5 phenotype has the ability to confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 through distortions of the lumbar spine.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="154">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that replacing simply the C-terminal with the Stat5 phenotype was considered to confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 by means of lumbar spine distortions.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="155">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that resistance can be conferred by AGT transformation to Alkylation-sensitive cells through distortions of the lumbar spine.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="156">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that resistance can be conferred by alkyguaning-DNA alkyltransferase to alkylation chemotherapies through distortions of the lumbar spine.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="157">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that resistance can be conferred by alkyltransferase of 06-alkyltransferase-DNA to alkyltransferase chemotherapies through distortions of the lumbar spine.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="158">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that resistance can be conferred by alkyltransferase-DNA alkyltransferase to alkylation chemotherapies through distortions of the lumbar spine.</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="159">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that resistance can be conferred by replaceing Gly156 and Lys165 to 06-BG through distortions of the lumbar spine.</text>
                    <arg n="0">replaceing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="160">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that resistance is able to be conferred by AGT to alkylation-sensitive cells through distortions of the lumbar spine.</text>
                    <arg n="0">AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="161">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that resistance is able to be conferred by AGT transformation to Kaina et al., 1991 through distortions of the lumbar spine.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="162">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that resistance is able to be conferred by alkyguaning-DNA alkyltransferase to alkylation chemotherapies through distortions of the lumbar spine.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="163">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that resistance is able to be conferred by alkyguaning-DNA alkyltransferase to alkylation routes through distortions of the lumbar spine.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="164">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that resistance is able to be conferred by alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase to alkylation pathways through distortions of the lumbar spine.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="165">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that resistance is able to be conferred by replacements in Gly156 and Lys165 to 06-BG through distortions of the lumbar spine.</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="166">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that resistance is considered conferred by AGT transformation to Alkylation-sensitive cells through distortions of the lumbar spine.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="167">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that resistance is considered conferred by AGT transformation to alkylation-sensitive cells through distortions of the lumbar spine.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="168">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that resistance is considered conferred by GAT transformation to Alkylation-sensitive cells through distortions of the lumbar spine.</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="169">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that resistance is considered conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation pathways through distortions of the lumbar spine.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="170">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that resistance is considered conferred by alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies through distortions of the lumbar spine.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="171">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that resistance is considered conferred by alkylguaning-DNA alkyltransferase to alkyl ways through distortions of the lumbar spine.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyl ways</arg>
                </example>
                <example src="PERMUTATE" no="172">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that resistance is considered conferred by alkylguaning-DNA alkyltransferase to alkylation routes through distortions of the lumbar spine.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="173">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that resistance is considered conferred by human alkyl-alkylation-DNA alkyltransferase to alkylation routes through distortions of the lumbar spine.</text>
                    <arg n="0">human alkyl-alkylation-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="174">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that resistance is considered conferred by substitutions to Gly156 and Lys165 to 06-BG through distortions of the lumbar spine.</text>
                    <arg n="0">substitutions to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="175">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that resistance is considered conferred by transfection of AGATT to alkylation-sensitive cells through distortions of the lumbar spine.</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="176">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that specificity can be conferred by the part of STATs to a MAPK substrate or a MAPK kinase (MAPKAP) through distortions of the lumbar spine.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="177">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that specificity can be conferred by the portion of the STATs to either a MAPK or a MAPK kinase substrate (MAPKAP) through distortions of the lumbar spine.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="178">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that specificity is considered conferred by the part of STATs to a MAPK substrate or a MAPK kinase (MAPKAP) through distortions of the lumbar spine.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="179">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that substituting only the C-terminal with Stat5 are observed to confer the Stat5 phenotype in the presence of MG132 to Stat1 by means of lumbar spine distortions.</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="180">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that substituting only the C-terminal with Stat5 may have conferred the Stat5 phenotype in the presence of MG132 to Stat1 through distortions of the lumbar spine.</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="181">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that substitutions to Gly156 and Lys165 are observed to confer resistance to 06-BG by means of lumbar spine distortions.</text>
                    <arg n="0">substitutions to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="182">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that the STAT part has the ability to confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) through distortions of the lumbar spine.</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="183">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that the STAT part may have conferred specificity to a MAPK or a MAPK substrate kinase (MAPKAP) through distortions of the lumbar spine.</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="184">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that the STAT part was considered to confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) by means of lumbar spine distortions.</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="185">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that the Stat5 phenotype in the presence of MG132 is able to be conferred by replacing simply the C-terminal with Stat5 to Stat1 through distortions of the lumbar spine.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="186">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that the Stat5 phenotype in the presence of MG132 is able to be conferred by substituting only the C-terminal with Stat5 to Stat1 through distortions of the lumbar spine.</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="187">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that the Stat5 phenotype in the presence of MG132 is considered conferred by replacing simply the C-terminal with Stat5 to Stat1 through distortions of the lumbar spine.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="188">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that the Stat5 phenotype in the presence of MG132 is considered conferred by substituting only the C-terminal with Stat5 to Stat1 through distortions of the lumbar spine.</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="189">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that the Stat5 phenotype of stability in the presence of MG132 can be conferred by only C-terminal substitution for Stat5 to State1 through distortions of the lumbar spine.</text>
                    <arg n="0">only C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="190">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that the Stat5 phenotype of stability in the presence of MG132 is able to be conferred by only C-terminal substitution for Stat5 to State1 through distortions of the lumbar spine.</text>
                    <arg n="0">only C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="191">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that the Stat5 phenotype of stability in the presence of MG132 is considered conferred by replacing simply the C-terminal with Stat5 to Stat1 through distortions of the lumbar spine.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="192">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that the Stat5 stability phenotype in the presence of MG132 is considered conferred by just replacing the C-terminal with the Stat5 phenotype to Stat1 through distortions of the lumbar spine.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="193">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that the part of STATs was considered to confer specificity to a MAPK substrate or a MAPK kinase (MAPKAP) by means of lumbar spine distortions.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="194">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that the portion of the STATs are able to confer specificity to either a MAPK or a MAPK kinase substrate (MAPKAP) through distortions of the lumbar spine.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="195">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that the portion of the STATs are observed to confer specificity to either a MAPK or a MAPK kinase substrate (MAPKAP) by means of lumbar spine distortions.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="196">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that the portion of the STATs has the ability to confer specificity to either a MAPK or a MAPK kinase substrate (MAPKAP) through distortions of the lumbar spine.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="197">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that the stability Stat5 phenotype in the presence of MG132 can be conferred by just replacing the C-terminal with the Stat5 phenotype to Stat1 through distortions of the lumbar spine.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="198">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that the stability phenotype Stat5 in the presence of MG132 is considered conferred by just replacing C-terminus by Stat5 to Stat1 through distortions of the lumbar spine.</text>
                    <arg n="0">just replacing C-terminus by Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="199">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that transfection of AGATT may have the ability to confer resistance to alkylation-sensitive cells through distortions of the lumbar spine.</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="200">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that transfection of AGT has the ability to confer resistance to alkylation-sensitive cells through distortions of the lumbar spine.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="201">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that transformation of AGT are observed to confer resistance to alkylation-sensitive cells by means of lumbar spine distortions.</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="202">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that transformation of AGT has the ability to confer resistance to alkylation-sensitive cells through distortions of the lumbar spine.</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="203">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that transformation of GAT has the ability to confer resistance to alkylation-sensitive cells through distortions of the lumbar spine.</text>
                    <arg n="0">transformation of GAT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="204">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that AGATT transfection is considered as conferring resistance to alkylation-sensitive cells through spine distortions.</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="205">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that AGT is considered as conferring resistance to alkylation-sensitive cells through spine distortions.</text>
                    <arg n="0">AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="206">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that AGT transformation conferred resistance to alkylation-sensitive cells by means of spinal distortions.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="207">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that AGT transformation is considered as conferring resistance to Alkylation-sensitive cells through spine distortions.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="208">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that AGT transformation was able to confer resistance to Kaina et al., 1991 by spine distortions.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="209">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that AGT transformation would have conferred resistance to Kaina et al., 1991 by means of spinal distortions.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="210">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that Human 06-alkylguaning-DNA alkyltransferase conferred resistance to alkylation pathways by means of spinal distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="211">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that The STAT portion was able to confer specificity to a MAPK substrate or a MAPK kinase (MAPKAP) by spine distortions.</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="212">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that The STAT portion would have conferred specificity to a MAPK substrate or a MAPK kinase (MAPKAP) by means of spinal distortions.</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="213">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that The portion of the STATs conferred specificity to either a MAPK or a MAPK substratum kinase (MAPKAP) by means of spinal distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="214">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that alkyguaning-DNA alkyltransferase was able to confer resistance to alkylation chemotherapies by spine distortions.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="215">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase conferred resistance to alkylation chemotherapies by means of spinal distortions.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="216">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase was able to confer resistance to alkylation pathways by spine distortions.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="217">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase would have conferred resistance to alkylation pathways by means of spinal distortions.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="218">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT conferred resistance to alkylation by means of spinal distortions.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="219">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that alkyltransferase of 06-alkyltransferase of AGT conferred resistance to alkylation by means of spinal distortions.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="220">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that alkyltransferase of 06-alkyltransferase of AGT conferred resistance to alkyltransferase chemotherapies by means of spinal distortions.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="221">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that alkyltransferase of 06-alkyltransferase-DNA conferred resistance to alkyltransferase chemotherapies by means of spinal distortions.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="222">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that alkyltransferase-DNA alkyltransferase would have conferred resistance to alkylation chemotherapies by means of spinal distortions.</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="223">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that human alkyl-alkylation-DNA alkyltransferase conferred resistance to alkylation routes by means of spinal distortions.</text>
                    <arg n="0">human alkyl-alkylation-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="224">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that human alkyl-alkylation-DNA alkyltransferase was able to confer resistance to alkylation routes by spine distortions.</text>
                    <arg n="0">human alkyl-alkylation-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="225">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that just replacing the C-terminal with the Stat5 phenotype is considered as conferring the stability Stat5 phenotype in the presence of MG132 to Stat1 through spine distortions.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="226">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that just replacing the C-terminal with the Stat5 phenotype would have conferred the stability Stat5 phenotype in the presence of MG132 to Stat1 by means of spinal distortions.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="227">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that replacements in Gly156 and Lys165 was able to confer resistance to 06-BG by spine distortions.</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="228">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that replacements to Gly156 and Lys165 conferred resistance to 06-BG by means of spinal distortions.</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="229">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that replacements to Gly156 and Lys165 was able to confer resistance to 06-BG by spine distortions.</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="230">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that replacing simply the C-terminal with Stat5 conferred the Stat5 phenotype of stability in the presence of MG132 to Stat1 by means of spinal distortions.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="231">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that replacing simply the C-terminal with Stat5 is considered as conferring the Stat5 phenotype in the presence of MG132 to Stat1 through spine distortions.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="232">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that replacing simply the C-terminal with Stat5 is considered as conferring the Stat5 phenotype of stability in the presence of MG132 to Stat1 through spine distortions.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="233">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that replacing simply the C-terminal with the Stat5 phenotype was able to confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 by spine distortions.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="234">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance can be conferred by AGATT transfection to alkylation-sensitive cells through spine distortions.</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="235">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance can be conferred by AGT transformation to Alkylation-sensitive cells through spine distortions.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="236">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance can be conferred by AGT transition to Kaina et al., 1991 through spine distortions.</text>
                    <arg n="0">AGT transition</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="237">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance can be conferred by alkylation of human alkyl hydroxyl-DNA alkyltransferase to alkylation routes through spine distortions.</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="238">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance can be conferred by alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies through spine distortions.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="239">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance can be conferred by alkylguaning-DNA alkyltransferase to alkylation routes through spine distortions.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="240">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance can be conferred by alkyltransferase of 06-alkyltransferase-DNA to alkyltransferase chemotherapies through spine distortions.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="241">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance can be conferred by human alkyl-alkylation-DNA alkyltransferase to alkylation routes through spine distortions.</text>
                    <arg n="0">human alkyl-alkylation-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="242">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance can be conferred by replacements in Gly156 and Lys165 to 06-BG through spine distortions.</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="243">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance can be conferred by substitutions in Gly156 and Lys165 to 06-BG through spine distortions.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="244">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance could be conferred by AGT transformation to Alkylation-sensitive cells through spine distortions.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="245">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance could be conferred by GAT transformation to Alkylation-sensitive cells through spine distortions.</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="246">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance could be conferred by alkyguaning-DNA alkyltransferase to alkylation chemotherapies through spine distortions.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="247">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance could be conferred by alkyguaning-DNA alkyltransferase to alkylation routes through spine distortions.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="248">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance could be conferred by alkyltransferase of 06-alkyltransferase of AGT to alkylation through spine distortions.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="249">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance could be conferred by human 06-alkylguaning-DNA alkyltransferase to alkylation pathways through spine distortions.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="250">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance could be conferred by human alkyl-alkylation-DNA alkyltransferase to alkylation routes through spine distortions.</text>
                    <arg n="0">human alkyl-alkylation-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="251">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance could be conferred by substitutions to Gly156 and Lys165 to 06-BG through spine distortions.</text>
                    <arg n="0">substitutions to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="252">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance could be conferred by transfection of AGT to alkylation-sensitive cells through spine distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="253">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance could be conferred by transformation of GAT to alkylation-sensitive cells through spine distortions.</text>
                    <arg n="0">transformation of GAT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="254">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance is able to be conferred by AGT transformation to Alkylation-sensitive cells through spine distortions.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="255">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance is able to be conferred by Gly156 and Lys165 replacement to 06-BG through spine distortions.</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="256">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance is able to be conferred by alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase to alkylation pathways through spine distortions.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="257">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance is able to be conferred by alkyltransferase of 06-alkyltransferase of AGT to alkyltransferase chemotherapies through spine distortions.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="258">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance is able to be conferred by alkyltransferase of 06-alkyltransferase-DNA to alkyltransferase chemotherapies through spine distortions.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="259">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance is able to be conferred by human alkyl-alkylation-DNA alkyltransferase to alkylation routes through spine distortions.</text>
                    <arg n="0">human alkyl-alkylation-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="260">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance is able to be conferred by substitutions in Gly156 and Lys165 to 06-BG through spine distortions.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="261">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance is able to be conferred by substitutions to Gly156 and Lys165 to 06-BG through spine distortions.</text>
                    <arg n="0">substitutions to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="262">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance is conferred as attributed by AGT transformation to Alkylation-sensitive cells through spine distortions.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="263">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance is conferred as attributed by AGT transformation to alkylation-sensitive cells through spine distortions.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="264">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance is conferred as attributed by alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT to alkylation through spine distortions.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="265">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance is conferred as attributed by replacements to Gly156 and Lys165 to 06-BG through spine distortions.</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="266">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance is conferred by AGATT transfection to alkylation-sensitive cells through spine distortions.</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="267">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance is conferred by AGT transformation to Kaina et al., 1991 through spine distortions.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="268">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance is conferred by alkyguaning-DNA alkyltransferase to alkylation chemotherapies through spine distortions.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="269">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance is conferred by alkyguaning-DNA alkyltransferase to alkylation routes through spine distortions.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="270">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance is conferred by alkylguaning-DNA alkyltransferase to alkyl ways through spine distortions.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyl ways</arg>
                </example>
                <example src="PERMUTATE" no="271">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance is conferred by alkyltransferase of 06-alkyltransferase-DNA to alkyltransferase chemotherapies through spine distortions.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="272">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance may have been conferred by AGATT transfection to alkylation-sensitive cells through spine distortions.</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="273">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance may have been conferred by AGT transformation to Kaina et al., 1991 through spine distortions.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="274">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance may have been conferred by AGT transition to Kaina et al., 1991 through spine distortions.</text>
                    <arg n="0">AGT transition</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="275">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance may have been conferred by Gly156 and Lys165 replacement to 06-BG through spine distortions.</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="276">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance may have been conferred by alkylguaning-DNA alkyltransferase to alkylation routes through spine distortions.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="277">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance may have been conferred by alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT to alkylation through spine distortions.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="278">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance may have been conferred by alkyltransferase of 06-alkyltransferase of AGT to alkyltransferase chemotherapies through spine distortions.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="279">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance may have been conferred by alkyltransferase of 06-alkyltransferase-DNA to alkyltransferase chemotherapies through spine distortions.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="280">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance may have been conferred by replacements to Gly156 and Lys165 to 06-BG through spine distortions.</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="281">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance may have been conferred by replacing Gly156 and Lys165 to 06-BG through spine distortions.</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="282">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance was able to be conferred by Gly156 and Lys165 replacement to 06-BG through spine distortions.</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="283">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance was able to be conferred by alkylation of human alkyl hydroxyl-DNA alkyltransferase to alkylation routes through spine distortions.</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="284">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance was able to be conferred by human 06-alkylguaning-DNA alkyltransferase to alkylation pathways through spine distortions.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="285">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance was able to be conferred by replacing Gly156 and Lys165 to 06-BG through spine distortions.</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="286">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance was conferred by AGATT transfection to alkylation-sensitive cells through spine distortions.</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="287">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance was conferred by alkylation of human alkyl hydroxyl-DNA alkyltransferase to alkylation routes through spine distortions.</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="288">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance was conferred by alkylguaning-DNA alkyltransferase to alkyl ways through spine distortions.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyl ways</arg>
                </example>
                <example src="PERMUTATE" no="289">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance was conferred by alkyltransferase of 06-alkyltransferase of AGT to alkyltransferase chemotherapies through spine distortions.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="290">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance was conferred by alkyltransferase-DNA alkyltransferase to alkylation chemotherapies through spine distortions.</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="291">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance was conferred by human alkyl-alkylation-DNA alkyltransferase to alkylation routes through spine distortions.</text>
                    <arg n="0">human alkyl-alkylation-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="292">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance was conferred by replaceing Gly156 and Lys165 to 06-BG through spine distortions.</text>
                    <arg n="0">replaceing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="293">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance was conferred by replacements to Gly156 and Lys165 to 06-BG through spine distortions.</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="294">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance was conferred by transfection of AGT to alkylation-sensitive cells through spine distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="295">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance was conferred by transformation of GAT to alkylation-sensitive cells through spine distortions.</text>
                    <arg n="0">transformation of GAT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="296">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance will be conferred by AGT transformation to Kaina et al., 1991 through spine distortions.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="297">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance will be conferred by Gly156 and Lys165 replacement to 06-BG through spine distortions.</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="298">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance will be conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation pathways through spine distortions.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="299">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance will be conferred by alkyltransferase of 06-alkyltransferase of AGT to alkyltransferase chemotherapies through spine distortions.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="300">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance will be conferred by alkyltransferase of 06-alkyltransferase of AGT to alkyltransferase of pathways through spine distortions.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase of pathways</arg>
                </example>
                <example src="PERMUTATE" no="301">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance will be conferred by substitutions in Gly156 and Lys165 to 06-BG through spine distortions.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="302">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance would be conferred by AGT transition to Kaina et al., 1991 by means of spine distortions.</text>
                    <arg n="0">AGT transition</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="303">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance would be conferred by Gly156 and Lys165 replacement to 06-BG by means of spine distortions.</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="304">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance would be conferred by replaceing Gly156 and Lys165 to 06-BG by means of spine distortions.</text>
                    <arg n="0">replaceing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="305">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance would be conferred by replacements in Gly156 and Lys165 to 06-BG by means of spine distortions.</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="306">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that resistance would be conferred by replacing Gly156 and Lys165 to 06-BG by means of spine distortions.</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="307">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that specificity can be conferred by The portion of the STATs to either a MAPK or a MAPK substratum kinase (MAPKAP) through spine distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="308">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that specificity could be conferred by The portion of the STATs to either a MAPK or a MAPK substratum kinase (MAPKAP) through spine distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="309">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that specificity is able to be conferred by The STAT portion to a MAPK substrate or a MAPK kinase (MAPKAP) through spine distortions.</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="310">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that specificity is able to be conferred by The portion of the STATs to either a MAPK or a MAPK substrat kinase (MAPKAP) through spine distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="311">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that specificity is able to be conferred by the part of STATs to a MAPK substrate or a MAPK kinase (MAPKAP) through spine distortions.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="312">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that specificity was able to be conferred by The STAT portion to a MAPK substrate or a MAPK kinase (MAPKAP) through spine distortions.</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="313">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that specificity was able to be conferred by The portion of the STATs to either a MAPK or a MAPK substrat kinase (MAPKAP) through spine distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="314">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that specificity was able to be conferred by the STAT part to a MAPK or a MAPK substrate kinase (MAPKAP) through spine distortions.</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="315">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that specificity was conferred by The STAT portion to a MAPK substrate or a MAPK kinase (MAPKAP) through spine distortions.</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="316">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that specificity was conferred by the STAT part to a MAPK or a MAPK substrate kinase (MAPKAP) through spine distortions.</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="317">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that specificity will be conferred by the part of STATs to a MAPK substrate or a MAPK kinase (MAPKAP) through spine distortions.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="318">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that specificity would be conferred by The portion of the STATs to either a MAPK or a MAPK substrat kinase (MAPKAP) by means of spine distortions.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="319">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that stat5 phenotype of stability in the presence of MG132 could be conferred by replacing simply the C-terminal with Stat5 to Stat1 through spine distortions.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="320">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that stat5 phenotype of stability in the presence of MG132 is able to be conferred by replacing simply the C-terminal with Stat5 to Stat1 through spine distortions.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="321">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that stat5 phenotype of stability in the presence of MG132 may have been conferred by replacing simply the C-terminal with Stat5 to Stat1 through spine distortions.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="322">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that stat5 phenotype of stability in the presence of MG132 was conferred by replacing simply the C-terminal with Stat5 to Stat1 through spine distortions.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="323">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that substituting only the C-terminal with Stat5 conferred the Stat5 phenotype in the presence of MG132 to Stat1 by means of spinal distortions.</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="324">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that substituting only the C-terminal with Stat5 was able to confer the Stat5 phenotype in the presence of MG132 to Stat1 by spine distortions.</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="325">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that substituting only the C-terminal with Stat5 would have conferred the Stat5 phenotype in the presence of MG132 to Stat1 by means of spinal distortions.</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="326">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that substitutions in Gly156 and Lys165 conferred resistance to 06-BG by means of spinal distortions.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="327">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that substitutions in Gly156 and Lys165 would have conferred resistance to 06-BG by means of spinal distortions.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="328">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the STAT part conferred specificity to a MAPK or a MAPK substrate kinase (MAPKAP) by means of spinal distortions.</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="329">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the STAT part is considered as conferring specificity to a MAPK or a MAPK substrate kinase (MAPKAP) through spine distortions.</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="330">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the STAT part was able to confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) by spine distortions.</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="331">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the Stat5 phenotype in the presence of MG132 can be conferred by replacing simply the C-terminal with Stat5 to Stat1 through spine distortions.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="332">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the Stat5 phenotype in the presence of MG132 is able to be conferred by substituting only the C-terminal with Stat5 to Stat1 through spine distortions.</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="333">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the Stat5 phenotype in the presence of MG132 is conferred as attributed by substituting only the C-terminal with Stat5 to Stat1 through spine distortions.</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="334">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the Stat5 phenotype in the presence of MG132 is conferred by substituting only the C-terminal with Stat5 to Stat1 through spine distortions.</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="335">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the Stat5 phenotype in the presence of MG132 may have been conferred by replacing simply the C-terminal with Stat5 to Stat1 through spine distortions.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="336">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the Stat5 phenotype in the presence of MG132 may have been conferred by substituting only the C-terminal with Stat5 to Stat1 through spine distortions.</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="337">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the Stat5 phenotype in the presence of MG132 was able to be conferred by replacing simply the C-terminal with Stat5 to Stat1 through spine distortions.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="338">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the Stat5 phenotype in the presence of MG132 was able to be conferred by substituting only the C-terminal with Stat5 to Stat1 through spine distortions.</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="339">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the Stat5 phenotype of stability in the presence of MG132 could be conferred by only C-terminal substitution for Stat5 to State1 through spine distortions.</text>
                    <arg n="0">only C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="340">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the Stat5 phenotype of stability in the presence of MG132 could be conferred by replacing simply the C-terminal with the Stat5 phenotype to Stat1 through spine distortions.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="341">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the Stat5 phenotype of stability in the presence of MG132 is able to be conferred by only C-terminal substitution for Stat5 to State1 through spine distortions.</text>
                    <arg n="0">only C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="342">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the Stat5 phenotype of stability in the presence of MG132 may have been conferred by only C-terminal substitution for Stat5 to State1 through spine distortions.</text>
                    <arg n="0">only C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="343">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the Stat5 phenotype of stability in the presence of MG132 was conferred by replacing simply the C-terminal with Stat5 to Stat1 through spine distortions.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="344">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the Stat5 phenotype of stability in the presence of MG132 will be conferred by only C-terminal substitution for Stat5 to State1 through spine distortions.</text>
                    <arg n="0">only C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="345">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the Stat5 phenotype of stability in the presence of MG132 will be conferred by replacing simply the C-terminal with the Stat5 phenotype to Stat1 through spine distortions.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="346">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the part of STATs would have conferred specificity to a MAPK substrate or a MAPK kinase (MAPKAP) by means of spinal distortions.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="347">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the portion of the STATs would have conferred specificity to either a MAPK or a MAPK kinase substrate (MAPKAP) by means of spinal distortions.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="348">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the stability Stat5 phenotype in the presence of MG132 can be conferred by just replacing the C-terminal with the Stat5 phenotype to Stat1 through spine distortions.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="349">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the stability Stat5 phenotype in the presence of MG132 could be conferred by just replacing the C-terminal with the Stat5 phenotype to Stat1 through spine distortions.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="350">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the stability Stat5 phenotype in the presence of MG132 was able to be conferred by just replacing the C-terminal with the Stat5 phenotype to Stat1 through spine distortions.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="351">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the stability Stat5 phenotype in the presence of MG132 will be conferred by just replacing the C-terminal with the Stat5 phenotype to Stat1 through spine distortions.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="352">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the stability Stat5 phenotype in the presence of MG132 would be conferred by just replacing the C-terminal with the Stat5 phenotype to Stat1 by means of spine distortions.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="353">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the stability phenotype Stat5 in the presence of MG132 is conferred by just replacing C-terminus by Stat5 to Stat1 through spine distortions.</text>
                    <arg n="0">just replacing C-terminus by Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="354">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the stability phenotype Stat5 in the presence of MG132 was able to be conferred by just replacing C-terminus by Stat5 to Stat1 through spine distortions.</text>
                    <arg n="0">just replacing C-terminus by Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="355">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the stability phenotype Stat5 in the presence of MG132 was conferred by just replacing C-terminus by Stat5 to Stat1 through spine distortions.</text>
                    <arg n="0">just replacing C-terminus by Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="356">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the stability phenotype Stat5 in the presence of MG132 would be conferred by just replacing C-terminus by Stat5 to Stat1 by means of spine distortions.</text>
                    <arg n="0">just replacing C-terminus by Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="357">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that transfection of AGATT is considered as conferring resistance to alkylation-sensitive cells through spine distortions.</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="358">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that transfection of AGT is considered as conferring resistance to alkylation-sensitive cells through spine distortions.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="359">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that transformation of AGT is considered as conferring resistance to alkylation-sensitive cells through spine distortions.</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="360">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that transformation of AGT would have conferred resistance to alkylation-sensitive cells by means of spinal distortions.</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="361">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on mutational data structures suggests that AGT can confer resistance to alkylation-sensitive cells through distortions of the lumbar vertebral column.</text>
                    <arg n="0">AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="362">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on mutational data structures suggests that AGT transformation can confer resistance to Alkylation-sensitive cells through distortions of the lumbar vertebral column.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="363">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on mutational data structures suggests that AGT transformation can confer resistance to Kaina et al., 1991 through distortions of the lumbar vertebral column.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="364">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on mutational data structures suggests that alkyguaning-DNA alkyltransferase can confer resistance to alkylation chemotherapies through distortions of the lumbar vertebral column.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="365">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on mutational data structures suggests that alkylguaning-DNA alkyltransferase can confer resistance to alkylation routes through distortions of the lumbar vertebral column.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="366">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on mutational data structures suggests that alkyltransferase of 06-alkyltransferase of AGT can confer resistance to alkylation through distortions of the lumbar vertebral column.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="367">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on mutational data structures suggests that just replacing the C-terminal with the Stat5 phenotype can confer the stability Stat5 phenotype in the presence of MG132 to Stat1 through distortions of the lumbar vertebral column.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="368">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on mutational data structures suggests that only C-terminal substitution for Stat5 can confer the Stat5 phenotype of stability in the presence of MG132 to State1 through distortions of the lumbar vertebral column.</text>
                    <arg n="0">only C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="369">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on mutational data structures suggests that replaceing Gly156 and Lys165 can confer resistance to 06-BG through distortions of the lumbar vertebral column.</text>
                    <arg n="0">replaceing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="370">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on mutational data structures suggests that replacing Gly156 and Lys165 can confer resistance to 06-BG through distortions of the lumbar vertebral column.</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="371">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on mutational data structures suggests that replacing simply the C-terminal with Stat5 can confer the Stat5 phenotype in the presence of MG132 to Stat1 through distortions of the lumbar vertebral column.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="372">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on mutational data structures suggests that substitutions in Gly156 and Lys165 can confer resistance to 06-BG through distortions of the lumbar vertebral column.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="373">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the mutation data structure suggests that AGT transformation would confer resistance to Alkylation-sensitive cells through distortions of the lumbar vertebral column.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="374">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the mutation data structure suggests that AGT transition could confer resistance to Kaina et al., 1991 through distortions of the lumbar vertebral column.</text>
                    <arg n="0">AGT transition</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="375">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the mutation data structure suggests that AGT would confer resistance to alkylation-sensitive cells through distortions of the lumbar vertebral column.</text>
                    <arg n="0">AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="376">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the mutation data structure suggests that GAT transformation would confer resistance to Alkylation-sensitive cells through distortions of the lumbar vertebral column.</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="377">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the mutation data structure suggests that Gly156 and Lys165 replacement would confer resistance to 06-BG through distortions of the lumbar vertebral column.</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="378">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the mutation data structure suggests that The STAT portion would confer specificity to a MAPK substrate or a MAPK kinase (MAPKAP) through distortions of the lumbar vertebral column.</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="379">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the mutation data structure suggests that alkyguaning-DNA alkyltransferase could confer resistance to alkylation chemotherapies through distortions of the lumbar vertebral column.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="380">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the mutation data structure suggests that alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase could confer resistance to alkylation chemotherapies through distortions of the lumbar vertebral column.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="381">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the mutation data structure suggests that alkylguaning-DNA alkyltransferase could confer resistance to alkylation routes through distortions of the lumbar vertebral column.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="382">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the mutation data structure suggests that alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT would confer resistance to alkylation through distortions of the lumbar vertebral column.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="383">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the mutation data structure suggests that alkyltransferase of 06-alkyltransferase of AGT could confer resistance to alkylation through distortions of the lumbar vertebral column.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="384">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the mutation data structure suggests that human 06-alkylguaning-DNA alkyltransferase would confer resistance to alkylation pathways through distortions of the lumbar vertebral column.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="385">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the mutation data structure suggests that just replacing the C-terminal with the Stat5 phenotype would confer the Stat5 stability phenotype in the presence of MG132 to Stat1 through distortions of the lumbar vertebral column.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="386">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the mutation data structure suggests that just replacing the C-terminal with the Stat5 phenotype would confer the stability Stat5 phenotype in the presence of MG132 to Stat1 through distortions of the lumbar vertebral column.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="387">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the mutation data structure suggests that only the C-terminal substitution for Stat5 would confer the Stat5 stability phenotype in the presence of MG132 to State1 through distortions of the lumbar vertebral column.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="388">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the mutation data structure suggests that replacements in Gly156 and Lys165 could confer resistance to 06-BG through distortions of the lumbar vertebral column.</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="389">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the mutation data structure suggests that replacements to Gly156 and Lys165 could confer resistance to 06-BG through distortions of the lumbar vertebral column.</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="390">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the mutation data structure suggests that replacing simply the C-terminal with Stat5 would confer the Stat5 phenotype in the presence of MG132 to Stat1 through distortions of the lumbar vertebral column.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="391">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the mutation data structure suggests that replacing simply the C-terminal with Stat5 would confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 through distortions of the lumbar vertebral column.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="392">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the mutation data structure suggests that replacing simply the C-terminal with the Stat5 phenotype could confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 through distortions of the lumbar vertebral column.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="393">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the mutation data structure suggests that substituting only the C-terminal with Stat5 would confer the Stat5 phenotype in the presence of MG132 to Stat1 through distortions of the lumbar vertebral column.</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="394">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the mutation data structure suggests that substitutions in Gly156 and Lys165 could confer resistance to 06-BG through distortions of the lumbar vertebral column.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="395">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the mutation data structure suggests that substitutions to Gly156 and Lys165 could confer resistance to 06-BG through distortions of the lumbar vertebral column.</text>
                    <arg n="0">substitutions to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="396">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the mutation data structure suggests that the portion of the STATs would confer specificity to either a MAPK or a MAPK kinase substrate (MAPKAP) through distortions of the lumbar vertebral column.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="397">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the mutation data structure suggests that transfection of AGT would confer resistance to alkylation-sensitive cells through distortions of the lumbar vertebral column.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="398">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the mutation data structure suggests that transformation of GAT would confer resistance to alkylation-sensitive cells through distortions of the lumbar vertebral column.</text>
                    <arg n="0">transformation of GAT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="399">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that AGATT transfection is thought to confer resistance to alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="400">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that AGT can confer resistance to alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="401">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that AGT transformation conferred resistance on Alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="402">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that AGT transformation conferred resistance on Kaina et al., 1991 through distortions of the vertebral column.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="403">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that AGT transformation could confer resistance to alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="404">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that AGT transformation have the ability to confer resistance to alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="405">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that AGT transformation may have conferred resistance on Kaina et al., 1991 through distortions of the vertebral column.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="406">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that AGT transformation was believed to confer resistance to Kaina et al., 1991 through distortions of the vertebral column.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="407">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that AGT transition can confer resistance to Kaina et al., 1991 through distortions of the vertebral column.</text>
                    <arg n="0">AGT transition</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="408">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that AGT transition were able to confer resistance to Kaina et al., 1991 through distortions of the vertebral column.</text>
                    <arg n="0">AGT transition</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="409">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that AGT transition would confer resistance to Kaina et al., 1991 through distortions of the vertebral column.</text>
                    <arg n="0">AGT transition</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="410">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that AGT will confer resistance to alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="411">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that GAT transformation are able to confer resistance to Alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="412">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that GAT transformation can confer resistance to Alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="413">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that GAT transformation may have conferred resistance on Alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="414">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that GAT transformation may have the ability to confer resistance to Alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="415">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that GAT transformation were able to confer resistance to Alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="416">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that GAT transformation would have conferred resistance on Alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="417">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that Gly156 and Lys165 replacement is thought to confer resistance to 06-BG through distortions of the vertebral column.</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="418">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that Gly156 and Lys165 replacement may have the ability to confer resistance to 06-BG through distortions of the vertebral column.</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="419">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that Human 06-alkylguaning-DNA alkyltransferase may have the ability to confer resistance to alkylation pathways through distortions of the vertebral column.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="420">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that Human 06-alkylguaning-DNA alkyltransferase were able to confer resistance to alkylation pathways through distortions of the vertebral column.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="421">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that The STAT portion may have the ability to confer specificity to a MAPK substrate or a MAPK kinase (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="422">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that The portion of the STATs are able to confer specificity to either a MAPK or a MAPK substrat kinase (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="423">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that The portion of the STATs can confer specificity to either a MAPK or a MAPK substrat kinase (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="424">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that The portion of the STATs could confer specificity to either a MAPK or a MAPK substratum kinase (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="425">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that The portion of the STATs is thought to confer specificity to either a MAPK or a MAPK substrat kinase (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="426">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that The portion of the STATs may have the ability to confer specificity to either a MAPK or a MAPK kinase substrate (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="427">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that The portion of the STATs will confer specificity to either a MAPK or a MAPK substrat kinase (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="428">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that alkyguaning-DNA alkyltransferase are able to confer resistance to alkylation routes through distortions of the vertebral column.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="429">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that alkyguaning-DNA alkyltransferase can confer resistance to alkylation chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="430">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that alkyguaning-DNA alkyltransferase can confer resistance to alkylation routes through distortions of the vertebral column.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="431">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that alkyguaning-DNA alkyltransferase have the ability to confer resistance to alkylation routes through distortions of the vertebral column.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="432">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that alkyguaning-DNA alkyltransferase was believed to confer resistance to alkylation chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="433">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that alkyguaning-DNA alkyltransferase were able to confer resistance to alkylation routes through distortions of the vertebral column.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="434">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that alkyguaning-DNA alkyltransferase would confer resistance to alkylation chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="435">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that alkyguaning-DNA alkyltransferase would have conferred resistance on alkylation routes through distortions of the vertebral column.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="436">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that alkylation of human alkyl hydroxyl-DNA alkyltransferase have the ability to confer resistance to alkylation routes through distortions of the vertebral column.</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="437">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase are able to confer resistance to alkylation pathways through distortions of the vertebral column.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="438">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase conferred resistance on alkylation pathways through distortions of the vertebral column.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="439">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase have the ability to confer resistance to alkylation chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="440">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase have the ability to confer resistance to alkylation pathways through distortions of the vertebral column.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="441">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase were able to confer resistance to alkylation chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="442">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase would confer resistance to alkylation chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="443">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that alkylguaning-DNA alkyltransferase can confer resistance to alkylation routes through distortions of the vertebral column.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="444">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that alkylguaning-DNA alkyltransferase have the ability to confer resistance to alkylation routes through distortions of the vertebral column.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="445">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that alkylguaning-DNA alkyltransferase were able to confer resistance to alkyl ways through distortions of the vertebral column.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyl ways</arg>
                </example>
                <example src="PERMUTATE" no="446">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that alkylguaning-DNA alkyltransferase would confer resistance to alkyl ways through distortions of the vertebral column.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyl ways</arg>
                </example>
                <example src="PERMUTATE" no="447">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT may have the ability to confer resistance to alkylation through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="448">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT was believed to confer resistance to alkylation through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="449">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that alkyltransferase of 06-alkyltransferase of AGT are able to confer resistance to alkyltransferase chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="450">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that alkyltransferase of 06-alkyltransferase of AGT conferred resistance on alkyltransferase of pathways through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase of pathways</arg>
                </example>
                <example src="PERMUTATE" no="451">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that alkyltransferase of 06-alkyltransferase of AGT could confer resistance to alkylation through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="452">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that alkyltransferase of 06-alkyltransferase of AGT have the ability to confer resistance to alkylation through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="453">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that alkyltransferase of 06-alkyltransferase of AGT was believed to confer resistance to alkylation through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="454">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that alkyltransferase of 06-alkyltransferase of AGT would confer resistance to alkylation through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="455">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that alkyltransferase of 06-alkyltransferase of AGT would have conferred resistance on alkylation through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="456">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that alkyltransferase of 06-alkyltransferase of AGT would have conferred resistance on alkyltransferase chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="457">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that alkyltransferase of 06-alkyltransferase-DNA are able to confer resistance to alkyltransferase chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="458">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that alkyltransferase of 06-alkyltransferase-DNA have the ability to confer resistance to alkyltransferase chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="459">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that alkyltransferase-DNA alkyltransferase may have the ability to confer resistance to alkylation chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="460">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that alkyltransferase-DNA alkyltransferase were able to confer resistance to alkylation chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="461">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that human 06-alkylguaning-DNA alkyltransferase may have the ability to confer resistance to alkylation pathways through distortions of the vertebral column.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="462">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that human 06-alkylguaning-DNA alkyltransferase was believed to confer resistance to alkylation pathways through distortions of the vertebral column.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="463">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that human 06-alkylguaning-DNA alkyltransferase would confer resistance to alkylation pathways through distortions of the vertebral column.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="464">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that human alkyl-alkylation-DNA alkyltransferase have the ability to confer resistance to alkylation routes through distortions of the vertebral column.</text>
                    <arg n="0">human alkyl-alkylation-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="465">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that human alkyl-alkylation-DNA alkyltransferase may have conferred resistance on alkylation routes through distortions of the vertebral column.</text>
                    <arg n="0">human alkyl-alkylation-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="466">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that human alkyl-alkylation-DNA alkyltransferase was believed to confer resistance to alkylation routes through distortions of the vertebral column.</text>
                    <arg n="0">human alkyl-alkylation-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="467">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that human alkyl-alkylation-DNA alkyltransferase were able to confer resistance to alkylation routes through distortions of the vertebral column.</text>
                    <arg n="0">human alkyl-alkylation-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="468">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that human alkyl-alkylation-DNA alkyltransferase will confer resistance to alkylation routes through distortions of the vertebral column.</text>
                    <arg n="0">human alkyl-alkylation-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="469">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that just replacing C-terminus by Stat5 is thought to confer the stability phenotype Stat5 in the presence of MG132 to Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">just replacing C-terminus by Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="470">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that just replacing C-terminus by Stat5 will confer the stability phenotype Stat5 in the presence of MG132 to Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">just replacing C-terminus by Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="471">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that just replacing the C-terminal with the Stat5 phenotype could confer the stability Stat5 phenotype in the presence of MG132 to Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="472">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that just replacing the C-terminal with the Stat5 phenotype is thought to confer the stability Stat5 phenotype in the presence of MG132 to Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="473">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that just replacing the C-terminal with the Stat5 phenotype may have conferred the Stat5 stability phenotype in the presence of MG132 on Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="474">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that just replacing the C-terminal with the Stat5 phenotype will confer the stability Stat5 phenotype in the presence of MG132 to Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="475">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that only C-terminal substitution for Stat5 could confer the Stat5 phenotype of stability in the presence of MG132 to State1 through distortions of the vertebral column.</text>
                    <arg n="0">only C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="476">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that only C-terminal substitution for Stat5 was believed to confer the Stat5 phenotype of stability in the presence of MG132 to State1 through distortions of the vertebral column.</text>
                    <arg n="0">only C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="477">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that only the C-terminal substitution for Stat5 were able to confer the Stat5 stability phenotype in the presence of MG132 to State1 through distortions of the vertebral column.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="478">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that replaceing Gly156 and Lys165 could confer resistance to 06-BG through distortions of the vertebral column.</text>
                    <arg n="0">replaceing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="479">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that replaceing Gly156 and Lys165 will confer resistance to 06-BG through distortions of the vertebral column.</text>
                    <arg n="0">replaceing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="480">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that replacements in Gly156 and Lys165 may have the ability to confer resistance to 06-BG through distortions of the vertebral column.</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="481">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that replacements in Gly156 and Lys165 would have conferred resistance on 06-BG through distortions of the vertebral column.</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="482">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that replacements to Gly156 and Lys165 were able to confer resistance to 06-BG through distortions of the vertebral column.</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="483">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that replacing simply the C-terminal with Stat5 may have conferred the Stat5 phenotype in the presence of MG132 on Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="484">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that replacing simply the C-terminal with Stat5 will confer the Stat5 phenotype in the presence of MG132 to Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="485">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that replacing simply the C-terminal with the Stat5 phenotype are able to confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="486">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that replacing simply the C-terminal with the Stat5 phenotype may have the ability to confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="487">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that replacing simply the C-terminal with the Stat5 phenotype will confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="488">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance can be conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation pathways through distortions of the vertebral column.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="489">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance can be conferred by alkyguaning-DNA alkyltransferase to alkylation chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="490">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance can be conferred by alkylation of human alkyl hydroxyl-DNA alkyltransferase to alkylation routes through distortions of the vertebral column.</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="491">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance can be conferred by alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="492">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance can be conferred by alkylguaning-DNA alkyltransferase to alkyl ways through distortions of the vertebral column.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyl ways</arg>
                </example>
                <example src="PERMUTATE" no="493">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance can be conferred by alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT to alkylation through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="494">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance can be conferred by alkyltransferase of 06-alkyltransferase of AGT to alkyltransferase chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="495">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance can be conferred by alkyltransferase of 06-alkyltransferase-DNA to alkyltransferase chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="496">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance can be conferred by alkyltransferase-DNA alkyltransferase to alkylation chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="497">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance can be conferred by human 06-alkylguaning-DNA alkyltransferase to alkylation pathways through distortions of the vertebral column.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="498">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance can be conferred by replacements in Gly156 and Lys165 to 06-BG through distortions of the vertebral column.</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="499">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance can be conferred by transformation of AGT to alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="500">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance could be conferred by alkylguaning-DNA alkyltransferase to alkyl ways through distortions of the vertebral column.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyl ways</arg>
                </example>
                <example src="PERMUTATE" no="501">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance could be conferred by alkyltransferase of 06-alkyltransferase of AGT to alkyltransferase of pathways through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase of pathways</arg>
                </example>
                <example src="PERMUTATE" no="502">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance could be conferred by alkyltransferase of 06-alkyltransferase-DNA to alkyltransferase chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="503">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance could be conferred by alkyltransferase-DNA alkyltransferase to alkylation chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="504">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance could be conferred by human 06-alkylguaning-DNA alkyltransferase to alkylation pathways through distortions of the vertebral column.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="505">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance has been able to be conferred by AGT transformation to alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="506">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance has been able to be conferred by alkyguaning-DNA alkyltransferase to alkylation chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="507">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance has been able to be conferred by alkylation of human alkyl hydroxyl-DNA alkyltransferase to alkylation routes through distortions of the vertebral column.</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="508">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance has been able to be conferred by alkylguaning-DNA alkyltransferase to alkyl ways through distortions of the vertebral column.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyl ways</arg>
                </example>
                <example src="PERMUTATE" no="509">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance has been able to be conferred by alkylguaning-DNA alkyltransferase to alkylation routes through distortions of the vertebral column.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="510">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance has been conferred by alkyguaning-DNA alkyltransferase to alkylation routes through distortions of the vertebral column.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="511">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance has been conferred by alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase to alkylation pathways through distortions of the vertebral column.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="512">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance has been conferred by alkyltransferase-DNA alkyltransferase to alkylation chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="513">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance has been conferred by substitutions to Gly156 and Lys165 to 06-BG through distortions of the vertebral column.</text>
                    <arg n="0">substitutions to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="514">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance has been conferred by transformation of AGT to alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="515">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance is conferred by AGT to alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="516">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance is conferred by AGT transformation to alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="517">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance is conferred by GAT transformation to Alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="518">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance is conferred by transformation of AGT to alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="519">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance is observed to be conferred by AGATT transfection to alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="520">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance is observed to be conferred by Gly156 and Lys165 replacement to 06-BG through distortions of the vertebral column.</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="521">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance is observed to be conferred by alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase to alkylation pathways through distortions of the vertebral column.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="522">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance is observed to be conferred by alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT to alkylation through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="523">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance is observed to be conferred by replaceing Gly156 and Lys165 to 06-BG through distortions of the vertebral column.</text>
                    <arg n="0">replaceing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="524">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance is observed to be conferred by transfection of AGATT to alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="525">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance is observed to be conferred by transformation of AGT to alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="526">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance is observed to be conferred by transformation of GAT to alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">transformation of GAT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="527">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance is thought to be conferred by alkyguaning-DNA alkyltransferase on alkylation chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="528">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance is thought to be conferred by alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase on alkylation chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="529">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance is thought to be conferred by replacements in Gly156 and Lys165 on 06-BG through distortions of the vertebral column.</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="530">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance is thought to be conferred by transfection of AGT on alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="531">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance is thought to be conferred by transformation of AGT on alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="532">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance is thought to have been conferred by alkyguaning-DNA alkyltransferase to alkylation routes through distortions of the vertebral column.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="533">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance is thought to have been conferred by alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="534">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance is thought to have been conferred by alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT to alkylation through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="535">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance is thought to have been conferred by alkyltransferase of 06-alkyltransferase-DNA to alkyltransferase chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="536">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance is thought to have been conferred by replacements in Gly156 and Lys165 to 06-BG through distortions of the vertebral column.</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="537">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance is thought to have been conferred by transfection of AGATT to alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="538">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance is thought to have been conferred by transfection of AGT to alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="539">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance may have been conferred by alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="540">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance may have been conferred by alkyltransferase of 06-alkyltransferase of AGT to alkyltransferase of pathways through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase of pathways</arg>
                </example>
                <example src="PERMUTATE" no="541">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance may have been conferred by replacements in Gly156 and Lys165 to 06-BG through distortions of the vertebral column.</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="542">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance may have been conferred by transformation of AGT to alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="543">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance was able to be conferred by AGATT transfection to alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="544">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance was able to be conferred by AGT to alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="545">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance was able to be conferred by GAT transformation to Alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="546">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance was able to be conferred by alkyguaning-DNA alkyltransferase to alkylation chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="547">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance was able to be conferred by alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="548">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance was able to be conferred by alkyltransferase of 06-alkyltransferase of AGT to alkylation through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="549">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance was able to be conferred by replacements in Gly156 and Lys165 to 06-BG through distortions of the vertebral column.</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="550">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance was able to be conferred by substitutions in Gly156 and Lys165 to 06-BG through distortions of the vertebral column.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="551">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance was believed to be conferred by GAT transformation on Alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="552">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance was believed to be conferred by alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase on alkylation chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="553">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance was believed to be conferred by alkyltransferase of 06-alkyltransferase of AGT on alkyltransferase chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="554">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance was believed to be conferred by alkyltransferase of 06-alkyltransferase of AGT on alkyltransferase of pathways through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase of pathways</arg>
                </example>
                <example src="PERMUTATE" no="555">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance was believed to be conferred by alkyltransferase-DNA alkyltransferase on alkylation chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="556">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance was believed to be conferred by transfection of AGATT on alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="557">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance was believed to be conferred by transformation of AGT on alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="558">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance was conferred by AGT transition to Kaina et al., 1991 through distortions of the vertebral column.</text>
                    <arg n="0">AGT transition</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="559">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance was conferred by alkylguaning-DNA alkyltransferase to alkylation routes through distortions of the vertebral column.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="560">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance was conferred by replacements in Gly156 and Lys165 to 06-BG through distortions of the vertebral column.</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="561">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance was conferred by substitutions to Gly156 and Lys165 to 06-BG through distortions of the vertebral column.</text>
                    <arg n="0">substitutions to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="562">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance was conferred by transformation of GAT to alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">transformation of GAT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="563">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance will be conferred by AGT transition to Kaina et al., 1991 through distortions of the vertebral column.</text>
                    <arg n="0">AGT transition</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="564">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance will be conferred by GAT transformation to Alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="565">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance will be conferred by alkyltransferase of 06-alkyltransferase of AGT to alkylation through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="566">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance will be conferred by alkyltransferase of 06-alkyltransferase of AGT to alkyltransferase chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="567">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance will be conferred by substitutions in Gly156 and Lys165 to 06-BG through distortions of the vertebral column.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="568">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance will be conferred by transfection of AGT to alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="569">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance would be conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation pathways through distortions of the vertebral column.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="570">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance would be conferred by alkyguaning-DNA alkyltransferase to alkylation routes through distortions of the vertebral column.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="571">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance would be conferred by alkyltransferase-DNA alkyltransferase to alkylation chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="572">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance would be conferred by replaceing Gly156 and Lys165 to 06-BG through distortions of the vertebral column.</text>
                    <arg n="0">replaceing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="573">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance would be conferred by replacements in Gly156 and Lys165 to 06-BG through distortions of the vertebral column.</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="574">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance would be conferred by substitutions to Gly156 and Lys165 to 06-BG through distortions of the vertebral column.</text>
                    <arg n="0">substitutions to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="575">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that resistance would be conferred by transfection of AGATT to alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="576">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity can be conferred by The STAT portion to a MAPK substrate or a MAPK kinase (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="577">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity can be conferred by The portion of the STATs to either a MAPK or a MAPK kinase substrate (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="578">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity can be conferred by The portion of the STATs to either a MAPK or a MAPK substratum kinase (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="579">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity can be conferred by the part of STATs to a MAPK substrate or a MAPK kinase (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="580">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity could be conferred by The portion of the STATs to either a MAPK or a MAPK substrat kinase (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="581">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity could be conferred by The portion of the STATs to either a MAPK or a MAPK substratum kinase (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="582">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity could be conferred by the STAT part to a MAPK or a MAPK substrate kinase (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="583">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity could be conferred by the part of STATs to a MAPK substrate or a MAPK kinase (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="584">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity has been able to be conferred by the portion of the STATs to either a MAPK or a MAPK kinase substrate (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="585">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity has been conferred by The portion of the STATs to either a MAPK or a MAPK kinase substrate (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="586">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity is conferred by the STAT part to a MAPK or a MAPK substrate kinase (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="587">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity is thought to be conferred by The STAT portion on a MAPK substrate or a MAPK kinase (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="588">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity is thought to be conferred by The portion of the STATs on either a MAPK or a MAPK substratum kinase (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="589">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity is thought to be conferred by the portion of the STATs on either a MAPK or a MAPK kinase substrate (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="590">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity is thought to have been conferred by The portion of the STATs to either a MAPK or a MAPK kinase substrate (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="591">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity is thought to have been conferred by the portion of the STATs to either a MAPK or a MAPK kinase substrate (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="592">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity may have been conferred by The portion of the STATs to either a MAPK or a MAPK kinase substrate (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="593">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity may have been conferred by The portion of the STATs to either a MAPK or a MAPK substrat kinase (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="594">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity may have been conferred by The portion of the STATs to either a MAPK or a MAPK substratum kinase (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="595">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity may have been conferred by the STAT part to a MAPK or a MAPK substrate kinase (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="596">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity may have been conferred by the part of STATs to a MAPK substrate or a MAPK kinase (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="597">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity may have been conferred by the portion of the STATs to either a MAPK or a MAPK kinase substrate (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="598">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity was believed to be conferred by the STAT part on a MAPK or a MAPK substrate kinase (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="599">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity was conferred by The portion of the STATs to either a MAPK or a MAPK kinase substrate (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="600">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity would be conferred by The portion of the STATs to either a MAPK or a MAPK substrat kinase (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="601">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that stat5 phenotype of stability in the presence of MG132 is thought to have been conferred by replacing simply the C-terminal with Stat5 to Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="602">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that stat5 phenotype of stability in the presence of MG132 was believed to be conferred by replacing simply the C-terminal with Stat5 on Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="603">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that stat5 phenotype of stability in the presence of MG132 would be conferred by replacing simply the C-terminal with Stat5 to Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="604">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that substituting only the C-terminal with Stat5 are able to confer the Stat5 phenotype in the presence of MG132 to Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="605">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that substituting only the C-terminal with Stat5 may have the ability to confer the Stat5 phenotype in the presence of MG132 to Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="606">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that substitutions in Gly156 and Lys165 are able to confer resistance to 06-BG through distortions of the vertebral column.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="607">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that substitutions in Gly156 and Lys165 conferred resistance on 06-BG through distortions of the vertebral column.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="608">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that substitutions in Gly156 and Lys165 may have conferred resistance on 06-BG through distortions of the vertebral column.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="609">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that substitutions in Gly156 and Lys165 will confer resistance to 06-BG through distortions of the vertebral column.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="610">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that substitutions in Gly156 and Lys165 would have conferred resistance on 06-BG through distortions of the vertebral column.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="611">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that substitutions to Gly156 and Lys165 conferred resistance on 06-BG through distortions of the vertebral column.</text>
                    <arg n="0">substitutions to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="612">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that substitutions to Gly156 and Lys165 have the ability to confer resistance to 06-BG through distortions of the vertebral column.</text>
                    <arg n="0">substitutions to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="613">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that substitutions to Gly156 and Lys165 will confer resistance to 06-BG through distortions of the vertebral column.</text>
                    <arg n="0">substitutions to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="614">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the STAT part have the ability to confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="615">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the STAT part may have conferred specificity on a MAPK or a MAPK substrate kinase (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="616">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the STAT part were able to confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="617">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the Stat5 phenotype in the presence of MG132 could be conferred by replacing simply the C-terminal with Stat5 to Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="618">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the Stat5 phenotype in the presence of MG132 has been conferred by replacing simply the C-terminal with Stat5 to Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="619">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the Stat5 phenotype in the presence of MG132 is thought to be conferred by replacing simply the C-terminal with Stat5 on Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="620">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the Stat5 phenotype in the presence of MG132 is thought to be conferred by substituting only the C-terminal with Stat5 on Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="621">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the Stat5 phenotype in the presence of MG132 is thought to have been conferred by substituting only the C-terminal with Stat5 to Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="622">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the Stat5 phenotype of stability in the presence of MG132 can be conferred by replacing simply the C-terminal with Stat5 to Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="623">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the Stat5 phenotype of stability in the presence of MG132 could be conferred by replacing simply the C-terminal with the Stat5 phenotype to Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="624">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the Stat5 phenotype of stability in the presence of MG132 has been able to be conferred by only C-terminal substitution for Stat5 to State1 through distortions of the vertebral column.</text>
                    <arg n="0">only C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="625">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the Stat5 phenotype of stability in the presence of MG132 has been able to be conferred by replacing simply the C-terminal with the Stat5 phenotype to Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="626">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the Stat5 phenotype of stability in the presence of MG132 is observed to be conferred by replacing simply the C-terminal with Stat5 to Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="627">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the Stat5 phenotype of stability in the presence of MG132 was believed to be conferred by only C-terminal substitution for Stat5 on State1 through distortions of the vertebral column.</text>
                    <arg n="0">only C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="628">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the Stat5 phenotype of stability in the presence of MG132 was conferred by replacing simply the C-terminal with the Stat5 phenotype to Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="629">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the Stat5 phenotype of stability in the presence of MG132 will be conferred by replacing simply the C-terminal with the Stat5 phenotype to Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="630">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the Stat5 phenotype of stability in the presence of MG132 would be conferred by replacing simply the C-terminal with Stat5 to Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="631">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the Stat5 stability phenotype in the presence of MG132 can be conferred by only the C-terminal substitution for Stat5 to State1 through distortions of the vertebral column.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="632">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the Stat5 stability phenotype in the presence of MG132 has been conferred by just replacing the C-terminal with the Stat5 phenotype to Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="633">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the Stat5 stability phenotype in the presence of MG132 is conferred by only the C-terminal substitution for Stat5 to State1 through distortions of the vertebral column.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="634">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the Stat5 stability phenotype in the presence of MG132 may have been conferred by just replacing the C-terminal with the Stat5 phenotype to Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="635">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the part of STATs could confer specificity to a MAPK substrate or a MAPK kinase (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="636">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the part of STATs is thought to confer specificity to a MAPK substrate or a MAPK kinase (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="637">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the part of STATs may have the ability to confer specificity to a MAPK substrate or a MAPK kinase (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="638">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the part of STATs were able to confer specificity to a MAPK substrate or a MAPK kinase (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="639">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the part of STATs will confer specificity to a MAPK substrate or a MAPK kinase (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="640">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the portion of the STATs can confer specificity to either a MAPK or a MAPK kinase substrate (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="641">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the portion of the STATs conferred specificity on either a MAPK or a MAPK kinase substrate (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="642">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the portion of the STATs have the ability to confer specificity to either a MAPK or a MAPK kinase substrate (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="643">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the portion of the STATs may have the ability to confer specificity to either a MAPK or a MAPK kinase substrate (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="644">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the portion of the STATs would have conferred specificity on either a MAPK or a MAPK kinase substrate (MAPKAP) through distortions of the vertebral column.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="645">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the stability Stat5 phenotype in the presence of MG132 has been conferred by just replacing the C-terminal with the Stat5 phenotype to Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="646">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the stability Stat5 phenotype in the presence of MG132 is thought to be conferred by just replacing the C-terminal with the Stat5 phenotype on Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="647">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the stability phenotype Stat5 in the presence of MG132 has been conferred by just replacing C-terminus by Stat5 to Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">just replacing C-terminus by Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="648">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the stability phenotype Stat5 in the presence of MG132 was believed to be conferred by just replacing C-terminus by Stat5 on Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">just replacing C-terminus by Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="649">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that transfection of AGATT are able to confer resistance to alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="650">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that transfection of AGATT could confer resistance to alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="651">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that transfection of AGT are able to confer resistance to alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="652">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that transfection of AGT can confer resistance to alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="653">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that transfection of AGT have the ability to confer resistance to alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="654">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that transfection of AGT was believed to confer resistance to alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="655">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that transfection of AGT were able to confer resistance to alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="656">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that transfection of AGT would have conferred resistance on alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="657">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that transformation of AGT would have conferred resistance on alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="658">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that transformation of GAT can confer resistance to alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">transformation of GAT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="659">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that transformation of GAT conferred resistance on alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">transformation of GAT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="660">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that transformation of GAT could confer resistance to alkylation-sensitive cells through distortions of the vertebral column.</text>
                    <arg n="0">transformation of GAT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="661">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests the ability of alkyguaning-DNA alkyltransferase to confer resistance to alkylation chemotherapies through distortions of the vertebral column.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="662">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests the ability of alkylguaning-DNA alkyltransferase to confer resistance to alkyl ways through distortions of the vertebral column.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyl ways</arg>
                </example>
                <example src="PERMUTATE" no="663">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests the ability of just replacing C-terminus by Stat5 to confer the stability phenotype Stat5 in the presence of MG132 to Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">just replacing C-terminus by Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="664">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests the ability of only the C-terminal substitution for Stat5 to confer the Stat5 stability phenotype in the presence of MG132 to State1 through distortions of the vertebral column.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="665">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests the ability of replaceing Gly156 and Lys165 to confer resistance to 06-BG through distortions of the vertebral column.</text>
                    <arg n="0">replaceing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="666">
                    <text>In addition, EvgA overexpression could not confer resistance to a strain with tolC problems.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="667">
                    <text>In addition, EvgA overexpression may not confer resistance in a tolC-deficient strain.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="668">
                    <text>In addition, The part of STATs cannot confer specificity in a tolC-deficient strain.</text>
                    <arg n="0">The part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="669">
                    <text>In addition, The part of STATs could not confer specificity to a strain with tolC problems.</text>
                    <arg n="0">The part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="670">
                    <text>In addition, The part of TASTs cannot confer specificity to a tolC problem-strain.</text>
                    <arg n="0">The part of TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="671">
                    <text>In addition, The part of TASTs may not confer specificity to a tolC deficient strain.</text>
                    <arg n="0">The part of TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="672">
                    <text>In addition, The part of TASTs would not confer specificity in a tolC-deficient strain.</text>
                    <arg n="0">The part of TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="673">
                    <text>In addition, These mutations cannot confer resistance 06-BG in a tolC-deficient strain.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="674">
                    <text>In addition, These mutations does not confer resistance 06-BG in a tolC-deficient strain.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="675">
                    <text>In addition, These mutations is not able to confer resistance 06-BG to a strain with tolC failure.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="676">
                    <text>In addition, gene variety could not confer increased risk of diabetes to a strain with tolC problems.</text>
                    <arg n="0">gene variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="677">
                    <text>In addition, gene variety is not able to confer increased risk of diabetes in a tolC-deficient strain.</text>
                    <arg n="0">gene variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="678">
                    <text>In addition, gene variety is not able to confer increased risk of diabetes to a strain with tolC failure.</text>
                    <arg n="0">gene variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="679">
                    <text>In addition, genetic variation cannot confer increased risk of diabetes to a tolC deficient strain.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="680">
                    <text>In addition, genetic variation cannot confer increasing risk of diabetes in a tolC-deficient strain.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="681">
                    <text>In addition, genetic variation cannot confer increasing risk of diabetes to a tolC problem-strain.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="682">
                    <text>In addition, genetic variation could not confer increasing risk of diabetes in a tolC-deficient strain.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="683">
                    <text>In addition, genetic variation could not confer increasing risk of diabetes to a strain with tolC problems.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="684">
                    <text>In addition, genetic variation does not confer increasing risk of diabetes on a strain with tolC deficiencies.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="685">
                    <text>In addition, genetic variation is not able to confer increasing risk of diabetes to a strain with tolC failure.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="686">
                    <text>In addition, genetic variation may not confer increasing risk of diabetes to a tolC deficient strain.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="687">
                    <text>In addition, genetic variation was not able to confer increased risk of diabetes in a tolC-deficient strain.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="688">
                    <text>In addition, genetic variation was not able to confer increasing risk of diabetes in a tolC-deficient strain.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="689">
                    <text>In addition, genetic variety cannot confer an increased risk of diabetes to a tolC deficient strain.</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="690">
                    <text>In addition, genetic variety cannot confer increased risk of diabetes in a tolC-deficient strain.</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="691">
                    <text>In addition, genetic variety cannot confer increased risk of diabetes to a tolC deficient strain.</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="692">
                    <text>In addition, genetic variety does not confer an increased risk of diabetes in a tolC-deficient strain.</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="693">
                    <text>In addition, genetic variety is not able to confer an increased risk of diabetes in a tolC-deficient strain.</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="694">
                    <text>In addition, genetic variety may not confer an increased risk of diabetes in a tolC-deficient strain.</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="695">
                    <text>In addition, genetic variety may not confer increased risk of diabetes in a tolC-deficient strain.</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="696">
                    <text>In addition, genetic variety was not able to confer an increased risk of diabetes in a strain with tolC failure.</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="697">
                    <text>In addition, genetic variety would not confer an increased risk of diabetes in a tolC-deficient strain.</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="698">
                    <text>In addition, over expression of EvgA cannot confer resistance to a tolC deficient strain.</text>
                    <arg n="0">over expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="699">
                    <text>In addition, over expression of EvgA could not confer resistance to a strain with tolC problems.</text>
                    <arg n="0">over expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="700">
                    <text>In addition, over expression of EvgA is not able to confer resistance to a strain with tolC failure.</text>
                    <arg n="0">over expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="701">
                    <text>In addition, overexpression of EvgA does not confer resistance on a strain with tolC deficiencies.</text>
                    <arg n="0">overexpression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="702">
                    <text>In addition, part of STATs cannot confer specificity in a tolC-deficient strain.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="703">
                    <text>In addition, part of STATs could not confer specificity in a tolC-deficient strain.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="704">
                    <text>In addition, part of STATs would not confer specificity to a tolC deficient strain.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="705">
                    <text>In addition, resistance 06-BG cannot confer resistance in a tolC-deficient strain.</text>
                    <arg n="0">resistance</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="706">
                    <text>In addition, resistance 06-BG does not confer resistance on a strain with tolC deficiencies.</text>
                    <arg n="0">resistance</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="707">
                    <text>In addition, resistance 06-BG was not able to confer resistance in a strain with tolC failure.</text>
                    <arg n="0">resistance</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="708">
                    <text>In addition, resistance 06-BG would not confer resistance to a tolC deficient strain.</text>
                    <arg n="0">resistance</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="709">
                    <text>In addition, senseless alteration or frame change of the codex sequence or by cutting variants is not able to confer mutation function miss in a tolC-deficient strain.</text>
                    <arg n="0">senseless alteration or frame change of the codex sequence or by cutting variants</arg>
                    <arg n="1">mutation function miss</arg>
                </example>
                <example src="PERMUTATE" no="710">
                    <text>In addition, senseless alteration or frame change of the codex sequence or by cutting variants may not confer mutation function miss to a tolC deficient strain.</text>
                    <arg n="0">senseless alteration or frame change of the codex sequence or by cutting variants</arg>
                    <arg n="1">mutation function miss</arg>
                </example>
                <example src="PERMUTATE" no="711">
                    <text>In addition, senseless alteration or frame change of the codex sequence or by cutting variants was not able to confer mutation function miss in a tolC-deficient strain.</text>
                    <arg n="0">senseless alteration or frame change of the codex sequence or by cutting variants</arg>
                    <arg n="1">mutation function miss</arg>
                </example>
                <example src="PERMUTATE" no="712">
                    <text>In addition, six mutations cannot confer resistance 06-BG to a tolC deficient strain.</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="713">
                    <text>In addition, six mutations could not confer resistance 06-BG in a tolC-deficient strain.</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="714">
                    <text>In addition, six mutations does not confer 06-BG in a tolC-deficient strain.</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="715">
                    <text>In addition, six mutations is not able to confer resistance 06-BG in a tolC-deficient strain.</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="716">
                    <text>In addition, six mutations was not able to confer 06-BG in a strain with tolC failure.</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="717">
                    <text>In addition, the excessive expression of EvgA may not confer resistance in a tolC-deficient strain.</text>
                    <arg n="0">the excessive expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="718">
                    <text>In addition, the gene variant cannot confer an increasing risk of diabetes to a tolC problem-strain.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="719">
                    <text>In addition, the gene variant could not confer a higher risk of diabetes in a tolC-deficient strain.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="720">
                    <text>In addition, the gene variant could not confer an increasing risk of diabetes in a tolC-deficient strain.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="721">
                    <text>In addition, the gene variant does not confer an increasing risk of diabetes in a tolC-deficient strain.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="722">
                    <text>In addition, the gene variant may not confer a higher risk of diabetes in a tolC-deficient strain.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="723">
                    <text>In addition, the gene variant may not confer an increasing risk of diabetes in a tolC-deficient strain.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="724">
                    <text>In addition, the gene variant was not able to confer a higher risk of diabetes in a strain with tolC failure.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="725">
                    <text>In addition, the genetic variant is not able to confer a higher risk of diabetes in a tolC-deficient strain.</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="726">
                    <text>In addition, the genetic variant may not confer a higher risk of diabetes in a tolC-deficient strain.</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="727">
                    <text>In addition, the genetic variant may not confer an increasing risk of diabetes to a tolC deficient strain.</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="728">
                    <text>In addition, the genetic variant was not able to confer a higher risk of diabetes in a strain with tolC failure.</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="729">
                    <text>In addition, the part of STATs cannot confer specificity in a tolC-deficient strain.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="730">
                    <text>In addition, the part of STATs could not confer specificity to a strain with tolC problems.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="731">
                    <text>In addition, the part of STATs may not confer specificity in a tolC-deficient strain.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="732">
                    <text>In addition, the part of STATs would not confer specificity in a tolC-deficient strain.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="733">
                    <text>In addition, the part of STATs would not confer specificity to a tolC deficient strain.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="734">
                    <text>In addition, the part of the STATs could not confer specificity in a tolC-deficient strain.</text>
                    <arg n="0">the part of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="735">
                    <text>In addition, the part of the STATs does not confer specificity in a tolC-deficient strain.</text>
                    <arg n="0">the part of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="736">
                    <text>In addition, the part of the STATs does not confer specificity on a strain with tolC deficiencies.</text>
                    <arg n="0">the part of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="737">
                    <text>In addition, the part of the STATs is not able to confer specificity to a strain with tolC failure.</text>
                    <arg n="0">the part of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="738">
                    <text>In addition, the part of the TASTs cannot confer specificity to a tolC problem-strain.</text>
                    <arg n="0">the part of the TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="739">
                    <text>In addition, the part of the TASTs was not able to confer specificity in a tolC-deficient strain.</text>
                    <arg n="0">the part of the TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="740">
                    <text>In addition, the portion of the STATs cannot confer specificity to a tolC deficient strain.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="741">
                    <text>In addition, these mutations cannot confer 06-BG resistant to a tolC problem-strain.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistant</arg>
                </example>
                <example src="PERMUTATE" no="742">
                    <text>In addition, these mutations cannot confer 06-BG to a tolC problem-strain.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="743">
                    <text>In addition, these mutations cannot confer resistant to Gly160His and Gly160Arg to a tolC problem-strain.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistant to Gly160His and Gly160Arg</arg>
                </example>
                <example src="PERMUTATE" no="744">
                    <text>In addition, these mutations could not confer 06-BG resistant to a strain with tolC problems.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistant</arg>
                </example>
                <example src="PERMUTATE" no="745">
                    <text>In addition, these mutations could not confer Xu-Welliver et al., 1999a to a strain with tolC problems.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">Xu-Welliver et al., 1999a</arg>
                </example>
                <example src="PERMUTATE" no="746">
                    <text>In addition, these mutations could not confer resistance of 06-BG to a strain with tolC problems.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance of 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="747">
                    <text>In addition, these mutations does not confer 06-BG on a strain with tolC deficiencies.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="748">
                    <text>In addition, these mutations does not confer resistance 06-BG in a tolC-deficient strain.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="749">
                    <text>In addition, these mutations does not confer resistance 06-BG on a strain with tolC deficiencies.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="750">
                    <text>In addition, these mutations is not able to confer resistance 06-BG to a strain with tolC failure.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="751">
                    <text>In addition, these mutations may not confer resistance 06-BG to a tolC deficient strain.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="752">
                    <text>In addition, these mutations may not confer resistance of 06-BG in a tolC-deficient strain.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance of 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="753">
                    <text>In addition, these mutations was not able to confer resistance 06-BG in a strain with tolC failure.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="754">
                    <text>In addition, these mutations would not confer 06-BG in a tolC-deficient strain.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="755">
                    <text>In addition, these mutations would not confer resistance of 06-BG in a tolC-deficient strain.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance of 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="756">
                    <text>In itself, 06-BG can be not conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="757">
                    <text>In itself, 06-BG could be not conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="758">
                    <text>In itself, 06-BG is not capable of being conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="759">
                    <text>In itself, 06-BG may be no has been conferred by six mutations.</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="760">
                    <text>In itself, 06-BG resistant is thought to be not conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistant</arg>
                </example>
                <example src="PERMUTATE" no="761">
                    <text>In itself, 06-BG resistant may be no has been conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistant</arg>
                </example>
                <example src="PERMUTATE" no="762">
                    <text>In itself, 06-BG resistant was not able to be conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistant</arg>
                </example>
                <example src="PERMUTATE" no="763">
                    <text>In itself, 06-BG resistant will be conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistant</arg>
                </example>
                <example src="PERMUTATE" no="764">
                    <text>In itself, 06-BG resistant would be conferred no by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistant</arg>
                </example>
                <example src="PERMUTATE" no="765">
                    <text>In itself, EvgA overexpression is not able to confer resistance.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="766">
                    <text>In itself, EvgA overexpression is thought to be not to confer resistance.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="767">
                    <text>In itself, EvgA overexpression will have conferred no resistance.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="768">
                    <text>In itself, The part of STATs is not able to confer specificity.</text>
                    <arg n="0">The part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="769">
                    <text>In itself, The part of STATs was not able to confer specificity.</text>
                    <arg n="0">The part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="770">
                    <text>In itself, The part of STATs will have conferred no specificity.</text>
                    <arg n="0">The part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="771">
                    <text>In itself, The part of TASTs is thought to be not to confer specificity.</text>
                    <arg n="0">The part of TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="772">
                    <text>In itself, These mutations conferred no resistance 06-BG.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="773">
                    <text>In itself, These mutations is thought to be not to confer resistance 06-BG.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="774">
                    <text>In itself, These mutations will confer no resistance 06-BG.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="775">
                    <text>In itself, Xu-Welliver et al., 1999a would be conferred no by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">Xu-Welliver et al., 1999a</arg>
                </example>
                <example src="PERMUTATE" no="776">
                    <text>In itself, a higher risk of diabetes can be not conferred by the genetic variant.</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="777">
                    <text>In itself, a higher risk of diabetes could be not conferred by the genetic variant.</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="778">
                    <text>In itself, a higher risk of diabetes is not capable of being conferred by the genetic variant.</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="779">
                    <text>In itself, a higher risk of diabetes is not conferred by the genetic variant.</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="780">
                    <text>In itself, a higher risk of diabetes may be no has been conferred by the genetic variant.</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="781">
                    <text>In itself, a higher risk of diabetes will be conferred by the gene variant.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="782">
                    <text>In itself, a higher risk of diabetes will be not conferred by the gene variant.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="783">
                    <text>In itself, an increased risk of diabetes may be no has been conferred by genetic variety.</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="784">
                    <text>In itself, an increased risk of diabetes was not conferred by genetic variety.</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="785">
                    <text>In itself, an increasing risk of diabetes could be not conferred by the gene variant.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="786">
                    <text>In itself, an increasing risk of diabetes is not capable of being conferred by the gene variant.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="787">
                    <text>In itself, an increasing risk of diabetes is thought to be not conferred by the gene variant.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="788">
                    <text>In itself, an increasing risk of diabetes was not conferred by the gene variant.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="789">
                    <text>In itself, an increasing risk of diabetes will be conferred by the genetic variant.</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="790">
                    <text>In itself, an increasing risk of diabetes will be not conferred by the gene variant.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="791">
                    <text>In itself, gene variety would confer no increased risk of diabetes.</text>
                    <arg n="0">gene variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="792">
                    <text>In itself, genetic variation is not able to confer increasing risk of diabetes.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="793">
                    <text>In itself, genetic variation was believed to be not to confer increased risk of diabetes.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="794">
                    <text>In itself, genetic variation was not able to confer increased risk of diabetes.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="795">
                    <text>In itself, genetic variation would confer no increasing risk of diabetes.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="796">
                    <text>In itself, genetic variety is not able to confer increased risk of diabetes.</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="797">
                    <text>In itself, genetic variety will have conferred no an increased risk of diabetes.</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="798">
                    <text>In itself, increased risk of diabetes can be not conferred by genetic variation.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="799">
                    <text>In itself, increased risk of diabetes is not conferred by gene variety.</text>
                    <arg n="0">gene variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="800">
                    <text>In itself, increased risk of diabetes is not conferred by genetic variety.</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="801">
                    <text>In itself, increased risk of diabetes may be no has been conferred by genetic variety.</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="802">
                    <text>In itself, increased risk of diabetes was not able to be conferred by genetic variation.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="803">
                    <text>In itself, increased risk of diabetes was not conferred by gene variety.</text>
                    <arg n="0">gene variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="804">
                    <text>In itself, increased risk of diabetes will be conferred by gene variety.</text>
                    <arg n="0">gene variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="805">
                    <text>In itself, increased risk of diabetes will be conferred by genetic variation.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="806">
                    <text>In itself, increased risk of diabetes would be conferred no by genetic variation.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="807">
                    <text>In itself, increasing risk of diabetes is not capable of being conferred by genetic variation.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="808">
                    <text>In itself, increasing risk of diabetes may be no has been conferred by genetic variation.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="809">
                    <text>In itself, increasing risk of diabetes was not conferred by genetic variation.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="810">
                    <text>In itself, increasing risk of diabetes will be not conferred by genetic variation.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="811">
                    <text>In itself, mutation function miss could be not conferred by senseless alteration or frame change of the codex sequence or by cutting variants.</text>
                    <arg n="0">senseless alteration or frame change of the codex sequence or by cutting variants</arg>
                    <arg n="1">mutation function miss</arg>
                </example>
                <example src="PERMUTATE" no="812">
                    <text>In itself, mutation function miss is not capable of being conferred by senseless alteration or frame change of the codex sequence or by cutting variants.</text>
                    <arg n="0">senseless alteration or frame change of the codex sequence or by cutting variants</arg>
                    <arg n="1">mutation function miss</arg>
                </example>
                <example src="PERMUTATE" no="813">
                    <text>In itself, mutation function miss is not conferred by senseless alteration or frame change of the codex sequence or by cutting variants.</text>
                    <arg n="0">senseless alteration or frame change of the codex sequence or by cutting variants</arg>
                    <arg n="1">mutation function miss</arg>
                </example>
                <example src="PERMUTATE" no="814">
                    <text>In itself, mutation function miss may be no has been conferred by senseless alteration or frame change of the codex sequence or by cutting variants.</text>
                    <arg n="0">senseless alteration or frame change of the codex sequence or by cutting variants</arg>
                    <arg n="1">mutation function miss</arg>
                </example>
                <example src="PERMUTATE" no="815">
                    <text>In itself, mutation function miss was not conferred by senseless alteration or frame change of the codex sequence or by cutting variants.</text>
                    <arg n="0">senseless alteration or frame change of the codex sequence or by cutting variants</arg>
                    <arg n="1">mutation function miss</arg>
                </example>
                <example src="PERMUTATE" no="816">
                    <text>In itself, mutation function miss would be conferred no by senseless alteration or frame change of the codex sequence or by cutting variants.</text>
                    <arg n="0">senseless alteration or frame change of the codex sequence or by cutting variants</arg>
                    <arg n="1">mutation function miss</arg>
                </example>
                <example src="PERMUTATE" no="817">
                    <text>In itself, over expression of EvgA would confer no resistance.</text>
                    <arg n="0">over expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="818">
                    <text>In itself, part of STATs conferred no specificity.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="819">
                    <text>In itself, resistance 06-BG can be not conferred by six mutations.</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="820">
                    <text>In itself, resistance 06-BG could be not conferred by resistance.</text>
                    <arg n="0">resistance</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="821">
                    <text>In itself, resistance 06-BG could be not conferred by resistances.</text>
                    <arg n="0">resistances</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="822">
                    <text>In itself, resistance 06-BG is thought to be not conferred by These mutations.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="823">
                    <text>In itself, resistance 06-BG is thought to be not conferred by resistances.</text>
                    <arg n="0">resistances</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="824">
                    <text>In itself, resistance 06-BG may be no has been conferred by These mutations.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="825">
                    <text>In itself, resistance 06-BG may be no has been conferred by resistances.</text>
                    <arg n="0">resistances</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="826">
                    <text>In itself, resistance 06-BG was not able to be conferred by These mutations.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="827">
                    <text>In itself, resistance 06-BG was not able to be conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="828">
                    <text>In itself, resistance 06-BG was not conferred by resistances.</text>
                    <arg n="0">resistances</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="829">
                    <text>In itself, resistance 06-BG will be conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="830">
                    <text>In itself, resistance 06-BG will be not conferred by resistances.</text>
                    <arg n="0">resistances</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="831">
                    <text>In itself, resistance could be not conferred by the excessive expression of EvgA.</text>
                    <arg n="0">the excessive expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="832">
                    <text>In itself, resistance is not conferred by over expression of EvgA.</text>
                    <arg n="0">over expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="833">
                    <text>In itself, resistance is thought to be not conferred by over expression of EvgA.</text>
                    <arg n="0">over expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="834">
                    <text>In itself, resistance of 06-BG is not conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance of 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="835">
                    <text>In itself, resistance of 06-BG was not able to be conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance of 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="836">
                    <text>In itself, resistance of 06-BG will be conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance of 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="837">
                    <text>In itself, resistance of 06-BG will be not conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance of 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="838">
                    <text>In itself, resistance was not conferred by the excessive expression of EvgA.</text>
                    <arg n="0">the excessive expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="839">
                    <text>In itself, resistance will be not conferred by overexpression of EvgA.</text>
                    <arg n="0">overexpression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="840">
                    <text>In itself, resistant to Gly160His and Gly160Arg may be no has been conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistant to Gly160His and Gly160Arg</arg>
                </example>
                <example src="PERMUTATE" no="841">
                    <text>In itself, resistant to Gly160His and Gly160Arg was not able to be conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistant to Gly160His and Gly160Arg</arg>
                </example>
                <example src="PERMUTATE" no="842">
                    <text>In itself, resistant to Gly160His and Gly160Arg would be conferred no by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistant to Gly160His and Gly160Arg</arg>
                </example>
                <example src="PERMUTATE" no="843">
                    <text>In itself, senseless alteration or frame change of the codex sequence or by cutting variants was not able to confer mutation function miss.</text>
                    <arg n="0">senseless alteration or frame change of the codex sequence or by cutting variants</arg>
                    <arg n="1">mutation function miss</arg>
                </example>
                <example src="PERMUTATE" no="844">
                    <text>In itself, senseless alteration or frame change of the codex sequence or by cutting variants will have conferred no mutation function miss.</text>
                    <arg n="0">senseless alteration or frame change of the codex sequence or by cutting variants</arg>
                    <arg n="1">mutation function miss</arg>
                </example>
                <example src="PERMUTATE" no="845">
                    <text>In itself, six mutations is not able to confer resistance 06-BG.</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="846">
                    <text>In itself, six mutations is thought to be not to confer 06-BG.</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="847">
                    <text>In itself, six mutations would confer no 06-BG.</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="848">
                    <text>In itself, specificity is not capable of being conferred by part of STATs.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="849">
                    <text>In itself, specificity may be no has been conferred by part of STATs.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="850">
                    <text>In itself, specificity may be no has been conferred by the portion of the STATs.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="851">
                    <text>In itself, specificity was not able to be conferred by The part of TASTs.</text>
                    <arg n="0">The part of TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="852">
                    <text>In itself, specificity was not conferred by The part of TASTs.</text>
                    <arg n="0">The part of TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="853">
                    <text>In itself, specificity will be conferred by part of STATs.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="854">
                    <text>In itself, specificity will be conferred by the portion of the STATs.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="855">
                    <text>In itself, specificity will be not conferred by the part of the TASTs.</text>
                    <arg n="0">the part of the TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="856">
                    <text>In itself, specificity will be not conferred by the portion of the STATs.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="857">
                    <text>In itself, specificity would be conferred no by the part of the STATs.</text>
                    <arg n="0">the part of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="858">
                    <text>In itself, the 06-BG was believed to be not conferred by six mutations.</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="859">
                    <text>In itself, the 06-BG was believed to be not conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="860">
                    <text>In itself, the gene variant is thought to be not to confer a higher risk of diabetes.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="861">
                    <text>In itself, the gene variant will confer no a higher risk of diabetes.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="862">
                    <text>In itself, the gene variant will confer no an increasing risk of diabetes.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="863">
                    <text>In itself, the gene variant will have conferred no a higher risk of diabetes.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="864">
                    <text>In itself, the genetic variant conferred no an increasing risk of diabetes.</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="865">
                    <text>In itself, the genetic variant was not able to confer an increasing risk of diabetes.</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="866">
                    <text>In itself, the part of STATs was not able to confer specificity.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="867">
                    <text>In itself, the part of STATs would confer no specificity.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="868">
                    <text>In itself, the part of the TASTs would confer no specificity.</text>
                    <arg n="0">the part of the TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="869">
                    <text>In itself, the portion of the STATs conferred no specificity.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="870">
                    <text>In itself, the portion of the STATs is not able to confer specificity.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="871">
                    <text>In itself, the resistance 06-BG was believed to be not conferred by These mutations.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="872">
                    <text>In itself, the resistance 06-BG was believed to be not conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="873">
                    <text>In itself, the resistance of 06-BG was believed to be not conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance of 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="874">
                    <text>In itself, the resistance was believed to be not conferred by overexpression of EvgA.</text>
                    <arg n="0">overexpression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="875">
                    <text>In itself, the resistant to Gly160His and Gly160Arg was believed to be not conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistant to Gly160His and Gly160Arg</arg>
                </example>
                <example src="PERMUTATE" no="876">
                    <text>In itself, the specificity was believed to be not conferred by The part of STATs.</text>
                    <arg n="0">The part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="877">
                    <text>In itself, these mutations conferred no 06-BG resistant.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistant</arg>
                </example>
                <example src="PERMUTATE" no="878">
                    <text>In itself, these mutations conferred no Xu-Welliver et al., 1999a.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">Xu-Welliver et al., 1999a</arg>
                </example>
                <example src="PERMUTATE" no="879">
                    <text>In itself, these mutations conferred no resistance 06-BG.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="880">
                    <text>In itself, these mutations conferred no resistance of 06-BG.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance of 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="881">
                    <text>In itself, these mutations is thought to be not to confer 06-BG resistant.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistant</arg>
                </example>
                <example src="PERMUTATE" no="882">
                    <text>In itself, these mutations is thought to be not to confer resistance of 06-BG.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance of 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="883">
                    <text>In itself, these mutations is thought to be not to confer resistant to Gly160His and Gly160Arg.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistant to Gly160His and Gly160Arg</arg>
                </example>
                <example src="PERMUTATE" no="884">
                    <text>In itself, these mutations was believed to be not to confer 06-BG resistant.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistant</arg>
                </example>
                <example src="PERMUTATE" no="885">
                    <text>In itself, these mutations was believed to be not to confer Xu-Welliver et al., 1999a.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">Xu-Welliver et al., 1999a</arg>
                </example>
                <example src="PERMUTATE" no="886">
                    <text>In itself, these mutations was believed to be not to confer resistance of 06-BG.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance of 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="887">
                    <text>In itself, these mutations will confer no 06-BG resistant.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistant</arg>
                </example>
                <example src="PERMUTATE" no="888">
                    <text>In itself, these mutations will have conferred no 06-BG.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="889">
                    <text>Increased AGT levels are associated with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGATT transfection to confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="890">
                    <text>Increased AGT levels are associated with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT transformation to confer resistance to Kaina et al., 1991 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="891">
                    <text>Increased AGT levels are associated with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and Gly156 and Lys165 replacement to confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="892">
                    <text>Increased AGT levels are associated with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and Human 06-alkylguaning-DNA alkyltransferase to confer resistance to alkylation pathways (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="893">
                    <text>Increased AGT levels are associated with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyguaning-DNA alkyltransferase to confer resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="894">
                    <text>Increased AGT levels are associated with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase to confer resistance to alkylation pathways (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="895">
                    <text>Increased AGT levels are associated with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkylguaning-DNA alkyltransferase to confer resistance to alkyl ways (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyl ways</arg>
                </example>
                <example src="PERMUTATE" no="896">
                    <text>Increased AGT levels are associated with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyltransferase of 06-alkyltransferase of AGT to confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="897">
                    <text>Increased AGT levels are associated with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyltransferase-DNA alkyltransferase to confer resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="898">
                    <text>Increased AGT levels are associated with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and replaceing Gly156 and Lys165 to confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">replaceing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="899">
                    <text>Increased AGT levels are associated with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and replaceing Gly156 and Lys165 to confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">replaceing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="900">
                    <text>Increased AGT levels are associated with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and replacements in Gly156 and Lys165 to confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="901">
                    <text>Increased AGT levels are associated with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance can be conferred by AGATT transfection on alkylation-sensitive cells, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="902">
                    <text>Increased AGT levels are associated with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance can be conferred by AGT transformation on Alkylation-sensitive cells, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="903">
                    <text>Increased AGT levels are associated with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance can be conferred by Gly156 and Lys165 replacement on 06-BG, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="904">
                    <text>Increased AGT levels are associated with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance can be conferred by alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase on alkylation pathways, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="905">
                    <text>Increased AGT levels are associated with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance can be conferred by alkyltransferase of 06-alkyltransferase of AGT on alkylation, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="906">
                    <text>Increased AGT levels are associated with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance can be conferred by alkyltransferase of 06-alkyltransferase of AGT on alkyltransferase chemotherapies, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="907">
                    <text>Increased AGT levels are associated with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance can be conferred by alkyltransferase of 06-alkyltransferase-DNA on alkyltransferase chemotherapies, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="908">
                    <text>Increased AGT levels are associated with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance can be conferred by replaceing Gly156 and Lys165 on 06-BG, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">replaceing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="909">
                    <text>Increased AGT levels are associated with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance can be conferred by replacements to Gly156 and Lys165 on 06-BG, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="910">
                    <text>Increased AGT levels are associated with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance is conferred by alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase on alkylation pathways, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="911">
                    <text>Increased AGT levels are associated with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance is conferred by alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT on alkylation, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="912">
                    <text>Increased AGT levels are associated with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance is conferred by alkyltransferase of 06-alkyltransferase of AGT on alkyltransferase of pathways, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase of pathways</arg>
                </example>
                <example src="PERMUTATE" no="913">
                    <text>Increased AGT levels are associated with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance is conferred by alkyltransferase of 06-alkyltransferase-DNA on alkyltransferase chemotherapies, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="914">
                    <text>Increased AGT levels are associated with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance is conferred by substitutions in Gly156 and Lys165 on 06-BG, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="915">
                    <text>Increased AGT levels are associated with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance is conferred by substitutions to Gly156 and Lys165 on 06-BG, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">substitutions to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="916">
                    <text>Increased AGT levels are associated with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance is conferred by transfection of AGT on alkylation-sensitive cells, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="917">
                    <text>Increased AGT levels are associated with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance is conferred by transformation of AGT on alkylation-sensitive cells, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="918">
                    <text>Increased AGT levels are associated with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and substitutions to Gly156 and Lys165 to confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">substitutions to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="919">
                    <text>Increased AGT levels are associated with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and substitutions to Gly156 and Lys165 to confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="920">
                    <text>Increased AGT levels are associated with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and transfection of AGT to confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="921">
                    <text>Increased AGT levels are associated with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and The portion of the STATs to confer resistance to either a MAPK or a MAPK substrat kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="922">
                    <text>Increased AGT levels are associated with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and The portion of the STATs to confer resistance to either a MAPK or a MAPK substratum kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="923">
                    <text>Increased AGT levels are associated with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance can be conferred by The STAT portion on a MAPK substrate or a MAPK kinase (MAPKAP), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="924">
                    <text>Increased AGT levels are associated with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance is conferred by The STAT portion on a MAPK substrate or a MAPK kinase (MAPKAP), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="925">
                    <text>Increased AGT levels are associated with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance is conferred by the STAT part on a MAPK or a MAPK substrate kinase (MAPKAP), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="926">
                    <text>Increased AGT levels are associated with acquired alkylation the Stat5 stability phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and just replacing the C-terminal with the Stat5 phenotype to confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="927">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGATT transfection can confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="928">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGATT transfection could confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in A1 treatment (resistance).</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="929">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGATT transfection could confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in the treatment resistance.</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="930">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGATT transfection may have conferred resistance on alkylation-sensitive cells, demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="931">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGATT transfection will conferred resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="932">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGATT transfection would confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="933">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT may have conferred resistance on alkylation-sensitive cells, demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="934">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT transformation could confer resistance to Kaina et al., 1991 (Kaina et al., 1991), demonstrating the role of AGT in the treatment resistance.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="935">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT transformation may confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="936">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT transformation may have conferred resistance on Alkylation-sensitive cells, demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="937">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT transformation would confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="938">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT transition will conferred resistance to Kaina et al., 1991 (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">AGT transition</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="939">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT transition will conferred resistance to Kaina et al., 1991 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">AGT transition</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="940">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT will conferred resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="941">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and GAT transformation may have conferred resistance on Alkylation-sensitive cells, demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="942">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and Gly156 and Lys165 replacement will conferred resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="943">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and Human 06-alkylguaning-DNA alkyltransferase could confer resistance to alkylation pathways (Kaina et al., 1991), demonstrating the role of AGT in A1 treatment (resistance).</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="944">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and Human 06-alkylguaning-DNA alkyltransferase would confer resistance to alkylation pathways (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="945">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyguaning-DNA alkyltransferase may confer resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="946">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyguaning-DNA alkyltransferase will conferred resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="947">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyguaning-DNA alkyltransferase will conferred resistance to alkylation routes (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="948">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyguaning-DNA alkyltransferase would confer resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="949">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkylation of human alkyl hydroxyl-DNA alkyltransferase could confer resistance to alkylation routes (Kaina et al., 1991), demonstrating the role of AGT in the treatment resistance.</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="950">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkylation of human alkyl hydroxyl-DNA alkyltransferase may confer resistance to alkylation routes (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="951">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkylation of human alkyl hydroxyl-DNA alkyltransferase would confer resistance to alkylation routes (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="952">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase can confer resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="953">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase may confer resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="954">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkylguaning-DNA alkyltransferase may confer resistance to alkyl ways (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyl ways</arg>
                </example>
                <example src="PERMUTATE" no="955">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkylguaning-DNA alkyltransferase may confer resistance to alkylation routes (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="956">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkylguaning-DNA alkyltransferase would confer resistance to alkylation routes (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="957">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT may have conferred resistance on alkylation, demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="958">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT would confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="959">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyltransferase of 06-alkyltransferase of AGT may confer resistance to alkyltransferase chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="960">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyltransferase of 06-alkyltransferase of AGT may have conferred resistance on alkyltransferase chemotherapies, demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="961">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyltransferase of 06-alkyltransferase of AGT will conferred resistance to alkyltransferase of pathways (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase of pathways</arg>
                </example>
                <example src="PERMUTATE" no="962">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyltransferase of 06-alkyltransferase-DNA may confer resistance to alkyltransferase chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="963">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyltransferase-DNA alkyltransferase will conferred resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="964">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and human 06-alkylguaning-DNA alkyltransferase could confer resistance to alkylation pathways (Kaina et al., 1991), demonstrating the role of AGT in A1 treatment (resistance).</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="965">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and human 06-alkylguaning-DNA alkyltransferase will conferred resistance to alkylation pathways (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="966">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and human alkyl-alkylation-DNA alkyltransferase can confer resistance to alkylation routes (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">human alkyl-alkylation-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="967">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and human alkyl-alkylation-DNA alkyltransferase could confer resistance to alkylation routes (Kaina et al., 1991), demonstrating the role of AGT in A1 treatment (resistance).</text>
                    <arg n="0">human alkyl-alkylation-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="968">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and replaceing Gly156 and Lys165 will conferred resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">replaceing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="969">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and replacements in Gly156 and Lys165 will conferred resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="970">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and replacements to Gly156 and Lys165 may confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="971">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and replacements to Gly156 and Lys165 may have conferred resistance on 06-BG, demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="972">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and replacements to Gly156 and Lys165 will conferred resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="973">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and replacing Gly156 and Lys165 could confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in the treatment resistance.</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="974">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and replacing Gly156 and Lys165 will conferred resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="975">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and replacing Gly156 and Lys165 would confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="976">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and substitutions in Gly156 and Lys165 could confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in the treatment resistance.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="977">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and substitutions in Gly156 and Lys165 may confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="978">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and substitutions to Gly156 and Lys165 can confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">substitutions to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="979">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and transfection of AGATT will conferred resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="980">
                    <text>Increased AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and transfection of AGT may have conferred resistance on alkylation-sensitive cells, demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="981">
                    <text>Increased AGT levels in parallel to acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and The STAT portion could confer resistance to a MAPK substrate or a MAPK kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in A1 treatment (resistance).</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="982">
                    <text>Increased AGT levels in parallel to acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and The portion of the STATs can confer resistance to either a MAPK or a MAPK substratum kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="983">
                    <text>Increased AGT levels in parallel to acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and The portion of the STATs may confer resistance to either a MAPK or a MAPK kinase substrate (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="984">
                    <text>Increased AGT levels in parallel to acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and The portion of the STATs may have conferred resistance on either a MAPK or a MAPK substratum kinase (MAPKAP), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="985">
                    <text>Increased AGT levels in parallel to acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and The portion of the STATs will conferred resistance to either a MAPK or a MAPK kinase substrate (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="986">
                    <text>Increased AGT levels in parallel to acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and The portion of the STATs will conferred resistance to either a MAPK or a MAPK substrat kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="987">
                    <text>Increased AGT levels in parallel to acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and The portion of the STATs will conferred resistance to either a MAPK or a MAPK substratum kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="988">
                    <text>Increased AGT levels in parallel to acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the STAT part could confer resistance to a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in A1 treatment (resistance).</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="989">
                    <text>Increased AGT levels in parallel to acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the STAT part could confer resistance to a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in the treatment resistance.</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="990">
                    <text>Increased AGT levels in parallel to acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the STAT part would confer resistance to a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="991">
                    <text>Increased AGT levels in parallel to acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the part of STATs will conferred resistance to a MAPK substrate or a MAPK kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="992">
                    <text>Increased AGT levels in parallel to acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the portion of the STATs could confer resistance to either a MAPK or a MAPK kinase substrate (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in the treatment resistance.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="993">
                    <text>Increased AGT levels in parallel to acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the portion of the STATs may have conferred resistance on either a MAPK or a MAPK kinase substrate (MAPKAP), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="994">
                    <text>Increased AGT levels in parallel to acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and replacing simply the C-terminal with Stat5 will conferred resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="995">
                    <text>Increased AGT levels in parallel to acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and substituting only the C-terminal with Stat5 can confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="996">
                    <text>Increased AGT levels in parallel to acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and substituting only the C-terminal with Stat5 may have conferred resistance on Stat1, demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="997">
                    <text>Increased AGT levels in parallel to acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and substituting only the C-terminal with Stat5 will conferred resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="998">
                    <text>Increased AGT levels in parallel to acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and substituting only the C-terminal with Stat5 would confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="999">
                    <text>Increased AGT levels in parallel to acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and only C-terminal substitution for Stat5 could confer resistance to State1 (Kaina et al., 1991), demonstrating the role of AGT in A1 treatment (resistance).</text>
                    <arg n="0">only C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="1000">
                    <text>Increased AGT levels in parallel to acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and only C-terminal substitution for Stat5 may have conferred resistance on State1, demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">only C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="1001">
                    <text>Increased AGT levels in parallel to acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and replacing simply the C-terminal with Stat5 can confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1002">
                    <text>Increased AGT levels in parallel to acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and replacing simply the C-terminal with Stat5 could confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in A1 treatment (resistance).</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1003">
                    <text>Increased AGT levels in parallel to acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and replacing simply the C-terminal with Stat5 may have conferred resistance on Stat1, demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1004">
                    <text>Increased AGT levels in parallel to acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and replacing simply the C-terminal with the Stat5 phenotype could confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in the treatment resistance.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1005">
                    <text>Increased AGT levels in parallel to acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and replacing simply the C-terminal with the Stat5 phenotype would confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1006">
                    <text>Increased AGT levels in parallel to acquired alkylation the Stat5 stability phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and only the C-terminal substitution for Stat5 could confer resistance to State1 (Kaina et al., 1991), demonstrating the role of AGT in A1 treatment (resistance).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="1007">
                    <text>Increased AGT levels in parallel to acquired alkylation the stability phenotype Stat5 in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and just replacing C-terminus by Stat5 could confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in A1 treatment (resistance).</text>
                    <arg n="0">just replacing C-terminus by Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1008">
                    <text>Increased AGT levels in parallel to acquired alkylation the stability phenotype Stat5 in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and just replacing C-terminus by Stat5 could confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in the treatment resistance.</text>
                    <arg n="0">just replacing C-terminus by Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1009">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and A1 (AGT transfection) are able to be conferred by AGATT transfection to alkylation-sensitive cells, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1010">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and A1 (AGT transfection) are able to be conferred by AGT to alkylation-sensitive cells, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1011">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and A1 (AGT transfection) are able to be conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation pathways, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1012">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and A1 (AGT transfection) are able to be conferred by alkylguaning-DNA alkyltransferase to alkyl ways, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyl ways</arg>
                </example>
                <example src="PERMUTATE" no="1013">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and A1 (AGT transfection) are able to be conferred by alkyltransferase of 06-alkyltransferase of AGT to alkyltransferase chemotherapies, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1014">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and A1 (AGT transfection) are able to be conferred by alkyltransferase of 06-alkyltransferase of AGT to alkyltransferase of pathways, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase of pathways</arg>
                </example>
                <example src="PERMUTATE" no="1015">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and A1 (AGT transfection) are able to be conferred by human 06-alkylguaning-DNA alkyltransferase to alkylation pathways, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1016">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and A1 (AGT transfection) are able to be conferred by replaceing Gly156 and Lys165 to 06-BG, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">replaceing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1017">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and A1 (AGT transfection) are able to be conferred by replacing Gly156 and Lys165 to 06-BG, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1018">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGATT transfection conferred resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1019">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGATT transfection were able to confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1020">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT conferred resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1021">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT have the ability to confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1022">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT transition are able to confer resistance to Kaina et al., 1991 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">AGT transition</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="1023">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT were observed to confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1024">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT will confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1025">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and GAT transformation conferred resistance to Alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1026">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and GAT transformation may confer resistance to Alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1027">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and Gly156 and Lys165 replacement conferred resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1028">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and Gly156 and Lys165 replacement were observed to confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1029">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and Gly156 and Lys165 replacement will confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1030">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and Human 06-alkylguaning-DNA alkyltransferase will confer resistance to alkylation pathways (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1031">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyguaning-DNA alkyltransferase may confer resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1032">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyguaning-DNA alkyltransferase may confer resistance to alkylation routes (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1033">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkylation of human alkyl hydroxyl-DNA alkyltransferase are able to confer resistance to alkylation routes (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1034">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkylation of human alkyl hydroxyl-DNA alkyltransferase conferred resistance to alkylation routes (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1035">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkylation of human alkyl hydroxyl-DNA alkyltransferase have the ability to confer resistance to alkylation routes (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1036">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase have the ability to confer resistance to alkylation pathways (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1037">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase were able to confer resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1038">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase were observed to confer resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1039">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase were observed to confer resistance to alkylation pathways (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1040">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkylguaning-DNA alkyltransferase were able to confer resistance to alkyl ways (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyl ways</arg>
                </example>
                <example src="PERMUTATE" no="1041">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT conferred resistance on alkylation, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="1042">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT were able to confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="1043">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT were observed to confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="1044">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyltransferase of 06-alkyltransferase of AGT are able to confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="1045">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyltransferase of 06-alkyltransferase of AGT are able to confer resistance to alkyltransferase of pathways (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase of pathways</arg>
                </example>
                <example src="PERMUTATE" no="1046">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyltransferase of 06-alkyltransferase of AGT conferred resistance to alkyltransferase of pathways (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase of pathways</arg>
                </example>
                <example src="PERMUTATE" no="1047">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyltransferase of 06-alkyltransferase of AGT have the ability to confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="1048">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyltransferase of 06-alkyltransferase-DNA are able to confer resistance to alkyltransferase chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1049">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyltransferase of 06-alkyltransferase-DNA conferred resistance to alkyltransferase chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1050">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyltransferase-DNA alkyltransferase conferred resistance on alkylation chemotherapies, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1051">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyltransferase-DNA alkyltransferase conferred resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1052">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyltransferase-DNA alkyltransferase may confer resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1053">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyltransferase-DNA alkyltransferase were able to confer resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1054">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and human 06-alkylguaning-DNA alkyltransferase conferred resistance to alkylation pathways (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1055">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and human 06-alkylguaning-DNA alkyltransferase may confer resistance to alkylation pathways (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1056">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and human 06-alkylguaning-DNA alkyltransferase were able to confer resistance to alkylation pathways (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1057">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and replaceing Gly156 and Lys165 conferred resistance on 06-BG, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">replaceing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1058">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance have been conferred by alkylguaning-DNA alkyltransferase to alkyl ways (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyl ways</arg>
                </example>
                <example src="PERMUTATE" no="1059">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance have been conferred by alkylguaning-DNA alkyltransferase to alkylation routes (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1060">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance have been conferred by alkyltransferase of 06-alkyltransferase of AGT to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="1061">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance have been conferred by alkyltransferase of 06-alkyltransferase-DNA to alkyltransferase chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1062">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance have been conferred by human 06-alkylguaning-DNA alkyltransferase to alkylation pathways (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1063">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance have been conferred by replacements to Gly156 and Lys165 to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1064">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance have been conferred by substitutions to Gly156 and Lys165 to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1065">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were able to be conferred by alkyguaning-DNA alkyltransferase on alkylation routes, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1066">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were able to be conferred by alkylguaning-DNA alkyltransferase on alkylation routes, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1067">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were able to be conferred by human alkyl-alkylation-DNA alkyltransferase on alkylation routes, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">human alkyl-alkylation-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1068">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were able to be conferred by transfection of AGATT on alkylation-sensitive cells, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1069">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were able to be conferred by transformation of AGT on alkylation-sensitive cells, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1070">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and transfection of AGATT conferred resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1071">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and transfection of AGT conferred resistance on alkylation-sensitive cells, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1072">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and transformation of AGT conferred resistance on alkylation-sensitive cells, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1073">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and transformation of GAT are able to confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">transformation of GAT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1074">
                    <text>Increased AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and transformation of GAT conferred resistance on alkylation-sensitive cells, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">transformation of GAT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1075">
                    <text>Increased AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and A1 (AGT transfection) are able to be conferred by The portion of the STATs to either a MAPK or a MAPK kinase substrate (MAPKAP), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1076">
                    <text>Increased AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and The portion of the STATs are able to confer resistance to either a MAPK or a MAPK substratum kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1077">
                    <text>Increased AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and The portion of the STATs conferred resistance on either a MAPK or a MAPK kinase substrate (MAPKAP), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1078">
                    <text>Increased AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and The portion of the STATs conferred resistance on either a MAPK or a MAPK substrat kinase (MAPKAP), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1079">
                    <text>Increased AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and The portion of the STATs conferred resistance to either a MAPK or a MAPK kinase substrate (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1080">
                    <text>Increased AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and The portion of the STATs may confer resistance to either a MAPK or a MAPK kinase substrate (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1081">
                    <text>Increased AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and The portion of the STATs were observed to confer resistance to either a MAPK or a MAPK kinase substrate (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1082">
                    <text>Increased AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and The portion of the STATs will confer resistance to either a MAPK or a MAPK substratum kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1083">
                    <text>Increased AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance have been conferred by The STAT portion to a MAPK substrate or a MAPK kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1084">
                    <text>Increased AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance have been conferred by the portion of the STATs to either a MAPK or a MAPK kinase substrate (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1085">
                    <text>Increased AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the STAT part are able to confer resistance to a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1086">
                    <text>Increased AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the STAT part were observed to confer resistance to a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1087">
                    <text>Increased AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the STAT part will confer resistance to a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1088">
                    <text>Increased AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the portion of the STATs may confer resistance to either a MAPK or a MAPK kinase substrate (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1089">
                    <text>Increased AGT levels in parallel with acquired alkylation stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and replacing simply the C-terminal with Stat5 are able to confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1090">
                    <text>Increased AGT levels in parallel with acquired alkylation stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and replacing simply the C-terminal with Stat5 conferred resistance on Stat1, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1091">
                    <text>Increased AGT levels in parallel with acquired alkylation stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and replacing simply the C-terminal with Stat5 were observed to confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1092">
                    <text>Increased AGT levels in parallel with acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and A1 (AGT transfection) are able to be conferred by substituting only the C-terminal with Stat5 to Stat1, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1093">
                    <text>Increased AGT levels in parallel with acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and replacing simply the C-terminal with Stat5 have the ability to confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1094">
                    <text>Increased AGT levels in parallel with acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and substituting only the C-terminal with Stat5 have the ability to confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1095">
                    <text>Increased AGT levels in parallel with acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and substituting only the C-terminal with Stat5 were able to confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1096">
                    <text>Increased AGT levels in parallel with acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and only C-terminal substitution for Stat5 conferred resistance on State1, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">only C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="1097">
                    <text>Increased AGT levels in parallel with acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and only C-terminal substitution for Stat5 conferred resistance to State1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">only C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="1098">
                    <text>Increased AGT levels in parallel with acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and only C-terminal substitution for Stat5 were able to confer resistance to State1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">only C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="1099">
                    <text>Increased AGT levels in parallel with acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and replacing simply the C-terminal with Stat5 are able to confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1100">
                    <text>Increased AGT levels in parallel with acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and replacing simply the C-terminal with Stat5 conferred resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1101">
                    <text>Increased AGT levels in parallel with acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and replacing simply the C-terminal with Stat5 will confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1102">
                    <text>Increased AGT levels in parallel with acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and replacing simply the C-terminal with the Stat5 phenotype are able to confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1103">
                    <text>Increased AGT levels in parallel with acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and replacing simply the C-terminal with the Stat5 phenotype were able to confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1104">
                    <text>Increased AGT levels in parallel with acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and replacing simply the C-terminal with the Stat5 phenotype were observed to confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1105">
                    <text>Increased AGT levels in parallel with acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were able to be conferred by replacing simply the C-terminal with the Stat5 phenotype on Stat1, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1106">
                    <text>Increased AGT levels in parallel with acquired alkylation the Stat5 stability phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and only the C-terminal substitution for Stat5 were able to confer resistance to State1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="1107">
                    <text>Increased AGT levels in parallel with acquired alkylation the Stat5 stability phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance have been conferred by only the C-terminal substitution for Stat5 to State1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="1108">
                    <text>Increased AGT levels in parallel with acquired alkylation the stability Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and A1 (AGT transfection) are able to be conferred by just replacing the C-terminal with the Stat5 phenotype to Stat1, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1109">
                    <text>Increased AGT levels in parallel with acquired alkylation the stability Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and just replacing the C-terminal with the Stat5 phenotype have the ability to confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1110">
                    <text>Increased AGT levels in parallel with acquired alkylation the stability Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and just replacing the C-terminal with the Stat5 phenotype may confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1111">
                    <text>Increased AGT levels in parallel with acquired alkylation the stability Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and just replacing the C-terminal with the Stat5 phenotype were able to confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1112">
                    <text>Increased AGT levels in parallel with acquired alkylation the stability Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and just replacing the C-terminal with the Stat5 phenotype will confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1113">
                    <text>Increased AGT levels in parallel with acquired alkylation the stability phenotype Stat5 in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and just replacing C-terminus by Stat5 have the ability to confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">just replacing C-terminus by Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1114">
                    <text>Increased GAT in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and Gly156 and Lys165 replacement was considered to confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of GAT in the treatment resistance.</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1115">
                    <text>Increased GAT in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase was considered to confer resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of GAT in the treatment resistance.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1116">
                    <text>Increased GAT in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkylguaning-DNA alkyltransferase was considered to confer resistance to alkylation routes (Kaina et al., 1991), demonstrating the role of GAT in the treatment resistance.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1117">
                    <text>Increased GAT in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyltransferase of 06-alkyltransferase-DNA was considered to confer resistance to alkyltransferase chemotherapies (Kaina et al., 1991), demonstrating the role of GAT in the treatment resistance.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1118">
                    <text>Increased GAT in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyltransferase-DNA alkyltransferase was considered to confer resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of GAT in the treatment resistance.</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1119">
                    <text>Increased GAT in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and substitutions in Gly156 and Lys165 was considered to confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of GAT in the treatment resistance.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1120">
                    <text>Increased GAT in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and transfection of AGATT was considered to confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of GAT in the treatment resistance.</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1121">
                    <text>Increased GAT in parallel with acquired alkylation stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and replacing simply the C-terminal with Stat5 was considered to confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of GAT in the treatment resistance.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1122">
                    <text>Increased GAT in parallel with acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and only C-terminal substitution for Stat5 was considered to confer resistance to State1 (Kaina et al., 1991), demonstrating the role of GAT in the treatment resistance.</text>
                    <arg n="0">only C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="1123">
                    <text>Increased GAT in parallel with acquired alkylation the Stat5 stability phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and just replacing the C-terminal with the Stat5 phenotype was considered to confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of GAT in the treatment resistance.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1124">
                    <text>It was believed that The part of STATs would confer no to specificity.</text>
                    <arg n="0">The part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1125">
                    <text>It was believed that genetic variation would confer no to increased risk of diabetes.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1126">
                    <text>It was believed that over expression of EvgA would confer no to resistance.</text>
                    <arg n="0">over expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="1127">
                    <text>It was believed that part of STATs would confer no to specificity.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1128">
                    <text>It was believed that resistance would confer no to resistance 06-BG.</text>
                    <arg n="0">resistance</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1129">
                    <text>It was believed that the portion of the STATs would confer no to specificity.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1130">
                    <text>It was believed that these mutations would confer no to Xu-Welliver et al., 1999a.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">Xu-Welliver et al., 1999a</arg>
                </example>
                <example src="PERMUTATE" no="1131">
                    <text>It was believed that these mutations would confer no to resistance of 06-BG.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance of 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1132">
                    <text>Similarly, the charge imposed by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), 06-BG will be conferred for these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1133">
                    <text>Similarly, the charge imposed by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), a higher risk of diabetes will be conferred for the gene variant (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1134">
                    <text>Similarly, the charge imposed by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), a higher risk of diabetes will be conferred for the genetic variant (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1135">
                    <text>Similarly, the charge imposed by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), an increased risk of diabetes will be conferred for genetic variety (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1136">
                    <text>Similarly, the charge imposed by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), resistance 06-BG will be conferred for resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">resistance</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1137">
                    <text>Similarly, the charge imposed by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), specificity will be conferred for The part of STATs (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">The part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1138">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), six mutations may confer the A1 resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">six mutations</arg>
                </example>
                <example src="PERMUTATE" no="1139">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the 06-BG could be conferred for these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1140">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the 06-BG resistant has been conferred for these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistant</arg>
                </example>
                <example src="PERMUTATE" no="1141">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the 06-BG would be conferred for six mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1142">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the Xu-Welliver et al., 1999a could be conferred for these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">Xu-Welliver et al., 1999a</arg>
                </example>
                <example src="PERMUTATE" no="1143">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the Xu-Welliver et al., 1999a was able to be conferred for these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">Xu-Welliver et al., 1999a</arg>
                </example>
                <example src="PERMUTATE" no="1144">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the an increased risk of diabetes is conferred for genetic variety (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1145">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the an increasing risk of diabetes could be conferred for the genetic variant (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1146">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the an increasing risk of diabetes has been conferred for the gene variant (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1147">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the an increasing risk of diabetes has been conferred for the genetic variant (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1148">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the an increasing risk of diabetes will be conferred for the genetic variant (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1149">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the increased risk of diabetes could be conferred for gene variety (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">gene variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1150">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the increased risk of diabetes could be conferred for genetic variety (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1151">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the increased risk of diabetes has been conferred for gene variety (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">gene variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1152">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the increased risk of diabetes is conferred for gene variety (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">gene variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1153">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the increased risk of diabetes was able to be conferred for genetic variety (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1154">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the increasing risk of diabetes would be conferred for genetic variation (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1155">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the mutation function miss has been conferred for senseless alteration or frame change of the codex sequence or by cutting variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless alteration or frame change of the codex sequence or by cutting variants</arg>
                    <arg n="1">mutation function miss</arg>
                </example>
                <example src="PERMUTATE" no="1156">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistance 06-BG could be conferred for resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">resistance</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1157">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistance 06-BG was able to be conferred for These mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1158">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistance 06-BG was able to be conferred for resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">resistance</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1159">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistance 06-BG would be conferred for six mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1160">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistance is conferred for the excessive expression of EvgA (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the excessive expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="1161">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistance of 06-BG was able to be conferred for these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance of 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1162">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistance will be conferred for over expression of EvgA (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">over expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="1163">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistance will be conferred for the excessive expression of EvgA (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the excessive expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="1164">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistance would be conferred for over expression of EvgA (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">over expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="1165">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistance would be conferred for overexpression of EvgA (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">overexpression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="1166">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistance would be conferred for the excessive expression of EvgA (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the excessive expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="1167">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistant to Gly160His and Gly160Arg is conferred for these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistant to Gly160His and Gly160Arg</arg>
                </example>
                <example src="PERMUTATE" no="1168">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistant to Gly160His and Gly160Arg would be conferred for these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistant to Gly160His and Gly160Arg</arg>
                </example>
                <example src="PERMUTATE" no="1169">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the specificity could be conferred for the part of the TASTs (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the part of the TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1170">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the specificity has been conferred for The part of TASTs (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">The part of TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1171">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the specificity has been conferred for the portion of the STATs (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1172">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the specificity is conferred for the part of the STATs (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the part of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1173">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the specificity was able to be conferred for the part of STATs (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1174">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the specificity would be conferred for part of STATs (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1175">
                    <text>Similarly, the imposition imposed by the mutants Gly160His and Gly160Arg repelled the benzyl group (Figure 3B), 06-BG resistant was able to be conferred to these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistant</arg>
                </example>
                <example src="PERMUTATE" no="1176">
                    <text>Similarly, the imposition imposed by the mutants Gly160His and Gly160Arg repelled the benzyl group (Figure 3B), 06-BG was able to be conferred to these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1177">
                    <text>Similarly, the imposition imposed by the mutants Gly160His and Gly160Arg repelled the benzyl group (Figure 3B), an increasing risk of diabetes was able to be conferred to the gene variant (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1178">
                    <text>Similarly, the imposition imposed by the mutants Gly160His and Gly160Arg repelled the benzyl group (Figure 3B), increased risk of diabetes was able to be conferred to genetic variation (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1179">
                    <text>Similarly, the imposition imposed by the mutants Gly160His and Gly160Arg repelled the benzyl group (Figure 3B), increasing risk of diabetes was able to be conferred to genetic variation (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1180">
                    <text>Similarly, the imposition imposed by the mutants Gly160His and Gly160Arg repelled the benzyl group (Figure 3B), resistance 06-BG was able to be conferred to resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">resistance</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1181">
                    <text>Similarly, the imposition imposed by the mutants Gly160His and Gly160Arg repelled the benzyl group (Figure 3B), resistance was able to be conferred to over expression of EvgA (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">over expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="1182">
                    <text>Similarly, the imposition imposed by the mutants Gly160His and Gly160Arg repelled the benzyl group (Figure 3B), resistance was able to be conferred to the excessive expression of EvgA (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the excessive expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="1183">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), The part of STATs confer specificity (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">The part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1184">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), The part of TASTs conferred specificity (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">The part of TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1185">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), The part of TASTs would confer specificity (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">The part of TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1186">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), gene variety confer increased risk of diabetes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">gene variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1187">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), genetic variation conferred increased risk of diabetes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1188">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), genetic variety have conferred an increased risk of diabetes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1189">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), genetic variety was believed to confer increased risk of diabetes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1190">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), genetic variety would confer increased risk of diabetes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1191">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), it was believed that 06-BG was conferred for six mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1192">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), it was believed that a higher risk of diabetes was conferred for the gene variant (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1193">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), it was believed that an increased risk of diabetes was conferred for genetic variety (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1194">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), it was believed that resistance was conferred for over expression of EvgA (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">over expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="1195">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), it was believed that specificity was conferred for The part of STATs (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">The part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1196">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), it was believed that specificity was conferred for part of STATs (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1197">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), over expression of EvgA have conferred resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">over expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="1198">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), overexpression of EvgA confer resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">overexpression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="1199">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), part of STATs was believed to confer specificity (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1200">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), resistance have conferred resistance 06-BG (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">resistance</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1201">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), resistances have conferred resistance 06-BG (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">resistances</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1202">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), six mutations conferred 06-BG (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1203">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), six mutations have conferred 06-BG (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1204">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the 06-BG is thought to be conferred by six mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1205">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the 06-BG resistant is thought to be conferred by these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistant</arg>
                </example>
                <example src="PERMUTATE" no="1206">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the Xu-Welliver et al., 1999a is thought to be conferred by these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">Xu-Welliver et al., 1999a</arg>
                </example>
                <example src="PERMUTATE" no="1207">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the excessive expression of EvgA confer resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the excessive expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="1208">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the genetic variant confer a higher risk of diabetes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1209">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the genetic variant would confer a higher risk of diabetes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1210">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the increased risk of diabetes is thought to be conferred by genetic variation (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1211">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the part of the TASTs confer specificity (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the part of the TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1212">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the portion of the STATs conferred specificity (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1213">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistance 06-BG is thought to be conferred by These mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1214">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistance 06-BG is thought to be conferred by resistances (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">resistances</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1215">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistance is thought to be conferred by overexpression of EvgA (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">overexpression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="1216">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistant to Gly160His and Gly160Arg is thought to be conferred by these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistant to Gly160His and Gly160Arg</arg>
                </example>
                <example src="PERMUTATE" no="1217">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), these mutations conferred 06-BG (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1218">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), these mutations conferred Xu-Welliver et al., 1999a (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">Xu-Welliver et al., 1999a</arg>
                </example>
                <example src="PERMUTATE" no="1219">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), these mutations conferred resistance of 06-BG (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance of 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1220">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), these mutations have conferred 06-BG (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1221">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), these mutations have conferred Xu-Welliver et al., 1999a (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">Xu-Welliver et al., 1999a</arg>
                </example>
                <example src="PERMUTATE" no="1222">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), these mutations have conferred resistant to Gly160His and Gly160Arg (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistant to Gly160His and Gly160Arg</arg>
                </example>
                <example src="PERMUTATE" no="1223">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), these mutations was believed to confer resistance of 06-BG (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance of 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1224">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), these mutations was believed to confer resistant to Gly160His and Gly160Arg (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistant to Gly160His and Gly160Arg</arg>
                </example>
                <example src="PERMUTATE" no="1225">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), 06-BG would be conferred by six mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1226">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), The part of TASTs was considered to confer specificity (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">The part of TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1227">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), an increasing risk of diabetes would be conferred by the gene variant (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1228">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), genetic variety was considered to confer an increased risk of diabetes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1229">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), increased risk of diabetes would be conferred by genetic variety (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1230">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), increasing risk of diabetes would be conferred by genetic variation (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1231">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), resistance 06-BG would be conferred by resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">resistance</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1232">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), resistance 06-BG would be conferred by six mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1233">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), resistance would be conferred by the excessive expression of EvgA (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the excessive expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="1234">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), six mutations was considered to confer 06-BG (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1235">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), specificity would be conferred by The part of STATs (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">The part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1236">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), specificity would be conferred by The part of TASTs (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">The part of TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1237">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), specificity would be conferred by part of STATs (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1238">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), the excessive expression of EvgA was considered to confer resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the excessive expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="1239">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), the gene variant was considered to confer an increasing risk of diabetes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1240">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), the genetic variant was considered to confer an increasing risk of diabetes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1241">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), the portion of the STATs was considered to confer specificity (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1242">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), these mutations was considered to confer resistance of 06-BG (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance of 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1243">
                    <text>Similarly, the introduction of the Gly160His and Gly160Arg mutant charge repels the benzyl group (Figure 3B), Xu-Welliver et al., 1999a can be conferred for these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">Xu-Welliver et al., 1999a</arg>
                </example>
                <example src="PERMUTATE" no="1244">
                    <text>Similarly, the introduction of the Gly160His and Gly160Arg mutant charge repels the benzyl group (Figure 3B), specificity can be conferred for The part of STATs (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">The part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1245">
                    <text>Similarly, the introduction of the Gly160His and Gly160Arg mutant charge repels the benzyl group (Figure 3B), specificity can be conferred for The part of TASTs (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">The part of TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1246">
                    <text>Similarly, the introduction of the charge of the mutations Gly160His and Gly160Arg repels the benzyl group (Figure 3B), senseless alteration or frame change of the codex sequence or by cutting variants is considered to confer the resistance mutation function miss (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless alteration or frame change of the codex sequence or by cutting variants</arg>
                    <arg n="1">mutation function miss</arg>
                </example>
                <example src="PERMUTATE" no="1247">
                    <text>Similarly, the introduction of the charge of the mutations Gly160His and Gly160Arg repels the benzyl group (Figure 3B), the part of the TASTs is considered to confer the resistance specificity (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the part of the TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1248">
                    <text>Similarly, the introduction of the charge of the mutations Gly160His and Gly160Arg repels the benzyl group (Figure 3B), these mutations is considered to confer the resistance 06-BG resistant (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistant</arg>
                </example>
                <example src="PERMUTATE" no="1249">
                    <text>Similarly, the introduction of the charge of the mutations Gly160His and Gly160Arg repels the benzyl group (Figure 3B), these mutations is considered to confer the resistance Xu-Welliver et al., 1999a (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">Xu-Welliver et al., 1999a</arg>
                </example>
                <example src="PERMUTATE" no="1250">
                    <text>Similarly, the introduction of the charge of the mutations Gly160His and Gly160Arg repels the benzyl group (Figure 3B), these mutations is considered to confer the resistance resistance 06-BG (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1251">
                    <text>Similarly, the introduction of the charge of the mutations Gly160His and Gly160Arg repels the benzyl group (Figure 3B), these mutations is considered to confer the resistance resistance of 06-BG (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance of 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1252">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), 06-BG could be conferred by these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1253">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), 06-BG has been conferred by these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1254">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), 06-BG is conferred by six mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1255">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), a higher risk of diabetes can be conferred by the gene variant (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1256">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), a higher risk of diabetes is able to be conferred by the genetic variant (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1257">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), an increased risk of diabetes can be conferred by genetic variety (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1258">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), an increased risk of diabetes is able to be conferred by genetic variety (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1259">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), an increasing risk of diabetes is able to be conferred by the genetic variant (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1260">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), increased risk of diabetes can be conferred by gene variety (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">gene variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1261">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), increased risk of diabetes has been conferred by gene variety (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">gene variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1262">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), increased risk of diabetes has been conferred by genetic variation (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1263">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), increased risk of diabetes is conferred by gene variety (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">gene variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1264">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), increasing risk of diabetes has been conferred by genetic variation (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1265">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), it is believed that a higher risk of diabetes is conferred by the gene variant (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1266">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), it is believed that a higher risk of diabetes is conferred by the genetic variant (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1267">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), it is believed that an increasing risk of diabetes is conferred by the gene variant (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1268">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), it is believed that an increasing risk of diabetes was conferred to the gene variant (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1269">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), it is believed that increased risk of diabetes is conferred by gene variety (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">gene variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1270">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), it is believed that increased risk of diabetes is conferred by genetic variation (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1271">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), it is believed that mutation function miss is conferred by senseless alteration or frame change of the codex sequence or by cutting variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless alteration or frame change of the codex sequence or by cutting variants</arg>
                    <arg n="1">mutation function miss</arg>
                </example>
                <example src="PERMUTATE" no="1272">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), it is believed that resistance 06-BG is conferred by six mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1273">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), it is believed that resistance of 06-BG is conferred by these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance of 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1274">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), it is believed that resistance of 06-BG was conferred to these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance of 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1275">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), it is believed that specificity was conferred to the part of the TASTs (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the part of the TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1276">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), resistance 06-BG has been conferred by resistances (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">resistances</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1277">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), resistance 06-BG has been conferred by six mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1278">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), resistance 06-BG is conferred by these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1279">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), resistance can be conferred by overexpression of EvgA (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">overexpression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="1280">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), resistance is able to be conferred by the excessive expression of EvgA (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the excessive expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="1281">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), resistance of 06-BG has been conferred by these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance of 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1282">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), resistant to Gly160His and Gly160Arg can be conferred by these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistant to Gly160His and Gly160Arg</arg>
                </example>
                <example src="PERMUTATE" no="1283">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), resistant to Gly160His and Gly160Arg is conferred by these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistant to Gly160His and Gly160Arg</arg>
                </example>
                <example src="PERMUTATE" no="1284">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), specificity could be conferred by The part of STATs (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">The part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1285">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), specificity has been conferred by the part of the STATs (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the part of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1286">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), specificity is able to be conferred by part of STATs (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1287">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), specificity is conferred by the portion of the STATs (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1288">
                    <text>Similarly, the introduction of the load of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), The part of STATs is considered to confer the resistance specificity (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">The part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1289">
                    <text>Similarly, the introduction of the load of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), The part of TASTs is considered to confer the resistance specificity (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">The part of TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1290">
                    <text>Similarly, the introduction of the load of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), a higher risk of diabetes was conferred by the genetic variant (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1291">
                    <text>Similarly, the introduction of the load of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), an increased risk of diabetes was conferred by genetic variety (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1292">
                    <text>Similarly, the introduction of the load of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), gene variety is considered to confer the resistance increased risk of diabetes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">gene variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1293">
                    <text>Similarly, the introduction of the load of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), genetic variation is considered to confer the resistance increased risk of diabetes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1294">
                    <text>Similarly, the introduction of the load of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), increased risk of diabetes was conferred by genetic variation (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1295">
                    <text>Similarly, the introduction of the load of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), resistance is considered to confer the resistance resistance 06-BG (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">resistance</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1296">
                    <text>Similarly, the introduction of the load of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), resistance was conferred by over expression of EvgA (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">over expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="1297">
                    <text>Similarly, the introduction of the load of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), resistant to Gly160His and Gly160Arg was conferred by these mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistant to Gly160His and Gly160Arg</arg>
                </example>
                <example src="PERMUTATE" no="1298">
                    <text>Similarly, the introduction of the load of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), six mutations is considered to confer the resistance resistance 06-BG (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1299">
                    <text>Similarly, the introduction of the load of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), specificity was conferred by the part of the STATs (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the part of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1300">
                    <text>Similarly, the introduction of the load of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), specificity was conferred by the portion of the STATs (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1301">
                    <text>Similarly, the introduction of the load of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), the gene variant is considered to confer the resistance an increasing risk of diabetes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1302">
                    <text>Similarly, the introduction of the load of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), the genetic variant is considered to confer the resistance an increasing risk of diabetes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1303">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repelled the benzyl group (Figure 3B), These mutations conferred the resistance resistance 06-BG (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1304">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repelled the benzyl group (Figure 3B), overexpression of EvgA conferred the resistance resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">overexpression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="1305">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repelled the benzyl group (Figure 3B), six mutations conferred the resistance 06-BG (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1306">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repelled the benzyl group (Figure 3B), six mutations conferred the resistance resistance 06-BG (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1307">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repelled the benzyl group (Figure 3B), the genetic variant conferred the resistance an increasing risk of diabetes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1308">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repelled the benzyl group (Figure 3B), the part of STATs conferred the resistance specificity (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1309">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repelled the benzyl group (Figure 3B), the portion of the STATs conferred the resistance specificity (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1310">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), The part of TASTs will confer the resistance specificity (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">The part of TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1311">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), genetic variation will confer the resistance increased risk of diabetes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1312">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), genetic variety will confer the resistance an increased risk of diabetes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1313">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), genetic variety will confer the resistance increased risk of diabetes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1314">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), senseless alteration or frame change of the codex sequence or by cutting variants will confer the resistance mutation function miss (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless alteration or frame change of the codex sequence or by cutting variants</arg>
                    <arg n="1">mutation function miss</arg>
                </example>
                <example src="PERMUTATE" no="1315">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), senseless alteration or frame change of the codex sequence or by cutting variants would confer mutation function miss (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless alteration or frame change of the codex sequence or by cutting variants</arg>
                    <arg n="1">mutation function miss</arg>
                </example>
                <example src="PERMUTATE" no="1316">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), the gene variant will confer the resistance an increasing risk of diabetes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1317">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), the gene variant would confer an increasing risk of diabetes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1318">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), the genetic variant will confer the resistance an increasing risk of diabetes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1319">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), these mutations would confer 06-BG resistant (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistant</arg>
                </example>
                <example src="PERMUTATE" no="1320">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), EvgA overexpression could confer the resistance resistance.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="1321">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), The part of TASTs could confer the resistance specificity.</text>
                    <arg n="0">The part of TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1322">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), gene variety could confer the resistance increased risk of diabetes.</text>
                    <arg n="0">gene variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1323">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), gene variety may confer the resistance increased risk of diabetes.</text>
                    <arg n="0">gene variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1324">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), over expression of EvgA could confer the resistance resistance.</text>
                    <arg n="0">over expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="1325">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), overexpression of EvgA and is able to confer the resistance resistance.</text>
                    <arg n="0">overexpression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="1326">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), part of STATs may confer the resistance specificity.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1327">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), resistances could confer the resistance resistance 06-BG.</text>
                    <arg n="0">resistances</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1328">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), senseless alteration or frame change of the codex sequence or by cutting variants may confer the resistance mutation function miss.</text>
                    <arg n="0">senseless alteration or frame change of the codex sequence or by cutting variants</arg>
                    <arg n="1">mutation function miss</arg>
                </example>
                <example src="PERMUTATE" no="1329">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), six mutations could confer the resistance 06-BG.</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1330">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), six mutations could confer the resistance resistance 06-BG.</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1331">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), six mutations may confer the resistance resistance 06-BG.</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1332">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), the gene variant may confer the resistance a higher risk of diabetes.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1333">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), the genetic variant could confer the resistance a higher risk of diabetes.</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1334">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), the part of the TASTs and is able to confer the resistance specificity.</text>
                    <arg n="0">the part of the TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1335">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), the part of the TASTs could confer the resistance specificity.</text>
                    <arg n="0">the part of the TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1336">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), the portion of the STATs could confer the resistance specificity.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1337">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), the portion of the STATs may confer the resistance specificity.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1338">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), these mutations could confer the resistance 06-BG.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1339">
                    <text>That AGT transformation can confer resistance for Alkylation-sensitive cells has not been determined.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1340">
                    <text>That The STAT portion can confer specificity for a MAPK substrate or a MAPK kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1341">
                    <text>That The portion of the STATs can confer specificity for either a MAPK or a MAPK substratum kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1342">
                    <text>That These mutations was able to confer resistance 06-BG for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1343">
                    <text>That alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase can confer resistance for alkylation pathways has not been determined.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1344">
                    <text>That genetic variation could confer increasing risk of diabetes for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1345">
                    <text>That genetic variety is able to confer an increased risk of diabetes for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1346">
                    <text>That only C-terminal substitution for Stat5 can confer the Stat5 phenotype of stability in the presence of MG132 for State1 has not been determined.</text>
                    <arg n="0">only C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="1347">
                    <text>That only the C-terminal substitution for Stat5 can confer the Stat5 stability phenotype in the presence of MG132 for State1 has not been determined.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="1348">
                    <text>That overexpression of EvgA is able to confer resistance for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">overexpression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="1349">
                    <text>That part of STATs could confer specificity for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1350">
                    <text>That part of STATs was able to confer specificity for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1351">
                    <text>That replacing simply the C-terminal with Stat5 can confer stat5 phenotype of stability in the presence of MG132 for Stat1 has not been determined.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1352">
                    <text>That replacing simply the C-terminal with Stat5 can confer the Stat5 phenotype of stability in the presence of MG132 for Stat1 has not been determined.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1353">
                    <text>That six mutations could confer 06-BG for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1354">
                    <text>That six mutations has conferred resistance 06-BG for A2 (either a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1355">
                    <text>That substitutions in Gly156 and Lys165 can confer resistance for 06-BG has not been determined.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1356">
                    <text>That the gene variant could confer a higher risk of diabetes for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1357">
                    <text>That the gene variant has the ability to confer an increasing risk of diabetes for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1358">
                    <text>That the gene variant was able to confer an increasing risk of diabetes for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1359">
                    <text>That the genetic variant could confer a higher risk of diabetes for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1360">
                    <text>That the genetic variant has conferred a higher risk of diabetes for A2 (either a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1361">
                    <text>That the genetic variant is able to confer an increasing risk of diabetes for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1362">
                    <text>That the genetic variant was able to confer a higher risk of diabetes for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1363">
                    <text>That the part of STATs could confer specificity for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1364">
                    <text>That the part of STATs has the ability to confer specificity for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1365">
                    <text>That the part of the STATs could confer specificity for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">the part of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1366">
                    <text>That the part of the STATs has conferred specificity for A2 (either a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">the part of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1367">
                    <text>That the part of the STATs has the ability to confer specificity for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">the part of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1368">
                    <text>That these mutations has conferred 06-BG for A2 (either a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1369">
                    <text>That these mutations has conferred 06-BG resistant for A2 (either a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistant</arg>
                </example>
                <example src="PERMUTATE" no="1370">
                    <text>That these mutations has conferred resistant to Gly160His and Gly160Arg for A2 (either a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistant to Gly160His and Gly160Arg</arg>
                </example>
                <example src="PERMUTATE" no="1371">
                    <text>That these mutations has the ability to confer Xu-Welliver et al., 1999a for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">Xu-Welliver et al., 1999a</arg>
                </example>
                <example src="PERMUTATE" no="1372">
                    <text>That these mutations is able to confer Xu-Welliver et al., 1999a for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">Xu-Welliver et al., 1999a</arg>
                </example>
                <example src="PERMUTATE" no="1373">
                    <text>That these mutations is able to confer resistance 06-BG for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1374">
                    <text>That these mutations is able to confer resistance of 06-BG for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance of 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1375">
                    <text>That these mutations was able to confer 06-BG for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1376">
                    <text>That these mutations was able to confer resistance of 06-BG for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance of 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1377">
                    <text>The 06-BG in a tolC deficit strain is conferred by the six mutations.</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1378">
                    <text>The 06-BG in a tolC deficit strain is conferred by the these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1379">
                    <text>The AGATT transfection (AGT) that has conferred resistance on alkylation-sensitive cells was therefore an active target of anti-drugs.</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1380">
                    <text>The AGT transformation (AGT) that can confer resistance to Alkylation-sensitive cells was therefore an active target of anti-drugs.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1381">
                    <text>The AGT transformation (AGT) that conferred resistance on Kaina et al., 1991 was therefore an active target of anti-drugs.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="1382">
                    <text>The AGT transformation (AGT) that has conferred resistance on Kaina et al., 1991 was therefore an active target of anti-drugs.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="1383">
                    <text>The AGT transition (AGT) that has conferred resistance on Kaina et al., 1991 was therefore an active target of anti-drugs.</text>
                    <arg n="0">AGT transition</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="1384">
                    <text>The EvgA overexpression conferred the resistance.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="1385">
                    <text>The GAT transformation (AGT) that can confer resistance to Alkylation-sensitive cells was therefore an active target of anti-drugs.</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1386">
                    <text>The Gly156 and Lys165 replacement (AGT) having conferred resistance on 06-BG was therefore an active target of anti-drugs.</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1387">
                    <text>The Gly156 and Lys165 replacement (AGT) that is observed to confer resistance on 06-BG was therefore an active target of anti-drugs.</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1388">
                    <text>The Human 06-alkylguaning-DNA alkyltransferase (AGT) that is observed to confer resistance on alkylation pathways was therefore an active target of anti-drugs.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1389">
                    <text>The STAT portion (AGT) that conferred specificity over a MAPK substrate or a MAPK kinase (MAPKAP) was therefore an active target for anti-drugs.</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1390">
                    <text>The STAT portion (AGT) that is able to confer specificity to a MAPK substrate or a MAPK kinase (MAPKAP) was therefore an active target of anti-drugs.</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1391">
                    <text>The STAT portion (AGT), which directly inverts endogenous alkylation to 06-position of guanine, is thought to confer specificity to a MAPK substrate or a MAPK kinase (MAPKAP) and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1392">
                    <text>The STAT portion (AGT), which directly inverts endogenous alkylation to 06-position of the guanine, would confer specificity to a MAPK substrate or a MAPK kinase (MAPKAP) and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1393">
                    <text>The STAT portion (AGT), which directly reverses the endogenous alkylation in 06 guanin positions, has the ability to confer specificity to a MAPK substrate or a MAPK kinase (MAPKAP) and therefore is an active target of antineoplastic drugs.</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1394">
                    <text>The STAT portion (AGT), which directly reverses the endogenous alkylation to the position 06 of guanin, is able to confer specificity to a MAPK substrate or a MAPK kinase (MAPKAP) and therefore is an active target of antineoplastic drugs.</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1395">
                    <text>The STAT portion has not been determined to be able to confer specificity to a MAPK substrate or a MAPK kinase (MAPKAP).</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1396">
                    <text>The The STAT portion (AGT) that is observed to confer specificity on a MAPK substrate or a MAPK kinase (MAPKAP) was therefore an active target of anti-drugs.</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1397">
                    <text>The The portion of the STATs (AGT) that conferred specificity on either a MAPK or a MAPK substrat kinase (MAPKAP) was therefore an active target of anti-drugs.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1398">
                    <text>The The portion of the STATs (AGT) that has conferred specificity on either a MAPK or a MAPK substratum kinase (MAPKAP) was therefore an active target of anti-drugs.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1399">
                    <text>The Xu-Welliver et al., 1999a in a tolC deficit strain is conferred by the these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">Xu-Welliver et al., 1999a</arg>
                </example>
                <example src="PERMUTATE" no="1400">
                    <text>The Xu-Welliver et al., 1999a in a tolC deficit strain may have been conferred by the these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">Xu-Welliver et al., 1999a</arg>
                </example>
                <example src="PERMUTATE" no="1401">
                    <text>The alkyguaning-DNA alkyltransferase (AGT) that has conferred resistance on alkylation chemotherapies was therefore an active target of anti-drugs.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1402">
                    <text>The alkylation of human alkyl hydroxyl-DNA alkyltransferase (AGT) having conferred resistance on alkylation routes was therefore an active target of anti-drugs.</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1403">
                    <text>The alkylation of human alkyl hydroxyl-DNA alkyltransferase (AGT) that conferred resistance on alkylation routes was therefore an active target of anti-drugs.</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1404">
                    <text>The alkylguaning-DNA alkyltransferase (AGT) that can confer resistance to alkyl ways was therefore an active target of anti-drugs.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyl ways</arg>
                </example>
                <example src="PERMUTATE" no="1405">
                    <text>The alkylguaning-DNA alkyltransferase (AGT) that can confer resistance to alkylation routes was therefore an active target of anti-drugs.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1406">
                    <text>The alkylguaning-DNA alkyltransferase (AGT) that conferred resistance on alkylation routes was therefore an active target of anti-drugs.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1407">
                    <text>The alkylguaning-DNA alkyltransferase (AGT) that has conferred resistance on alkylation routes was therefore an active target of anti-drugs.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1408">
                    <text>The alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase (AGT) that can confer resistance to alkylation chemotherapies was therefore an active target of anti-drugs.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1409">
                    <text>The alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase (AGT) that can confer resistance to alkylation pathways was therefore an active target of anti-drugs.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1410">
                    <text>The alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT (AGT) that can confer resistance to alkylation was therefore an active target of anti-drugs.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="1411">
                    <text>The alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT (AGT) that conferred resistance on alkylation was therefore an active target of anti-drugs.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="1412">
                    <text>The alkyltransferase of 06-alkyltransferase-DNA (AGT) that has conferred resistance on alkyltransferase chemotherapies was therefore an active target of anti-drugs.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1413">
                    <text>The alkyltransferase-DNA alkyltransferase (AGT) that can confer resistance to alkylation chemotherapies was therefore an active target of anti-drugs.</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1414">
                    <text>The chimera data conferred that the difference is due to the absence of carboxyl sequences in 06-BG , since resistance can be checked in A2 (Stat1 ) by A0 (Gly156 and Lys165 replacement) (can be checked in Stat1 by just replacing the C-terminal with the Stat5 phenotype.</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1415">
                    <text>The chimera data conferred that the difference is due to the absence of carboxyl sequences in 06-BG , since resistance can be checked in A2 (Stat1 ) by A0 (replacing Gly156 and Lys165) (can be checked in Stat1 by just replacing the C-terminal with the Stat5 phenotype.</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1416">
                    <text>The chimera data conferred that the difference is due to the absence of carboxyl sequences in 06-BG , since resistance is able to be checked in A2 (Stat1) by Gly156 and Lys165 replacement .</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1417">
                    <text>The chimera data conferred that the difference is due to the absence of carboxyl sequences in 06-BG , since resistance is able to be checked in A2 (Stat1) by replaceing Gly156 and Lys165 .</text>
                    <arg n="0">replaceing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1418">
                    <text>The chimera data conferred that the difference is due to the absence of carboxyl sequences in 06-BG , since resistance is able to be checked in A2 (Stat1) by replacements in Gly156 and Lys165 .</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1419">
                    <text>The chimera data conferred that the difference is due to the absence of carboxyl sequences in Alkylation-sensitive cells , since resistance can be checked in A2 (Stat1 ) by A0 (AGT transformation) (can be checked in Stat1 by just replacing the C-terminal with the Stat5 phenotype.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1420">
                    <text>The chimera data conferred that the difference is due to the absence of carboxyl sequences in Kaina et al., 1991 , since resistance is able to be checked in A2 (Stat1) by AGT transformation .</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="1421">
                    <text>The chimera data conferred that the difference is due to the absence of carboxyl sequences in Stat1 , since stat5 phenotype of stability in the presence of MG132 is able to be checked in A2 (Stat1) by replacing simply the C-terminal with Stat5 .</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1422">
                    <text>The chimera data conferred that the difference is due to the absence of carboxyl sequences in Stat1 , since the Stat5 phenotype in the presence of MG132 is able to be checked in A2 (Stat1) by replacing simply the C-terminal with Stat5 .</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1423">
                    <text>The chimera data conferred that the difference is due to the absence of carboxyl sequences in Stat1 , since the Stat5 phenotype of stability in the presence of MG132 can be checked in A2 (Stat1 ) by A0 (replacing simply the C-terminal with the Stat5 phenotype) (can be checked in Stat1 by just replacing the C-terminal with the Stat5 phenotype.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1424">
                    <text>The chimera data conferred that the difference is due to the absence of carboxyl sequences in Stat1 , since the Stat5 stability phenotype in the presence of MG132 is able to be checked in A2 (Stat1) by just replacing the C-terminal with the Stat5 phenotype .</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1425">
                    <text>The chimera data conferred that the difference is due to the absence of carboxyl sequences in Stat1 , since the stability Stat5 phenotype in the presence of MG132 can be checked in A2 (Stat1 ) by A0 (just replacing the C-terminal with the Stat5 phenotype) (can be checked in Stat1 by just replacing the C-terminal with the Stat5 phenotype.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1426">
                    <text>The chimera data conferred that the difference is due to the absence of carboxyl sequences in alkylation chemotherapies , since resistance is able to be checked in A2 (Stat1) by alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase .</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1427">
                    <text>The chimera data conferred that the difference is due to the absence of carboxyl sequences in alkylation pathways , since resistance can be checked in A2 (Stat1 ) by A0 (human 06-alkylguaning-DNA alkyltransferase) (can be checked in Stat1 by just replacing the C-terminal with the Stat5 phenotype.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1428">
                    <text>The chimera data conferred that the difference is due to the absence of carboxyl sequences in alkylation pathways , since resistance is able to be checked in A2 (Stat1) by Human 06-alkylguaning-DNA alkyltransferase .</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1429">
                    <text>The chimera data conferred that the difference is due to the absence of carboxyl sequences in alkylation pathways , since resistance is able to be checked in A2 (Stat1) by alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase .</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1430">
                    <text>The chimera data conferred that the difference is due to the absence of carboxyl sequences in alkylation pathways , since resistance is able to be checked in A2 (Stat1) by human 06-alkylguaning-DNA alkyltransferase .</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1431">
                    <text>The chimera data conferred that the difference is due to the absence of carboxyl sequences in alkylation routes , since resistance is able to be checked in A2 (Stat1) by alkylation of human alkyl hydroxyl-DNA alkyltransferase .</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1432">
                    <text>The chimera data conferred that the difference is due to the absence of carboxyl sequences in alkylation-sensitive cells , since resistance can be checked in A2 (Stat1 ) by A0 (transfection of AGATT) (can be checked in Stat1 by just replacing the C-terminal with the Stat5 phenotype.</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1433">
                    <text>The chimera data conferred that the difference is due to the absence of carboxyl sequences in alkylation-sensitive cells , since resistance can be checked in A2 (Stat1 ) by A0 (transformation of AGT) (can be checked in Stat1 by just replacing the C-terminal with the Stat5 phenotype.</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1434">
                    <text>The chimera data conferred that the difference is due to the absence of carboxyl sequences in alkylation-sensitive cells , since resistance is able to be checked in A2 (Stat1) by AGT .</text>
                    <arg n="0">AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1435">
                    <text>The chimera data conferred that the difference is due to the absence of carboxyl sequences in alkylation-sensitive cells , since resistance is able to be checked in A2 (Stat1) by transformation of AGT .</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1436">
                    <text>The chimera data conferred that the difference is due to the absence of carboxyl sequences in either a MAPK or a MAPK kinase substrate (MAPKAP) , since specificity can be checked in A2 (Stat1 ) by A0 (The portion of the STATs) (can be checked in Stat1 by just replacing the C-terminal with the Stat5 phenotype.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1437">
                    <text>The chimera data conferred that the difference is due to the absence of carboxyl sequences in either a MAPK or a MAPK kinase substrate (MAPKAP) , since specificity can be checked in A2 (Stat1 ) by A0 (the portion of the STATs) (can be checked in Stat1 by just replacing the C-terminal with the Stat5 phenotype.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1438">
                    <text>The chimera data conferred that the difference is due to the absence of carboxyl sequences in either a MAPK or a MAPK kinase substrate (MAPKAP) , since specificity is able to be checked in A2 (Stat1) by the portion of the STATs .</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1439">
                    <text>The chimera data conferred that the difference is due to the absence of carboxyl sequences in either a MAPK or a MAPK substrat kinase (MAPKAP) , since specificity can be checked in A2 (Stat1 ) by A0 (The portion of the STATs) (can be checked in Stat1 by just replacing the C-terminal with the Stat5 phenotype.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1440">
                    <text>The chimera data conferred that the difference is due to the absence of carboxyl sequences in either a MAPK or a MAPK substrat kinase (MAPKAP) , since specificity is able to be checked in A2 (Stat1) by The portion of the STATs .</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1441">
                    <text>The chimera data conferred that the difference is due to the absence of carboxyl sequences in either a MAPK or a MAPK substratum kinase (MAPKAP) , since specificity can be checked in A2 (Stat1 ) by A0 (The portion of the STATs) (can be checked in Stat1 by just replacing the C-terminal with the Stat5 phenotype.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1442">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in 06-BG , since Gly156 and Lys165 replacement will confer resistance in Stat1 .</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1443">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in 06-BG , since replaceing Gly156 and Lys165 was able to confer resistance in State1 .</text>
                    <arg n="0">replaceing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1444">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in 06-BG , since replacements in Gly156 and Lys165 can confer resistance in Stat1 .</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1445">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in 06-BG , since replacements in Gly156 and Lys165 is able to confer resistance in Stat1 .</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1446">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in 06-BG , since replacements in Gly156 and Lys165 is able to confer resistance in State1 .</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1447">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in 06-BG , since replacements to Gly156 and Lys165 can confer resistance in Stat1 .</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1448">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in 06-BG , since replacements to Gly156 and Lys165 can confer resistance in State1 .</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1449">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in 06-BG , since replacements to Gly156 and Lys165 is able to confer resistance in Stat1 .</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1450">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in 06-BG , since replacing Gly156 and Lys165 will confer resistance in Stat1 .</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1451">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in 06-BG , since resistance pot was conferred in Stat1 by Gly156 and Lys165 replacement.</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1452">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in 06-BG , since resistance pot was conferred in Stat1 by replacements to Gly156 and Lys165.</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1453">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in 06-BG , since substitutions in Gly156 and Lys165 will confer resistance in Stat1 .</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1454">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in 06-BG , since substitutions to Gly156 and Lys165 can confer resistance in Stat1 .</text>
                    <arg n="0">substitutions to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1455">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in 06-BG , since substitutions to Gly156 and Lys165 can confer resistance in State1 .</text>
                    <arg n="0">substitutions to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1456">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in 06-BG , since substitutions to Gly156 and Lys165 is able to confer resistance in Stat1 .</text>
                    <arg n="0">substitutions to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1457">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in 06-BG , since substitutions to Gly156 and Lys165 is able to confer resistance in State1 .</text>
                    <arg n="0">substitutions to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1458">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in Alkylation-sensitive cells , since AGT transformation can confer resistance in State1 .</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1459">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in Alkylation-sensitive cells , since AGT transformation has the ability to confer resistance in Stat1 .</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1460">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in Alkylation-sensitive cells , since AGT transformation is able to confer resistance in State1 .</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1461">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in Alkylation-sensitive cells , since GAT transformation has the ability to confer resistance in Stat1 .</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1462">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in Alkylation-sensitive cells , since GAT transformation was able to confer resistance in State1 .</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1463">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in Kaina et al., 1991 , since AGT transformation can confer resistance in State1 .</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="1464">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in Kaina et al., 1991 , since AGT transformation is able to confer resistance in State1 .</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="1465">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in Kaina et al., 1991 , since AGT transformation was able to confer resistance in State1 .</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="1466">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in Kaina et al., 1991 , since AGT transition was able to confer resistance in State1 .</text>
                    <arg n="0">AGT transition</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="1467">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in Stat1 , since just replacing C-terminus by Stat5 is able to confer the stability phenotype Stat5 in the presence of MG132 in State1 .</text>
                    <arg n="0">just replacing C-terminus by Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1468">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in Stat1 , since just replacing the C-terminal with the Stat5 phenotype can confer the Stat5 stability phenotype in the presence of MG132 in State1 .</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1469">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in Stat1 , since just replacing the C-terminal with the Stat5 phenotype can confer the stability Stat5 phenotype in the presence of MG132 in Stat1 .</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1470">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in Stat1 , since just replacing the C-terminal with the Stat5 phenotype is able to confer the Stat5 stability phenotype in the presence of MG132 in State1 .</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1471">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in Stat1 , since just replacing the C-terminal with the Stat5 phenotype was able to confer the stability Stat5 phenotype in the presence of MG132 in State1 .</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1472">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in Stat1 , since just replacing the C-terminal with the Stat5 phenotype will confer the stability Stat5 phenotype in the presence of MG132 in Stat1 .</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1473">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in Stat1 , since replacing simply the C-terminal with Stat5 can confer stat5 phenotype of stability in the presence of MG132 in State1 .</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1474">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in Stat1 , since replacing simply the C-terminal with Stat5 can confer the Stat5 phenotype in the presence of MG132 in Stat1 .</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1475">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in Stat1 , since replacing simply the C-terminal with Stat5 has the ability to confer the Stat5 phenotype of stability in the presence of MG132 in Stat1 .</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1476">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in Stat1 , since replacing simply the C-terminal with Stat5 is able to confer the Stat5 phenotype in the presence of MG132 in State1 .</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1477">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in Stat1 , since replacing simply the C-terminal with the Stat5 phenotype can confer the Stat5 phenotype of stability in the presence of MG132 in Stat1 .</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1478">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in Stat1 , since replacing simply the C-terminal with the Stat5 phenotype was able to confer the Stat5 phenotype of stability in the presence of MG132 in State1 .</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1479">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in Stat1 , since substituting only the C-terminal with Stat5 can confer the Stat5 phenotype in the presence of MG132 in Stat1 .</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1480">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in Stat1 , since substituting only the C-terminal with Stat5 is able to confer the Stat5 phenotype in the presence of MG132 in Stat1 .</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1481">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in Stat1 , since substituting only the C-terminal with Stat5 was able to confer the Stat5 phenotype in the presence of MG132 in State1 .</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1482">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in Stat1 , since the Stat5 phenotype in the presence of MG132 pot was conferred in Stat1 by replacing simply the C-terminal with Stat5.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1483">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in State1 , since only the C-terminal substitution for Stat5 will confer the Stat5 stability phenotype in the presence of MG132 in Stat1 .</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="1484">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in State1 , since the Stat5 stability phenotype in the presence of MG132 pot was conferred in Stat1 by only the C-terminal substitution for Stat5.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="1485">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in a MAPK substrate or a MAPK kinase (MAPKAP) , since The STAT portion was able to confer specificity in State1 .</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1486">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in a MAPK substrate or a MAPK kinase (MAPKAP) , since the part of STATs can confer specificity in Stat1 .</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1487">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in a MAPK substrate or a MAPK kinase (MAPKAP) , since the part of STATs can confer specificity in State1 .</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1488">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkyl ways , since alkylguaning-DNA alkyltransferase is able to confer resistance in State1 .</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyl ways</arg>
                </example>
                <example src="PERMUTATE" no="1489">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkyl ways , since alkylguaning-DNA alkyltransferase was able to confer resistance in State1 .</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyl ways</arg>
                </example>
                <example src="PERMUTATE" no="1490">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation , since alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT has the ability to confer resistance in Stat1 .</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="1491">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation , since alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT was able to confer resistance in State1 .</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="1492">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation , since alkyltransferase of 06-alkyltransferase of AGT can confer resistance in State1 .</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="1493">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation , since alkyltransferase of 06-alkyltransferase of AGT is able to confer resistance in Stat1 .</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="1494">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation , since resistance pot was conferred in Stat1 by alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="1495">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation , since resistance pot was conferred in Stat1 by alkyltransferase of 06-alkyltransferase of AGT.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="1496">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation chemotherapies , since alkyguaning-DNA alkyltransferase has the ability to confer resistance in Stat1 .</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1497">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation chemotherapies , since alkyguaning-DNA alkyltransferase is able to confer resistance in Stat1 .</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1498">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation chemotherapies , since alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase has the ability to confer resistance in Stat1 .</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1499">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation chemotherapies , since alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase is able to confer resistance in Stat1 .</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1500">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation chemotherapies , since alkyltransferase-DNA alkyltransferase can confer resistance in Stat1 .</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1501">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation chemotherapies , since alkyltransferase-DNA alkyltransferase has the ability to confer resistance in Stat1 .</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1502">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation chemotherapies , since alkyltransferase-DNA alkyltransferase will confer resistance in Stat1 .</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1503">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation chemotherapies , since resistance pot was conferred in Stat1 by alkyltransferase-DNA alkyltransferase.</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1504">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation pathways , since Human 06-alkylguaning-DNA alkyltransferase can confer resistance in Stat1 .</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1505">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation pathways , since Human 06-alkylguaning-DNA alkyltransferase can confer resistance in State1 .</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1506">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation pathways , since Human 06-alkylguaning-DNA alkyltransferase was able to confer resistance in State1 .</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1507">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation pathways , since alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase was able to confer resistance in State1 .</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1508">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation pathways , since human 06-alkylguaning-DNA alkyltransferase will confer resistance in Stat1 .</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1509">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation routes , since alkyguaning-DNA alkyltransferase can confer resistance in Stat1 .</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1510">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation routes , since alkyguaning-DNA alkyltransferase can confer resistance in State1 .</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1511">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation routes , since alkylation of human alkyl hydroxyl-DNA alkyltransferase can confer resistance in Stat1 .</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1512">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation routes , since alkylation of human alkyl hydroxyl-DNA alkyltransferase is able to confer resistance in State1 .</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1513">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation routes , since alkylguaning-DNA alkyltransferase can confer resistance in Stat1 .</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1514">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation routes , since human alkyl-alkylation-DNA alkyltransferase has the ability to confer resistance in Stat1 .</text>
                    <arg n="0">human alkyl-alkylation-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1515">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation routes , since human alkyl-alkylation-DNA alkyltransferase is able to confer resistance in State1 .</text>
                    <arg n="0">human alkyl-alkylation-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1516">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation routes , since resistance pot was conferred in Stat1 by alkyguaning-DNA alkyltransferase.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1517">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation-sensitive cells , since AGATT transfection was able to confer resistance in State1 .</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1518">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation-sensitive cells , since AGT transformation is able to confer resistance in State1 .</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1519">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation-sensitive cells , since resistance pot was conferred in Stat1 by AGT.</text>
                    <arg n="0">AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1520">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation-sensitive cells , since resistance pot was conferred in Stat1 by transfection of AGT.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1521">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation-sensitive cells , since transfection of AGATT can confer resistance in Stat1 .</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1522">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation-sensitive cells , since transfection of AGATT can confer resistance in State1 .</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1523">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation-sensitive cells , since transfection of AGATT is able to confer resistance in State1 .</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1524">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation-sensitive cells , since transfection of AGATT will confer resistance in Stat1 .</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1525">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation-sensitive cells , since transfection of AGT will confer resistance in Stat1 .</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1526">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation-sensitive cells , since transformation of AGT is able to confer resistance in State1 .</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1527">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation-sensitive cells , since transformation of GAT can confer resistance in Stat1 .</text>
                    <arg n="0">transformation of GAT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1528">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkylation-sensitive cells , since transformation of GAT is able to confer resistance in State1 .</text>
                    <arg n="0">transformation of GAT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1529">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkyltransferase chemotherapies , since alkyltransferase of 06-alkyltransferase of AGT has the ability to confer resistance in Stat1 .</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1530">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkyltransferase chemotherapies , since alkyltransferase of 06-alkyltransferase of AGT was able to confer resistance in State1 .</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1531">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkyltransferase chemotherapies , since alkyltransferase of 06-alkyltransferase-DNA can confer resistance in Stat1 .</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1532">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkyltransferase chemotherapies , since alkyltransferase of 06-alkyltransferase-DNA was able to confer resistance in State1 .</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1533">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkyltransferase of pathways , since alkyltransferase of 06-alkyltransferase of AGT can confer resistance in State1 .</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase of pathways</arg>
                </example>
                <example src="PERMUTATE" no="1534">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkyltransferase of pathways , since alkyltransferase of 06-alkyltransferase of AGT is able to confer resistance in Stat1 .</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase of pathways</arg>
                </example>
                <example src="PERMUTATE" no="1535">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in alkyltransferase of pathways , since alkyltransferase of 06-alkyltransferase of AGT was able to confer resistance in State1 .</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase of pathways</arg>
                </example>
                <example src="PERMUTATE" no="1536">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in either a MAPK or a MAPK kinase substrate (MAPKAP) , since The portion of the STATs can confer specificity in Stat1 .</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1537">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in either a MAPK or a MAPK kinase substrate (MAPKAP) , since The portion of the STATs can confer specificity in State1 .</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1538">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in either a MAPK or a MAPK kinase substrate (MAPKAP) , since The portion of the STATs is able to confer specificity in Stat1 .</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1539">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in either a MAPK or a MAPK substrat kinase (MAPKAP) , since The portion of the STATs is able to confer specificity in Stat1 .</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1540">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in either a MAPK or a MAPK substratum kinase (MAPKAP) , since The portion of the STATs can confer specificity in Stat1 .</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1541">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in either a MAPK or a MAPK substratum kinase (MAPKAP) , since specificity pot was conferred in Stat1 by The portion of the STATs.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1542">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in 06-BG , since Gly156 and Lys165 replacement is thought to confer resistance in Stat1 .</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1543">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in 06-BG , since replacing Gly156 and Lys165 was able to confer resistance in Stat1 .</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1544">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in 06-BG , since resistance can be conferred on Stat1 for replacing Gly156 and Lys165 .</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1545">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in 06-BG , since resistance could be conferred on Stat1 by substitutions to Gly156 and Lys165.</text>
                    <arg n="0">substitutions to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1546">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in Kaina et al., 1991 , since resistance can be conferred on Stat1 for AGT transformation .</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="1547">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in Kaina et al., 1991 , since resistance could be conferred on Stat1 by AGT transformation.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="1548">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in Kaina et al., 1991 , since resistance pot has been conferred on Stat1 by AGT transformation.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="1549">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in Stat1 , since just replacing C-terminus by Stat5 was able to confer the stability phenotype Stat5 in the presence of MG132 in Stat1 .</text>
                    <arg n="0">just replacing C-terminus by Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1550">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in Stat1 , since the Stat5 phenotype in the presence of MG132 could be conferred on Stat1 by substituting only the C-terminal with Stat5.</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1551">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in Stat1 , since the Stat5 phenotype in the presence of MG132 pot has been conferred on Stat1 by substituting only the C-terminal with Stat5.</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1552">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in Stat1 , since the Stat5 phenotype of stability in the presence of MG132 can be conferred on Stat1 for replacing simply the C-terminal with the Stat5 phenotype .</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1553">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in Stat1 , since the Stat5 stability phenotype in the presence of MG132 could be conferred on Stat1 by just replacing the C-terminal with the Stat5 phenotype.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1554">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in Stat1 , since the stability Stat5 phenotype in the presence of MG132 pot has been conferred on Stat1 by just replacing the C-terminal with the Stat5 phenotype.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1555">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in State1 , since only C-terminal substitution for Stat5 was able to confer the Stat5 phenotype of stability in the presence of MG132 in Stat1 .</text>
                    <arg n="0">only C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="1556">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in State1 , since only the C-terminal substitution for Stat5 was able to confer the Stat5 stability phenotype in the presence of MG132 in Stat1 .</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="1557">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in a MAPK or a MAPK substrate kinase (MAPKAP) , since specificity could be conferred on Stat1 by the STAT part.</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1558">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in a MAPK or a MAPK substrate kinase (MAPKAP) , since specificity pot has been conferred on Stat1 by the STAT part.</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1559">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in a MAPK substrate or a MAPK kinase (MAPKAP) , since The STAT portion is thought to confer specificity in Stat1 .</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1560">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in a MAPK substrate or a MAPK kinase (MAPKAP) , since specificity could be conferred on Stat1 by the part of STATs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1561">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in a MAPK substrate or a MAPK kinase (MAPKAP) , since specificity pot has been conferred on Stat1 by the part of STATs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1562">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkyl ways , since resistance could be conferred on Stat1 by alkylguaning-DNA alkyltransferase.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyl ways</arg>
                </example>
                <example src="PERMUTATE" no="1563">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation , since resistance pot has been conferred on Stat1 by alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="1564">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation chemotherapies , since alkyguaning-DNA alkyltransferase was able to confer resistance in Stat1 .</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1565">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation chemotherapies , since alkyltransferase-DNA alkyltransferase is thought to confer resistance in Stat1 .</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1566">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation chemotherapies , since resistance pot has been conferred on Stat1 by alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1567">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation pathways , since resistance can be conferred on Stat1 for Human 06-alkylguaning-DNA alkyltransferase .</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1568">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation pathways , since resistance pot has been conferred on Stat1 by human 06-alkylguaning-DNA alkyltransferase.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1569">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation routes , since alkylation of human alkyl hydroxyl-DNA alkyltransferase was able to confer resistance in Stat1 .</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1570">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation routes , since resistance can be conferred on Stat1 for alkylation of human alkyl hydroxyl-DNA alkyltransferase .</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1571">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation routes , since resistance could be conferred on Stat1 by alkylation of human alkyl hydroxyl-DNA alkyltransferase.</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1572">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation routes , since resistance pot has been conferred on Stat1 by alkyguaning-DNA alkyltransferase.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1573">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation routes , since resistance pot has been conferred on Stat1 by alkylation of human alkyl hydroxyl-DNA alkyltransferase.</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1574">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation routes , since resistance pot has been conferred on Stat1 by human alkyl-alkylation-DNA alkyltransferase.</text>
                    <arg n="0">human alkyl-alkylation-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1575">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation-sensitive cells , since AGATT transfection is thought to confer resistance in Stat1 .</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1576">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation-sensitive cells , since AGT was able to confer resistance in Stat1 .</text>
                    <arg n="0">AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1577">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation-sensitive cells , since resistance can be conferred on Stat1 for transformation of GAT .</text>
                    <arg n="0">transformation of GAT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1578">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation-sensitive cells , since resistance could be conferred on Stat1 by AGT transformation.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1579">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation-sensitive cells , since resistance could be conferred on Stat1 by AGT.</text>
                    <arg n="0">AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1580">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation-sensitive cells , since resistance pot has been conferred on Stat1 by AGATT transfection.</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1581">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkylation-sensitive cells , since transfection of AGATT was able to confer resistance in Stat1 .</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1582">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkyltransferase chemotherapies , since resistance can be conferred on Stat1 for alkyltransferase of 06-alkyltransferase-DNA .</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1583">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in alkyltransferase chemotherapies , since resistance pot has been conferred on Stat1 by alkyltransferase of 06-alkyltransferase of AGT.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1584">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in either a MAPK or a MAPK kinase substrate (MAPKAP) , since The portion of the STATs was able to confer specificity in Stat1 .</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1585">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in either a MAPK or a MAPK kinase substrate (MAPKAP) , since specificity pot has been conferred on Stat1 by the portion of the STATs.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1586">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in either a MAPK or a MAPK substrat kinase (MAPKAP) , since The portion of the STATs was able to confer specificity in Stat1 .</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1587">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in either a MAPK or a MAPK substratum kinase (MAPKAP) , since The portion of the STATs is thought to confer specificity in Stat1 .</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1588">
                    <text>The highest levels of AGAT are thought to be conferred by AGT transformation to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1589">
                    <text>The highest levels of AGAT are thought to be conferred by GAT transformation to Alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance.</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1590">
                    <text>The highest levels of AGAT are thought to be conferred by Gly156 and Lys165 replacement to 06-BG (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance.</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1591">
                    <text>The highest levels of AGAT are thought to be conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation pathways (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1592">
                    <text>The highest levels of AGAT are thought to be conferred by The STAT portion to a MAPK substrate or a MAPK kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic specificity.</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1593">
                    <text>The highest levels of AGAT are thought to be conferred by alkylguaning-DNA alkyltransferase to alkyl ways (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyl ways</arg>
                </example>
                <example src="PERMUTATE" no="1594">
                    <text>The highest levels of AGAT are thought to be conferred by alkyltransferase of 06-alkyltransferase of AGT to alkylation (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="1595">
                    <text>The highest levels of AGAT are thought to be conferred by alkyltransferase of 06-alkyltransferase of AGT to alkyltransferase chemotherapies (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1596">
                    <text>The highest levels of AGAT are thought to be conferred by alkyltransferase of 06-alkyltransferase of AGT to alkyltransferase of pathways (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase of pathways</arg>
                </example>
                <example src="PERMUTATE" no="1597">
                    <text>The highest levels of AGAT are thought to be conferred by just replacing the C-terminal with the Stat5 phenotype to Stat1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic the stability Stat5 phenotype in the presence of MG132.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1598">
                    <text>The highest levels of AGAT are thought to be conferred by replacing simply the C-terminal with Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic the Stat5 phenotype in the presence of MG132.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1599">
                    <text>The highest levels of AGAT are thought to be conferred by the portion of the STATs to either a MAPK or a MAPK kinase substrate (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic specificity.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1600">
                    <text>The human 06-alkylguaning-DNA alkyltransferase (AGT) having conferred resistance on alkylation pathways was therefore an active target of anti-drugs.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1601">
                    <text>The increase in parallel AGT levels acquired the alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and GAT transformation may have conferred resistance to Alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AAGT in therapy resistance.</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1602">
                    <text>The increase in parallel AGT levels acquired the alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and Human 06-alkylguaning-DNA alkyltransferase may have conferred resistance to alkylation pathways (Kaina et al., 1991), demonstrating the role of AAGT in therapy resistance.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1603">
                    <text>The increase in parallel AGT levels acquired the alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyguaning-DNA alkyltransferase may have conferred resistance to alkylation routes (Kaina et al., 1991), demonstrating the role of AAGT in therapy resistance.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1604">
                    <text>The increase in parallel AGT levels acquired the alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkylation of human alkyl hydroxyl-DNA alkyltransferase may have conferred resistance to alkylation routes (Kaina et al., 1991), demonstrating the role of AAGT in therapy resistance.</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1605">
                    <text>The increase in parallel AGT levels acquired the alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and only C-terminal substitution for Stat5 may have conferred resistance to State1 (Kaina et al., 1991), demonstrating the role of AAGT in therapy resistance.</text>
                    <arg n="0">only C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="1606">
                    <text>The increase in parallel AGT levels conferred alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance would be attributed by AGT to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1607">
                    <text>The increase in parallel AGT levels conferred alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance would be attributed by AGT transformation to Alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1608">
                    <text>The increase in parallel AGT levels conferred alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance would be attributed by Gly156 and Lys165 replacement to 06-BG (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1609">
                    <text>The increase in parallel AGT levels conferred alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance would be attributed by alkyguaning-DNA alkyltransferase to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1610">
                    <text>The increase in parallel AGT levels conferred alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance would be attributed by alkyguaning-DNA alkyltransferase to alkylation routes (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1611">
                    <text>The increase in parallel AGT levels conferred alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance would be attributed by alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase to alkylation pathways (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1612">
                    <text>The increase in parallel AGT levels conferred alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance would be attributed by alkyltransferase of 06-alkyltransferase-DNA to alkyltransferase chemotherapies (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1613">
                    <text>The increase in parallel AGT levels conferred alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance would be attributed by alkyltransferase-DNA alkyltransferase to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1614">
                    <text>The increase in parallel AGT levels conferred alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance would be attributed by substitutions in Gly156 and Lys165 to 06-BG (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1615">
                    <text>The increase in parallel AGT levels conferred alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance would be attributed by The STAT portion to a MAPK substrate or a MAPK kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1616">
                    <text>The increase in parallel AGT levels conferred alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance would be attributed by substituting only the C-terminal with Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1617">
                    <text>The increase in parallel AGT levels conferred alkylation the stability phenotype Stat5 in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance would be attributed by just replacing C-terminus by Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">just replacing C-terminus by Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1618">
                    <text>The increase in parallel AGT levels conferred from resistance alkylation in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance will be attributed by Gly156 and Lys165 replacement to 06-BG (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1619">
                    <text>The increase in parallel AGT levels conferred from resistance alkylation in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance will be attributed by Human 06-alkylguaning-DNA alkyltransferase to alkylation pathways (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1620">
                    <text>The increase in parallel AGT levels conferred from resistance alkylation in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance will be attributed by alkyguaning-DNA alkyltransferase to alkylation routes (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1621">
                    <text>The increase in parallel AGT levels conferred from resistance alkylation in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance will be attributed by alkyltransferase of 06-alkyltransferase of AGT to alkyltransferase of pathways (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase of pathways</arg>
                </example>
                <example src="PERMUTATE" no="1622">
                    <text>The increase in parallel AGT levels conferred from resistance alkylation in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance will be attributed by human 06-alkylguaning-DNA alkyltransferase to alkylation pathways (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1623">
                    <text>The increase in parallel AGT levels conferred from resistance alkylation in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance will be attributed by human alkyl-alkylation-DNA alkyltransferase to alkylation routes (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">human alkyl-alkylation-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1624">
                    <text>The increase in parallel AGT levels conferred from resistance alkylation in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance will be attributed by transformation of AGT to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1625">
                    <text>The increase in parallel AGT levels conferred from resistance alkylation in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance will be attributed by transformation of GAT to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">transformation of GAT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1626">
                    <text>The increase in parallel AGT levels conferred from specificity alkylation in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance will be attributed by The portion of the STATs to either a MAPK or a MAPK substrat kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1627">
                    <text>The increase in parallel AGT levels conferred from the stability Stat5 phenotype in the presence of MG132 alkylation in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance will be attributed by just replacing the C-terminal with the Stat5 phenotype to Stat1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1628">
                    <text>The increase in parallel AGT levels conferred the resistance alkylation in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance alkylation could be attributed by alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase to alkylation pathways (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1629">
                    <text>The increase in parallel AGT levels conferred the resistance alkylation in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance alkylation could be attributed by alkyltransferase of 06-alkyltransferase of AGT to alkylation (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="1630">
                    <text>The increase in parallel AGT levels conferred the specificity alkylation in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance alkylation could be attributed by The STAT portion to a MAPK substrate or a MAPK kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1631">
                    <text>The increase in parallel AGT levels conferred the the Stat5 phenotype in the presence of MG132 alkylation in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance alkylation could be attributed by substituting only the C-terminal with Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1632">
                    <text>The increase in parallel AGT levels conferred the the Stat5 phenotype of stability in the presence of MG132 alkylation in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance alkylation could be attributed by replacing simply the C-terminal with the Stat5 phenotype to Stat1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1633">
                    <text>The increase in parallel AGT levels conferred the the stability phenotype Stat5 in the presence of MG132 alkylation in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance alkylation could be attributed by just replacing C-terminus by Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">just replacing C-terminus by Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1634">
                    <text>The increase in parallel AGT transformation levels conferred the resistance alkylation in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance alkylation, which can be attributed by the AGT to Alkylation-sensitive cells transformation (Kaina et al., 1991), demonstrating the role of AGT in resistance thera</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1635">
                    <text>The increase in parallel The portion of the STATs levels conferred the specificity alkylation in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance alkylation, which can be attributed by the AGT to either a MAPK or a MAPK substratum kinase (MAPKAP) transformation (Kaina et al., 1991), demonstrating the role of AGT in resistance thera</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1636">
                    <text>The increase in parallel alkyguaning-DNA alkyltransferase levels conferred the resistance alkylation in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance alkylation, which can be attributed by the AGT to alkylation routes transformation (Kaina et al., 1991), demonstrating the role of AGT in resistance thera</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1637">
                    <text>The increase in parallel alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase levels conferred the resistance alkylation in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance alkylation, which can be attributed by the AGT to alkylation chemotherapies transformation (Kaina et al., 1991), demonstrating the role of AGT in resistance thera</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1638">
                    <text>The increase in parallel alkylguaning-DNA alkyltransferase levels conferred the resistance alkylation in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance alkylation, which can be attributed by the AGT to alkyl ways transformation (Kaina et al., 1991), demonstrating the role of AGT in resistance thera</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyl ways</arg>
                </example>
                <example src="PERMUTATE" no="1639">
                    <text>The increase in parallel alkyltransferase of 06-alkyltransferase of AGT levels conferred the resistance alkylation in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance alkylation, which can be attributed by the AGT to alkyltransferase chemotherapies transformation (Kaina et al., 1991), demonstrating the role of AGT in resistance thera</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1640">
                    <text>The increase in parallel replacements in Gly156 and Lys165 levels conferred the resistance alkylation in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance alkylation, which can be attributed by the AGT to 06-BG transformation (Kaina et al., 1991), demonstrating the role of AGT in resistance thera</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1641">
                    <text>The increase in parallel replacements to Gly156 and Lys165 levels conferred the resistance alkylation in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance alkylation, which can be attributed by the AGT to 06-BG transformation (Kaina et al., 1991), demonstrating the role of AGT in resistance thera</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1642">
                    <text>The increase in parallel replacing Gly156 and Lys165 levels conferred the resistance alkylation in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance alkylation, which can be attributed by the AGT to 06-BG transformation (Kaina et al., 1991), demonstrating the role of AGT in resistance thera</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1643">
                    <text>The increase in parallel the STAT part levels conferred the specificity alkylation in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance alkylation, which can be attributed by the AGT to a MAPK or a MAPK substrate kinase (MAPKAP) transformation (Kaina et al., 1991), demonstrating the role of AGT in resistance thera</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1644">
                    <text>The increase in parallel transfection of AGATT levels conferred the resistance alkylation in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance alkylation, which can be attributed by the AGT to alkylation-sensitive cells transformation (Kaina et al., 1991), demonstrating the role of AGT in resistance thera</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1645">
                    <text>The increase of CATs in parallel with the acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT transformation was considered to confer resistance to Alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of CAT in resistance.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1646">
                    <text>The increase of CATs in parallel with the acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT transformation was considered to confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of CAT in resistance.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1647">
                    <text>The increase of CATs in parallel with the acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkylation of human alkyl hydroxyl-DNA alkyltransferase was considered to confer resistance to alkylation routes (Kaina et al., 1991), demonstrating the role of CAT in resistance.</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1648">
                    <text>The increase of CATs in parallel with the acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkylguaning-DNA alkyltransferase was considered to confer resistance to alkylation routes (Kaina et al., 1991), demonstrating the role of CAT in resistance.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1649">
                    <text>The increase of CATs in parallel with the acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyltransferase-DNA alkyltransferase was considered to confer resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of CAT in resistance.</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1650">
                    <text>The increase of CATs in parallel with the acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and replacements to Gly156 and Lys165 was considered to confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of CAT in resistance.</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1651">
                    <text>The increase of CATs in parallel with the acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and substitutions to Gly156 and Lys165 was considered to confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of CAT in resistance.</text>
                    <arg n="0">substitutions to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1652">
                    <text>The increase of CATs in parallel with the acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and transformation of AGT was considered to confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of CAT in resistance.</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1653">
                    <text>The increase of CATs in parallel with the acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and transformation of GAT was considered to confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of CAT in resistance.</text>
                    <arg n="0">transformation of GAT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1654">
                    <text>The increase of CATs in parallel with the acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and The portion of the STATs was considered to confer resistance to either a MAPK or a MAPK substratum kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of CAT in resistance.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1655">
                    <text>The increase of CATs in parallel with the acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the part of STATs was considered to confer resistance to a MAPK substrate or a MAPK kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of CAT in resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1656">
                    <text>The increase of CATs in parallel with the acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and replacing simply the C-terminal with Stat5 was considered to confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of CAT in resistance.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1657">
                    <text>The increase of CATs in parallel with the acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and replacing simply the C-terminal with Stat5 was considered to confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of CAT in resistance.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1658">
                    <text>The increased risk of diabetes in a tolC deficit strain may have been conferred by the gene variety.</text>
                    <arg n="0">gene variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1659">
                    <text>The increased risk of diabetes in a tolC deficit strain may have been conferred by the genetic variation.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1660">
                    <text>The just replacing C-terminus by Stat5 (AGT) that conferred the stability phenotype Stat5 in the presence of MG132 on Stat1 was therefore an active target of anti-drugs.</text>
                    <arg n="0">just replacing C-terminus by Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1661">
                    <text>The only C-terminal substitution for Stat5 (AGT) having conferred the Stat5 phenotype of stability in the presence of MG132 on State1 was therefore an active target of anti-drugs.</text>
                    <arg n="0">only C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="1662">
                    <text>The part of STATs can confer specificity.</text>
                    <arg n="0">The part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1663">
                    <text>The part of STATs conferred the specificity.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1664">
                    <text>The part of STATs could confer specificity.</text>
                    <arg n="0">The part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1665">
                    <text>The part of STATs was not able to confer specificity.</text>
                    <arg n="0">The part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1666">
                    <text>The part of STATs which confers specificity to A2 (a MAPK substrate or a MAPK kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">The part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1667">
                    <text>The part of STATs would confer specificity.</text>
                    <arg n="0">The part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1668">
                    <text>The part of TASTs is considered to be no to confer specificity.</text>
                    <arg n="0">The part of TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1669">
                    <text>The part of TASTs is considered to be the one that confers specificity on A2 (a MAPK or a MAPK substrate of kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">The part of TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1670">
                    <text>The part of TASTs may confer specificity to A2 (a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">The part of TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1671">
                    <text>The part of TASTs might have not conferred specificity.</text>
                    <arg n="0">The part of TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1672">
                    <text>The part of TASTs which confers specificity to A2 (a MAPK substrate or a MAPK kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">The part of TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1673">
                    <text>The part of TASTs will confer specificity.</text>
                    <arg n="0">The part of TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1674">
                    <text>The portion of the STATs (AGT) is thought to confer specificity on either a MAPK or a MAPK kinase substrate (MAPKAP) was therefore an active target of anti-tank drugs.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1675">
                    <text>The portion of the STATs (AGT) that is able to confer specificity to either a MAPK or a MAPK substratum kinase (MAPKAP) was therefore an active target of anti-drugs.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1676">
                    <text>The portion of the STATs (AGT), which directly inverts endogenous alkylation to 06-position of guanine, conferred specificity on either a MAPK or a MAPK substratum kinase (MAPKAP) and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1677">
                    <text>The portion of the STATs (AGT), which directly inverts endogenous alkylation to 06-position of guanine, is able to confer specificity to either a MAPK or a MAPK kinase substrate (MAPKAP) and is therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1678">
                    <text>The portion of the STATs (AGT), which directly inverts endogenous alkylation to 06-position of guanine, is observed to confer specificity to either a MAPK or a MAPK kinase substrate (MAPKAP) and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1679">
                    <text>The portion of the STATs (AGT), which directly inverts endogenous alkylation to 06-position of guanine, is observed to confer specificity to either a MAPK or a MAPK substrat kinase (MAPKAP) and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1680">
                    <text>The portion of the STATs (AGT), which directly inverts endogenous alkylation to 06-position of the guanine, can confer specificity to either a MAPK or a MAPK substratum kinase (MAPKAP) and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1681">
                    <text>The portion of the STATs (AGT), which directly inverts endogenous alkylation to 06-position of the guanine, could confer specificity to either a MAPK or a MAPK kinase substrate (MAPKAP) and thus was an active target of anti-cancer drugs.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1682">
                    <text>The portion of the STATs (AGT), which directly inverts endogenous alkylation to 06-position of the guanine, could confer specificity to either a MAPK or a MAPK substrat kinase (MAPKAP) and thus was an active target of anti-cancer drugs.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1683">
                    <text>The portion of the STATs (AGT), which directly reverses endogenous alkylation at 06-position of guanine, was able to confer specificity to either a MAPK or a MAPK kinase substrate (MAPKAP) and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1684">
                    <text>The portion of the STATs (AGT), which directly reverses endogenous alkylation at 06-position of guanine, was observed to confer specificity on either a MAPK or a MAPK substrat kinase (MAPKAP) and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1685">
                    <text>The portion of the STATs (AGT), which directly reverses endogenous alkylation at 06-position of the guanine, has the ability to confer specificity to either a MAPK or a MAPK kinase substrate (MAPKAP) and is therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1686">
                    <text>The portion of the STATs (AGT), which directly reverses endogenous alkylation at 06-position of the guanine, has the ability to confer specificity to either a MAPK or a MAPK substrat kinase (MAPKAP) and is therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1687">
                    <text>The portion of the STATs (AGT), which directly reverses endogenous alkylation at 06-position of the guanine, was believed to confer specificity on either a MAPK or a MAPK substratum kinase (MAPKAP) and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1688">
                    <text>The portion of the STATs (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, may confer specificity to either a MAPK or a MAPK substrat kinase (MAPKAP) and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1689">
                    <text>The portion of the STATs (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, was able to confer specificity to either a MAPK or a MAPK kinase substrate (MAPKAP) and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1690">
                    <text>The portion of the STATs (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, was able to confer specificity to either a MAPK or a MAPK substrat kinase (MAPKAP) and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1691">
                    <text>The portion of the STATs (AGT), which directly reverses the endogenous alkylation in 06 guanin positions, has the ability to confer specificity to either a MAPK or a MAPK substrat kinase (MAPKAP) and therefore is an active target of antineoplastic drugs.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1692">
                    <text>The portion of the STATs (AGT), which directly reverses the endogenous alkylation to the position 06 of guanin, is able to confer specificity to either a MAPK or a MAPK substrat kinase (MAPKAP) and therefore is an active target of antineoplastic drugs.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1693">
                    <text>The portion of the STATs (AGT), which directly reverses the endogenous alkylation to the position 06 of guanin, is able to confer specificity to either a MAPK or a MAPK substratum kinase (MAPKAP) and therefore is an active target of antineoplastic drugs.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1694">
                    <text>The portion of the STATs 06 human (AGT) that conferred specificity over either a MAPK or a MAPK substrat kinase (MAPKAP) was therefore an active target of anti-drugs.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1695">
                    <text>The portion of the STATs conferred specificity for either a MAPK or a MAPK substratum kinase (MAPKAP).</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1696">
                    <text>The portion of the STATs has not been determined to be able to confer specificity to either a MAPK or a MAPK substratum kinase (MAPKAP).</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1697">
                    <text>The portion of the STATs human 06-alkylguaning-DNA (AGT) that conferred specificity to either a MAPK or a MAPK substrat kinase (MAPKAP) was therefore an active target of anti-drugs.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1698">
                    <text>The replaceing Gly156 and Lys165 (AGT) that can confer resistance to 06-BG was therefore an active target of anti-drugs.</text>
                    <arg n="0">replaceing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1699">
                    <text>The replaceing Gly156 and Lys165 (AGT) that is observed to confer resistance on 06-BG was therefore an active target of anti-drugs.</text>
                    <arg n="0">replaceing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1700">
                    <text>The replacements in Gly156 and Lys165 (AGT) that is observed to confer resistance on 06-BG was therefore an active target of anti-drugs.</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1701">
                    <text>The replacements to Gly156 and Lys165 (AGT) that can confer resistance to 06-BG was therefore an active target of anti-drugs.</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1702">
                    <text>The replacements to Gly156 and Lys165 (AGT) that has conferred resistance on 06-BG was therefore an active target of anti-drugs.</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1703">
                    <text>The replacing Gly156 and Lys165 (AGT) that can confer resistance to 06-BG was therefore an active target of anti-drugs.</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1704">
                    <text>The replacing Gly156 and Lys165 (AGT) that has conferred resistance on 06-BG was therefore an active target of anti-drugs.</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1705">
                    <text>The replacing simply the C-terminal with Stat5 (AGT) that can confer the Stat5 phenotype in the presence of MG132 to Stat1 was therefore an active target of anti-drugs.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1706">
                    <text>The replacing simply the C-terminal with Stat5 (AGT) that conferred stat5 phenotype of stability in the presence of MG132 on Stat1 was therefore an active target of anti-drugs.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1707">
                    <text>The replacing simply the C-terminal with Stat5 (AGT) that has conferred the Stat5 phenotype of stability in the presence of MG132 on Stat1 was therefore an active target of anti-drugs.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1708">
                    <text>The replacing simply the C-terminal with the Stat5 phenotype (AGT) having conferred the Stat5 phenotype of stability in the presence of MG132 on Stat1 was therefore an active target of anti-drugs.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1709">
                    <text>The replacing simply the C-terminal with the Stat5 phenotype (AGT) that can confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 was therefore an active target of anti-drugs.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1710">
                    <text>The resistance of 06-BG in a tolC deficit strain is conferred by the these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance of 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1711">
                    <text>The resistances conferred the resistance 06-BG.</text>
                    <arg n="0">resistances</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1712">
                    <text>The rise in AGT levels was attributed to resistance acquired in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance conferred by AGT to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1713">
                    <text>The rise in AGT levels was attributed to resistance acquired in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance conferred by Gly156 and Lys165 replacement to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1714">
                    <text>The rise in AGT levels was attributed to resistance acquired in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance conferred by alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase to alkylation pathways (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1715">
                    <text>The rise in AGT levels was attributed to resistance acquired in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance conferred by replacing Gly156 and Lys165 to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1716">
                    <text>The rise in AGT levels was attributed to the Stat5 phenotype in the presence of MG132 acquired in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance conferred by substituting only the C-terminal with Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1717">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and AGATT transfection could confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1718">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and AGT could confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1719">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and AGT transition was observed to confer resistance to Kaina et al., 1991 (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">AGT transition</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="1720">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and AGT was observed to confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1721">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and Gly156 and Lys165 replacement can confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1722">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and Gly156 and Lys165 replacement was observed to confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1723">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and Human 06-alkylguaning-DNA alkyltransferase could confer resistance to alkylation pathways (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1724">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and Human 06-alkylguaning-DNA alkyltransferase was observed to confer resistance to alkylation pathways (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1725">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and alkyguaning-DNA alkyltransferase can confer resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1726">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and alkyguaning-DNA alkyltransferase was observed to confer resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1727">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and alkylation of human alkyl hydroxyl-DNA alkyltransferase was observed to confer resistance to alkylation routes (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1728">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase is thought to confer resistance to alkylation pathways (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1729">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and alkylguaning-DNA alkyltransferase can confer resistance to alkylation routes (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1730">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and alkylguaning-DNA alkyltransferase is thought to confer resistance to alkylation routes (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1731">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and alkyltransferase of 06-alkyltransferase of AGT can confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="1732">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and alkyltransferase of 06-alkyltransferase of AGT can confer resistance to alkyltransferase of pathways (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase of pathways</arg>
                </example>
                <example src="PERMUTATE" no="1733">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and alkyltransferase of 06-alkyltransferase of AGT is thought to confer resistance to alkyltransferase of pathways (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase of pathways</arg>
                </example>
                <example src="PERMUTATE" no="1734">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and alkyltransferase of 06-alkyltransferase of AGT was observed to confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="1735">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and alkyltransferase of 06-alkyltransferase of AGT was observed to confer resistance to alkyltransferase chemotherapies (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1736">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and alkyltransferase of 06-alkyltransferase-DNA was observed to confer resistance to alkyltransferase chemotherapies (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1737">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and alkyltransferase-DNA alkyltransferase is thought to confer resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1738">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and human 06-alkylguaning-DNA alkyltransferase can confer resistance to alkylation pathways (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1739">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and human 06-alkylguaning-DNA alkyltransferase was observed to confer resistance to alkylation pathways (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1740">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and replaceing Gly156 and Lys165 could confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">replaceing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1741">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and replaceing Gly156 and Lys165 is thought to confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">replaceing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1742">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and replaceing Gly156 and Lys165 was observed to confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">replaceing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1743">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and replacements in Gly156 and Lys165 could confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1744">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and replacements to Gly156 and Lys165 can confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1745">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and replacements to Gly156 and Lys165 is thought to confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1746">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is conferred by AGATT transfection to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1747">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is conferred by alkyguaning-DNA alkyltransferase to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1748">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is conferred by alkyguaning-DNA alkyltransferase to alkylation routes (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1749">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is conferred by alkylguaning-DNA alkyltransferase to alkylation routes (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1750">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is conferred by alkyltransferase-DNA alkyltransferase to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1751">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is conferred by transfection of AGATT to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1752">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was conferred by AGT to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1753">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was conferred by AGT transition to Kaina et al., 1991 (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">AGT transition</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="1754">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was conferred by alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1755">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was conferred by alkylguaning-DNA alkyltransferase to alkylation routes (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1756">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was conferred by alkyltransferase of 06-alkyltransferase of AGT to alkylation (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="1757">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was conferred by alkyltransferase of 06-alkyltransferase of AGT to alkyltransferase of pathways (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase of pathways</arg>
                </example>
                <example src="PERMUTATE" no="1758">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was conferred by human alkyl-alkylation-DNA alkyltransferase to alkylation routes (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">human alkyl-alkylation-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1759">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was conferred by replaceing Gly156 and Lys165 to 06-BG (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">replaceing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1760">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was conferred by replacements in Gly156 and Lys165 to 06-BG (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1761">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and substitutions in Gly156 and Lys165 could confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1762">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and substitutions in Gly156 and Lys165 was observed to confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1763">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and substitutions to Gly156 and Lys165 can confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">substitutions to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1764">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and transfection of AGATT could confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1765">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and transfection of AGT is thought to confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1766">
                    <text>The rise in parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and transformation of AGT was observed to confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1767">
                    <text>The rise in parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and The STAT portion could confer resistance to a MAPK substrate or a MAPK kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1768">
                    <text>The rise in parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was conferred by The STAT portion to a MAPK substrate or a MAPK kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1769">
                    <text>The rise in parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and the STAT part was observed to confer resistance to a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1770">
                    <text>The rise in parallel AGT levels acquired alkylation stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and replacing simply the C-terminal with Stat5 can confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1771">
                    <text>The rise in parallel AGT levels acquired alkylation stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was conferred by replacing simply the C-terminal with Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1772">
                    <text>The rise in parallel AGT levels acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was conferred by substituting only the C-terminal with Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1773">
                    <text>The rise in parallel AGT levels acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and substituting only the C-terminal with Stat5 can confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1774">
                    <text>The rise in parallel AGT levels acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and replacing simply the C-terminal with the Stat5 phenotype is thought to confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1775">
                    <text>The rise in parallel AGT levels acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is conferred by replacing simply the C-terminal with Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1776">
                    <text>The rise in parallel AGT levels acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was conferred by replacing simply the C-terminal with Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1777">
                    <text>The rise in parallel AGT levels acquired alkylation the Stat5 stability phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and only the C-terminal substitution for Stat5 is thought to confer resistance to State1 (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="1778">
                    <text>The rise in parallel AGT levels acquired alkylation the Stat5 stability phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and only the C-terminal substitution for Stat5 was observed to confer resistance to State1 (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="1779">
                    <text>The rise in parallel AGT levels acquired alkylation the stability phenotype Stat5 in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and just replacing C-terminus by Stat5 can confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">just replacing C-terminus by Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1780">
                    <text>The rise in parallel AGT levels has acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance has been conferred by AGATT transfection to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1781">
                    <text>The rise in parallel AGT levels has acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance has been conferred by alkylguaning-DNA alkyltransferase to alkylation routes (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1782">
                    <text>The rise in parallel AGT levels has acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance has been conferred by alkyltransferase of 06-alkyltransferase of AGT to alkyltransferase chemotherapies (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1783">
                    <text>The rise in parallel AGT levels has acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance has been conferred by human alkyl-alkylation-DNA alkyltransferase to alkylation routes (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">human alkyl-alkylation-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1784">
                    <text>The rise in parallel AGT levels has acquired alkylation the Stat5 stability phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance has been conferred by just replacing the C-terminal with the Stat5 phenotype to Stat1 (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1785">
                    <text>The rise of AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by GAT transformation to Alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1786">
                    <text>The rise of AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by alkylguaning-DNA alkyltransferase to alkylation routes (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1787">
                    <text>The rise of AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by alkyltransferase of 06-alkyltransferase of AGT to alkyltransferase chemotherapies (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1788">
                    <text>The rise of AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by replacements in Gly156 and Lys165 to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1789">
                    <text>The rise of AGT levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by replacements to Gly156 and Lys165 to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1790">
                    <text>The rise of AGT levels in parallel to acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by The portion of the STATs to either a MAPK or a MAPK kinase substrate (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1791">
                    <text>The rise of AGT levels in parallel to acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by The portion of the STATs to either a MAPK or a MAPK substrat kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1792">
                    <text>The rise of AGT levels in parallel to acquired alkylation the Stat5 stability phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by only the C-terminal substitution for Stat5 to State1 (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="1793">
                    <text>The rise of AGT levels in parallel to acquired alkylation the stability Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by just replacing the C-terminal with the Stat5 phenotype to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1794">
                    <text>The rise of AGT levels in parallel to acquired alkylation the stability phenotype Stat5 in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by just replacing C-terminus by Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">just replacing C-terminus by Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1795">
                    <text>The rise of AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by AGATT transfection on alkylation-sensitive cells, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1796">
                    <text>The rise of AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by alkyguaning-DNA alkyltransferase on alkylation routes, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1797">
                    <text>The rise of AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by alkylguaning-DNA alkyltransferase on alkyl ways, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyl ways</arg>
                </example>
                <example src="PERMUTATE" no="1798">
                    <text>The rise of AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by alkylguaning-DNA alkyltransferase on alkylation routes, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1799">
                    <text>The rise of AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by alkyltransferase of 06-alkyltransferase of AGT on alkylation, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="1800">
                    <text>The rise of AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by replacing Gly156 and Lys165 on 06-BG, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1801">
                    <text>The rise of AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by substitutions in Gly156 and Lys165 on 06-BG, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1802">
                    <text>The rise of AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were conferred by alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase on alkylation chemotherapies, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1803">
                    <text>The rise of AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were conferred by alkylguaning-DNA alkyltransferase on alkyl ways, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyl ways</arg>
                </example>
                <example src="PERMUTATE" no="1804">
                    <text>The rise of AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were conferred by alkylguaning-DNA alkyltransferase on alkylation routes, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1805">
                    <text>The rise of AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were conferred by alkyltransferase of 06-alkyltransferase of AGT on alkylation, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="1806">
                    <text>The rise of AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were conferred by alkyltransferase-DNA alkyltransferase on alkylation chemotherapies, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1807">
                    <text>The rise of AGT levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were conferred by replacements in Gly156 and Lys165 on 06-BG, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1808">
                    <text>The rise of AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by the portion of the STATs on either a MAPK or a MAPK kinase substrate (MAPKAP), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1809">
                    <text>The rise of AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were conferred by the STAT part on a MAPK or a MAPK substrate kinase (MAPKAP), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1810">
                    <text>The rise of AGT levels in parallel with acquired alkylation stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by replacing simply the C-terminal with Stat5 on Stat1, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1811">
                    <text>The rise of AGT levels in parallel with acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by replacing simply the C-terminal with Stat5 on Stat1, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1812">
                    <text>The rise of AGT levels in parallel with acquired alkylation the stability Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were conferred by just replacing the C-terminal with the Stat5 phenotype on Stat1, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1813">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and AGATT transfection is able to confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1814">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and AGT transformation has the ability to confer resistance to Kaina et al., 1991 (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="1815">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and AGT transition has the ability to confer resistance to Kaina et al., 1991 (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">AGT transition</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="1816">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and GAT transformation was able to confer resistance to Alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1817">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and Human 06-alkylguaning-DNA alkyltransferase conferred resistance on alkylation pathways (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1818">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and Human 06-alkylguaning-DNA alkyltransferase has the ability to confer resistance to alkylation pathways (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1819">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and Human 06-alkylguaning-DNA alkyltransferase is able to confer resistance to alkylation pathways (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1820">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and alkyguaning-DNA alkyltransferase has the ability to confer resistance to alkylation routes (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1821">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and alkyguaning-DNA alkyltransferase is able to confer resistance to alkylation routes (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1822">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and alkylation of human alkyl hydroxyl-DNA alkyltransferase was able to confer resistance to alkylation routes (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1823">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and alkylation of human alkyl hydroxyl-DNA alkyltransferase would confer resistance to alkylation routes (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1824">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase was able to confer resistance to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1825">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase will confer resistance to alkylation pathways (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1826">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase would confer resistance to alkylation pathways (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1827">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT conferred resistance on alkylation (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="1828">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and alkyltransferase of 06-alkyltransferase of AGT has the ability to confer resistance to alkyltransferase chemotherapies (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1829">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and alkyltransferase of 06-alkyltransferase of AGT is able to confer resistance to alkyltransferase of pathways (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase of pathways</arg>
                </example>
                <example src="PERMUTATE" no="1830">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and alkyltransferase of 06-alkyltransferase of AGT was able to confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="1831">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and alkyltransferase of 06-alkyltransferase of AGT will confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="1832">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and alkyltransferase of 06-alkyltransferase of AGT will confer resistance to alkyltransferase of pathways (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase of pathways</arg>
                </example>
                <example src="PERMUTATE" no="1833">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and alkyltransferase of 06-alkyltransferase of AGT would confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="1834">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and alkyltransferase of 06-alkyltransferase-DNA conferred resistance on alkyltransferase chemotherapies (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1835">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and human 06-alkylguaning-DNA alkyltransferase is able to confer resistance to alkylation pathways (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1836">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and human alkyl-alkylation-DNA alkyltransferase will confer resistance to alkylation routes (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">human alkyl-alkylation-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1837">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and replaceing Gly156 and Lys165 conferred resistance on 06-BG (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">replaceing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1838">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and replaceing Gly156 and Lys165 would confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">replaceing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1839">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and replacements in Gly156 and Lys165 will confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1840">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and replacing Gly156 and Lys165 will confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1841">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance can be conferred by AGT transformation to Alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1842">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance can be conferred by AGT transition to Kaina et al., 1991 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">AGT transition</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="1843">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance can be conferred by alkyguaning-DNA alkyltransferase to alkylation routes (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1844">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance can be conferred by alkyltransferase of 06-alkyltransferase of AGT to alkyltransferase chemotherapies (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1845">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance can be conferred by human alkyl-alkylation-DNA alkyltransferase to alkylation routes (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">human alkyl-alkylation-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1846">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance could be conferred by AGT transformation to Alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1847">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance could be conferred by AGT transformation to Kaina et al., 1991 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="1848">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance could be conferred by alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1849">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance could be conferred by alkyltransferase of 06-alkyltransferase of AGT to alkyltransferase chemotherapies (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1850">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance could be conferred by alkyltransferase of 06-alkyltransferase-DNA to alkyltransferase chemotherapies (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1851">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance could be conferred by alkyltransferase-DNA alkyltransferase to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1852">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance could be conferred by human alkyl-alkylation-DNA alkyltransferase to alkylation routes (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">human alkyl-alkylation-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1853">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is able to be conferred by AGT transformation to Kaina et al., 1991 (Kaina et al., 1991), demonstrating the role of AGATT in A1 therapy (resistance).</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="1854">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is able to be conferred by alkylguaning-DNA alkyltransferase to alkyl ways (Kaina et al., 1991), demonstrating the role of AGATT in A1 therapy (resistance).</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyl ways</arg>
                </example>
                <example src="PERMUTATE" no="1855">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is able to be conferred by alkylguaning-DNA alkyltransferase to alkylation routes (Kaina et al., 1991), demonstrating the role of AGATT in A1 therapy (resistance).</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1856">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is able to be conferred by alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT to alkylation (Kaina et al., 1991), demonstrating the role of AGATT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="1857">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is able to be conferred by alkyltransferase of 06-alkyltransferase of AGT to alkyltransferase chemotherapies (Kaina et al., 1991), demonstrating the role of AGATT in A1 therapy (resistance).</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1858">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is able to be conferred by replacements in Gly156 and Lys165 to 06-BG (Kaina et al., 1991), demonstrating the role of AGATT in A1 therapy (resistance).</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1859">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is able to be conferred by replacements to Gly156 and Lys165 to 06-BG (Kaina et al., 1991), demonstrating the role of AGATT in A1 therapy (resistance).</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1860">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is able to be conferred by substitutions to Gly156 and Lys165 to 06-BG (Kaina et al., 1991), demonstrating the role of AGATT in A1 therapy (resistance).</text>
                    <arg n="0">substitutions to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1861">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is thought to be conferred by AGATT transfection to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1862">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is thought to be conferred by AGT transformation to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1863">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is thought to be conferred by alkyltransferase-DNA alkyltransferase to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1864">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is thought to be conferred by human alkyl-alkylation-DNA alkyltransferase to alkylation routes (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">human alkyl-alkylation-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1865">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is thought to be conferred by replaceing Gly156 and Lys165 to 06-BG (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">replaceing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1866">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is thought to be conferred by substitutions to Gly156 and Lys165 to 06-BG (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">substitutions to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1867">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance may have been conferred by GAT transformation to Alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1868">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance may have been conferred by alkylguaning-DNA alkyltransferase to alkylation routes (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1869">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance may have been conferred by alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT to alkylation (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="1870">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance may have been conferred by alkyltransferase of 06-alkyltransferase of AGT to alkyltransferase chemotherapies (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1871">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was able to be conferred by AGT transformation to Alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1872">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was able to be conferred by AGT transformation to Kaina et al., 1991 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="1873">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was able to be conferred by AGT transition to Kaina et al., 1991 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">AGT transition</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="1874">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was able to be conferred by alkyguaning-DNA alkyltransferase to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1875">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was able to be conferred by human alkyl-alkylation-DNA alkyltransferase to alkylation routes (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">human alkyl-alkylation-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1876">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was able to be conferred by replacements to Gly156 and Lys165 to 06-BG (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1877">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was believed to be conferred by alkylation of human alkyl hydroxyl-DNA alkyltransferase to alkylation routes (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1878">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was believed to be conferred by human 06-alkylguaning-DNA alkyltransferase to alkylation pathways (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1879">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was believed to be conferred by replacing Gly156 and Lys165 to 06-BG (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1880">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was believed to be conferred by transformation of GAT to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">transformation of GAT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1881">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance will be conferred by AGT transformation to Alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1882">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance will be conferred by human 06-alkylguaning-DNA alkyltransferase to alkylation pathways (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1883">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance will be conferred by replacing Gly156 and Lys165 to 06-BG (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1884">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance will be conferred by transfection of AGT to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1885">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance would be conferred by AGT transformation to Kaina et al., 1991 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="1886">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance would be conferred by Human 06-alkylguaning-DNA alkyltransferase to alkylation pathways (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="1887">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance would be conferred by alkyltransferase-DNA alkyltransferase to alkylation chemotherapies (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1888">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and substitutions in Gly156 and Lys165 was able to confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1889">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and substitutions in Gly156 and Lys165 will confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1890">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and substitutions in Gly156 and Lys165 would confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1891">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and substitutions to Gly156 and Lys165 is able to confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">substitutions to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1892">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and substitutions to Gly156 and Lys165 was able to confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">substitutions to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1893">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and transfection of AGATT conferred resistance on alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1894">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and transfection of AGT conferred resistance on alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1895">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and transformation of AGT conferred resistance on alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1896">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and transformation of AGT was able to confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1897">
                    <text>The rise of parallel AGT levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and transformation of GAT is able to confer resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">transformation of GAT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1898">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and The STAT portion conferred resistance on a MAPK substrate or a MAPK kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1899">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and The STAT portion was able to confer resistance to a MAPK substrate or a MAPK kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1900">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and The portion of the STATs has the ability to confer resistance to either a MAPK or a MAPK kinase substrate (MAPKAP) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1901">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and The portion of the STATs is able to confer resistance to either a MAPK or a MAPK substrat kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1902">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and The portion of the STATs was able to confer resistance to either a MAPK or a MAPK kinase substrate (MAPKAP) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1903">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and The portion of the STATs will confer resistance to either a MAPK or a MAPK substrat kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1904">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is able to be conferred by the portion of the STATs to either a MAPK or a MAPK kinase substrate (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGATT in A1 therapy (resistance).</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1905">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance may have been conferred by The STAT portion to a MAPK substrate or a MAPK kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1906">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was able to be conferred by The STAT portion to a MAPK substrate or a MAPK kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1907">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was able to be conferred by The portion of the STATs to either a MAPK or a MAPK substrat kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1908">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was able to be conferred by the STAT part to a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1909">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was believed to be conferred by the part of STATs to a MAPK substrate or a MAPK kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1910">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance will be conferred by The portion of the STATs to either a MAPK or a MAPK substratum kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1911">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance will be conferred by the STAT part to a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1912">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance will be conferred by the portion of the STATs to either a MAPK or a MAPK kinase substrate (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1913">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance would be conferred by The STAT portion to a MAPK substrate or a MAPK kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1914">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance would be conferred by The portion of the STATs to either a MAPK or a MAPK kinase substrate (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1915">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance would be conferred by the STAT part to a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1916">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and the STAT part conferred resistance on a MAPK or a MAPK substrate kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1917">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and the part of STATs conferred resistance on a MAPK substrate or a MAPK kinase (MAPKAP) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1918">
                    <text>The rise of parallel AGT levels acquired alkylation stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and replacing simply the C-terminal with Stat5 was able to confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1919">
                    <text>The rise of parallel AGT levels acquired alkylation stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance can be conferred by replacing simply the C-terminal with Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1920">
                    <text>The rise of parallel AGT levels acquired alkylation stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance would be conferred by replacing simply the C-terminal with Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1921">
                    <text>The rise of parallel AGT levels acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and replacing simply the C-terminal with Stat5 was able to confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1922">
                    <text>The rise of parallel AGT levels acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and replacing simply the C-terminal with Stat5 will confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1923">
                    <text>The rise of parallel AGT levels acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance could be conferred by substituting only the C-terminal with Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1924">
                    <text>The rise of parallel AGT levels acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is thought to be conferred by substituting only the C-terminal with Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1925">
                    <text>The rise of parallel AGT levels acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and only C-terminal substitution for Stat5 was able to confer resistance to State1 (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">only C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="1926">
                    <text>The rise of parallel AGT levels acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and replacing simply the C-terminal with the Stat5 phenotype was able to confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1927">
                    <text>The rise of parallel AGT levels acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance can be conferred by replacing simply the C-terminal with Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1928">
                    <text>The rise of parallel AGT levels acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is thought to be conferred by replacing simply the C-terminal with Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1929">
                    <text>The rise of parallel AGT levels acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is thought to be conferred by replacing simply the C-terminal with the Stat5 phenotype to Stat1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1930">
                    <text>The rise of parallel AGT levels acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was able to be conferred by replacing simply the C-terminal with Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1931">
                    <text>The rise of parallel AGT levels acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was believed to be conferred by only C-terminal substitution for Stat5 to State1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">only C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="1932">
                    <text>The rise of parallel AGT levels acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance will be conferred by replacing simply the C-terminal with the Stat5 phenotype to Stat1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1933">
                    <text>The rise of parallel AGT levels acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance would be conferred by replacing simply the C-terminal with the Stat5 phenotype to Stat1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1934">
                    <text>The rise of parallel AGT levels acquired alkylation the Stat5 stability phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and just replacing the C-terminal with the Stat5 phenotype is able to confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1935">
                    <text>The rise of parallel AGT levels acquired alkylation the Stat5 stability phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and only the C-terminal substitution for Stat5 will confer resistance to State1 (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="1936">
                    <text>The rise of parallel AGT levels acquired alkylation the Stat5 stability phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is able to be conferred by just replacing the C-terminal with the Stat5 phenotype to Stat1 (Kaina et al., 1991), demonstrating the role of AGATT in A1 therapy (resistance).</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1937">
                    <text>The rise of parallel AGT levels acquired alkylation the Stat5 stability phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was able to be conferred by only the C-terminal substitution for Stat5 to State1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="1938">
                    <text>The rise of parallel AGT levels acquired alkylation the Stat5 stability phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance will be conferred by only the C-terminal substitution for Stat5 to State1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="1939">
                    <text>The rise of parallel AGT levels acquired alkylation the stability Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and just replacing the C-terminal with the Stat5 phenotype would confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1940">
                    <text>The rise of parallel AGT levels acquired alkylation the stability Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is thought to be conferred by just replacing the C-terminal with the Stat5 phenotype to Stat1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1941">
                    <text>The rise of parallel AGT levels acquired alkylation the stability Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was able to be conferred by just replacing the C-terminal with the Stat5 phenotype to Stat1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1942">
                    <text>The rise of parallel AGT levels acquired alkylation the stability phenotype Stat5 in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and just replacing C-terminus by Stat5 would confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">just replacing C-terminus by Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1943">
                    <text>The rise of parallel AGT levels acquired alkylation the stability phenotype Stat5 in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was believed to be conferred by just replacing C-terminus by Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">just replacing C-terminus by Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="1944">
                    <text>The senseless alteration or frame change of the codex sequence or by cutting variants conferred the mutation function miss.</text>
                    <arg n="0">senseless alteration or frame change of the codex sequence or by cutting variants</arg>
                    <arg n="1">mutation function miss</arg>
                </example>
                <example src="PERMUTATE" no="1945">
                    <text>The six mutations conferred the resistance 06-BG.</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1946">
                    <text>The specificity in a tolC deficit strain is conferred by the The part of TASTs.</text>
                    <arg n="0">The part of TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1947">
                    <text>The specificity in a tolC deficit strain is conferred by the part of STATs.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1948">
                    <text>The specificity in a tolC deficit strain is conferred by the the part of the TASTs.</text>
                    <arg n="0">the part of the TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1949">
                    <text>The substitutions to Gly156 and Lys165 (AGT) that conferred resistance on 06-BG was therefore an active target of anti-drugs.</text>
                    <arg n="0">substitutions to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1950">
                    <text>The the STAT part (AGT) that conferred specificity on a MAPK or a MAPK substrate kinase (MAPKAP) was therefore an active target of anti-drugs.</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1951">
                    <text>The the gene variant conferred the a higher risk of diabetes.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1952">
                    <text>The the genetic variant conferred the an increasing risk of diabetes.</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1953">
                    <text>The the part of STATs (AGT) that has conferred specificity on a MAPK substrate or a MAPK kinase (MAPKAP) was therefore an active target of anti-drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="1954">
                    <text>The the part of the STATs conferred the specificity.</text>
                    <arg n="0">the part of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1955">
                    <text>The transfection of AGATT (AGT) having conferred resistance on alkylation-sensitive cells was therefore an active target of anti-drugs.</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1956">
                    <text>The transfection of AGATT (AGT) that is observed to confer resistance on alkylation-sensitive cells was therefore an active target of anti-drugs.</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1957">
                    <text>The transformation of AGT (AGT) that has conferred resistance on alkylation-sensitive cells was therefore an active target of anti-drugs.</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1958">
                    <text>The transformation of GAT (AGT) that conferred resistance on alkylation-sensitive cells was therefore an active target of anti-drugs.</text>
                    <arg n="0">transformation of GAT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="1959">
                    <text>These mutations is not able to confer resistance 06-BG.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1960">
                    <text>These mutations may not have conferred resistance 06-BG.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1961">
                    <text>These mutations was considered to be the one that confers resistance 06-BG to A2 (a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1962">
                    <text>These mutations which confers resistance 06-BG to A2 (a MAPK substrate or a MAPK kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1963">
                    <text>Xu-Welliver et al., 1999a in a tolC problem strain has been conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">Xu-Welliver et al., 1999a</arg>
                </example>
                <example src="PERMUTATE" no="1964">
                    <text>Xu-Welliver et al., 1999a in a tolC-deficient strain is able to be conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">Xu-Welliver et al., 1999a</arg>
                </example>
                <example src="PERMUTATE" no="1965">
                    <text>Xu-Welliver et al., 1999a in a tolC-deficient strain was conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">Xu-Welliver et al., 1999a</arg>
                </example>
                <example src="PERMUTATE" no="1966">
                    <text>You may not have The part of STATs and no conferred specificity.</text>
                    <arg n="0">The part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1967">
                    <text>You may not have These mutations and no conferred resistance 06-BG.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1968">
                    <text>You may not have gene variety and no conferred increased risk of diabetes.</text>
                    <arg n="0">gene variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1969">
                    <text>You may not have over expression of EvgA and no conferred resistance.</text>
                    <arg n="0">over expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="1970">
                    <text>You may not have resistance and no conferred resistance 06-BG.</text>
                    <arg n="0">resistance</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1971">
                    <text>You may not have senseless alteration or frame change of the codex sequence or by cutting variants and no conferred mutation function miss.</text>
                    <arg n="0">senseless alteration or frame change of the codex sequence or by cutting variants</arg>
                    <arg n="1">mutation function miss</arg>
                </example>
                <example src="PERMUTATE" no="1972">
                    <text>You may not have the gene variant and no conferred a higher risk of diabetes.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1973">
                    <text>You may not have the genetic variant and no conferred an increasing risk of diabetes.</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1974">
                    <text>You may not have the portion of the STATs and no conferred specificity.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="1975">
                    <text>You may not have these mutations and no conferred resistance 06-BG.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="1976">
                    <text>a higher risk of diabetes in a strain with deficiencies in the tolC can be conferred via the genetic variant.</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1977">
                    <text>a higher risk of diabetes in a strain with tolC deficiencies is able to be conferred by the genetic variant.</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1978">
                    <text>a higher risk of diabetes in a tolC-deficient strain is conferred by the genetic variant.</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1979">
                    <text>a higher risk of diabetes in a tolC-deficient strain was conferred by the genetic variant.</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1980">
                    <text>a higher risk of diabetes is the not conferred by the genetic variant.</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1981">
                    <text>a higher risk of diabetes is thought to be conferred by M-NG (not) for the gene variant.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="1982">
                    <text>alkyguaning-DNA alkyltransferase (AGT) that can confer resistance to alkylation chemotherapies was therefore an active target of anti-drugs.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1983">
                    <text>alkyguaning-DNA alkyltransferase (AGT), which directly inverts endogenous alkylation to 06-position of guanine, is observed to confer resistance to alkylation routes and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1984">
                    <text>alkyguaning-DNA alkyltransferase (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, was able to confer resistance to alkylation routes and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1985">
                    <text>alkyguaning-DNA alkyltransferase (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, was observed to confer resistance to alkylation routes and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1986">
                    <text>alkyguaning-DNA alkyltransferase (AGT), which directly reverses the endogenous alkylation to the position 06 of guanin, may confer resistance to alkylation chemotherapies and is therefore an active target of anticancer drugs.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1987">
                    <text>alkyguaning-DNA alkyltransferase 06 human (AGT) that conferred resistance over alkylation chemotherapies was therefore an active target of anti-drugs.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1988">
                    <text>alkyguaning-DNA alkyltransferase has not been determined to be able to confer resistance to alkylation chemotherapies.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1989">
                    <text>alkyguaning-DNA alkyltransferase human 06-alkylguaning-DNA (AGT) that conferred resistance to alkylation chemotherapies was therefore an active target of anti-drugs.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="1990">
                    <text>alkyguaning-DNA alkyltransferase may confer resistance to alkylation routes has not been determined.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1991">
                    <text>alkylation of human alkyl hydroxyl-DNA alkyltransferase (AGT) that can confer resistance to alkylation routes was therefore an active target of anti-drugs.</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1992">
                    <text>alkylation of human alkyl hydroxyl-DNA alkyltransferase (AGT), which directly inverts endogenous alkylation to 06-position of guanine, is able to confer resistance to alkylation routes and is therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1993">
                    <text>alkylation of human alkyl hydroxyl-DNA alkyltransferase (AGT), which directly inverts endogenous alkylation to 06-position of the guanine, would confer resistance to alkylation routes and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1994">
                    <text>alkylation of human alkyl hydroxyl-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at 06-position of the guanine, has the ability to confer resistance to alkylation routes and is therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1995">
                    <text>alkylation of human alkyl hydroxyl-DNA alkyltransferase (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, was observed to confer resistance to alkylation routes and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1996">
                    <text>alkylation of human alkyl hydroxyl-DNA alkyltransferase (AGT), which directly reverses the endogenous alkylation at the position of guanin 6, conferred resistance to alkylation routes and is therefore an active target of anticancer drugs.</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1997">
                    <text>alkylguaning-DNA alkyltransferase (AGT) is thought to confer resistance on alkylation routes was therefore an active target of anti-tank drugs.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1998">
                    <text>alkylguaning-DNA alkyltransferase (AGT) that conferred resistance over alkylation routes was therefore an active target for anti-drugs.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="1999">
                    <text>alkylguaning-DNA alkyltransferase (AGT), which directly inverts endogenous alkylation to 06-position of guanine, conferred resistance on alkylation routes and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="2000">
                    <text>alkylguaning-DNA alkyltransferase (AGT), which directly inverts endogenous alkylation to 06-position of guanine, is able to confer resistance to alkyl ways and is therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyl ways</arg>
                </example>
                <example src="PERMUTATE" no="2001">
                    <text>alkylguaning-DNA alkyltransferase (AGT), which directly inverts endogenous alkylation to 06-position of guanine, is thought to confer resistance to alkylation routes and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="2002">
                    <text>alkylguaning-DNA alkyltransferase (AGT), which directly inverts endogenous alkylation to 06-position of the guanine, can confer resistance to alkyl ways and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyl ways</arg>
                </example>
                <example src="PERMUTATE" no="2003">
                    <text>alkylguaning-DNA alkyltransferase (AGT), which directly inverts endogenous alkylation to 06-position of the guanine, could confer resistance to alkyl ways and thus was an active target of anti-cancer drugs.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyl ways</arg>
                </example>
                <example src="PERMUTATE" no="2004">
                    <text>alkylguaning-DNA alkyltransferase (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, may confer resistance to alkyl ways and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyl ways</arg>
                </example>
                <example src="PERMUTATE" no="2005">
                    <text>alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase (AGT) is thought to confer resistance on alkylation pathways was therefore an active target of anti-tank drugs.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="2006">
                    <text>alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase (AGT) that conferred resistance over alkylation chemotherapies was therefore an active target for anti-drugs.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2007">
                    <text>alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase (AGT), which directly inverts endogenous alkylation to 06-position of guanine, conferred resistance on alkylation pathways and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="2008">
                    <text>alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at 06-position of guanine, was able to confer resistance to alkylation pathways and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="2009">
                    <text>alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at 06-position of the guanine, was believed to confer resistance on alkylation chemotherapies and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2010">
                    <text>alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses the endogenous alkylation in 06 guanin positions, has the ability to confer resistance to alkylation chemotherapies and therefore is an active target of antineoplastic drugs.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2011">
                    <text>alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses the endogenous alkylation to the position 06 of guanin, could confer resistance to alkylation chemotherapies and thus was an active target of antineoplastic drugs.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2012">
                    <text>alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses the endogenous alkylation to the position 06 of guanin, may confer resistance to alkylation pathways and is therefore an active target of anticancer drugs.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="2013">
                    <text>alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase has not been determined to be able to confer resistance to alkylation pathways.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="2014">
                    <text>alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase human 06-alkylguaning-DNA (AGT) that conferred resistance to alkylation pathways was therefore an active target of anti-drugs.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="2015">
                    <text>alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase may confer resistance to alkylation chemotherapies has not been determined.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2016">
                    <text>alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase may confer resistance to alkylation pathways has not been determined.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="2017">
                    <text>alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT (AGT), which directly inverts endogenous alkylation to 06-position of guanine, is thought to confer resistance to alkylation and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="2018">
                    <text>alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT (AGT), which directly inverts endogenous alkylation to 06-position of the guanine, can confer resistance to alkylation and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="2019">
                    <text>alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT (AGT), which directly inverts endogenous alkylation to 06-position of the guanine, could confer resistance to alkylation and thus was an active target of anti-cancer drugs.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="2020">
                    <text>alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT (AGT), which directly reverses endogenous alkylation at 06-position of guanine, was able to confer resistance to alkylation and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="2021">
                    <text>alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, may confer resistance to alkylation and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="2022">
                    <text>alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT (AGT), which directly reverses the endogenous alkylation to 06-platinin position, would confer resistance to alkylation and therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="2023">
                    <text>alkyltransferase of 06-alkyltransferase of AGT (AGT) that conferred resistance over alkyltransferase chemotherapies was therefore an active target for anti-drugs.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2024">
                    <text>alkyltransferase of 06-alkyltransferase of AGT (AGT), which directly inverts endogenous alkylation to 06-position of guanine, conferred resistance on alkylation and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="2025">
                    <text>alkyltransferase of 06-alkyltransferase of AGT (AGT), which directly inverts endogenous alkylation to 06-position of guanine, is observed to confer resistance to alkylation and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="2026">
                    <text>alkyltransferase of 06-alkyltransferase of AGT (AGT), which directly inverts endogenous alkylation to 06-position of guanine, is thought to confer resistance to alkyltransferase chemotherapies and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2027">
                    <text>alkyltransferase of 06-alkyltransferase of AGT (AGT), which directly inverts endogenous alkylation to 06-position of the guanine, would confer resistance to alkyltransferase of pathways and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase of pathways</arg>
                </example>
                <example src="PERMUTATE" no="2028">
                    <text>alkyltransferase of 06-alkyltransferase of AGT (AGT), which directly reverses endogenous alkylation at 06-position of guanine, was observed to confer resistance on alkyltransferase chemotherapies and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2029">
                    <text>alkyltransferase of 06-alkyltransferase of AGT (AGT), which directly reverses endogenous alkylation at 06-position of the guanine, was believed to confer resistance on alkyltransferase of pathways and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase of pathways</arg>
                </example>
                <example src="PERMUTATE" no="2030">
                    <text>alkyltransferase of 06-alkyltransferase of AGT (AGT), which directly reverses the endogenous alkyl to the 6-position of guanin, is observed to confer resistance to alkyltransferase chemotherapies and is therefore an active target for anticancer drugs.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2031">
                    <text>alkyltransferase of 06-alkyltransferase of AGT (AGT), which directly reverses the endogenous alkyl to the 6-position of guanin, is observed to confer resistance to alkyltransferase of pathways and is therefore an active target for anticancer drugs.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase of pathways</arg>
                </example>
                <example src="PERMUTATE" no="2032">
                    <text>alkyltransferase of 06-alkyltransferase of AGT (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, may confer resistance to alkylation and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="2033">
                    <text>alkyltransferase of 06-alkyltransferase of AGT (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, may confer resistance to alkyltransferase of pathways and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase of pathways</arg>
                </example>
                <example src="PERMUTATE" no="2034">
                    <text>alkyltransferase of 06-alkyltransferase of AGT (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, was able to confer resistance to alkyltransferase chemotherapies and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2035">
                    <text>alkyltransferase of 06-alkyltransferase of AGT (AGT), which directly reverses the endogenous alkylation to the position 06 of guanin, could confer resistance to alkyltransferase of pathways and thus was an active target of antineoplastic drugs.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase of pathways</arg>
                </example>
                <example src="PERMUTATE" no="2036">
                    <text>alkyltransferase of 06-alkyltransferase of AGT (AGT), which directly reverses the endogenous alkylation to the position 06 of guanin, is able to confer resistance to alkylation and therefore is an active target of antineoplastic drugs.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="2037">
                    <text>alkyltransferase of 06-alkyltransferase of AGT (AGT), which directly reverses the endogenous alkylation to the position 06 of guanin, is able to confer resistance to alkyltransferase chemotherapies and therefore is an active target of antineoplastic drugs.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2038">
                    <text>alkyltransferase of 06-alkyltransferase of AGT (AGT), which directly reverses the endogenous alkylation to the position 06 of guanin, is able to confer resistance to alkyltransferase of pathways and therefore is an active target of antineoplastic drugs.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase of pathways</arg>
                </example>
                <example src="PERMUTATE" no="2039">
                    <text>alkyltransferase of 06-alkyltransferase-DNA (AGT) that is able to confer resistance to alkyltransferase chemotherapies was therefore an active target of anti-drugs.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2040">
                    <text>alkyltransferase of 06-alkyltransferase-DNA (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, may confer resistance to alkyltransferase chemotherapies and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2041">
                    <text>alkyltransferase of 06-alkyltransferase-DNA (AGT), which directly reverses the endogenous alkylation in 06 guanin positions, has the ability to confer resistance to alkyltransferase chemotherapies and therefore is an active target of antineoplastic drugs.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2042">
                    <text>alkyltransferase of 06-alkyltransferase-DNA (AGT), which directly reverses the endogenous alkylation to the position 06 of guanin, could confer resistance to alkyltransferase chemotherapies and thus was an active target of antineoplastic drugs.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2043">
                    <text>alkyltransferase-DNA alkyltransferase (AGT) is thought to confer resistance on alkylation chemotherapies was therefore an active target of anti-tank drugs.</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2044">
                    <text>alkyltransferase-DNA alkyltransferase (AGT) which conferring resistance on alkylation chemotherapies is therefore an active target of anti-tank drugs.</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2045">
                    <text>alkyltransferase-DNA alkyltransferase (AGT), which directly reverses the endogenous alkyl to the 6-position of guanin, is observed to confer resistance to alkylation chemotherapies and is therefore an active target for anticancer drugs.</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2046">
                    <text>alkyltransferase-DNA alkyltransferase (AGT), which directly reverses the endogenous alkylation to the position 06 of guanin, could confer resistance to alkylation chemotherapies and thus was an active target of antineoplastic drugs.</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2047">
                    <text>an increased risk of diabetes in a strain with deficiencies in the tolC can be conferred via genetic variety.</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="2048">
                    <text>an increasing risk of diabetes can be conferred by the gene variant.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="2049">
                    <text>an increasing risk of diabetes in a tolC-deficient strain can be conferred by the genetic variant.</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="2050">
                    <text>an increasing risk of diabetes in a tolC-deficient strain is able to be conferred by the genetic variant.</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="2051">
                    <text>an increasing risk of diabetes in a tolC-deficient strain was conferred by the gene variant.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="2052">
                    <text>an increasing risk of diabetes was considered as not conferred by the gene variant.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="2053">
                    <text>gene variety can be conferred to increased risk of diabetes.</text>
                    <arg n="0">gene variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="2054">
                    <text>gene variety is not able to confer increased risk of diabetes.</text>
                    <arg n="0">gene variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="2055">
                    <text>genetic variation conferred increasing risk of diabetes to A2 (one MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="2056">
                    <text>genetic variation is able to confer increased risk of diabetes to A2 (a MAPK substrate or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="2057">
                    <text>genetic variation is considered to be no to confer increasing risk of diabetes.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="2058">
                    <text>genetic variation may not have conferred increased risk of diabetes.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="2059">
                    <text>genetic variation might have not conferred increased risk of diabetes.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="2060">
                    <text>genetic variation of M-NEG does not confer increased risk of diabetes.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="2061">
                    <text>genetic variation will confer increased risk of diabetes.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="2062">
                    <text>genetic variety conferred an increased risk of diabetes to A2 (one MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="2063">
                    <text>genetic variety conferred increased risk of diabetes to A2 (one MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="2064">
                    <text>genetic variety is considered to be no to confer an increased risk of diabetes.</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="2065">
                    <text>genetic variety is considered to be the one that confers an increased risk of diabetes on A2 (a MAPK or a MAPK substrate of kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="2066">
                    <text>genetic variety is not able to confer increased risk of diabetes.</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="2067">
                    <text>genetic variety was considered to be the one that confers an increased risk of diabetes to A2 (a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="2068">
                    <text>genetic variety was not able to confer an increased risk of diabetes.</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">an increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="2069">
                    <text>genetic variety which confers increased risk of diabetes to A2 (a MAPK substrate or a MAPK kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="2070">
                    <text>human alkyl-alkylation-DNA alkyltransferase (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, may confer resistance to alkylation routes and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">human alkyl-alkylation-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="2071">
                    <text>increased risk of diabetes in a strain with a tolC deficit was conferred by genetic variety.</text>
                    <arg n="0">genetic variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="2072">
                    <text>increased risk of diabetes was the not conferred by gene variety.</text>
                    <arg n="0">gene variety</arg>
                    <arg n="1">increased risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="2073">
                    <text>increasing risk of diabetes in a tolC problem strain has been conferred by genetic variation.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="2074">
                    <text>increasing risk of diabetes in a tolC-deficient strain may have been conferred by genetic variation.</text>
                    <arg n="0">genetic variation</arg>
                    <arg n="1">increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="2075">
                    <text>just replacing C-terminus by Stat5 (AGT) is thought to confer the stability phenotype Stat5 in the presence of MG132 on Stat1 was therefore an active target of anti-tank drugs.</text>
                    <arg n="0">just replacing C-terminus by Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2076">
                    <text>just replacing C-terminus by Stat5 (AGT) that can confer the stability phenotype Stat5 in the presence of MG132 to Stat1 was therefore an active target of anti-drugs.</text>
                    <arg n="0">just replacing C-terminus by Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2077">
                    <text>just replacing C-terminus by Stat5 (AGT), which directly reverses endogenous alkylation at 06-position of guanine, was able to confer the stability phenotype Stat5 in the presence of MG132 to Stat1 and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">just replacing C-terminus by Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2078">
                    <text>just replacing C-terminus by Stat5 (AGT), which directly reverses the endogenous alkyl to the 6-position of guanin, is observed to confer the stability phenotype Stat5 in the presence of MG132 to Stat1 and is therefore an active target for anticancer drugs.</text>
                    <arg n="0">just replacing C-terminus by Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2079">
                    <text>just replacing C-terminus by Stat5 (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, may confer the stability phenotype Stat5 in the presence of MG132 to Stat1 and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">just replacing C-terminus by Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2080">
                    <text>just replacing C-terminus by Stat5 (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, was able to confer the stability phenotype Stat5 in the presence of MG132 to Stat1 and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">just replacing C-terminus by Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2081">
                    <text>just replacing C-terminus by Stat5 may confer the stability phenotype Stat5 in the presence of MG132 to Stat1 has not been determined.</text>
                    <arg n="0">just replacing C-terminus by Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2082">
                    <text>just replacing the C-terminal with the Stat5 phenotype (AGT) that is able to confer the Stat5 stability phenotype in the presence of MG132 to Stat1 was therefore an active target of anti-drugs.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2083">
                    <text>just replacing the C-terminal with the Stat5 phenotype (AGT), which directly inverts endogenous alkylation to 06-position of guanine, is able to confer the stability Stat5 phenotype in the presence of MG132 to Stat1 and is therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2084">
                    <text>just replacing the C-terminal with the Stat5 phenotype (AGT), which directly inverts endogenous alkylation to 06-position of guanine, is thought to confer the Stat5 stability phenotype in the presence of MG132 to Stat1 and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2085">
                    <text>just replacing the C-terminal with the Stat5 phenotype (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, may confer the Stat5 stability phenotype in the presence of MG132 to Stat1 and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2086">
                    <text>just replacing the C-terminal with the Stat5 phenotype (AGT), which directly reverses the endogenous alkylation to 06-platinin position, would confer the Stat5 stability phenotype in the presence of MG132 to Stat1 and therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2087">
                    <text>just replacing the C-terminal with the Stat5 phenotype (AGT), which directly reverses the endogenous alkylation to 06-platinin position, would confer the stability Stat5 phenotype in the presence of MG132 to Stat1 and therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2088">
                    <text>just replacing the C-terminal with the Stat5 phenotype (AGT), which directly reverses the endogenous alkylation to the position 06 of guanin, is able to confer the Stat5 stability phenotype in the presence of MG132 to Stat1 and therefore is an active target of antineoplastic drugs.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2089">
                    <text>just replacing the C-terminal with the Stat5 phenotype (AGT), which directly reverses the endogenous alkylation to the position 06 of guanin, may confer the Stat5 stability phenotype in the presence of MG132 to Stat1 and is therefore an active target of anticancer drugs.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2090">
                    <text>just replacing the C-terminal with the Stat5 phenotype 06 human (AGT) that conferred the stability Stat5 phenotype in the presence of MG132 over Stat1 was therefore an active target of anti-drugs.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2091">
                    <text>just replacing the C-terminal with the Stat5 phenotype conferred the stability Stat5 phenotype in the presence of MG132 for Stat1.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2092">
                    <text>just replacing the C-terminal with the Stat5 phenotype conferred the stability Stat5 phenotype in the presence of MG132 to Stat1.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2093">
                    <text>just replacing the C-terminal with the Stat5 phenotype human 06-alkylguaning-DNA (AGT) that conferred the stability Stat5 phenotype in the presence of MG132 to Stat1 was therefore an active target of anti-drugs.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2094">
                    <text>just replacing the C-terminal with the Stat5 phenotype may confer the stability Stat5 phenotype in the presence of MG132 to Stat1 has not been determined.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2095">
                    <text>mutation function miss was the not conferred by senseless alteration or frame change of the codex sequence or by cutting variants.</text>
                    <arg n="0">senseless alteration or frame change of the codex sequence or by cutting variants</arg>
                    <arg n="1">mutation function miss</arg>
                </example>
                <example src="PERMUTATE" no="2096">
                    <text>mutation function miss will be conferred by senseless alteration or frame change of the codex sequence or by cutting variants.</text>
                    <arg n="0">senseless alteration or frame change of the codex sequence or by cutting variants</arg>
                    <arg n="1">mutation function miss</arg>
                </example>
                <example src="PERMUTATE" no="2097">
                    <text>only C-terminal substitution for Stat5 (AGT) is thought to confer the Stat5 phenotype of stability in the presence of MG132 on State1 was therefore an active target of anti-tank drugs.</text>
                    <arg n="0">only C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="2098">
                    <text>only C-terminal substitution for Stat5 (AGT) that can confer the Stat5 phenotype of stability in the presence of MG132 to State1 was therefore an active target of anti-drugs.</text>
                    <arg n="0">only C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="2099">
                    <text>only the C-terminal substitution for Stat5 (AGT) that can confer the Stat5 stability phenotype in the presence of MG132 to State1 was therefore an active target of anti-drugs.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="2100">
                    <text>only the C-terminal substitution for Stat5 (AGT) that is able to confer the Stat5 stability phenotype in the presence of MG132 to State1 was therefore an active target of anti-drugs.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="2101">
                    <text>only the C-terminal substitution for Stat5 (AGT), which directly reverses endogenous alkylation at 06-position of the guanine, has the ability to confer the Stat5 stability phenotype in the presence of MG132 to State1 and is therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="2102">
                    <text>only the C-terminal substitution for Stat5 (AGT), which directly reverses endogenous alkylation at 06-position of the guanine, was believed to confer the Stat5 stability phenotype in the presence of MG132 on State1 and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="2103">
                    <text>only the C-terminal substitution for Stat5 conferred the Stat5 stability phenotype in the presence of MG132 for State1.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="2104">
                    <text>over expression of EvgA conferred resistance to A2 (one MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">over expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="2105">
                    <text>over expression of EvgA is not able to confer resistance.</text>
                    <arg n="0">over expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="2106">
                    <text>over expression of EvgA will confer resistance.</text>
                    <arg n="0">over expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="2107">
                    <text>overexpression of EvgA can be conferred to resistance.</text>
                    <arg n="0">overexpression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="2108">
                    <text>overexpression of EvgA could confer resistance.</text>
                    <arg n="0">overexpression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="2109">
                    <text>overexpression of EvgA may not have conferred resistance.</text>
                    <arg n="0">overexpression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="2110">
                    <text>overexpression of EvgA might have not conferred resistance.</text>
                    <arg n="0">overexpression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="2111">
                    <text>overexpression of EvgA was considered to be the one that confers resistance to A2 (a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">overexpression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="2112">
                    <text>overexpression of EvgA was not able to confer resistance.</text>
                    <arg n="0">overexpression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="2113">
                    <text>part of STATs can confer specificity.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="2114">
                    <text>part of STATs could confer specificity.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="2115">
                    <text>part of STATs may not have conferred specificity.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="2116">
                    <text>replaceing Gly156 and Lys165 (AGT) that is able to confer resistance to 06-BG was therefore an active target of anti-drugs.</text>
                    <arg n="0">replaceing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2117">
                    <text>replacements in Gly156 and Lys165 (AGT), which directly reverses endogenous alkylation at 06-position of the guanine, has the ability to confer resistance to 06-BG and is therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2118">
                    <text>replacements in Gly156 and Lys165 (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, may confer resistance to 06-BG and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2119">
                    <text>replacements in Gly156 and Lys165 (AGT), which directly reverses the endogenous alkylation at the position of guanin 6, conferred resistance to 06-BG and is therefore an active target of anticancer drugs.</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2120">
                    <text>replacements in Gly156 and Lys165 conferred resistance to 06-BG.</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2121">
                    <text>replacements to Gly156 and Lys165 (AGT) that conferred resistance over 06-BG was therefore an active target for anti-drugs.</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2122">
                    <text>replacements to Gly156 and Lys165 (AGT), which directly inverts endogenous alkylation to 06-position of guanine, conferred resistance on 06-BG and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2123">
                    <text>replacements to Gly156 and Lys165 (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, may confer resistance to 06-BG and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2124">
                    <text>replacements to Gly156 and Lys165 (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, was able to confer resistance to 06-BG and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2125">
                    <text>replacing Gly156 and Lys165 (AGT) is thought to confer resistance on 06-BG was therefore an active target of anti-tank drugs.</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2126">
                    <text>replacing Gly156 and Lys165 (AGT), which directly reverses the endogenous alkylation in 06 guanin positions, has the ability to confer resistance to 06-BG and therefore is an active target of antineoplastic drugs.</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2127">
                    <text>replacing Gly156 and Lys165 06 human (AGT) that conferred resistance over 06-BG was therefore an active target of anti-drugs.</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2128">
                    <text>replacing simply the C-terminal with Stat5 (AGT) that conferred the Stat5 phenotype of stability in the presence of MG132 over Stat1 was therefore an active target for anti-drugs.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2129">
                    <text>replacing simply the C-terminal with Stat5 (AGT) that is able to confer stat5 phenotype of stability in the presence of MG132 to Stat1 was therefore an active target of anti-drugs.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2130">
                    <text>replacing simply the C-terminal with Stat5 (AGT) that is able to confer the Stat5 phenotype in the presence of MG132 to Stat1 was therefore an active target of anti-drugs.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2131">
                    <text>replacing simply the C-terminal with Stat5 (AGT), which directly inverts endogenous alkylation to 06-position of guanine, is able to confer stat5 phenotype of stability in the presence of MG132 to Stat1 and is therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2132">
                    <text>replacing simply the C-terminal with Stat5 (AGT), which directly inverts endogenous alkylation to 06-position of guanine, is thought to confer stat5 phenotype of stability in the presence of MG132 to Stat1 and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2133">
                    <text>replacing simply the C-terminal with Stat5 (AGT), which directly inverts endogenous alkylation to 06-position of the guanine, would confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2134">
                    <text>replacing simply the C-terminal with Stat5 (AGT), which directly reverses endogenous alkylation at 06-position of guanine, was able to confer stat5 phenotype of stability in the presence of MG132 to Stat1 and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2135">
                    <text>replacing simply the C-terminal with Stat5 (AGT), which directly reverses endogenous alkylation at 06-position of the guanine, was believed to confer the Stat5 phenotype of stability in the presence of MG132 on Stat1 and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2136">
                    <text>replacing simply the C-terminal with Stat5 (AGT), which directly reverses the endogenous alkylation at the position of guanin 6, conferred the Stat5 phenotype of stability in the presence of MG132 to Stat1 and is therefore an active target of anticancer drugs.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2137">
                    <text>replacing simply the C-terminal with Stat5 conferred the Stat5 phenotype of stability in the presence of MG132 to Stat1.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2138">
                    <text>replacing simply the C-terminal with the Stat5 phenotype (AGT) that conferred the Stat5 phenotype of stability in the presence of MG132 over Stat1 was therefore an active target for anti-drugs.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2139">
                    <text>replacing simply the C-terminal with the Stat5 phenotype (AGT), which directly inverts endogenous alkylation to 06-position of guanine, is able to confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 and is therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2140">
                    <text>replacing simply the C-terminal with the Stat5 phenotype (AGT), which directly reverses endogenous alkylation at 06-position of guanine, was able to confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2141">
                    <text>replacing simply the C-terminal with the Stat5 phenotype (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, was able to confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2142">
                    <text>replacing simply the C-terminal with the Stat5 phenotype (AGT), which directly reverses the endogenous alkylation to the position 06 of guanin, may confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 and is therefore an active target of anticancer drugs.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2143">
                    <text>replacing simply the C-terminal with the Stat5 phenotype conferred the Stat5 phenotype of stability in the presence of MG132 for Stat1.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2144">
                    <text>replacing simply the C-terminal with the Stat5 phenotype may confer the Stat5 phenotype of stability in the presence of MG132 to Stat1 has not been determined.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2145">
                    <text>resistance 06-BG can be conferred by These mutations.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2146">
                    <text>resistance 06-BG can be conferred by no by These mutations.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2147">
                    <text>resistance 06-BG can be conferred to M-NG (no) by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2148">
                    <text>resistance 06-BG in a strain with a tolC deficit was conferred by resistances.</text>
                    <arg n="0">resistances</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2149">
                    <text>resistance 06-BG in a tolC problem strain has been conferred by six mutations.</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2150">
                    <text>resistance 06-BG in a tolC-deficient strain was conferred by These mutations.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2151">
                    <text>resistance 06-BG in a tolC-deficient strain was conferred by resistance.</text>
                    <arg n="0">resistance</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2152">
                    <text>resistance 06-BG is the not conferred by These mutations.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2153">
                    <text>resistance 06-BG is thought to be conferred by M-NG (not) for These mutations.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2154">
                    <text>resistance 06-BG was the not conferred by These mutations.</text>
                    <arg n="0">These mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2155">
                    <text>resistance 06-BG will be conferred by these mutations by not.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2156">
                    <text>resistance can be conferred by AGT transformation, which directly reverses the endogenous alkylation to the position of 06-guanin, to Kaina et al., 1991.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="2157">
                    <text>resistance can be conferred by AGT transition (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin to Kaina et al., 1991.</text>
                    <arg n="0">AGT transition</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="2158">
                    <text>resistance can be conferred by GAT transformation, which directly reverses the endogenous alkylation in the position of 06-guanin, in Alkylation-sensitive cells.</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2159">
                    <text>resistance can be conferred by Gly156 and Lys165 replacement (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin to 06-BG.</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2160">
                    <text>resistance can be conferred by alkylation of human alkyl hydroxyl-DNA alkyltransferase, which directly reverses the endogenous alkylation to the position of 06-guanin, to alkylation routes.</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="2161">
                    <text>resistance can be conferred by alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin to alkylation pathways.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="2162">
                    <text>resistance can be conferred by alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase, which directly reverses the endogenous alkylation to the position of 06-guanin, to alkylation pathways.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="2163">
                    <text>resistance can be conferred by alkylguaning-DNA alkyltransferase, which directly reverses the endogenous alkylation in the position of 06-guanin, in alkylation routes.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="2164">
                    <text>resistance can be conferred by alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin to alkylation.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="2165">
                    <text>resistance can be conferred by human 06-alkylguaning-DNA alkyltransferase, which directly reverses the endogenous alkylation to the position of 06-guanin, to alkylation pathways.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="2166">
                    <text>resistance can be conferred by replacing Gly156 and Lys165, which directly reverses the endogenous alkylation in the position of 06-guanin, in 06-BG.</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2167">
                    <text>resistance can be conferred by substitutions in Gly156 and Lys165, which directly reverses the endogenous alkylation in the position of 06-guanin, in 06-BG.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2168">
                    <text>resistance can be conferred by transfection of AGATT, which directly reverses the endogenous alkylation in the position of 06-guanin, in alkylation-sensitive cells.</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2169">
                    <text>resistance can be conferred by transformation of AGT (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin to alkylation-sensitive cells.</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2170">
                    <text>resistance can be conferred to M-NG (no) by overexpression of EvgA.</text>
                    <arg n="0">overexpression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="2171">
                    <text>resistance for 06-BG has been conferred by replacements to Gly156 and Lys165.</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2172">
                    <text>resistance for 06-BG is conferred by Gly156 and Lys165 replacement</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2173">
                    <text>resistance for 06-BG is conferred by replacing Gly156 and Lys165</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2174">
                    <text>resistance for Alkylation-sensitive cells has been conferred by AGT transformation.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2175">
                    <text>resistance for Alkylation-sensitive cells has been conferred by GAT transformation.</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2176">
                    <text>resistance for Kaina et al., 1991 is conferred by AGT transformation</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="2177">
                    <text>resistance for Kaina et al., 1991 was conferred by AGT transformation.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="2178">
                    <text>resistance for alkylation pathways is conferred by human 06-alkylguaning-DNA alkyltransferase</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="2179">
                    <text>resistance for alkylation pathways was conferred by Human 06-alkylguaning-DNA alkyltransferase.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="2180">
                    <text>resistance for alkylation pathways was conferred by alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="2181">
                    <text>resistance for alkylation routes has been conferred by alkylation of human alkyl hydroxyl-DNA alkyltransferase.</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="2182">
                    <text>resistance for alkylation routes has been conferred by alkylguaning-DNA alkyltransferase.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="2183">
                    <text>resistance for alkylation routes was conferred by alkyguaning-DNA alkyltransferase.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="2184">
                    <text>resistance for alkylation was conferred by alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="2185">
                    <text>resistance for alkylation-sensitive cells has been conferred by AGT transformation.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2186">
                    <text>resistance for alkylation-sensitive cells has been conferred by transformation of AGT.</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2187">
                    <text>resistance for alkylation-sensitive cells is conferred by transfection of AGATT</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2188">
                    <text>resistance for alkylation-sensitive cells is conferred by transformation of AGT</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2189">
                    <text>resistance for alkylation-sensitive cells was conferred by AGATT transfection.</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2190">
                    <text>resistance for alkyltransferase chemotherapies is conferred by alkyltransferase of 06-alkyltransferase of AGT</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2191">
                    <text>resistance for alkyltransferase chemotherapies is conferred by alkyltransferase of 06-alkyltransferase-DNA</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2192">
                    <text>resistance for alkyltransferase chemotherapies was conferred by alkyltransferase of 06-alkyltransferase of AGT.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2193">
                    <text>resistance for alkyltransferase chemotherapies was conferred by alkyltransferase of 06-alkyltransferase-DNA.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2194">
                    <text>resistance has the ability to confer AGATT transfection (AGT), which directly reverses endogenous alkylation in the 06-guanine position, to alkylation-sensitive cells.</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2195">
                    <text>resistance has the ability to confer AGT transformation (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to Alkylation-sensitive cells.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2196">
                    <text>resistance has the ability to confer Gly156 and Lys165 replacement (AGT), which directly reverses endogenous alkylation in the 06-guanine position, to 06-BG.</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2197">
                    <text>resistance has the ability to confer Human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to alkylation pathways.</text>
                    <arg n="0">Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="2198">
                    <text>resistance has the ability to confer alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation in the 06-guanine position, to alkyl ways.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyl ways</arg>
                </example>
                <example src="PERMUTATE" no="2199">
                    <text>resistance has the ability to confer alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation in the 06-guanine position, to alkylation chemotherapies.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2200">
                    <text>resistance has the ability to confer alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to alkylation pathways.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase Human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="2201">
                    <text>resistance has the ability to confer alkyltransferase of 06-alkyltransferase of AGT (AGT), which directly reverses endogenous alkylation in the 06-guanine position, to alkylation.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation</arg>
                </example>
                <example src="PERMUTATE" no="2202">
                    <text>resistance has the ability to confer alkyltransferase of 06-alkyltransferase of AGT (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to alkyltransferase chemotherapies.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2203">
                    <text>resistance has the ability to confer replaceing Gly156 and Lys165 (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to 06-BG.</text>
                    <arg n="0">replaceing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2204">
                    <text>resistance has the ability to confer transfection of AGT (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to alkylation-sensitive cells.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2205">
                    <text>resistance has the ability to confer transformation of AGT (AGT), which directly reverses endogenous alkylation in the 06-guanine position, to alkylation-sensitive cells.</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2206">
                    <text>resistance has the ability to confer transformation of GAT (AGT), which directly reverses endogenous alkylation in the 06-guanine position, to alkylation-sensitive cells.</text>
                    <arg n="0">transformation of GAT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2207">
                    <text>resistance in a tolC-deficient strain is able to be conferred by over expression of EvgA.</text>
                    <arg n="0">over expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="2208">
                    <text>resistance in a tolC-deficient strain may have been conferred by over expression of EvgA.</text>
                    <arg n="0">over expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="2209">
                    <text>resistance is able to confer AGT transformation (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to Kaina et al., 1991.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="2210">
                    <text>resistance is able to confer AGT transformation, which directly reverses the endogenous alkylation-sensitive cells to the position of 06-guanin, to alkylation.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2211">
                    <text>resistance is able to confer Gly156 and Lys165 replacement (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to 06-BG.</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2212">
                    <text>resistance is able to confer Gly156 and Lys165 replacement, which directly reverses the endogenous 06-BG to the position of 06-guanin, to alkylation.</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2213">
                    <text>resistance is able to confer alkyguaning-DNA alkyltransferase, which directly reverses the endogenous alkylation routes to the position of 06-guanin, to alkylation.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="2214">
                    <text>resistance is able to confer alkylation of human alkyl hydroxyl-DNA alkyltransferase (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to alkylation routes.</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="2215">
                    <text>resistance is able to confer alkylguaning-DNA alkyltransferase, which directly reverses the endogenous alkyl ways to the position of 06-guanin, to alkylation.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyl ways</arg>
                </example>
                <example src="PERMUTATE" no="2216">
                    <text>resistance is able to confer replacements in Gly156 and Lys165, which directly reverses the endogenous 06-BG to the position of 06-guanin, to alkylation.</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2217">
                    <text>resistance is able to confer transfection of AGT (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to alkylation-sensitive cells.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2218">
                    <text>resistance is conferred by AGT transformation (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to Alkylation-sensitive cells.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2219">
                    <text>resistance is conferred by AGT transformation (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to alkylation-sensitive cells.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2220">
                    <text>resistance is conferred by alkylguaning-DNA alkyltransferase (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to alkyl ways.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyl ways</arg>
                </example>
                <example src="PERMUTATE" no="2221">
                    <text>resistance is conferred by alkyltransferase-DNA alkyltransferase (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to alkylation chemotherapies.</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2222">
                    <text>resistance is conferred by replaceing Gly156 and Lys165 (AGT), which directly reverses endogenous alkylation at the 06-guanine position, in 06-BG.</text>
                    <arg n="0">replaceing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2223">
                    <text>resistance is conferred by replacing Gly156 and Lys165 (AGT), which directly reverses endogenous alkylation at the 06-guanine position, in 06-BG.</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2224">
                    <text>resistance is conferred by substitutions in Gly156 and Lys165 (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to 06-BG.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2225">
                    <text>resistance is conferred by transfection of AGATT (AGT), which directly reverses endogenous alkylation at the 06-guanine position, in alkylation-sensitive cells.</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2226">
                    <text>resistance is conferred by transfection of AGT (AGT), which directly reverses endogenous alkylation at the 06-guanine position, in alkylation-sensitive cells.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2227">
                    <text>resistance is considered to be the one that confers resistance 06-BG on A2 (a MAPK or a MAPK substrate of kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">resistance</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2228">
                    <text>resistance may have been conferred by AGATT transfection (AGT), which directly reverses the endogenous alkylation at the position of 06- guanin, to alkylation-sensitive cells.</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2229">
                    <text>resistance may have been conferred by AGT transformation (AGT), which directly reverses endogenous alkylation at the 06-guanine position, in Kaina et al., 1991.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="2230">
                    <text>resistance may have been conferred by AGT transformation (AGT), which directly reverses the endogenous alkylation at the position of 06- guanin, to Kaina et al., 1991.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="2231">
                    <text>resistance may have been conferred by AGT transformation (AGT), which directly reverses the endogenous alkylation at the position of 06- guanin, to alkylation-sensitive cells.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2232">
                    <text>resistance may have been conferred by AGT transition (AGT), which directly reverses the endogenous alkylation at the position of 06- guanin, to Kaina et al., 1991.</text>
                    <arg n="0">AGT transition</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="2233">
                    <text>resistance may have been conferred by GAT transformation (AGT), which directly reverses endogenous alkylation at the 06-guanine position, in Alkylation-sensitive cells.</text>
                    <arg n="0">GAT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2234">
                    <text>resistance may have been conferred by alkyguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at the 06-guanine position, in alkylation chemotherapies.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2235">
                    <text>resistance may have been conferred by alkyguaning-DNA alkyltransferase (AGT), which directly reverses the endogenous alkylation at the position of 06- guanin, to alkylation chemotherapies.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2236">
                    <text>resistance may have been conferred by alkyltransferase of 06-alkyltransferase of AGT (AGT), which directly reverses the endogenous alkylation at the position of 06- guanin, to alkyltransferase chemotherapies.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2237">
                    <text>resistance may have been conferred by alkyltransferase of 06-alkyltransferase-DNA (AGT), which directly reverses endogenous alkylation at the 06-guanine position, in alkyltransferase chemotherapies.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2238">
                    <text>resistance may have been conferred by human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at the 06-guanine position, in alkylation pathways.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="2239">
                    <text>resistance may have been conferred by human alkyl-alkylation-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at the 06-guanine position, in alkylation routes.</text>
                    <arg n="0">human alkyl-alkylation-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="2240">
                    <text>resistance may have been conferred by substitutions in Gly156 and Lys165 (AGT), which directly reverses the endogenous alkylation at the position of 06- guanin, to 06-BG.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2241">
                    <text>resistance may have been conferred by transfection of AGATT (AGT), which directly reverses endogenous alkylation at the 06-guanine position, in alkylation-sensitive cells.</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2242">
                    <text>resistance of 06-BG in a strain with tolC deficiencies is able to be conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance of 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2243">
                    <text>resistance of 06-BG in a tolC problem strain has been conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance of 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2244">
                    <text>resistance of 06-BG in a tolC-deficient strain can be conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance of 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2245">
                    <text>resistance was believed to confer for AGT transformation (AGT), which directly reverses endogenous alkylation to 06-guanine position, to Alkylation-sensitive cells.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2246">
                    <text>resistance was believed to confer for alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation to 06-guanine position, to alkyl ways.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyl ways</arg>
                </example>
                <example src="PERMUTATE" no="2247">
                    <text>resistance was believed to confer for transfection of AGATT (AGT), which directly reverses endogenous alkylation to 06-guanine position, to alkylation-sensitive cells.</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2248">
                    <text>resistance was believed to confer for transfection of AGT (AGT), which directly reverses endogenous alkylation to 06-guanine position, to alkylation-sensitive cells.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2249">
                    <text>resistance was believed to confer for transformation of AGT (AGT), which directly reverses endogenous alkylation to 06-guanine position, to alkylation-sensitive cells.</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2250">
                    <text>resistance was believed to confer for transformation of GAT (AGT), which directly reverses endogenous alkylation to 06-guanine position, to alkylation-sensitive cells.</text>
                    <arg n="0">transformation of GAT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2251">
                    <text>resistance was confer as AGATT transfection, which directly reverses the endogenous alkylation-sensitive cells to the position of 06-guanin, to alkylation.</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2252">
                    <text>resistance was confer as AGT transformation, which directly reverses the endogenous Alkylation-sensitive cells to the position of 06-guanin, to alkylation.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2253">
                    <text>resistance was confer as replacements in Gly156 and Lys165, which directly reverses the endogenous 06-BG to the position of 06-guanin, to alkylation.</text>
                    <arg n="0">replacements in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2254">
                    <text>resistance was confer as replacements to Gly156 and Lys165, which directly reverses the endogenous 06-BG to the position of 06-guanin, to alkylation.</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2255">
                    <text>resistance was confer as substitutions in Gly156 and Lys165, which directly reverses the endogenous 06-BG to the position of 06-guanin, to alkylation.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2256">
                    <text>resistance was confer as transfection of AGATT, which directly reverses the endogenous alkylation-sensitive cells to the position of 06-guanin, to alkylation.</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2257">
                    <text>resistance was conferred by AGATT transfection (AGT), which directly reverses endogenous alkylation at the 06-guanine position, in alkylation-sensitive cells.</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2258">
                    <text>resistance was conferred by AGATT transfection, which directly reverses the endogenous alkylation to the position of 06-guanin, to alkylation-sensitive cells.</text>
                    <arg n="0">AGATT transfection</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2259">
                    <text>resistance was conferred by AGT transformation (AGT), which directly reverses endogenous alkylation at the 06-guanine position, in Kaina et al., 1991.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="2260">
                    <text>resistance was conferred by Gly156 and Lys165 replacement (AGT), which directly reverses endogenous alkylation at the 06-guanine position, in 06-BG.</text>
                    <arg n="0">Gly156 and Lys165 replacement</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2261">
                    <text>resistance was conferred by alkyguaning-DNA alkyltransferase, which directly reverses the endogenous alkylation to the position of 06-guanin, to alkylation chemotherapies.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2262">
                    <text>resistance was conferred by alkyltransferase of 06-alkyltransferase of AGT (AGT), which directly reverses endogenous alkylation at the 06-guanine position, in alkyltransferase chemotherapies.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2263">
                    <text>resistance was conferred by alkyltransferase of 06-alkyltransferase-DNA (AGT), which directly reverses the endogenous alkylation at the position of 06- guanin, to alkyltransferase chemotherapies.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase-DNA</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2264">
                    <text>resistance was conferred by alkyltransferase-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at the 06-guanine position, in alkylation chemotherapies.</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2265">
                    <text>resistance was conferred by alkyltransferase-DNA alkyltransferase (AGT), which directly reverses the endogenous alkylation at the position of 06- guanin, to alkylation chemotherapies.</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2266">
                    <text>resistance was conferred by human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at the 06-guanine position, in alkylation pathways.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="2267">
                    <text>resistance was conferred by replaceing Gly156 and Lys165 (AGT), which directly reverses the endogenous alkylation at the position of 06- guanin, to 06-BG.</text>
                    <arg n="0">replaceing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2268">
                    <text>resistance was conferred by replacements to Gly156 and Lys165, which directly reverses the endogenous alkylation to the position of 06-guanin, to 06-BG.</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2269">
                    <text>resistance was conferred by substitutions in Gly156 and Lys165 (AGT), which directly reverses the endogenous alkylation at the position of 06- guanin, to 06-BG.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2270">
                    <text>resistance was conferred by transfection of AGT, which directly reverses the endogenous alkylation to the position of 06-guanin, to alkylation-sensitive cells.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2271">
                    <text>resistance was considered as not conferred by over expression of EvgA.</text>
                    <arg n="0">over expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="2272">
                    <text>resistance which confers resistance 06-BG to A2 (a MAPK substrate or a MAPK kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">resistance</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2273">
                    <text>resistance will be conferred by EvgA overexpression.</text>
                    <arg n="0">EvgA overexpression</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="2274">
                    <text>resistance will be conferred by alkyguaning-DNA alkyltransferase (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to alkylation routes.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="2275">
                    <text>resistance will be conferred by alkylation of human alkyl hydroxyl-DNA alkyltransferase (AGT), which directly reverses the endogenous alkylation in the position of 06-guanin in alkylation routes.</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="2276">
                    <text>resistance will be conferred by alkylguaning-DNA alkyltransferase (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to alkyl ways.</text>
                    <arg n="0">alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyl ways</arg>
                </example>
                <example src="PERMUTATE" no="2277">
                    <text>resistance will be conferred by alkyltransferase of 06-alkyltransferase of AGT (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to alkyltransferase chemotherapies.</text>
                    <arg n="0">alkyltransferase of 06-alkyltransferase of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkyltransferase chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2278">
                    <text>resistance will be conferred by alkyltransferase-DNA alkyltransferase (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to alkylation chemotherapies.</text>
                    <arg n="0">alkyltransferase-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation chemotherapies</arg>
                </example>
                <example src="PERMUTATE" no="2279">
                    <text>resistance will be conferred by human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses the endogenous alkylation in the position of 06-guanin in alkylation pathways.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="PERMUTATE" no="2280">
                    <text>resistance will be conferred by replacements to Gly156 and Lys165 (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to 06-BG.</text>
                    <arg n="0">replacements to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2281">
                    <text>resistance will be conferred by transformation of AGT (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to alkylation-sensitive cells.</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2282">
                    <text>resistance would be conferred by AGT transformation (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to Alkylation-sensitive cells.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2283">
                    <text>resistance would be conferred by AGT transformation, which directly reverses the endogenous alkylation in the position of 06-guanin, in Kaina et al., 1991.</text>
                    <arg n="0">AGT transformation</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">Kaina et al., 1991</arg>
                </example>
                <example src="PERMUTATE" no="2284">
                    <text>resistance would be conferred by alkyguaning-DNA alkyltransferase (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to alkylation routes.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="2285">
                    <text>resistance would be conferred by alkylation of human alkyl hydroxyl-DNA alkyltransferase, which directly reverses the endogenous alkylation in the position of 06-guanin, in alkylation routes.</text>
                    <arg n="0">alkylation of human alkyl hydroxyl-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="PERMUTATE" no="2286">
                    <text>resistance would be conferred by substitutions in Gly156 and Lys165 (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to 06-BG.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2287">
                    <text>resistance would be conferred by transfection of AGT (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to alkylation-sensitive cells.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2288">
                    <text>resistance would be conferred by transfection of AGT, which directly reverses the endogenous alkylation in the position of 06-guanin, in alkylation-sensitive cells.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2289">
                    <text>resistances of M-NEG does not confer resistance 06-BG.</text>
                    <arg n="0">resistances</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2290">
                    <text>resistant to Gly160His and Gly160Arg can be conferred by no by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistant to Gly160His and Gly160Arg</arg>
                </example>
                <example src="PERMUTATE" no="2291">
                    <text>resistant to Gly160His and Gly160Arg in a tolC problem strain has been conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistant to Gly160His and Gly160Arg</arg>
                </example>
                <example src="PERMUTATE" no="2292">
                    <text>resistant to Gly160His and Gly160Arg in a tolC-deficient strain is able to be conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistant to Gly160His and Gly160Arg</arg>
                </example>
                <example src="PERMUTATE" no="2293">
                    <text>resistant to Gly160His and Gly160Arg in a tolC-deficient strain was conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistant to Gly160His and Gly160Arg</arg>
                </example>
                <example src="PERMUTATE" no="2294">
                    <text>resistant to Gly160His and Gly160Arg was considered as not conferred by these mutations.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistant to Gly160His and Gly160Arg</arg>
                </example>
                <example src="PERMUTATE" no="2295">
                    <text>senseless alteration or frame change of the codex sequence or by cutting variants can confer mutation function miss.</text>
                    <arg n="0">senseless alteration or frame change of the codex sequence or by cutting variants</arg>
                    <arg n="1">mutation function miss</arg>
                </example>
                <example src="PERMUTATE" no="2296">
                    <text>senseless alteration or frame change of the codex sequence or by cutting variants may not have conferred mutation function miss.</text>
                    <arg n="0">senseless alteration or frame change of the codex sequence or by cutting variants</arg>
                    <arg n="1">mutation function miss</arg>
                </example>
                <example src="PERMUTATE" no="2297">
                    <text>senseless alteration or frame change of the codex sequence or by cutting variants was considered to be the one that confers mutation function miss to A2 (a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">senseless alteration or frame change of the codex sequence or by cutting variants</arg>
                    <arg n="1">mutation function miss</arg>
                </example>
                <example src="PERMUTATE" no="2298">
                    <text>six mutations can be conferred to 06-BG.</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2299">
                    <text>six mutations could confer 06-BG.</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2300">
                    <text>six mutations is able to confer 06-BG to A2 (a MAPK substrate or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2301">
                    <text>six mutations of M-NEG does not confer resistance 06-BG.</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2302">
                    <text>six mutations was able to confer resistance 06-BG to A2 (a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2303">
                    <text>six mutations will confer 06-BG.</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2304">
                    <text>six mutations would confer 06-BG.</text>
                    <arg n="0">six mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2305">
                    <text>specificity can be conferred by The portion of the STATs (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin to either a MAPK or a MAPK substratum kinase (MAPKAP).</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2306">
                    <text>specificity can be conferred by no by The part of TASTs.</text>
                    <arg n="0">The part of TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="2307">
                    <text>specificity can be conferred by no by the part of the TASTs.</text>
                    <arg n="0">the part of the TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="2308">
                    <text>specificity can be conferred by the STAT part, which directly reverses the endogenous alkylation to the position of 06-guanin, to a MAPK or a MAPK substrate kinase (MAPKAP).</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2309">
                    <text>specificity can be conferred by the part of STATs, which directly reverses the endogenous alkylation to the position of 06-guanin, to a MAPK substrate or a MAPK kinase (MAPKAP).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2310">
                    <text>specificity can be conferred by the part of the TASTs.</text>
                    <arg n="0">the part of the TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="2311">
                    <text>specificity can be conferred to M-NG (no) by the part of the STATs.</text>
                    <arg n="0">the part of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="2312">
                    <text>specificity for a MAPK substrate or a MAPK kinase (MAPKAP) was conferred by the part of STATs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2313">
                    <text>specificity for either a MAPK or a MAPK substrat kinase (MAPKAP) was conferred by The portion of the STATs.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2314">
                    <text>specificity has the ability to confer The STAT portion (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to a MAPK substrate or a MAPK kinase (MAPKAP).</text>
                    <arg n="0">The STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2315">
                    <text>specificity has the ability to confer The portion of the STATs (AGT), which directly reverses endogenous alkylation in the 06-guanine position, to either a MAPK or a MAPK substratum kinase (MAPKAP).</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2316">
                    <text>specificity has the ability to confer the portion of the STATs (AGT), which directly reverses endogenous alkylation in the 06-guanine position, to either a MAPK or a MAPK kinase substrate (MAPKAP).</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2317">
                    <text>specificity in a strain with a tolC deficit was conferred by part of STATs.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="2318">
                    <text>specificity in a strain with a tolC deficit was conferred by the part of the TASTs.</text>
                    <arg n="0">the part of the TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="2319">
                    <text>specificity in a strain with a tolC deficit was conferred by the portion of the STATs.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="2320">
                    <text>specificity in a strain with tolC deficiencies is able to be conferred by the part of the STATs.</text>
                    <arg n="0">the part of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="2321">
                    <text>specificity in a tolC problem strain has been conferred by The part of STATs.</text>
                    <arg n="0">The part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="2322">
                    <text>specificity in a tolC-deficient strain may have been conferred by The part of STATs.</text>
                    <arg n="0">The part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="2323">
                    <text>specificity in a tolC-deficient strain may have been conferred by the part of the TASTs.</text>
                    <arg n="0">the part of the TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="2324">
                    <text>specificity in a tolC-deficient strain was conferred by the part of the STATs.</text>
                    <arg n="0">the part of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="2325">
                    <text>specificity is able to confer The portion of the STATs, which directly reverses the endogenous either a MAPK or a MAPK substrat kinase (MAPKAP) to the position of 06-guanin, to alkylation.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2326">
                    <text>specificity is able to confer The portion of the STATs, which directly reverses the endogenous either a MAPK or a MAPK substratum kinase (MAPKAP) to the position of 06-guanin, to alkylation.</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2327">
                    <text>specificity is able to confer the portion of the STATs, which directly reverses the endogenous either a MAPK or a MAPK kinase substrate (MAPKAP) to the position of 06-guanin, to alkylation.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2328">
                    <text>specificity is conferred by The portion of the STATs (AGT), which directly reverses endogenous alkylation at the 06-guanine position, in either a MAPK or a MAPK substrat kinase (MAPKAP).</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substrat kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2329">
                    <text>specificity is the not conferred by The part of STATs.</text>
                    <arg n="0">The part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="2330">
                    <text>specificity is the not conferred by the part of the STATs.</text>
                    <arg n="0">the part of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="2331">
                    <text>specificity may have been conferred by The portion of the STATs (AGT), which directly reverses the endogenous alkylation at the position of 06- guanin, to either a MAPK or a MAPK substratum kinase (MAPKAP).</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2332">
                    <text>specificity was conferred by the portion of the STATs (AGT), which directly reverses endogenous alkylation at the 06-guanine position, in either a MAPK or a MAPK kinase substrate (MAPKAP).</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2333">
                    <text>specificity was considered as not conferred by The part of STATs.</text>
                    <arg n="0">The part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="2334">
                    <text>specificity was the not conferred by the part of STATs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="2335">
                    <text>specificity will be conferred by The portion of the STATs (AGT), which directly reverses the endogenous alkylation in the position of 06-guanin in either a MAPK or a MAPK kinase substrate (MAPKAP).</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2336">
                    <text>specificity will be conferred by the part of STATs (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to a MAPK substrate or a MAPK kinase (MAPKAP).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2337">
                    <text>specificity will be conferred by the part of STATs (AGT), which directly reverses the endogenous alkylation in the position of 06-guanin in a MAPK substrate or a MAPK kinase (MAPKAP).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2338">
                    <text>specificity would be conferred by The portion of the STATs, which directly reverses the endogenous alkylation in the position of 06-guanin, in either a MAPK or a MAPK substratum kinase (MAPKAP).</text>
                    <arg n="0">The portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK substratum kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2339">
                    <text>specificity would be conferred by the portion of the STATs (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to either a MAPK or a MAPK kinase substrate (MAPKAP).</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2340">
                    <text>stat5 phenotype of stability in the presence of MG132 is able to confer replacing simply the C-terminal with Stat5, which directly reverses the endogenous Stat1 to the position of 06-guanin, to alkylation.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2341">
                    <text>stat5 phenotype of stability in the presence of MG132 is conferred by replacing simply the C-terminal with Stat5 (AGT), which directly reverses endogenous alkylation at the 06-guanine position, in Stat1.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2342">
                    <text>stat5 phenotype of stability in the presence of MG132 was conferred by replacing simply the C-terminal with Stat5 (AGT), which directly reverses endogenous alkylation at the 06-guanine position, in Stat1.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2343">
                    <text>stat5 phenotype of stability in the presence of MG132 was conferred by replacing simply the C-terminal with Stat5, which directly reverses the endogenous alkylation to the position of 06-guanin, to Stat1.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2344">
                    <text>substituting only the C-terminal with Stat5 (AGT), which directly inverts endogenous alkylation to 06-position of guanine, conferred the Stat5 phenotype in the presence of MG132 on Stat1 and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2345">
                    <text>substituting only the C-terminal with Stat5 (AGT), which directly reverses endogenous alkylation at 06-position of the guanine, has the ability to confer the Stat5 phenotype in the presence of MG132 to Stat1 and is therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2346">
                    <text>substituting only the C-terminal with Stat5 (AGT), which directly reverses the endogenous alkylation to the position 06 of guanin, could confer the Stat5 phenotype in the presence of MG132 to Stat1 and thus was an active target of antineoplastic drugs.</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2347">
                    <text>substituting only the C-terminal with Stat5 06 human (AGT) that conferred the Stat5 phenotype in the presence of MG132 over Stat1 was therefore an active target of anti-drugs.</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2348">
                    <text>substitutions in Gly156 and Lys165 (AGT) that conferred resistance over 06-BG was therefore an active target for anti-drugs.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2349">
                    <text>substitutions in Gly156 and Lys165 (AGT), which directly inverts endogenous alkylation to 06-position of guanine, is able to confer resistance to 06-BG and is therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2350">
                    <text>substitutions in Gly156 and Lys165 (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, was observed to confer resistance to 06-BG and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2351">
                    <text>substitutions in Gly156 and Lys165 (AGT), which directly reverses the endogenous alkylation to the position 06 of guanin, may confer resistance to 06-BG and is therefore an active target of anticancer drugs.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2352">
                    <text>substitutions in Gly156 and Lys165 human 06-alkylguaning-DNA (AGT) that conferred resistance to 06-BG was therefore an active target of anti-drugs.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2353">
                    <text>substitutions to Gly156 and Lys165 (AGT) that conferred resistance over 06-BG was therefore an active target for anti-drugs.</text>
                    <arg n="0">substitutions to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2354">
                    <text>substitutions to Gly156 and Lys165 (AGT), which directly reverses endogenous alkylation at 06-position of the guanine, was believed to confer resistance on 06-BG and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">substitutions to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2355">
                    <text>substitutions to Gly156 and Lys165 (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, may confer resistance to 06-BG and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">substitutions to Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2356">
                    <text>the STAT part (AGT), which directly inverts endogenous alkylation to 06-position of guanine, conferred specificity on a MAPK or a MAPK substrate kinase (MAPKAP) and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2357">
                    <text>the STAT part (AGT), which directly inverts endogenous alkylation to 06-position of the guanine, would confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2358">
                    <text>the STAT part (AGT), which directly reverses endogenous alkylation at 06-position of the guanine, was believed to confer specificity on a MAPK or a MAPK substrate kinase (MAPKAP) and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2359">
                    <text>the STAT part (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, may confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2360">
                    <text>the STAT part (AGT), which directly reverses the endogenous alkylation at the position of guanin 6, conferred specificity to a MAPK or a MAPK substrate kinase (MAPKAP) and is therefore an active target of anticancer drugs.</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2361">
                    <text>the STAT part 06 human (AGT) that conferred specificity over a MAPK or a MAPK substrate kinase (MAPKAP) was therefore an active target of anti-drugs.</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2362">
                    <text>the STAT part conferred specificity to a MAPK or a MAPK substrate kinase (MAPKAP).</text>
                    <arg n="0">the STAT part</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2363">
                    <text>the Stat5 phenotype in the presence of MG132 can be conferred by replacing simply the C-terminal with Stat5, which directly reverses the endogenous alkylation to the position of 06-guanin, to Stat1.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2364">
                    <text>the Stat5 phenotype in the presence of MG132 for Stat1 has been conferred by substituting only the C-terminal with Stat5.</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2365">
                    <text>the Stat5 phenotype in the presence of MG132 for Stat1 is conferred by substituting only the C-terminal with Stat5</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2366">
                    <text>the Stat5 phenotype in the presence of MG132 for Stat1 was conferred by substituting only the C-terminal with Stat5.</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2367">
                    <text>the Stat5 phenotype in the presence of MG132 may have been conferred by substituting only the C-terminal with Stat5 (AGT), which directly reverses endogenous alkylation at the 06-guanine position, in Stat1.</text>
                    <arg n="0">substituting only the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2368">
                    <text>the Stat5 phenotype of stability in the presence of MG132 can be conferred by replacing simply the C-terminal with the Stat5 phenotype, which directly reverses the endogenous alkylation in the position of 06-guanin, in Stat1.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2369">
                    <text>the Stat5 phenotype of stability in the presence of MG132 for Stat1 is conferred by replacing simply the C-terminal with Stat5</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2370">
                    <text>the Stat5 phenotype of stability in the presence of MG132 has the ability to confer only C-terminal substitution for Stat5 (AGT), which directly reverses endogenous alkylation in the 06-guanine position, to State1.</text>
                    <arg n="0">only C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="2371">
                    <text>the Stat5 phenotype of stability in the presence of MG132 has the ability to confer replacing simply the C-terminal with Stat5 (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to Stat1.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2372">
                    <text>the Stat5 phenotype of stability in the presence of MG132 is able to confer replacing simply the C-terminal with Stat5, which directly reverses the endogenous Stat1 to the position of 06-guanin, to alkylation.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2373">
                    <text>the Stat5 phenotype of stability in the presence of MG132 was believed to confer for replacing simply the C-terminal with the Stat5 phenotype (AGT), which directly reverses endogenous alkylation to 06-guanine position, to Stat1.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2374">
                    <text>the Stat5 phenotype of stability in the presence of MG132 was conferred by replacing simply the C-terminal with the Stat5 phenotype (AGT), which directly reverses endogenous alkylation at the 06-guanine position, in Stat1.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2375">
                    <text>the Stat5 phenotype of stability in the presence of MG132 was conferred by replacing simply the C-terminal with the Stat5 phenotype, which directly reverses the endogenous alkylation to the position of 06-guanin, to Stat1.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2376">
                    <text>the Stat5 phenotype of stability in the presence of MG132 would be conferred by replacing simply the C-terminal with Stat5 (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to Stat1.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2377">
                    <text>the Stat5 phenotype of stability in the presence of MG132 would be conferred by replacing simply the C-terminal with the Stat5 phenotype (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to Stat1.</text>
                    <arg n="0">replacing simply the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2378">
                    <text>the Stat5 stability phenotype in the presence of MG132 can be conferred by just replacing the C-terminal with the Stat5 phenotype, which directly reverses the endogenous alkylation in the position of 06-guanin, in Stat1.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2379">
                    <text>the Stat5 stability phenotype in the presence of MG132 has the ability to confer only the C-terminal substitution for Stat5 (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to State1.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="2380">
                    <text>the Stat5 stability phenotype in the presence of MG132 is able to confer just replacing the C-terminal with the Stat5 phenotype (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to Stat1.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2381">
                    <text>the Stat5 stability phenotype in the presence of MG132 will be conferred by only the C-terminal substitution for Stat5 (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to State1.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="2382">
                    <text>the Stat5 stability phenotype in the presence of MG132 would be conferred by only the C-terminal substitution for Stat5 (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to State1.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 stability phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="PERMUTATE" no="2383">
                    <text>the excessive expression of EvgA is considered to be the one that confers resistance on A2 (a MAPK or a MAPK substrate of kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">the excessive expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="2384">
                    <text>the excessive expression of EvgA was able to confer resistance to A2 (a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">the excessive expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="2385">
                    <text>the excessive expression of EvgA will confer resistance.</text>
                    <arg n="0">the excessive expression of EvgA</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="PERMUTATE" no="2386">
                    <text>the gene variant is considered to be no to confer a higher risk of diabetes.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="2387">
                    <text>the gene variant will confer a higher risk of diabetes.</text>
                    <arg n="0">the gene variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="2388">
                    <text>the genetic variant conferred a higher risk of diabetes to A2 (one MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="2389">
                    <text>the genetic variant may not have conferred a higher risk of diabetes.</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="2390">
                    <text>the genetic variant was not able to confer a higher risk of diabetes.</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">a higher risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="2391">
                    <text>the genetic variant will confer an increasing risk of diabetes.</text>
                    <arg n="0">the genetic variant</arg>
                    <arg n="1">an increasing risk of diabetes</arg>
                </example>
                <example src="PERMUTATE" no="2392">
                    <text>the part of STATs (AGT), which directly reverses the endogenous alkyl to the 6-position of guanin, is observed to confer specificity to a MAPK substrate or a MAPK kinase (MAPKAP) and is therefore an active target for anticancer drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2393">
                    <text>the part of STATs 06 human (AGT) that conferred specificity over a MAPK substrate or a MAPK kinase (MAPKAP) was therefore an active target of anti-drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2394">
                    <text>the part of STATs has not been determined to be able to confer specificity to a MAPK substrate or a MAPK kinase (MAPKAP).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK substrate or a MAPK kinase (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2395">
                    <text>the part of STATs is able to confer specificity to A2 (a MAPK substrate or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="2396">
                    <text>the part of STATs may confer specificity to A2 (a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="2397">
                    <text>the part of STATs might have not conferred specificity.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="2398">
                    <text>the part of the STATs of M-NEG does not confer specificity.</text>
                    <arg n="0">the part of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="2399">
                    <text>the part of the TASTs can confer specificity.</text>
                    <arg n="0">the part of the TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="2400">
                    <text>the part of the TASTs may confer specificity to A2 (a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">the part of the TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="2401">
                    <text>the part of the TASTs was able to confer specificity to A2 (a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">the part of the TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="2402">
                    <text>the part of the TASTs will confer specificity.</text>
                    <arg n="0">the part of the TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="PERMUTATE" no="2403">
                    <text>the portion of the STATs (AGT) that is able to confer specificity to either a MAPK or a MAPK kinase substrate (MAPKAP) was therefore an active target of anti-drugs.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2404">
                    <text>the portion of the STATs (AGT), which directly reverses endogenous alkylation at 06-position of the guanine, has the ability to confer specificity to either a MAPK or a MAPK kinase substrate (MAPKAP) and is therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2405">
                    <text>the portion of the STATs (AGT), which directly reverses endogenous alkylation at 06-position of the guanine, was believed to confer specificity on either a MAPK or a MAPK kinase substrate (MAPKAP) and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2406">
                    <text>the portion of the STATs (AGT), which directly reverses the endogenous alkyl to the 6-position of guanin, is observed to confer specificity to either a MAPK or a MAPK kinase substrate (MAPKAP) and is therefore an active target for anticancer drugs.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2407">
                    <text>the portion of the STATs (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, may confer specificity to either a MAPK or a MAPK kinase substrate (MAPKAP) and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2408">
                    <text>the portion of the STATs (AGT), which directly reverses the endogenous alkylation to the position 06 of guanin, could confer specificity to either a MAPK or a MAPK kinase substrate (MAPKAP) and thus was an active target of antineoplastic drugs.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2409">
                    <text>the portion of the STATs conferred specificity for either a MAPK or a MAPK kinase substrate (MAPKAP).</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2410">
                    <text>the portion of the STATs human 06-alkylguaning-DNA (AGT) that conferred specificity to either a MAPK or a MAPK kinase substrate (MAPKAP) was therefore an active target of anti-drugs.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">either a MAPK or a MAPK kinase substrate (MAPKAP)</arg>
                </example>
                <example src="PERMUTATE" no="2411">
                    <text>the stability Stat5 phenotype in the presence of MG132 for Stat1 has been conferred by just replacing the C-terminal with the Stat5 phenotype.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2412">
                    <text>the stability Stat5 phenotype in the presence of MG132 has the ability to confer just replacing the C-terminal with the Stat5 phenotype (AGT), which directly reverses endogenous alkylation in the 06-guanine position, to Stat1.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2413">
                    <text>the stability Stat5 phenotype in the presence of MG132 is conferred by just replacing the C-terminal with the Stat5 phenotype (AGT), which directly reverses endogenous alkylation at the 06-guanine position, in Stat1.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2414">
                    <text>the stability Stat5 phenotype in the presence of MG132 was confer as just replacing the C-terminal with the Stat5 phenotype, which directly reverses the endogenous Stat1 to the position of 06-guanin, to alkylation.</text>
                    <arg n="0">just replacing the C-terminal with the Stat5 phenotype</arg>
                    <arg n="1">the stability Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2415">
                    <text>the stability phenotype Stat5 in the presence of MG132 is able to confer just replacing C-terminus by Stat5, which directly reverses the endogenous Stat1 to the position of 06-guanin, to alkylation.</text>
                    <arg n="0">just replacing C-terminus by Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2416">
                    <text>the stability phenotype Stat5 in the presence of MG132 was conferred by just replacing C-terminus by Stat5, which directly reverses the endogenous alkylation to the position of 06-guanin, to Stat1.</text>
                    <arg n="0">just replacing C-terminus by Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="PERMUTATE" no="2417">
                    <text>these mutations can confer resistance 06-BG.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2418">
                    <text>these mutations is able to confer 06-BG to A2 (a MAPK substrate or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2419">
                    <text>these mutations is considered to be no to confer 06-BG.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2420">
                    <text>these mutations is considered to be the one that confers Xu-Welliver et al., 1999a on A2 (a MAPK or a MAPK substrate of kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">Xu-Welliver et al., 1999a</arg>
                </example>
                <example src="PERMUTATE" no="2421">
                    <text>these mutations may confer 06-BG to A2 (a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2422">
                    <text>these mutations may confer resistance of 06-BG to A2 (a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance of 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2423">
                    <text>these mutations of M-NEG does not confer resistance 06-BG.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2424">
                    <text>these mutations of M-NEG does not confer resistant to Gly160His and Gly160Arg.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistant to Gly160His and Gly160Arg</arg>
                </example>
                <example src="PERMUTATE" no="2425">
                    <text>these mutations was not able to confer Xu-Welliver et al., 1999a.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">Xu-Welliver et al., 1999a</arg>
                </example>
                <example src="PERMUTATE" no="2426">
                    <text>these mutations which confers 06-BG resistant to A2 (a MAPK substrate or a MAPK kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistant</arg>
                </example>
                <example src="PERMUTATE" no="2427">
                    <text>these mutations will confer 06-BG resistant.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistant</arg>
                </example>
                <example src="PERMUTATE" no="2428">
                    <text>these mutations will confer resistance of 06-BG.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistance of 06-BG</arg>
                </example>
                <example src="PERMUTATE" no="2429">
                    <text>these mutations will confer resistant to Gly160His and Gly160Arg.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistant to Gly160His and Gly160Arg</arg>
                </example>
                <example src="PERMUTATE" no="2430">
                    <text>these mutations would confer 06-BG resistant.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">06-BG resistant</arg>
                </example>
                <example src="PERMUTATE" no="2431">
                    <text>these mutations would confer resistant to Gly160His and Gly160Arg.</text>
                    <arg n="0">these mutations</arg>
                    <arg n="1">resistant to Gly160His and Gly160Arg</arg>
                </example>
                <example src="PERMUTATE" no="2432">
                    <text>transfection of AGATT (AGT) that is able to confer resistance to alkylation-sensitive cells was therefore an active target of anti-drugs.</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2433">
                    <text>transfection of AGATT (AGT), which directly reverses endogenous alkylation at 06-position of guanine, was observed to confer resistance on alkylation-sensitive cells and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2434">
                    <text>transfection of AGATT (AGT), which directly reverses endogenous alkylation at 06-position of the guanine, was believed to confer resistance on alkylation-sensitive cells and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2435">
                    <text>transfection of AGATT has not been determined to be able to confer resistance to alkylation-sensitive cells.</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2436">
                    <text>transfection of AGATT human 06-alkylguaning-DNA (AGT) that conferred resistance to alkylation-sensitive cells was therefore an active target of anti-drugs.</text>
                    <arg n="0">transfection of AGATT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2437">
                    <text>transfection of AGT (AGT), which directly inverts endogenous alkylation to 06-position of the guanine, can confer resistance to alkylation-sensitive cells and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2438">
                    <text>transfection of AGT (AGT), which directly reverses the endogenous alkyl to the 6-position of guanin, is observed to confer resistance to alkylation-sensitive cells and is therefore an active target for anticancer drugs.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2439">
                    <text>transfection of AGT human 06-alkylguaning-DNA (AGT) that conferred resistance to alkylation-sensitive cells was therefore an active target of anti-drugs.</text>
                    <arg n="0">transfection of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2440">
                    <text>transformation of AGT (AGT), which directly reverses the endogenous alkyl to the 6-position of guanin, is observed to confer resistance to alkylation-sensitive cells and is therefore an active target for anticancer drugs.</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2441">
                    <text>transformation of AGT (AGT), which directly reverses the endogenous alkylation to 06-platinin position, would confer resistance to alkylation-sensitive cells and therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2442">
                    <text>transformation of AGT (AGT), which directly reverses the endogenous alkylation to the position 06 of guanin, is able to confer resistance to alkylation-sensitive cells and therefore is an active target of antineoplastic drugs.</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2443">
                    <text>transformation of AGT conferred resistance for alkylation-sensitive cells.</text>
                    <arg n="0">transformation of AGT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2444">
                    <text>transformation of GAT (AGT), which directly inverts endogenous alkylation to 06-position of guanine, is thought to confer resistance to alkylation-sensitive cells and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">transformation of GAT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="PERMUTATE" no="2445">
                    <text>transformation of GAT (AGT), which directly reverses the endogenous alkylation to the position 06 of guanin, could confer resistance to alkylation-sensitive cells and thus was an active target of antineoplastic drugs.</text>
                    <arg n="0">transformation of GAT</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation-sensitive cells</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>Elevated AGT levels in parallel with acquired Stat1 the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were considered to be conferred by only the C-terminal substitution for Stat5 to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>Elevated AGT levels in parallel with acquired a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were considered to be conferred by the part of STATs to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>Elevated AGT levels in parallel with acquired a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were considered to be conferred by the part of STATs to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>Elevated AGT levels in parallel with acquired a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were considered to be conferred by the part of STATs to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>Elevated AGT levels in parallel with acquired a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were considered to be conferred by the part of STATs to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>Elevated AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were considered to be conferred by the part of STATs to a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>Elevated replacing Gly156 and Lys165 levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were considered to be conferred by AGT to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>Elevated the part of STATs levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were considered to be conferred by AGT to a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="9">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structure suggests the ability of only the C-terminal substitution for Stat5 to confer the Stat5 phenotype of stability in the presence of MG132 to State1 through distortions of the lumbar spine.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="10">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structure suggests the ability of the part of STATs to confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs) through distortions of the lumbar spine.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="11">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that only the C-terminal substitution for Stat5 may have conferred the Stat5 phenotype of stability in the presence of MG132 to State1 through distortions of the lumbar spine.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="12">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that part of STATs are able to confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) through distortions of the lumbar spine.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="13">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that part of STATs are able to confer specificity to a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs) through distortions of the lumbar spine.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="14">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that part of STATs was considered to confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) by means of lumbar spine distortions.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="15">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that specificity can be conferred by the STAT portion to a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) through distortions of the lumbar spine.</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="16">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that specificity can be conferred by the part of STATs to a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs) through distortions of the lumbar spine.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="17">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that specificity can be conferred by the part of STATs to a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs) through distortions of the lumbar spine.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="18">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that specificity can be conferred by the part of STATs to a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) through distortions of the lumbar spine.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="19">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that specificity is able to be conferred by part of STATs to a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) through distortions of the lumbar spine.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="20">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that specificity is able to be conferred by the part of STATs to a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs) through distortions of the lumbar spine.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="21">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that specificity is considered conferred by the part of STATs to a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) through distortions of the lumbar spine.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="22">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that the STAT portion may confer specificity to a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) through distortions of the lumbar spine.</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="23">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that the Stat5 phenotype in the presence of MG132 is able to be conferred by only the C-terminal substitution for Stat5 to Stat1 through distortions of the lumbar spine.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="24">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that the Stat5 phenotype in the presence of MG132 is able to be conferred by only the C-terminal substitution for Stat5 to State1 through distortions of the lumbar spine.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="25">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that the part of STATs are able to confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs) through distortions of the lumbar spine.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="26">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that the part of STATs are able to confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) through distortions of the lumbar spine.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="27">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that the part of STATs are observed to confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs) by means of lumbar spine distortions.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="28">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that the part of STATs may confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) through distortions of the lumbar spine.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="29">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that the part of STATs may confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs) through distortions of the lumbar spine.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="30">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that the part of STATs may have conferred specificity to a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs) through distortions of the lumbar spine.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="31">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that the part of STATs may have the ability to confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) through distortions of the lumbar spine.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="32">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that the stability phenotype Stat5 in the presence of MG132 is able to be conferred by which simply replaces C-terminus for Stat5 to Stat1 through distortions of the lumbar spine.</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="33">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that which simply replaces C-terminus for Stat5 may have the ability to confer the stability phenotype Stat5 in the presence of MG132 to Stat1 through distortions of the lumbar spine.</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="34">
                    <text>In addition to these interactions in side chain with the 06-alkyl group, the analysis based on mutational data structures suggests that which simply replaces C-terminus for Stat5 was considered to confer the stability phenotype Stat5 in the presence of MG132 to Stat1 by means of lumbar spine distortions.</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="35">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that only the C-terminal substitution for Stat5 conferred the Stat5 phenotype in the presence of MG132 to Stat1 by means of spinal distortions.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="36">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that only the C-terminal substitution for Stat5 was able to confer the Stat5 phenotype of stability in the presence of MG132 to State1 by spine distortions.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="37">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that specificity could be conferred by part of STATs to a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) through spine distortions.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="38">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that specificity could be conferred by the part of STATs to a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) through spine distortions.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="39">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that specificity could be conferred by the part of STATs to a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) through spine distortions.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="40">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that specificity is able to be conferred by part of STATs to a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) through spine distortions.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="41">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that specificity is able to be conferred by the part of STATs to a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) through spine distortions.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="42">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that specificity is conferred by the part of STATs to a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs) through spine distortions.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="43">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that specificity is conferred by the part of STATs to a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) through spine distortions.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="44">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that specificity may have been conferred by the part of STATs to a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) through spine distortions.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="45">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that specificity may have been conferred by the part of STATs to a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) through spine distortions.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="46">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that specificity may have been conferred by the part of STATs to a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) through spine distortions.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="47">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that specificity was conferred by the part of STATs to a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs) through spine distortions.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="48">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that specificity was conferred by the part of STATs to a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) through spine distortions.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="49">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that specificity will be conferred by the part of STATs to a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs) through spine distortions.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="50">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the Stat5 phenotype in the presence of MG132 was conferred by only the C-terminal substitution for Stat5 to Stat1 through spine distortions.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="51">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the Stat5 phenotype of stability in the presence of MG132 can be conferred by only the C-terminal substitution for Stat5 to State1 through spine distortions.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="52">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the Stat5 phenotype of stability in the presence of MG132 is able to be conferred by only the C-terminal substitution for Stat5 to State1 through spine distortions.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="53">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the part of STATs is considered as conferring specificity to a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs) through spine distortions.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="54">
                    <text>In addition to these lateral chain interactions with the 06-alkyl group, the analysis based on the structure of mutation data suggests that the stability phenotype Stat5 in the presence of MG132 was able to be conferred by which simply replaces C-terminus for Stat5 to Stat1 through spine distortions.</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="55">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on mutational data structures suggests that only the C-terminal substitution for Stat5 can confer the Stat5 phenotype in the presence of MG132 to Stat1 through distortions of the lumbar vertebral column.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="56">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on mutational data structures suggests that the part of STATs can confer specificity to a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) through distortions of the lumbar vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="57">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the mutation data structure suggests that only the C-terminal substitution for Stat5 could confer the Stat5 phenotype in the presence of MG132 to State1 through distortions of the lumbar vertebral column.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="58">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the mutation data structure suggests that only the C-terminal substitution for Stat5 would confer the Stat5 phenotype in the presence of MG132 to Stat1 through distortions of the lumbar vertebral column.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="59">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the mutation data structure suggests that the part of STATs could confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs) through distortions of the lumbar vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="60">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the mutation data structure suggests that the part of STATs would confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs) through distortions of the lumbar vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="61">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that only the C-terminal substitution for Stat5 have the ability to confer the Stat5 phenotype of stability in the presence of MG132 to State1 through distortions of the vertebral column.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="62">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that only the C-terminal substitution for Stat5 were able to confer the Stat5 phenotype of stability in the presence of MG132 to State1 through distortions of the vertebral column.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="63">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that part of STATs are able to confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) through distortions of the vertebral column.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="64">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that part of STATs may have conferred specificity on a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) through distortions of the vertebral column.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="65">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that part of STATs would confer specificity to a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs) through distortions of the vertebral column.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="66">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity can be conferred by part of STATs to a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) through distortions of the vertebral column.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="67">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity can be conferred by the part of STATs to a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="68">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity can be conferred by the part of STATs to a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="69">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity can be conferred by the part of STATs to a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="70">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity could be conferred by part of STATs to a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs) through distortions of the vertebral column.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="71">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity could be conferred by the part of STATs to a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="72">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity could be conferred by the part of STATs to a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="73">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity could be conferred by the part of STATs to a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="74">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity has been conferred by the part of STATs to a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="75">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity has been conferred by the part of STATs to a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="76">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity is conferred by the part of STATs to a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="77">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity is observed to be conferred by the part of STATs to a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="78">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity is thought to be conferred by the part of STATs on a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="79">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity is thought to be conferred by the part of STATs on a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="80">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity is thought to be conferred by the part of STATs on a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="81">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity was able to be conferred by part of STATs to a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs) through distortions of the vertebral column.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="82">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity was able to be conferred by the part of STATs to a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="83">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity would be conferred by the part of STATs to a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="84">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that specificity would be conferred by the part of STATs to a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="85">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the STAT portion is thought to confer specificity to a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) through distortions of the vertebral column.</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="86">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the STAT portion will confer specificity to a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) through distortions of the vertebral column.</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="87">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the STAT portion would confer specificity to a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) through distortions of the vertebral column.</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="88">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the Stat5 phenotype in the presence of MG132 could be conferred by only the C-terminal substitution for Stat5 to State1 through distortions of the vertebral column.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="89">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the Stat5 phenotype in the presence of MG132 was believed to be conferred by only the C-terminal substitution for Stat5 on Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="90">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the Stat5 phenotype of stability in the presence of MG132 can be conferred by only the C-terminal substitution for Stat5 to State1 through distortions of the vertebral column.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="91">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the Stat5 phenotype of stability in the presence of MG132 was believed to be conferred by only the C-terminal substitution for Stat5 on State1 through distortions of the vertebral column.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="92">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the Stat5 phenotype of stability in the presence of MG132 would be conferred by only the C-terminal substitution for Stat5 to State1 through distortions of the vertebral column.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="93">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the part of STATs can confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="94">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the part of STATs conferred specificity on a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="95">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the part of STATs conferred specificity on a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="96">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the part of STATs could confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="97">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the part of STATs could confer specificity to a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="98">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the part of STATs may have conferred specificity on a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="99">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the part of STATs may have conferred specificity on a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="100">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the part of STATs may have conferred specificity on a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="101">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the part of STATs was believed to confer specificity to a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="102">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the part of STATs will confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="103">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the part of STATs would have conferred specificity on a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="104">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that the stability phenotype Stat5 in the presence of MG132 has been able to be conferred by which simply replaces C-terminus for Stat5 to Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="105">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that which simply replaces C-terminus for Stat5 would confer the stability phenotype Stat5 in the presence of MG132 to Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="106">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests that which simply replaces C-terminus for Stat5 would have conferred the stability phenotype Stat5 in the presence of MG132 on Stat1 through distortions of the vertebral column.</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="107">
                    <text>In addition to these side-chain interactions with the 06-alkyl group, analysis based on the structure of the mutation data suggests the ability of the part of STATs to confer specificity to a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) through distortions of the vertebral column.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="108">
                    <text>In addition, alkyguaning-DNA alkyltransferase does not confer resistance on a strain with tolC deficiencies.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="109">
                    <text>In addition, alterations of discount or frame change in the encoding sequence or for splice variants cannot confer mutations of loss of functions to a tolC problem-strain.</text>
                    <arg n="0">alterations of discount or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="110">
                    <text>In addition, alterations of discount or frame change in the encoding sequence or for splice variants was not able to confer mutations of loss of functions in a strain with tolC failure.</text>
                    <arg n="0">alterations of discount or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="111">
                    <text>In addition, alterations of frame shift in the encoding sequence or by splice variants may not confer mutations of loss of functions in a tolC-deficient strain.</text>
                    <arg n="0">alterations of frame shift in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="112">
                    <text>In addition, change of frame in the coding sequence or by splice variants cannot confer motors of loss of function to a tolC problem-strain.</text>
                    <arg n="0">change of frame in the coding sequence or by splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="113">
                    <text>In addition, changes in frame in the coding sequence or by splice variants cannot confer changes in function loss in a tolC-deficient strain.</text>
                    <arg n="0">changes in frame in the coding sequence or by splice variants</arg>
                    <arg n="1">changes in function loss</arg>
                </example>
                <example src="REPLACE" no="114">
                    <text>In addition, changes in frame in the coding sequence or by splice variants could not confer changes in function loss in a tolC-deficient strain.</text>
                    <arg n="0">changes in frame in the coding sequence or by splice variants</arg>
                    <arg n="1">changes in function loss</arg>
                </example>
                <example src="REPLACE" no="115">
                    <text>In addition, changes in frame in the coding sequence or by splice variants does not confer changes in function loss in a tolC-deficient strain.</text>
                    <arg n="0">changes in frame in the coding sequence or by splice variants</arg>
                    <arg n="1">changes in function loss</arg>
                </example>
                <example src="REPLACE" no="116">
                    <text>In addition, changes in frame in the coding sequence or by splice variants does not confer changes in function loss on a strain with tolC deficiencies.</text>
                    <arg n="0">changes in frame in the coding sequence or by splice variants</arg>
                    <arg n="1">changes in function loss</arg>
                </example>
                <example src="REPLACE" no="117">
                    <text>In addition, chapter changes or change of frame in the coding sequence or by splice variants could not confer motors of loss of function in a tolC-deficient strain.</text>
                    <arg n="0">chapter changes or change of frame in the coding sequence or by splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="118">
                    <text>In addition, debarred or frame alterations in the encoding sequence or by splice variants cannot confer mutations of loss of functions in a tolC-deficient strain.</text>
                    <arg n="0">debarred or frame alterations in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="119">
                    <text>In addition, debarred or frame alterations in the encoding sequence or by splice variants is not able to confer mutations of loss of functions in a tolC-deficient strain.</text>
                    <arg n="0">debarred or frame alterations in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="120">
                    <text>In addition, discount alterations or frame change in the encoding sequence or by splice variants could not confer function loss engines to a strain with tolC problems.</text>
                    <arg n="0">discount alterations or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="121">
                    <text>In addition, discount alterations or frame change in the encoding sequence or by splice variants was not able to confer function loss engines in a strain with tolC failure.</text>
                    <arg n="0">discount alterations or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="122">
                    <text>In addition, frame shift alterations in the encoding sequence or by splice variants would not confer function loss engines in a tolC-deficient strain.</text>
                    <arg n="0">frame shift alterations in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="123">
                    <text>In addition, human 06-alkylguaning-DNA alkyltransferase does not confer resistance in a tolC-deficient strain.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="124">
                    <text>In addition, no change in meaning or change in table in the coding sequence or by splice variants cannot confer movement of loss of function to a tolC problem-strain.</text>
                    <arg n="0">no change in meaning or change in table in the coding sequence or by splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="125">
                    <text>In addition, no meaningless alterations or frame change in the encoding sequence or for splice variants cannot confer mutations of loss of functions in a tolC-deficient strain.</text>
                    <arg n="0">no meaningless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="126">
                    <text>In addition, no sense alterations or frame change in the encoding sequence or by splice variants could not confer function loss motion to a strain with tolC problems.</text>
                    <arg n="0">no sense alterations or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="127">
                    <text>In addition, no sense alterations or frame change in the encoding sequence or for splice variants cannot confer function loss motion to a tolC problem-strain.</text>
                    <arg n="0">no sense alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="128">
                    <text>In addition, no sense alterations or frame shifts in the encoding sequence or for splice variants is not able to confer function loss engines in a tolC-deficient strain.</text>
                    <arg n="0">no sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="129">
                    <text>In addition, no sense alterations or frame shifts in the encoding sequence or for splice variants was not able to confer function loss engines in a strain with tolC failure.</text>
                    <arg n="0">no sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="130">
                    <text>In addition, no significant change or change in frame in the coding sequence or for splice variants is not able to confer loss of functions mutations to a strain with tolC failure.</text>
                    <arg n="0">no significant change or change in frame in the coding sequence or for splice variants</arg>
                    <arg n="1">loss of functions mutations</arg>
                </example>
                <example src="REPLACE" no="131">
                    <text>In addition, no-sense alterations or frame shifts in the encoding sequence or for splice variants could not confer function loss motion in a tolC-deficient strain.</text>
                    <arg n="0">no-sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="132">
                    <text>In addition, no-sense alterations or frame shifts in the encoding sequence or for splice variants may not confer function loss motion in a tolC-deficient strain.</text>
                    <arg n="0">no-sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="133">
                    <text>In addition, no-sense change or change of frame in the coding sequence or for splice variants cannot confer change of loss of function to a tolC deficient strain.</text>
                    <arg n="0">no-sense change or change of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">change of loss of function</arg>
                </example>
                <example src="REPLACE" no="134">
                    <text>In addition, no-sense change or change of frame in the coding sequence or for splice variants cannot confer change of loss of function to a tolC problem-strain.</text>
                    <arg n="0">no-sense change or change of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">change of loss of function</arg>
                </example>
                <example src="REPLACE" no="135">
                    <text>In addition, no-sense change or change of frame in the coding sequence or for splice variants may not confer change of loss of function to a tolC deficient strain.</text>
                    <arg n="0">no-sense change or change of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">change of loss of function</arg>
                </example>
                <example src="REPLACE" no="136">
                    <text>In addition, no-sense change or change of frame in the coding sequence or to splice variants does not confer change of loss of function on a strain with tolC deficiencies.</text>
                    <arg n="0">no-sense change or change of frame in the coding sequence or to splice variants</arg>
                    <arg n="1">change of loss of function</arg>
                </example>
                <example src="REPLACE" no="137">
                    <text>In addition, no-sense change or change of frame in the coding sequence or to splice variants may not confer change of loss of function in a tolC-deficient strain.</text>
                    <arg n="0">no-sense change or change of frame in the coding sequence or to splice variants</arg>
                    <arg n="1">change of loss of function</arg>
                </example>
                <example src="REPLACE" no="138">
                    <text>In addition, non-sense change or deviation of frame in the coding sequence or for splice variants may not confer movement of loss of function in a tolC-deficient strain.</text>
                    <arg n="0">non-sense change or deviation of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="139">
                    <text>In addition, non-sense change or deviation of frame in the coding sequence or for splice variants was not able to confer movement of loss of function in a tolC-deficient strain.</text>
                    <arg n="0">non-sense change or deviation of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="140">
                    <text>In addition, non-sense change or frame deviation in the coding sequence or for splice variants cannot confer movement of loss of function to a tolC deficient strain.</text>
                    <arg n="0">non-sense change or frame deviation in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="141">
                    <text>In addition, non-sense change or frame deviation in the coding sequence or for splice variants may not confer movement of loss of function in a tolC-deficient strain.</text>
                    <arg n="0">non-sense change or frame deviation in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="142">
                    <text>In addition, nonsense or frameshift alteration in the coding sequence or by splice variants cannot confer function loss mutations to a tolC deficient strain.</text>
                    <arg n="0">nonsense or frameshift alteration in the coding sequence or by splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="143">
                    <text>In addition, nonsense or frameshift alteration in the coding sequence or by splice variants is not able to confer function loss mutations in a tolC-deficient strain.</text>
                    <arg n="0">nonsense or frameshift alteration in the coding sequence or by splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="144">
                    <text>In addition, nonsense or frameshift alteration in the coding sequence or by splice variants was not able to confer function loss mutations in a strain with tolC failure.</text>
                    <arg n="0">nonsense or frameshift alteration in the coding sequence or by splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="145">
                    <text>In addition, nonsense or frameshift alteration of the codiding sequence or by splice variants could not confer loss of function mutation in a tolC-deficient strain.</text>
                    <arg n="0">nonsense or frameshift alteration of the codiding sequence or by splice variants</arg>
                    <arg n="1">loss of function mutation</arg>
                </example>
                <example src="REPLACE" no="146">
                    <text>In addition, nonsense or frameshift alteration of the codiding sequence or by splice variants does not confer loss of mutation function on a strain with tolC deficiencies.</text>
                    <arg n="0">nonsense or frameshift alteration of the codiding sequence or by splice variants</arg>
                    <arg n="1">loss of mutation function</arg>
                </example>
                <example src="REPLACE" no="147">
                    <text>In addition, nonsense or frameshift alteration of the codiding sequence or by splice variants is not able to confer loss of function mutation in a tolC-deficient strain.</text>
                    <arg n="0">nonsense or frameshift alteration of the codiding sequence or by splice variants</arg>
                    <arg n="1">loss of function mutation</arg>
                </example>
                <example src="REPLACE" no="148">
                    <text>In addition, nonsense or frameshift alteration of the codiding sequence or by splice variants would not confer loss of function mutation to a tolC deficient strain.</text>
                    <arg n="0">nonsense or frameshift alteration of the codiding sequence or by splice variants</arg>
                    <arg n="1">loss of function mutation</arg>
                </example>
                <example src="REPLACE" no="149">
                    <text>In addition, only the C-terminal substitution for Stat5 cannot confer the Stat5 phenotype in the presence of MG132 to a tolC deficient strain.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="150">
                    <text>In addition, only the C-terminal substitution for Stat5 is not able to confer the Stat5 phenotype in the presence of MG132 to a strain with tolC failure.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="151">
                    <text>In addition, only the C-terminal substitution for Stat5 would not confer the Stat5 phenotype in the presence of MG132 to a tolC deficient strain.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="152">
                    <text>In addition, replacing Gly156 and Lys165 was not able to confer resistance in a tolC-deficient strain.</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="153">
                    <text>In addition, replacing simply the C-terminal with Stat5 is not able to confer the Stat5 phenotype of stability in the presence of MG132 in a tolC-deficient strain.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="154">
                    <text>In addition, replacing simply the C-terminal with Stat5 may not confer the Stat5 phenotype of stability in the presence of MG132 in a tolC-deficient strain.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="155">
                    <text>In addition, replacing simply the C-terminal with Stat5 would not confer the Stat5 phenotype of stability in the presence of MG132 in a tolC-deficient strain.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="156">
                    <text>In addition, senseless alteration or frame change after encoding or splice variants cannot confer mutations of loss of functions in a tolC-deficient strain.</text>
                    <arg n="0">senseless alteration or frame change after encoding or splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="157">
                    <text>In addition, senseless alteration or frame change after encoding or splice variants is not able to confer mutations of loss of functions in a tolC-deficient strain.</text>
                    <arg n="0">senseless alteration or frame change after encoding or splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="158">
                    <text>In addition, senseless alteration or frame change in the encoding sequence or by splice variants may not confer mutations of loss of functions in a tolC-deficient strain.</text>
                    <arg n="0">senseless alteration or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="159">
                    <text>In addition, senseless alteration or frame change of the encoded sequence or by splice variants could not confer missing function mutation in a tolC-deficient strain.</text>
                    <arg n="0">senseless alteration or frame change of the encoded sequence or by splice variants</arg>
                    <arg n="1">missing function mutation</arg>
                </example>
                <example src="REPLACE" no="160">
                    <text>In addition, senseless alteration or frame change of the encoded sequence or by splice variants was not able to confer missing function mutation in a strain with tolC failure.</text>
                    <arg n="0">senseless alteration or frame change of the encoded sequence or by splice variants</arg>
                    <arg n="1">missing function mutation</arg>
                </example>
                <example src="REPLACE" no="161">
                    <text>In addition, senseless alterations or frame change in the encoding sequence or for splice variants may not confer function loss engines in a tolC-deficient strain.</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="162">
                    <text>In addition, senseless change or change in frame in the coding sequence or for splice variants cannot confer function loss change to a tolC deficient strain.</text>
                    <arg n="0">senseless change or change in frame in the coding sequence or for splice variants</arg>
                    <arg n="1">function loss change</arg>
                </example>
                <example src="REPLACE" no="163">
                    <text>In addition, senseless change or change in frame in the coding sequence or to splice variants does not confer function loss mutations in a tolC-deficient strain.</text>
                    <arg n="0">senseless change or change in frame in the coding sequence or to splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="164">
                    <text>In addition, senseless change or change in frame in the coding sequence or to splice variants may not confer function loss mutations in a tolC-deficient strain.</text>
                    <arg n="0">senseless change or change in frame in the coding sequence or to splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="165">
                    <text>In addition, substitutions in Gly156 and Lys165 cannot confer resistance in a tolC-deficient strain.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="166">
                    <text>In addition, the part of TASTs cannot confer specificity in a tolC-deficient strain.</text>
                    <arg n="0">the part of TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="REPLACE" no="167">
                    <text>In addition, the part of TASTs cannot confer specificity to a tolC problem-strain.</text>
                    <arg n="0">the part of TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="REPLACE" no="168">
                    <text>In addition, the part of TASTs would not confer specificity in a tolC-deficient strain.</text>
                    <arg n="0">the part of TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="REPLACE" no="169">
                    <text>In addition, without change of meaning or change of table in the coding sequence or for splice variants cannot confer movement of loss of function in a tolC-deficient strain.</text>
                    <arg n="0">without change of meaning or change of table in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="170">
                    <text>In addition, without change of meaning or change of table in the coding sequence or for splice variants may not confer movement of loss of function to a tolC deficient strain.</text>
                    <arg n="0">without change of meaning or change of table in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="171">
                    <text>In addition, without significant changes or frame deviations in the coding sequence or for splice variants does not confer function loss engines on a strain with tolC deficiencies.</text>
                    <arg n="0">without significant changes or frame deviations in the coding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="172">
                    <text>In addition, without significant changes or frame deviations in the coding sequence or for splice variants would not confer function loss engines to a tolC deficient strain.</text>
                    <arg n="0">without significant changes or frame deviations in the coding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="173">
                    <text>In itself, alkyguaning-DNA alkyltransferase is not able to confer resistance.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="174">
                    <text>In itself, alterations of discount or frame change in the encoding sequence or for splice variants was believed to be not to confer mutations of loss of functions.</text>
                    <arg n="0">alterations of discount or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="175">
                    <text>In itself, alterations of frame shift in the encoding sequence or by splice variants would confer no mutations of loss of functions.</text>
                    <arg n="0">alterations of frame shift in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="176">
                    <text>In itself, change of loss of function may be no has been conferred by no-sense change or change of frame in the coding sequence or to splice variants.</text>
                    <arg n="0">no-sense change or change of frame in the coding sequence or to splice variants</arg>
                    <arg n="1">change of loss of function</arg>
                </example>
                <example src="REPLACE" no="177">
                    <text>In itself, changes in frame in the coding sequence or by splice variants conferred no changes in function loss.</text>
                    <arg n="0">changes in frame in the coding sequence or by splice variants</arg>
                    <arg n="1">changes in function loss</arg>
                </example>
                <example src="REPLACE" no="178">
                    <text>In itself, changes in frame in the coding sequence or by splice variants is thought to be not to confer changes in function loss.</text>
                    <arg n="0">changes in frame in the coding sequence or by splice variants</arg>
                    <arg n="1">changes in function loss</arg>
                </example>
                <example src="REPLACE" no="179">
                    <text>In itself, chapter changes or change of frame in the coding sequence or by splice variants was not able to confer motors of loss of function.</text>
                    <arg n="0">chapter changes or change of frame in the coding sequence or by splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="180">
                    <text>In itself, chapter changes or change of frame in the coding sequence or by splice variants will confer no motors of loss of function.</text>
                    <arg n="0">chapter changes or change of frame in the coding sequence or by splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="181">
                    <text>In itself, discount alterations or frame change in the encoding sequence or by splice variants will have conferred no function loss engines.</text>
                    <arg n="0">discount alterations or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="182">
                    <text>In itself, frame shift alterations in the encoding sequence or by splice variants conferred no function loss engines.</text>
                    <arg n="0">frame shift alterations in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="183">
                    <text>In itself, frame shift alterations in the encoding sequence or by splice variants was believed to be not to confer function loss engines.</text>
                    <arg n="0">frame shift alterations in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="184">
                    <text>In itself, frame shift alterations in the encoding sequence or by splice variants will have conferred no function loss engines.</text>
                    <arg n="0">frame shift alterations in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="185">
                    <text>In itself, function loss change could be not conferred by senseless change or change in frame in the coding sequence or for splice variants.</text>
                    <arg n="0">senseless change or change in frame in the coding sequence or for splice variants</arg>
                    <arg n="1">function loss change</arg>
                </example>
                <example src="REPLACE" no="186">
                    <text>In itself, function loss change will be conferred by senseless change or change in frame in the coding sequence or for splice variants.</text>
                    <arg n="0">senseless change or change in frame in the coding sequence or for splice variants</arg>
                    <arg n="1">function loss change</arg>
                </example>
                <example src="REPLACE" no="187">
                    <text>In itself, function loss engines can be not conferred by discount alterations or frame change in the encoding sequence or by splice variants.</text>
                    <arg n="0">discount alterations or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="188">
                    <text>In itself, function loss engines is thought to be not conferred by no sense alterations or frame shifts in the encoding sequence or for splice variants.</text>
                    <arg n="0">no sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="189">
                    <text>In itself, function loss engines may be no has been conferred by discount alterations or frame change in the encoding sequence or by splice variants.</text>
                    <arg n="0">discount alterations or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="190">
                    <text>In itself, function loss engines was not able to be conferred by no sense alterations or frame shifts in the encoding sequence or for splice variants.</text>
                    <arg n="0">no sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="191">
                    <text>In itself, function loss engines will be conferred by senseless alterations or frame change in the encoding sequence or for splice variants.</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="192">
                    <text>In itself, function loss engines will be not conferred by frame shift alterations in the encoding sequence or by splice variants.</text>
                    <arg n="0">frame shift alterations in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="193">
                    <text>In itself, function loss engines will be not conferred by without significant changes or frame deviations in the coding sequence or for splice variants.</text>
                    <arg n="0">without significant changes or frame deviations in the coding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="194">
                    <text>In itself, function loss motion can be not conferred by no sense alterations or frame change in the encoding sequence or for splice variants.</text>
                    <arg n="0">no sense alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="195">
                    <text>In itself, function loss motion can be not conferred by no-sense alterations or frame shifts in the encoding sequence or for splice variants.</text>
                    <arg n="0">no-sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="196">
                    <text>In itself, function loss motion will be not conferred by no sense alterations or frame change in the encoding sequence or for splice variants.</text>
                    <arg n="0">no sense alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="197">
                    <text>In itself, function loss mutations is not capable of being conferred by nonsense or frameshift alteration in the coding sequence or by splice variants.</text>
                    <arg n="0">nonsense or frameshift alteration in the coding sequence or by splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="198">
                    <text>In itself, function loss mutations is thought to be not conferred by senseless alterations or frame change in the encoding sequence or for splice variants.</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="199">
                    <text>In itself, function loss mutations was not conferred by nonsense or frameshift alteration in the coding sequence or by splice variants.</text>
                    <arg n="0">nonsense or frameshift alteration in the coding sequence or by splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="200">
                    <text>In itself, human 06-alkylguaning-DNA alkyltransferase is not able to confer resistance.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="201">
                    <text>In itself, human 06-alkylguaning-DNA alkyltransferase was not able to confer resistance.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="202">
                    <text>In itself, loss of function mutation would be conferred no by nonsense or frameshift alteration of the codiding sequence or by splice variants.</text>
                    <arg n="0">nonsense or frameshift alteration of the codiding sequence or by splice variants</arg>
                    <arg n="1">loss of function mutation</arg>
                </example>
                <example src="REPLACE" no="203">
                    <text>In itself, loss of functions mutations was not conferred by no significant change or change in frame in the coding sequence or for splice variants.</text>
                    <arg n="0">no significant change or change in frame in the coding sequence or for splice variants</arg>
                    <arg n="1">loss of functions mutations</arg>
                </example>
                <example src="REPLACE" no="204">
                    <text>In itself, missing function mutation is not capable of being conferred by senseless alteration or frame change of the encoded sequence or by splice variants.</text>
                    <arg n="0">senseless alteration or frame change of the encoded sequence or by splice variants</arg>
                    <arg n="1">missing function mutation</arg>
                </example>
                <example src="REPLACE" no="205">
                    <text>In itself, missing function mutation may be no has been conferred by senseless alteration or frame change of the encoded sequence or by splice variants.</text>
                    <arg n="0">senseless alteration or frame change of the encoded sequence or by splice variants</arg>
                    <arg n="1">missing function mutation</arg>
                </example>
                <example src="REPLACE" no="206">
                    <text>In itself, motors of loss of function can be not conferred by chapter changes or change of frame in the coding sequence or by splice variants.</text>
                    <arg n="0">chapter changes or change of frame in the coding sequence or by splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="207">
                    <text>In itself, motors of loss of function can be not conferred by no change in meaning or deviation of frame in the coding sequence or for splice variants.</text>
                    <arg n="0">no change in meaning or deviation of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="208">
                    <text>In itself, motors of loss of function could be not conferred by chapter changes or change of frame in the coding sequence or by splice variants.</text>
                    <arg n="0">chapter changes or change of frame in the coding sequence or by splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="209">
                    <text>In itself, motors of loss of function is not conferred by no change in meaning or deviation of frame in the coding sequence or for splice variants.</text>
                    <arg n="0">no change in meaning or deviation of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="210">
                    <text>In itself, motors of loss of function may be no has been conferred by change of frame in the coding sequence or by splice variants.</text>
                    <arg n="0">change of frame in the coding sequence or by splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="211">
                    <text>In itself, motors of loss of function may be no has been conferred by chapter changes or change of frame in the coding sequence or by splice variants.</text>
                    <arg n="0">chapter changes or change of frame in the coding sequence or by splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="212">
                    <text>In itself, motors of loss of function would be conferred no by no change in meaning or deviation of frame in the coding sequence or for splice variants.</text>
                    <arg n="0">no change in meaning or deviation of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="213">
                    <text>In itself, movement of loss of function can be not conferred by no change in meaning or change in table in the coding sequence or by splice variants.</text>
                    <arg n="0">no change in meaning or change in table in the coding sequence or by splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="214">
                    <text>In itself, movement of loss of function could be not conferred by without change of meaning or change of table in the coding sequence or for splice variants.</text>
                    <arg n="0">without change of meaning or change of table in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="215">
                    <text>In itself, movement of loss of function may be no has been conferred by non-sense change or deviation of frame in the coding sequence or for splice variants.</text>
                    <arg n="0">non-sense change or deviation of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="216">
                    <text>In itself, movement of loss of function was not able to be conferred by non-sense change or deviation of frame in the coding sequence or for splice variants.</text>
                    <arg n="0">non-sense change or deviation of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="217">
                    <text>In itself, movement of loss of function was not able to be conferred by non-sense change or frame deviation in the coding sequence or for splice variants.</text>
                    <arg n="0">non-sense change or frame deviation in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="218">
                    <text>In itself, movement of loss of function was not conferred by non-sense change or deviation of frame in the coding sequence or for splice variants.</text>
                    <arg n="0">non-sense change or deviation of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="219">
                    <text>In itself, movement of loss of function will be conferred by non-sense change or frame deviation in the coding sequence or for splice variants.</text>
                    <arg n="0">non-sense change or frame deviation in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="220">
                    <text>In itself, movement of loss of function will be not conferred by without change of meaning or change of table in the coding sequence or for splice variants.</text>
                    <arg n="0">without change of meaning or change of table in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="221">
                    <text>In itself, mutations of loss of functions can be not conferred by alterations of discount or frame change in the encoding sequence or for splice variants.</text>
                    <arg n="0">alterations of discount or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="222">
                    <text>In itself, mutations of loss of functions could be not conferred by senseless alteration or frame change after encoding or splice variants.</text>
                    <arg n="0">senseless alteration or frame change after encoding or splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="223">
                    <text>In itself, mutations of loss of functions is not conferred by alterations of discount or frame change in the encoding sequence or for splice variants.</text>
                    <arg n="0">alterations of discount or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="224">
                    <text>In itself, mutations of loss of functions will be not conferred by senseless alteration or frame change after encoding or splice variants.</text>
                    <arg n="0">senseless alteration or frame change after encoding or splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="225">
                    <text>In itself, mutations of loss of functions will be not conferred by senseless alterations or frame change in the encoding sequence or for splice variants.</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="226">
                    <text>In itself, no meaningless alterations or frame change in the encoding sequence or for splice variants was not able to confer mutations of loss of functions.</text>
                    <arg n="0">no meaningless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="227">
                    <text>In itself, no sense alterations or frame change in the encoding sequence or for splice variants is not able to confer function loss motion.</text>
                    <arg n="0">no sense alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="228">
                    <text>In itself, no sense alterations or frame change in the encoding sequence or for splice variants was believed to be not to confer function loss motion.</text>
                    <arg n="0">no sense alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="229">
                    <text>In itself, no significant change or change in frame in the coding sequence or for splice variants was believed to be not to confer loss of functions mutations.</text>
                    <arg n="0">no significant change or change in frame in the coding sequence or for splice variants</arg>
                    <arg n="1">loss of functions mutations</arg>
                </example>
                <example src="REPLACE" no="230">
                    <text>In itself, no significant change or change in table in the coding sequence or for splice variants was not able to confer change in function loss.</text>
                    <arg n="0">no significant change or change in table in the coding sequence or for splice variants</arg>
                    <arg n="1">change in function loss</arg>
                </example>
                <example src="REPLACE" no="231">
                    <text>In itself, no significant changes or changes in the frame in the coding sequence or for splice variants was not able to confer loss of function changes.</text>
                    <arg n="0">no significant changes or changes in the frame in the coding sequence or for splice variants</arg>
                    <arg n="1">loss of function changes</arg>
                </example>
                <example src="REPLACE" no="232">
                    <text>In itself, no-sense alterations or frame shifts in the encoding sequence or for splice variants will confer no function loss motion.</text>
                    <arg n="0">no-sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="233">
                    <text>In itself, non-sense change or frame deviation in the coding sequence or for splice variants was believed to be not to confer movement of loss of function.</text>
                    <arg n="0">non-sense change or frame deviation in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="234">
                    <text>In itself, nonsense or frameshift alteration in the coding sequence or by splice variants conferred no function loss mutations.</text>
                    <arg n="0">nonsense or frameshift alteration in the coding sequence or by splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="235">
                    <text>In itself, only the C-terminal substitution for Stat5 conferred no the Stat5 phenotype of stability in the presence of MG132.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="236">
                    <text>In itself, only the C-terminal substitution for Stat5 was not able to confer the Stat5 phenotype of stability in the presence of MG132.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="237">
                    <text>In itself, only the C-terminal substitution for Stat5 will confer no the Stat5 phenotype in the presence of MG132.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="238">
                    <text>In itself, only the C-terminal substitution for Stat5 will have conferred no the Stat5 phenotype in the presence of MG132.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="239">
                    <text>In itself, resistance is thought to be not conferred by human 06-alkylguaning-DNA alkyltransferase.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="240">
                    <text>In itself, resistance was not able to be conferred by alkyguaning-DNA alkyltransferase.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="241">
                    <text>In itself, resistance will be conferred by replacing Gly156 and Lys165.</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="242">
                    <text>In itself, resistance will be not conferred by replacing Gly156 and Lys165.</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="243">
                    <text>In itself, resistance would be conferred no by human 06-alkylguaning-DNA alkyltransferase.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="244">
                    <text>In itself, senseless alteration or frame change after encoding or splice variants conferred no mutations of loss of functions.</text>
                    <arg n="0">senseless alteration or frame change after encoding or splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="245">
                    <text>In itself, senseless alteration or frame change in the encoding sequence or by splice variants conferred no mutations of loss of functions.</text>
                    <arg n="0">senseless alteration or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="246">
                    <text>In itself, senseless alterations or frame change in the encoding sequence or for splice variants conferred no function loss mutations.</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="247">
                    <text>In itself, senseless alterations or frame change in the encoding sequence or for splice variants was believed to be not to confer mutations of loss of functions.</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="248">
                    <text>In itself, senseless alterations or frame change in the encoding sequence or for splice variants will confer no function loss mutations.</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="249">
                    <text>In itself, senseless change or change in frame in the coding sequence or for splice variants would confer no function loss change.</text>
                    <arg n="0">senseless change or change in frame in the coding sequence or for splice variants</arg>
                    <arg n="1">function loss change</arg>
                </example>
                <example src="REPLACE" no="250">
                    <text>In itself, senseless change or change in frame in the coding sequence or to splice variants is not able to confer function loss mutations.</text>
                    <arg n="0">senseless change or change in frame in the coding sequence or to splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="251">
                    <text>In itself, specificity is thought to be not conferred by the part of TASTs.</text>
                    <arg n="0">the part of TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="REPLACE" no="252">
                    <text>In itself, specificity may be no has been conferred by the STAT portion.</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="REPLACE" no="253">
                    <text>In itself, specificity was not conferred by the part of TASTs.</text>
                    <arg n="0">the part of TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="REPLACE" no="254">
                    <text>In itself, specificity would be conferred no by the STAT portion.</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="REPLACE" no="255">
                    <text>In itself, specificity would be conferred no by the part of TASTs.</text>
                    <arg n="0">the part of TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="REPLACE" no="256">
                    <text>In itself, the STAT portion will have conferred no specificity.</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="REPLACE" no="257">
                    <text>In itself, the Stat5 phenotype in the presence of MG132 is not capable of being conferred by only the C-terminal substitution for Stat5.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="258">
                    <text>In itself, the Stat5 phenotype of stability in the presence of MG132 is not conferred by only the C-terminal substitution for Stat5.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="259">
                    <text>In itself, the Stat5 phenotype of stability in the presence of MG132 was not conferred by only the C-terminal substitution for Stat5.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="260">
                    <text>In itself, the Stat5 phenotype of stability in the presence of MG132 was not conferred by replacing simply the C-terminal with Stat5.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="261">
                    <text>In itself, the change in function loss was believed to be not conferred by no significant change or change in table in the coding sequence or for splice variants.</text>
                    <arg n="0">no significant change or change in table in the coding sequence or for splice variants</arg>
                    <arg n="1">change in function loss</arg>
                </example>
                <example src="REPLACE" no="262">
                    <text>In itself, the loss of mutation function was believed to be not conferred by nonsense or frameshift alteration of the codiding sequence or by splice variants.</text>
                    <arg n="0">nonsense or frameshift alteration of the codiding sequence or by splice variants</arg>
                    <arg n="1">loss of mutation function</arg>
                </example>
                <example src="REPLACE" no="263">
                    <text>In itself, the mutations of loss of functions was believed to be not conferred by no meaningless alterations or frame change in the encoding sequence or for splice variants.</text>
                    <arg n="0">no meaningless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="264">
                    <text>In itself, the part of TASTs was believed to be not to confer specificity.</text>
                    <arg n="0">the part of TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="REPLACE" no="265">
                    <text>In itself, the stability phenotype Stat5 in the presence of MG132 was not able to be conferred by which simply replaces C-terminus for Stat5.</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="266">
                    <text>In itself, without significant changes or frame deviations in the coding sequence or for splice variants is not able to confer function loss engines.</text>
                    <arg n="0">without significant changes or frame deviations in the coding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="267">
                    <text>Increased AGT levels are associated with acquired 06-BG resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and substitutions in Gly156 and Lys165 to confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="REPLACE" no="268">
                    <text>Increased AGT levels are associated with acquired a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance can be conferred by part of STATs on alkylation, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="269">
                    <text>Increased AGT levels are associated with acquired a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the part of STATs to confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="270">
                    <text>Increased AGT levels are associated with acquired a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the part of STATs to confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="271">
                    <text>Increased AGT levels are associated with acquired a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance is conferred by the STAT portion on alkylation, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="272">
                    <text>Increased AGT levels are associated with acquired alkylation pathways resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and human 06-alkylguaning-DNA alkyltransferase to confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="REPLACE" no="273">
                    <text>Increased AGT levels are associated with acquired alkylation routes resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance is conferred by alkyguaning-DNA alkyltransferase on alkylation, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="REPLACE" no="274">
                    <text>Increased AGT levels are associated with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance is conferred by the STAT portion on a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="275">
                    <text>Increased AGT levels are associated with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the part of STATs to confer resistance to a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="276">
                    <text>Increased AGT levels are associated with acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and only the C-terminal substitution for Stat5 to confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="277">
                    <text>Increased AGT levels are associated with acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and only the C-terminal substitution for Stat5 to confer resistance to State1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="278">
                    <text>Increased AGT levels are associated with acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance is conferred by only the C-terminal substitution for Stat5 on State1, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="279">
                    <text>Increased AGT levels are associated with acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance is conferred by only the C-terminal substitution for Stat5 on State1, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="280">
                    <text>Increased AGT levels in parallel to acquired Stat1 the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and replacing simply the C-terminal with Stat5 could confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in the treatment resistance.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="281">
                    <text>Increased AGT levels in parallel to acquired Stat1 the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and replacing simply the C-terminal with Stat5 may confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="282">
                    <text>Increased AGT levels in parallel to acquired Stat1 the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and replacing simply the C-terminal with Stat5 may have conferred resistance on alkylation, demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="283">
                    <text>Increased AGT levels in parallel to acquired State1 the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and only the C-terminal substitution for Stat5 could confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in A1 treatment (resistance).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="284">
                    <text>Increased AGT levels in parallel to acquired State1 the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and only the C-terminal substitution for Stat5 could confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in the treatment resistance.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="285">
                    <text>Increased AGT levels in parallel to acquired State1 the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and only the C-terminal substitution for Stat5 would confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="286">
                    <text>Increased AGT levels in parallel to acquired a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the part of STATs can confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="287">
                    <text>Increased AGT levels in parallel to acquired a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the part of STATs could confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in A1 treatment (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="288">
                    <text>Increased AGT levels in parallel to acquired a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the part of STATs can confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="289">
                    <text>Increased AGT levels in parallel to acquired a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and part of STATs could confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in A1 treatment (resistance).</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="290">
                    <text>Increased AGT levels in parallel to acquired a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and part of STATs could confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in the treatment resistance.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="291">
                    <text>Increased AGT levels in parallel to acquired a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and part of STATs will conferred resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="292">
                    <text>Increased AGT levels in parallel to acquired a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and part of STATs would confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="293">
                    <text>Increased AGT levels in parallel to acquired a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the part of STATs could confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in the treatment resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="294">
                    <text>Increased AGT levels in parallel to acquired a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the part of STATs will conferred resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="295">
                    <text>Increased AGT levels in parallel to acquired a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the part of STATs will conferred resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="296">
                    <text>Increased AGT levels in parallel to acquired a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and part of STATs may confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="297">
                    <text>Increased AGT levels in parallel to acquired a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the part of STATs may confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="298">
                    <text>Increased AGT levels in parallel to acquired a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the part of STATs will conferred resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="299">
                    <text>Increased AGT levels in parallel to acquired a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the STAT portion will conferred resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="300">
                    <text>Increased AGT levels in parallel to acquired a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the STAT portion would confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="301">
                    <text>Increased AGT levels in parallel to acquired alkylation pathways resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and human 06-alkylguaning-DNA alkyltransferase may confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="REPLACE" no="302">
                    <text>Increased AGT levels in parallel to acquired alkylation pathways resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and human 06-alkylguaning-DNA alkyltransferase would confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="REPLACE" no="303">
                    <text>Increased AGT levels in parallel to acquired alkylation routes resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyguaning-DNA alkyltransferase can confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="REPLACE" no="304">
                    <text>Increased AGT levels in parallel to acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the STAT portion could confer resistance to a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) (Kaina et al., 1991), demonstrating the role of AGT in the treatment resistance.</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="305">
                    <text>Increased AGT levels in parallel to acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the part of STATs can confer resistance to a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="306">
                    <text>Increased AGT levels in parallel to acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the part of STATs could confer resistance to a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in the treatment resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="307">
                    <text>Increased AGT levels in parallel to acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the part of STATs may have conferred resistance on a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="308">
                    <text>Increased AGT levels in parallel to acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the part of STATs would confer resistance to a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="309">
                    <text>Increased AGT levels in parallel to acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and only the C-terminal substitution for Stat5 will conferred resistance to State1 (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="310">
                    <text>Increased AGT levels in parallel to acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and only the C-terminal substitution for Stat5 may confer resistance to State1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="311">
                    <text>Increased AGT levels in parallel to acquired alkylation the stability phenotype Stat5 in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and which simply replaces C-terminus for Stat5 could confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in the treatment resistance.</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="312">
                    <text>Increased AGT levels in parallel with acquired 06-BG resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and replacing Gly156 and Lys165 will confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="REPLACE" no="313">
                    <text>Increased AGT levels in parallel with acquired 06-BG resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance have been conferred by substitutions in Gly156 and Lys165 to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="REPLACE" no="314">
                    <text>Increased AGT levels in parallel with acquired 06-BG resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were able to be conferred by replacing Gly156 and Lys165 on alkylation, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="REPLACE" no="315">
                    <text>Increased AGT levels in parallel with acquired Stat1 the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and only the C-terminal substitution for Stat5 will confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="316">
                    <text>Increased AGT levels in parallel with acquired Stat1 the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and replacing simply the C-terminal with Stat5 will confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="317">
                    <text>Increased AGT levels in parallel with acquired Stat1 the stability phenotype Stat5 in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and A1 (AGT transfection) are able to be conferred by which simply replaces C-terminus for Stat5 to alkylation, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="318">
                    <text>Increased AGT levels in parallel with acquired Stat1 the stability phenotype Stat5 in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and which simply replaces C-terminus for Stat5 will confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="319">
                    <text>Increased AGT levels in parallel with acquired a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and A1 (AGT transfection) are able to be conferred by the part of STATs to alkylation, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="320">
                    <text>Increased AGT levels in parallel with acquired a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the part of STATs conferred resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="321">
                    <text>Increased AGT levels in parallel with acquired a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and A1 (AGT transfection) are able to be conferred by the part of STATs to alkylation, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="322">
                    <text>Increased AGT levels in parallel with acquired a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance have been conferred by the part of STATs to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="323">
                    <text>Increased AGT levels in parallel with acquired a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and part of STATs are able to confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="324">
                    <text>Increased AGT levels in parallel with acquired a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were able to be conferred by the part of STATs on alkylation, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="325">
                    <text>Increased AGT levels in parallel with acquired a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and part of STATs were able to confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="326">
                    <text>Increased AGT levels in parallel with acquired a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance have been conferred by the part of STATs to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="327">
                    <text>Increased AGT levels in parallel with acquired a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the STAT portion have the ability to confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="328">
                    <text>Increased AGT levels in parallel with acquired a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the part of STATs conferred resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="329">
                    <text>Increased AGT levels in parallel with acquired a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the part of STATs have the ability to confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="330">
                    <text>Increased AGT levels in parallel with acquired alkylation pathways resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and human 06-alkylguaning-DNA alkyltransferase conferred resistance on alkylation, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="REPLACE" no="331">
                    <text>Increased AGT levels in parallel with acquired alkylation pathways resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and human 06-alkylguaning-DNA alkyltransferase may confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="REPLACE" no="332">
                    <text>Increased AGT levels in parallel with acquired alkylation routes resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyguaning-DNA alkyltransferase conferred resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="REPLACE" no="333">
                    <text>Increased AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and part of STATs conferred resistance on a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="334">
                    <text>Increased AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and part of STATs were observed to confer resistance to a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="335">
                    <text>Increased AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and part of STATs will confer resistance to a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="336">
                    <text>Increased AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance have been conferred by part of STATs to a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="337">
                    <text>Increased AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance have been conferred by the part of STATs to a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="338">
                    <text>Increased AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance have been conferred by the part of STATs to a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="339">
                    <text>Increased AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance have been conferred by the part of STATs to a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="340">
                    <text>Increased AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were able to be conferred by the STAT portion on a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="341">
                    <text>Increased AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the part of STATs conferred resistance on a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="342">
                    <text>Increased AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the part of STATs conferred resistance to a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="343">
                    <text>Increased AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the part of STATs conferred resistance to a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="344">
                    <text>Increased AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the part of STATs have the ability to confer resistance to a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="345">
                    <text>Increased AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the part of STATs were able to confer resistance to a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="346">
                    <text>Increased AGT levels in parallel with acquired alkylation the stability phenotype Stat5 in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and which simply replaces C-terminus for Stat5 conferred resistance on Stat1, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="347">
                    <text>Increased GAT in parallel with acquired 06-BG resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and replacing Gly156 and Lys165 was considered to confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of GAT in the treatment resistance.</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="REPLACE" no="348">
                    <text>Increased GAT in parallel with acquired Stat1 the stability phenotype Stat5 in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and which simply replaces C-terminus for Stat5 was considered to confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of GAT in the treatment resistance.</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="349">
                    <text>Increased GAT in parallel with acquired a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the part of STATs was considered to confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of GAT in the treatment resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="350">
                    <text>Increased GAT in parallel with acquired alkylation routes resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and alkyguaning-DNA alkyltransferase was considered to confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of GAT in the treatment resistance.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="REPLACE" no="351">
                    <text>Increased GAT in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the part of STATs was considered to confer resistance to a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of GAT in the treatment resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="352">
                    <text>Increased GAT in parallel with acquired alkylation the stability phenotype Stat5 in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and which simply replaces C-terminus for Stat5 was considered to confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of GAT in the treatment resistance.</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="353">
                    <text>Increased human 06-alkylguaning-DNA alkyltransferase levels in parallel to acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT will conferred resistance to alkylation pathways (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="REPLACE" no="354">
                    <text>Increased human 06-alkylguaning-DNA alkyltransferase levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT are able to confer resistance to alkylation pathways (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="REPLACE" no="355">
                    <text>Increased human 06-alkylguaning-DNA alkyltransferase levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT will confer resistance to alkylation pathways (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="REPLACE" no="356">
                    <text>Increased only the C-terminal substitution for Stat5 levels in parallel to acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT may confer resistance to State1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="357">
                    <text>Increased only the C-terminal substitution for Stat5 levels in parallel with acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT conferred resistance on State1, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="358">
                    <text>Increased only the C-terminal substitution for Stat5 levels in parallel with acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT conferred resistance to State1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="359">
                    <text>Increased part of STATs levels are associated with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT to confer resistance to a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="360">
                    <text>Increased part of STATs levels in parallel to acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT will conferred resistance to a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="361">
                    <text>Increased part of STATs levels in parallel to acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT will conferred resistance to a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="362">
                    <text>Increased part of STATs levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT may confer resistance to a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="363">
                    <text>Increased part of STATs levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT were able to confer resistance to a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="364">
                    <text>Increased part of STATs levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance have been conferred by AGT to a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="365">
                    <text>Increased replacing Gly156 and Lys165 levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and A1 (AGT transfection) are able to be conferred by AGT to 06-BG, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="REPLACE" no="366">
                    <text>Increased replacing simply the C-terminal with Stat5 levels in parallel with acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT conferred resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="367">
                    <text>Increased substitutions in Gly156 and Lys165 levels are associated with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT to confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="REPLACE" no="368">
                    <text>Increased the STAT portion levels in parallel to acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT could confer resistance to a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) (Kaina et al., 1991), demonstrating the role of AGT in the treatment resistance.</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="369">
                    <text>Increased the STAT portion levels in parallel to acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT will conferred resistance to a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="370">
                    <text>Increased the STAT portion levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT conferred resistance to a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="371">
                    <text>Increased the part of STATs levels are associated with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT to confer resistance to a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="372">
                    <text>Increased the part of STATs levels are associated with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT to confer resistance to a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="373">
                    <text>Increased the part of STATs levels are associated with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance is conferred by AGT on a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="374">
                    <text>Increased the part of STATs levels are associated with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance is conferred by AGT on a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="375">
                    <text>Increased the part of STATs levels in parallel to acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT can confer resistance to a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="376">
                    <text>Increased the part of STATs levels in parallel to acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT could confer resistance to a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in A1 treatment (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="377">
                    <text>Increased the part of STATs levels in parallel to acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT could confer resistance to a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in the treatment resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="378">
                    <text>Increased the part of STATs levels in parallel to acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT could confer resistance to a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in A1 treatment (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="379">
                    <text>Increased the part of STATs levels in parallel to acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT will conferred resistance to a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="380">
                    <text>Increased the part of STATs levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT conferred resistance on a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="381">
                    <text>Increased the part of STATs levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT conferred resistance on a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="382">
                    <text>Increased the part of STATs levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT conferred resistance to a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="383">
                    <text>Increased the part of STATs levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT have the ability to confer resistance to a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="384">
                    <text>Increased the part of STATs levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT have the ability to confer resistance to a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="385">
                    <text>Increased the part of STATs levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT may confer resistance to a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="386">
                    <text>Increased the part of STATs levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were able to be conferred by AGT on a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="387">
                    <text>Increased the part of STATs levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were able to be conferred by AGT on a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="388">
                    <text>Increased the part of STATs levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were able to be conferred by AGT on a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="389">
                    <text>Increased which simply replaces C-terminus for Stat5 levels in parallel to acquired alkylation the stability phenotype Stat5 in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT would confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="390">
                    <text>Increased which simply replaces C-terminus for Stat5 levels in parallel with acquired alkylation the stability phenotype Stat5 in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT were able to confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in therapeutic resistance.</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="391">
                    <text>It was believed that debarred or frame alterations in the encoding sequence or by splice variants would confer no to mutations of loss of functions.</text>
                    <arg n="0">debarred or frame alterations in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="392">
                    <text>It was believed that no change in meaning or change in table in the coding sequence or by splice variants would confer no to movement of loss of function.</text>
                    <arg n="0">no change in meaning or change in table in the coding sequence or by splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="393">
                    <text>It was believed that no sense alterations or frame shifts in the encoding sequence or for splice variants would confer no to function loss engines.</text>
                    <arg n="0">no sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="394">
                    <text>It was believed that nonsense or frameshift alteration of the codiding sequence or by splice variants would confer no to loss of function mutation.</text>
                    <arg n="0">nonsense or frameshift alteration of the codiding sequence or by splice variants</arg>
                    <arg n="1">loss of function mutation</arg>
                </example>
                <example src="REPLACE" no="395">
                    <text>It was believed that senseless alteration or frame change in the encoding sequence or by splice variants would confer no to mutations of loss of functions.</text>
                    <arg n="0">senseless alteration or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="396">
                    <text>Likewise, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), discount alterations or frame change in the encoding sequence or by splice variants is able to confer the A1 resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">discount alterations or frame change in the encoding sequence or by splice variants</arg>
                </example>
                <example src="REPLACE" no="397">
                    <text>Likewise, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), no sense alterations or frame shifts in the encoding sequence or for splice variants is able to confer the A1 resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                </example>
                <example src="REPLACE" no="398">
                    <text>Likewise, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), no significant change or change in frame in the coding sequence or for splice variants is able to confer the A1 resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no significant change or change in frame in the coding sequence or for splice variants</arg>
                </example>
                <example src="REPLACE" no="399">
                    <text>Likewise, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), no significant changes or changes in the frame in the coding sequence or for splice variants is able to confer the A1 resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no significant changes or changes in the frame in the coding sequence or for splice variants</arg>
                </example>
                <example src="REPLACE" no="400">
                    <text>Likewise, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), no-sense change or change of frame in the coding sequence or for splice variants is able to confer the A1 resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no-sense change or change of frame in the coding sequence or for splice variants</arg>
                </example>
                <example src="REPLACE" no="401">
                    <text>Likewise, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), senseless change or change in frame in the coding sequence or to splice variants is able to confer the A1 resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless change or change in frame in the coding sequence or to splice variants</arg>
                </example>
                <example src="REPLACE" no="402">
                    <text>Similarly, the charge imposed by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), function loss engines will be conferred for no sense alterations or frame shifts in the encoding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="403">
                    <text>Similarly, the charge imposed by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), the Stat5 phenotype of stability in the presence of MG132 will be conferred for only the C-terminal substitution for Stat5 (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="404">
                    <text>Similarly, the charge imposed by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), the Stat5 phenotype of stability in the presence of MG132 will be conferred for replacing simply the C-terminal with Stat5 (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="405">
                    <text>Similarly, the charge imposed by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), the stability phenotype Stat5 in the presence of MG132 will be conferred for which simply replaces C-terminus for Stat5 (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="406">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), change of frame in the coding sequence or by splice variants may confer the A1 resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">change of frame in the coding sequence or by splice variants</arg>
                </example>
                <example src="REPLACE" no="407">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), no change in meaning or deviation of frame in the coding sequence or for splice variants may confer the A1 resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no change in meaning or deviation of frame in the coding sequence or for splice variants</arg>
                </example>
                <example src="REPLACE" no="408">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), no-sense change or change of frame in the coding sequence or for splice variants may confer the A1 resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no-sense change or change of frame in the coding sequence or for splice variants</arg>
                </example>
                <example src="REPLACE" no="409">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), non-sense change or deviation of frame in the coding sequence or for splice variants could confer the A1 resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">non-sense change or deviation of frame in the coding sequence or for splice variants</arg>
                </example>
                <example src="REPLACE" no="410">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), non-sense change or frame deviation in the coding sequence or for splice variants may confer the A1 resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">non-sense change or frame deviation in the coding sequence or for splice variants</arg>
                </example>
                <example src="REPLACE" no="411">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), senseless change or change in frame in the coding sequence or to splice variants could confer the A1 resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless change or change in frame in the coding sequence or to splice variants</arg>
                </example>
                <example src="REPLACE" no="412">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the STAT portion could confer the A1 resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the STAT portion</arg>
                </example>
                <example src="REPLACE" no="413">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the STAT portion may confer the A1 resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the STAT portion</arg>
                </example>
                <example src="REPLACE" no="414">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the change in function loss was able to be conferred for no significant change or change in table in the coding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no significant change or change in table in the coding sequence or for splice variants</arg>
                    <arg n="1">change in function loss</arg>
                </example>
                <example src="REPLACE" no="415">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the change of loss of function could be conferred for no-sense change or change of frame in the coding sequence or to splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no-sense change or change of frame in the coding sequence or to splice variants</arg>
                    <arg n="1">change of loss of function</arg>
                </example>
                <example src="REPLACE" no="416">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the change of loss of function has been conferred for no-sense change or change of frame in the coding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no-sense change or change of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">change of loss of function</arg>
                </example>
                <example src="REPLACE" no="417">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the change of loss of function was able to be conferred for no-sense change or change of frame in the coding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no-sense change or change of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">change of loss of function</arg>
                </example>
                <example src="REPLACE" no="418">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the change of loss of function will be conferred for no-sense change or change of frame in the coding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no-sense change or change of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">change of loss of function</arg>
                </example>
                <example src="REPLACE" no="419">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the function loss engines has been conferred for frame shift alterations in the encoding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">frame shift alterations in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="420">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the function loss engines is conferred for no sense alterations or frame shifts in the encoding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="421">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the function loss engines is conferred for senseless alterations or frame change in the encoding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="422">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the function loss motion was able to be conferred for no-sense alterations or frame shifts in the encoding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no-sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="423">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the function loss mutations has been conferred for senseless change or change in frame in the coding sequence or to splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless change or change in frame in the coding sequence or to splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="424">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the function loss mutations was able to be conferred for senseless alterations or frame change in the encoding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="425">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the loss of function changes was able to be conferred for no significant changes or changes in the frame in the coding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no significant changes or changes in the frame in the coding sequence or for splice variants</arg>
                    <arg n="1">loss of function changes</arg>
                </example>
                <example src="REPLACE" no="426">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the loss of function mutation has been conferred for nonsense or frameshift alteration of the codiding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alteration of the codiding sequence or by splice variants</arg>
                    <arg n="1">loss of function mutation</arg>
                </example>
                <example src="REPLACE" no="427">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the loss of function mutation was able to be conferred for nonsense or frameshift alteration of the codiding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alteration of the codiding sequence or by splice variants</arg>
                    <arg n="1">loss of function mutation</arg>
                </example>
                <example src="REPLACE" no="428">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the loss of mutation function would be conferred for nonsense or frameshift alteration of the codiding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alteration of the codiding sequence or by splice variants</arg>
                    <arg n="1">loss of mutation function</arg>
                </example>
                <example src="REPLACE" no="429">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the motors of loss of function was able to be conferred for no change in meaning or deviation of frame in the coding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no change in meaning or deviation of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="430">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the movement of loss of function could be conferred for no change in meaning or change in table in the coding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no change in meaning or change in table in the coding sequence or by splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="431">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the movement of loss of function will be conferred for non-sense change or deviation of frame in the coding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">non-sense change or deviation of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="432">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the mutations of loss of functions is conferred for no meaningless alterations or frame change in the encoding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no meaningless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="433">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the mutations of loss of functions was able to be conferred for debarred or frame alterations in the encoding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">debarred or frame alterations in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="434">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the mutations of loss of functions was able to be conferred for senseless alteration or frame change in the encoding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless alteration or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="435">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the mutations of loss of functions will be conferred for senseless alteration or frame change in the encoding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless alteration or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="436">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the mutations of loss of functions would be conferred for alterations of frame shift in the encoding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">alterations of frame shift in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="437">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the part of TASTs may confer the A1 resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the part of TASTs</arg>
                </example>
                <example src="REPLACE" no="438">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the portion of the STATs could confer the A1 resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the portion of the STATs</arg>
                </example>
                <example src="REPLACE" no="439">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistance was able to be conferred for alkyguaning-DNA alkyltransferase (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="440">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistance will be conferred for human 06-alkylguaning-DNA alkyltransferase (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="441">
                    <text>Similarly, the charge introduced by the Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the the stability phenotype Stat5 in the presence of MG132 would be conferred for which simply replaces C-terminus for Stat5 (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="442">
                    <text>Similarly, the imposition imposed by the mutants Gly160His and Gly160Arg repelled the benzyl group (Figure 3B), function loss motion was able to be conferred to no sense alterations or frame change in the encoding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no sense alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="443">
                    <text>Similarly, the imposition imposed by the mutants Gly160His and Gly160Arg repelled the benzyl group (Figure 3B), missing function mutation was able to be conferred to senseless alteration or frame change of the encoded sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless alteration or frame change of the encoded sequence or by splice variants</arg>
                    <arg n="1">missing function mutation</arg>
                </example>
                <example src="REPLACE" no="444">
                    <text>Similarly, the imposition imposed by the mutants Gly160His and Gly160Arg repelled the benzyl group (Figure 3B), mutations of loss of functions was able to be conferred to senseless alteration or frame change after encoding or splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless alteration or frame change after encoding or splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="445">
                    <text>Similarly, the imposition imposed by the mutants Gly160His and Gly160Arg repelled the benzyl group (Figure 3B), resistance was able to be conferred to substitutions in Gly156 and Lys165 (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="446">
                    <text>Similarly, the imposition imposed by the mutants Gly160His and Gly160Arg repelled the benzyl group (Figure 3B), the stability phenotype Stat5 in the presence of MG132 was able to be conferred to which simply replaces C-terminus for Stat5 (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="447">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), alterations of frame shift in the encoding sequence or by splice variants conferred mutations of loss of functions (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">alterations of frame shift in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="448">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), alterations of frame shift in the encoding sequence or by splice variants would confer the A1 resistance (06-BG) (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">alterations of frame shift in the encoding sequence or by splice variants</arg>
                </example>
                <example src="REPLACE" no="449">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), change of frame in the coding sequence or by splice variants have conferred motors of loss of function (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">change of frame in the coding sequence or by splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="450">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), changes in frame in the coding sequence or by splice variants conferred changes in function loss (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">changes in frame in the coding sequence or by splice variants</arg>
                    <arg n="1">changes in function loss</arg>
                </example>
                <example src="REPLACE" no="451">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), debarred or frame alterations in the encoding sequence or by splice variants conferred mutations of loss of functions (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">debarred or frame alterations in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="452">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), debarred or frame alterations in the encoding sequence or by splice variants would confer the A1 resistance (06-BG) (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">debarred or frame alterations in the encoding sequence or by splice variants</arg>
                </example>
                <example src="REPLACE" no="453">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), discount alterations or frame change in the encoding sequence or by splice variants have conferred function loss engines (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">discount alterations or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="454">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), frame shift alterations in the encoding sequence or by splice variants confer function loss engines (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">frame shift alterations in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="455">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), human 06-alkylguaning-DNA alkyltransferase conferred resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="456">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), it was believed that function loss engines was conferred for no sense alterations or frame shifts in the encoding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="457">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), it was believed that function loss mutations was conferred for nonsense or frameshift alteration in the coding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alteration in the coding sequence or by splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="458">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), it was believed that loss of function mutation was conferred for nonsense or frameshift alteration of the codiding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alteration of the codiding sequence or by splice variants</arg>
                    <arg n="1">loss of function mutation</arg>
                </example>
                <example src="REPLACE" no="459">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), it was believed that loss of mutation function was conferred for nonsense or frameshift alteration of the codiding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alteration of the codiding sequence or by splice variants</arg>
                    <arg n="1">loss of mutation function</arg>
                </example>
                <example src="REPLACE" no="460">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), it was believed that mutations of loss of functions was conferred for senseless alteration or frame change after encoding or splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless alteration or frame change after encoding or splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="461">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), no change in meaning or change in table in the coding sequence or by splice variants conferred movement of loss of function (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no change in meaning or change in table in the coding sequence or by splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="462">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), no meaningless alterations or frame change in the encoding sequence or for splice variants would confer mutations of loss of functions (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no meaningless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="463">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), no sense alterations or frame change in the encoding sequence or by splice variants have conferred function loss motion (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no sense alterations or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="464">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), no sense alterations or frame change in the encoding sequence or by splice variants was able to confer the A1 resistance (06-BG) (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no sense alterations or frame change in the encoding sequence or by splice variants</arg>
                </example>
                <example src="REPLACE" no="465">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), no significant change or change in frame in the coding sequence or for splice variants confer loss of functions mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no significant change or change in frame in the coding sequence or for splice variants</arg>
                    <arg n="1">loss of functions mutations</arg>
                </example>
                <example src="REPLACE" no="466">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), no significant change or change in table in the coding sequence or for splice variants was able to confer the A1 resistance (06-BG) (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no significant change or change in table in the coding sequence or for splice variants</arg>
                </example>
                <example src="REPLACE" no="467">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), no-sense change or change of frame in the coding sequence or to splice variants would confer the A1 resistance (06-BG) (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no-sense change or change of frame in the coding sequence or to splice variants</arg>
                </example>
                <example src="REPLACE" no="468">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), non-sense change or frame deviation in the coding sequence or for splice variants have conferred movement of loss of function (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">non-sense change or frame deviation in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="469">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), nonsense or frameshift alteration in the coding sequence or by splice variants would confer function loss mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alteration in the coding sequence or by splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="470">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), nonsense or frameshift alteration in the coding sequence or by splice variants would confer the A1 resistance (06-BG) (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alteration in the coding sequence or by splice variants</arg>
                </example>
                <example src="REPLACE" no="471">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), nonsense or frameshift alteration of the codiding sequence or by splice variants was able to confer the A1 resistance (06-BG) (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alteration of the codiding sequence or by splice variants</arg>
                </example>
                <example src="REPLACE" no="472">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), only the C-terminal substitution for Stat5 have conferred the Stat5 phenotype in the presence of MG132 (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="473">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), only the C-terminal substitution for Stat5 was able to confer the A1 resistance (06-BG) (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                </example>
                <example src="REPLACE" no="474">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), only the C-terminal substitution for Stat5 would confer the A1 resistance (06-BG) (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                </example>
                <example src="REPLACE" no="475">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), replacing Gly156 and Lys165 confer resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="476">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), replacing Gly156 and Lys165 conferred resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="477">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), replacing Gly156 and Lys165 would confer the A1 resistance (06-BG) (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                </example>
                <example src="REPLACE" no="478">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), senseless alteration or frame change in the encoding sequence or by splice variants conferred mutations of loss of functions (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless alteration or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="479">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), senseless alteration or frame change in the encoding sequence or by splice variants would confer the A1 resistance (06-BG) (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless alteration or frame change in the encoding sequence or by splice variants</arg>
                </example>
                <example src="REPLACE" no="480">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), senseless alteration or frame change of the encoded sequence or by splice variants conferred missing function mutation (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless alteration or frame change of the encoded sequence or by splice variants</arg>
                    <arg n="1">missing function mutation</arg>
                </example>
                <example src="REPLACE" no="481">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), senseless alteration or frame change of the encoded sequence or by splice variants have conferred missing function mutation (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless alteration or frame change of the encoded sequence or by splice variants</arg>
                    <arg n="1">missing function mutation</arg>
                </example>
                <example src="REPLACE" no="482">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), senseless alterations or frame change in the encoding sequence or for splice variants have conferred mutations of loss of functions (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="483">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the STAT portion would confer specificity (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="REPLACE" no="484">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the function loss motion is thought to be conferred by no sense alterations or frame change in the encoding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no sense alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="485">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the mutations of loss of functions is thought to be conferred by alterations of frame shift in the encoding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">alterations of frame shift in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="486">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the mutations of loss of functions is thought to be conferred by debarred or frame alterations in the encoding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">debarred or frame alterations in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="487">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the part of TASTs have conferred specificity (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the part of TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="REPLACE" no="488">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistance is thought to be conferred by human 06-alkylguaning-DNA alkyltransferase (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="489">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the resistance is thought to be conferred by substitutions in Gly156 and Lys165 (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="490">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), the the stability phenotype Stat5 in the presence of MG132 is thought to be conferred by which simply replaces C-terminus for Stat5 (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="491">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), which simply replaces C-terminus for Stat5 was able to confer the A1 resistance (06-BG) (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                </example>
                <example src="REPLACE" no="492">
                    <text>Similarly, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), without change of meaning or change of table in the coding sequence or for splice variants was believed to confer movement of loss of function (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">without change of meaning or change of table in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="493">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), alterations of discount or frame change in the encoding sequence or for splice variants was considered to confer mutations of loss of functions (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">alterations of discount or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="494">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), alterations of frame shift in the encoding sequence or by splice variants was considered to confer mutations of loss of functions (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">alterations of frame shift in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="495">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), change of loss of function would be conferred by no-sense change or change of frame in the coding sequence or to splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no-sense change or change of frame in the coding sequence or to splice variants</arg>
                    <arg n="1">change of loss of function</arg>
                </example>
                <example src="REPLACE" no="496">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), changes in frame in the coding sequence or by splice variants was considered to confer changes in function loss (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">changes in frame in the coding sequence or by splice variants</arg>
                    <arg n="1">changes in function loss</arg>
                </example>
                <example src="REPLACE" no="497">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), changes in function loss would be conferred by changes in frame in the coding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">changes in frame in the coding sequence or by splice variants</arg>
                    <arg n="1">changes in function loss</arg>
                </example>
                <example src="REPLACE" no="498">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), debarred or frame alterations in the encoding sequence or by splice variants was considered to confer mutations of loss of functions (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">debarred or frame alterations in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="499">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), frame shift alterations in the encoding sequence or by splice variants was considered to confer function loss engines (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">frame shift alterations in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="500">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), function loss change would be conferred by senseless change or change in frame in the coding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless change or change in frame in the coding sequence or for splice variants</arg>
                    <arg n="1">function loss change</arg>
                </example>
                <example src="REPLACE" no="501">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), function loss engines would be conferred by senseless alterations or frame change in the encoding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="502">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), human 06-alkylguaning-DNA alkyltransferase was considered to confer resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="503">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), loss of function changes would be conferred by no significant changes or changes in the frame in the coding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no significant changes or changes in the frame in the coding sequence or for splice variants</arg>
                    <arg n="1">loss of function changes</arg>
                </example>
                <example src="REPLACE" no="504">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), loss of functions mutations would be conferred by no significant change or change in frame in the coding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no significant change or change in frame in the coding sequence or for splice variants</arg>
                    <arg n="1">loss of functions mutations</arg>
                </example>
                <example src="REPLACE" no="505">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), missing function mutation would be conferred by senseless alteration or frame change of the encoded sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless alteration or frame change of the encoded sequence or by splice variants</arg>
                    <arg n="1">missing function mutation</arg>
                </example>
                <example src="REPLACE" no="506">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), no change in meaning or deviation of frame in the coding sequence or for splice variants confers the A1 resistance (06-BG) (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no change in meaning or deviation of frame in the coding sequence or for splice variants</arg>
                </example>
                <example src="REPLACE" no="507">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), no sense alterations or frame shifts in the encoding sequence or for splice variants confers the A1 resistance (06-BG) (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                </example>
                <example src="REPLACE" no="508">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), no sense alterations or frame shifts in the encoding sequence or for splice variants was considered to confer function loss engines (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="509">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), no significant changes or changes in the frame in the coding sequence or for splice variants confers the A1 resistance (06-BG) (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no significant changes or changes in the frame in the coding sequence or for splice variants</arg>
                </example>
                <example src="REPLACE" no="510">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), no significant changes or changes in the frame in the coding sequence or for splice variants was considered to confer loss of function changes (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no significant changes or changes in the frame in the coding sequence or for splice variants</arg>
                    <arg n="1">loss of function changes</arg>
                </example>
                <example src="REPLACE" no="511">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), non-sense change or frame deviation in the coding sequence or for splice variants was considered to confer movement of loss of function (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">non-sense change or frame deviation in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="512">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), nonsense or frameshift alteration in the coding sequence or by splice variants confers the A1 resistance (06-BG) (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alteration in the coding sequence or by splice variants</arg>
                </example>
                <example src="REPLACE" no="513">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), only the C-terminal substitution for Stat5 was considered to confer the Stat5 phenotype in the presence of MG132 (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="514">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), replacing Gly156 and Lys165 was considered to confer resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="515">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), resistance would be conferred by alkyguaning-DNA alkyltransferase (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="516">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), substitutions in Gly156 and Lys165 was considered to confer resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="517">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), the STAT portion was considered to confer specificity (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="REPLACE" no="518">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), the Stat5 phenotype in the presence of MG132 would be conferred by only the C-terminal substitution for Stat5 (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="519">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), the portion of the STATs confers the A1 resistance (06-BG) (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the portion of the STATs</arg>
                </example>
                <example src="REPLACE" no="520">
                    <text>Similarly, the introduced imposition of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), without significant changes or frame deviations in the coding sequence or for splice variants was considered to confer function loss engines (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">without significant changes or frame deviations in the coding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="521">
                    <text>Similarly, the introduction of the Gly160His and Gly160Arg mutant charge repels the benzyl group (Figure 3B), function loss engines can be conferred for frame shift alterations in the encoding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">frame shift alterations in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="522">
                    <text>Similarly, the introduction of the Gly160His and Gly160Arg mutant charge repels the benzyl group (Figure 3B), function loss motion can be conferred for no sense alterations or frame change in the encoding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no sense alterations or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="523">
                    <text>Similarly, the introduction of the Gly160His and Gly160Arg mutant charge repels the benzyl group (Figure 3B), function loss motion can be conferred for no sense alterations or frame change in the encoding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no sense alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="524">
                    <text>Similarly, the introduction of the Gly160His and Gly160Arg mutant charge repels the benzyl group (Figure 3B), function loss mutations can be conferred for senseless alterations or frame change in the encoding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="525">
                    <text>Similarly, the introduction of the Gly160His and Gly160Arg mutant charge repels the benzyl group (Figure 3B), mutations of loss of functions can be conferred for debarred or frame alterations in the encoding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">debarred or frame alterations in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="526">
                    <text>Similarly, the introduction of the Gly160His and Gly160Arg mutants repelled the benzyl group (Figure 3B), alkyguaning-DNA alkyltransferase was able to confer the A1 resistance (06-BG) (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                </example>
                <example src="REPLACE" no="527">
                    <text>Similarly, the introduction of the Gly160His and Gly160Arg mutants repelled the benzyl group (Figure 3B), discount alterations or frame change in the encoding sequence or by splice variants was able to confer the A1 resistance (06-BG) (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">discount alterations or frame change in the encoding sequence or by splice variants</arg>
                </example>
                <example src="REPLACE" no="528">
                    <text>Similarly, the introduction of the Gly160His and Gly160Arg mutants repelled the benzyl group (Figure 3B), no significant change or change in table in the coding sequence or for splice variants was able to confer the A1 resistance (06-BG) (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no significant change or change in table in the coding sequence or for splice variants</arg>
                </example>
                <example src="REPLACE" no="529">
                    <text>Similarly, the introduction of the Gly160His and Gly160Arg mutants repelled the benzyl group (Figure 3B), senseless alteration or frame change after encoding or splice variants was able to confer the A1 resistance (06-BG) (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless alteration or frame change after encoding or splice variants</arg>
                </example>
                <example src="REPLACE" no="530">
                    <text>Similarly, the introduction of the Gly160His and Gly160Arg mutants repelled the benzyl group (Figure 3B), senseless alterations or frame change in the encoding sequence or for splice variants was able to confer the A1 resistance (06-BG) (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                </example>
                <example src="REPLACE" no="531">
                    <text>Similarly, the introduction of the charge of the mutations Gly160His and Gly160Arg repels the benzyl group (Figure 3B), change of frame in the coding sequence or by splice variants is considered to confer the resistance motors of loss of function (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">change of frame in the coding sequence or by splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="532">
                    <text>Similarly, the introduction of the charge of the mutations Gly160His and Gly160Arg repels the benzyl group (Figure 3B), changes in frame in the coding sequence or by splice variants is considered to confer the changes in function loss resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">changes in frame in the coding sequence or by splice variants</arg>
                    <arg n="1">changes in function loss</arg>
                </example>
                <example src="REPLACE" no="533">
                    <text>Similarly, the introduction of the charge of the mutations Gly160His and Gly160Arg repels the benzyl group (Figure 3B), discount alterations or frame change in the encoding sequence or by splice variants is considered to confer the resistance function loss engines (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">discount alterations or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="534">
                    <text>Similarly, the introduction of the charge of the mutations Gly160His and Gly160Arg repels the benzyl group (Figure 3B), no sense alterations or frame change in the encoding sequence or for splice variants is considered to confer the resistance function loss motion (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no sense alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="535">
                    <text>Similarly, the introduction of the charge of the mutations Gly160His and Gly160Arg repels the benzyl group (Figure 3B), no sense alterations or frame shifts in the encoding sequence or for splice variants is considered to confer the function loss engines resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="536">
                    <text>Similarly, the introduction of the charge of the mutations Gly160His and Gly160Arg repels the benzyl group (Figure 3B), nonsense or frameshift alteration of the codiding sequence or by splice variants is considered to confer the resistance loss of function mutation (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alteration of the codiding sequence or by splice variants</arg>
                    <arg n="1">loss of function mutation</arg>
                </example>
                <example src="REPLACE" no="537">
                    <text>Similarly, the introduction of the charge of the mutations Gly160His and Gly160Arg repels the benzyl group (Figure 3B), nonsense or frameshift alteration of the codiding sequence or by splice variants is considered to confer the resistance loss of mutation function (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alteration of the codiding sequence or by splice variants</arg>
                    <arg n="1">loss of mutation function</arg>
                </example>
                <example src="REPLACE" no="538">
                    <text>Similarly, the introduction of the charge of the mutations Gly160His and Gly160Arg repels the benzyl group (Figure 3B), only the C-terminal substitution for Stat5 is considered to confer the the Stat5 phenotype of stability in the presence of MG132 resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="539">
                    <text>Similarly, the introduction of the charge of the mutations Gly160His and Gly160Arg repels the benzyl group (Figure 3B), the STAT portion is considered to confer the resistance specificity (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="REPLACE" no="540">
                    <text>Similarly, the introduction of the charge of the mutations Gly160His and Gly160Arg repels the benzyl group (Figure 3B), without change of meaning or change of table in the coding sequence or for splice variants is considered to confer the movement of loss of function resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">without change of meaning or change of table in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="541">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), change in function loss can be conferred by no significant change or change in table in the coding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no significant change or change in table in the coding sequence or for splice variants</arg>
                    <arg n="1">change in function loss</arg>
                </example>
                <example src="REPLACE" no="542">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), changes in function loss could be conferred by changes in frame in the coding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">changes in frame in the coding sequence or by splice variants</arg>
                    <arg n="1">changes in function loss</arg>
                </example>
                <example src="REPLACE" no="543">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), function loss engines is able to be conferred by discount alterations or frame change in the encoding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">discount alterations or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="544">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), function loss motion could be conferred by no sense alterations or frame change in the encoding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no sense alterations or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="545">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), function loss mutations could be conferred by senseless alterations or frame change in the encoding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="546">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), function loss mutations is conferred by senseless alterations or frame change in the encoding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="547">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), it is believed that change of loss of function was conferred to no-sense change or change of frame in the coding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no-sense change or change of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">change of loss of function</arg>
                </example>
                <example src="REPLACE" no="548">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), it is believed that changes in function loss is conferred by changes in frame in the coding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">changes in frame in the coding sequence or by splice variants</arg>
                    <arg n="1">changes in function loss</arg>
                </example>
                <example src="REPLACE" no="549">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), it is believed that function loss engines was conferred to no sense alterations or frame shifts in the encoding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="550">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), it is believed that motors of loss of function was conferred to no change in meaning or deviation of frame in the coding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no change in meaning or deviation of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="551">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), it is believed that movement of loss of function is conferred by without change of meaning or change of table in the coding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">without change of meaning or change of table in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="552">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), it is believed that mutations of loss of functions is conferred by alterations of frame shift in the encoding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">alterations of frame shift in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="553">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), it is believed that mutations of loss of functions is conferred by senseless alteration or frame change in the encoding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless alteration or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="554">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), it is believed that resistance was conferred to alkyguaning-DNA alkyltransferase (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="555">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), it is believed that resistance was conferred to human 06-alkylguaning-DNA alkyltransferase (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="556">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), it is believed that resistance was conferred to replacing Gly156 and Lys165 (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="557">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), loss of function changes is conferred by no significant changes or changes in the frame in the coding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no significant changes or changes in the frame in the coding sequence or for splice variants</arg>
                    <arg n="1">loss of function changes</arg>
                </example>
                <example src="REPLACE" no="558">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), loss of functions mutations has been conferred by no significant change or change in frame in the coding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no significant change or change in frame in the coding sequence or for splice variants</arg>
                    <arg n="1">loss of functions mutations</arg>
                </example>
                <example src="REPLACE" no="559">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), loss of mutation function has been conferred by nonsense or frameshift alteration of the codiding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alteration of the codiding sequence or by splice variants</arg>
                    <arg n="1">loss of mutation function</arg>
                </example>
                <example src="REPLACE" no="560">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), missing function mutation has been conferred by senseless alteration or frame change of the encoded sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless alteration or frame change of the encoded sequence or by splice variants</arg>
                    <arg n="1">missing function mutation</arg>
                </example>
                <example src="REPLACE" no="561">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), motors of loss of function has been conferred by change of frame in the coding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">change of frame in the coding sequence or by splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="562">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), motors of loss of function has been conferred by no change in meaning or deviation of frame in the coding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no change in meaning or deviation of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="563">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), motors of loss of function is able to be conferred by change of frame in the coding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">change of frame in the coding sequence or by splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="564">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), motors of loss of function is conferred by chapter changes or change of frame in the coding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">chapter changes or change of frame in the coding sequence or by splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="565">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), movement of loss of function has been conferred by without change of meaning or change of table in the coding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">without change of meaning or change of table in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="566">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), movement of loss of function is conferred by non-sense change or deviation of frame in the coding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">non-sense change or deviation of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="567">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), mutations of loss of functions can be conferred by alterations of discount or frame change in the encoding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">alterations of discount or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="568">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), mutations of loss of functions can be conferred by no meaningless alterations or frame change in the encoding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no meaningless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="569">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), mutations of loss of functions could be conferred by senseless alterations or frame change in the encoding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="570">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), resistance is conferred by alkyguaning-DNA alkyltransferase (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="571">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), specificity could be conferred by the STAT portion (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="REPLACE" no="572">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), specificity has been conferred by the part of TASTs (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the part of TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="REPLACE" no="573">
                    <text>Similarly, the introduction of the load of Gly160His and Gly160Arg mutants repels the benzyl group (Figure 3B), the Stat5 phenotype of stability in the presence of MG132 could be conferred by only the C-terminal substitution for Stat5 (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="574">
                    <text>Similarly, the introduction of the load of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), change of frame in the coding sequence or by splice variants is considered to confer the motors of loss of function resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">change of frame in the coding sequence or by splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="575">
                    <text>Similarly, the introduction of the load of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), change of frame in the coding sequence or by splice variants is considered to confer the resistance motors of loss of function (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">change of frame in the coding sequence or by splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="576">
                    <text>Similarly, the introduction of the load of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), discount alterations or frame change in the encoding sequence or by splice variants is considered to confer the function loss engines resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">discount alterations or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="577">
                    <text>Similarly, the introduction of the load of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), function loss mutations was conferred by nonsense or frameshift alteration in the coding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">nonsense or frameshift alteration in the coding sequence or by splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="578">
                    <text>Similarly, the introduction of the load of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), loss of function changes was conferred by no significant changes or changes in the frame in the coding sequence or for splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no significant changes or changes in the frame in the coding sequence or for splice variants</arg>
                    <arg n="1">loss of function changes</arg>
                </example>
                <example src="REPLACE" no="579">
                    <text>Similarly, the introduction of the load of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), mutations of loss of functions was conferred by senseless alteration or frame change in the encoding sequence or by splice variants (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless alteration or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="580">
                    <text>Similarly, the introduction of the load of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), no sense alterations or frame change in the encoding sequence or for splice variants is considered to confer the function loss motion resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no sense alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="581">
                    <text>Similarly, the introduction of the load of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), no-sense change or change of frame in the coding sequence or to splice variants is considered to confer the change of loss of function resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no-sense change or change of frame in the coding sequence or to splice variants</arg>
                    <arg n="1">change of loss of function</arg>
                </example>
                <example src="REPLACE" no="582">
                    <text>Similarly, the introduction of the load of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), non-sense change or deviation of frame in the coding sequence or for splice variants is considered to confer the movement of loss of function resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">non-sense change or deviation of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="583">
                    <text>Similarly, the introduction of the load of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), only the C-terminal substitution for Stat5 is considered to confer the resistance the Stat5 phenotype in the presence of MG132 (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="584">
                    <text>Similarly, the introduction of the load of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), only the C-terminal substitution for Stat5 is considered to confer the resistance the Stat5 phenotype of stability in the presence of MG132 (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="585">
                    <text>Similarly, the introduction of the load of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), resistance was conferred by replacing Gly156 and Lys165 (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="586">
                    <text>Similarly, the introduction of the load of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), the Stat5 phenotype in the presence of MG132 was conferred by only the C-terminal substitution for Stat5 (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="587">
                    <text>Similarly, the introduction of the load of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), the part of STATs is considered to confer the specificity resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="REPLACE" no="588">
                    <text>Similarly, the introduction of the load of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), which simply replaces C-terminus for Stat5 is considered to confer the resistance the stability phenotype Stat5 in the presence of MG132 (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="589">
                    <text>Similarly, the introduction of the load of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), without change of meaning or change of table in the coding sequence or for splice variants is considered to confer the movement of loss of function resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">without change of meaning or change of table in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="590">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repelled the benzyl group (Figure 3B), no change in meaning or deviation of frame in the coding sequence or for splice variants conferred the resistance motors of loss of function (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no change in meaning or deviation of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="591">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repelled the benzyl group (Figure 3B), no meaningless alterations or frame change in the encoding sequence or for splice variants conferred the mutations of loss of functions resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no meaningless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="592">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repelled the benzyl group (Figure 3B), no sense alterations or frame shifts in the encoding sequence or for splice variants conferred the function loss engines resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="593">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repelled the benzyl group (Figure 3B), no sense alterations or frame shifts in the encoding sequence or for splice variants conferred the resistance function loss engines (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="594">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repelled the benzyl group (Figure 3B), no significant change or change in frame in the coding sequence or for splice variants conferred the resistance loss of functions mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no significant change or change in frame in the coding sequence or for splice variants</arg>
                    <arg n="1">loss of functions mutations</arg>
                </example>
                <example src="REPLACE" no="595">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repelled the benzyl group (Figure 3B), no significant change or change in table in the coding sequence or for splice variants conferred the change in function loss resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no significant change or change in table in the coding sequence or for splice variants</arg>
                    <arg n="1">change in function loss</arg>
                </example>
                <example src="REPLACE" no="596">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repelled the benzyl group (Figure 3B), no significant change or change in table in the coding sequence or for splice variants conferred the resistance change in function loss (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no significant change or change in table in the coding sequence or for splice variants</arg>
                    <arg n="1">change in function loss</arg>
                </example>
                <example src="REPLACE" no="597">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repelled the benzyl group (Figure 3B), no-sense change or change of frame in the coding sequence or for splice variants conferred the change of loss of function resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no-sense change or change of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">change of loss of function</arg>
                </example>
                <example src="REPLACE" no="598">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repelled the benzyl group (Figure 3B), replacing Gly156 and Lys165 conferred the resistance resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="599">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repelled the benzyl group (Figure 3B), senseless change or change in frame in the coding sequence or for splice variants conferred the resistance function loss change (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless change or change in frame in the coding sequence or for splice variants</arg>
                    <arg n="1">function loss change</arg>
                </example>
                <example src="REPLACE" no="600">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repelled the benzyl group (Figure 3B), senseless change or change in frame in the coding sequence or to splice variants conferred the resistance function loss mutations (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless change or change in frame in the coding sequence or to splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="601">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repelled the benzyl group (Figure 3B), which simply replaces C-terminus for Stat5 conferred the the stability phenotype Stat5 in the presence of MG132 resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="602">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), alterations of discount or frame change in the encoding sequence or for splice variants would confer mutations of loss of functions (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">alterations of discount or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="603">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), chapter changes or change of frame in the coding sequence or by splice variants will confer the resistance motors of loss of function (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">chapter changes or change of frame in the coding sequence or by splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="604">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), frame shift alterations in the encoding sequence or by splice variants will confer the resistance function loss engines (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">frame shift alterations in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="605">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), human 06-alkylguaning-DNA alkyltransferase would confer resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="606">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), no-sense change or change of frame in the coding sequence or for splice variants will confer the resistance change of loss of function (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no-sense change or change of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">change of loss of function</arg>
                </example>
                <example src="REPLACE" no="607">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), no-sense change or change of frame in the coding sequence or to splice variants will confer the resistance change of loss of function (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">no-sense change or change of frame in the coding sequence or to splice variants</arg>
                    <arg n="1">change of loss of function</arg>
                </example>
                <example src="REPLACE" no="608">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), senseless change or change in frame in the coding sequence or for splice variants will confer the resistance function loss change (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">senseless change or change in frame in the coding sequence or for splice variants</arg>
                    <arg n="1">function loss change</arg>
                </example>
                <example src="REPLACE" no="609">
                    <text>Similarly, the introduction of the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), without change of meaning or change of table in the coding sequence or for splice variants will confer the movement of loss of function resistance (Xu-Welliver et al., 1999a).</text>
                    <arg n="0">without change of meaning or change of table in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="610">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), change of frame in the coding sequence or by splice variants could confer the resistance motors of loss of function.</text>
                    <arg n="0">change of frame in the coding sequence or by splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="611">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), frame shift alterations in the encoding sequence or by splice variants could confer the function loss engines resistance.</text>
                    <arg n="0">frame shift alterations in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="612">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), human 06-alkylguaning-DNA alkyltransferase could confer the resistance resistance.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="613">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), no change in meaning or deviation of frame in the coding sequence or for splice variants could confer the resistance motors of loss of function.</text>
                    <arg n="0">no change in meaning or deviation of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="614">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), no meaningless alterations or frame change in the encoding sequence or for splice variants and is able to confer the mutations of loss of functions resistance.</text>
                    <arg n="0">no meaningless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="615">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), no meaningless alterations or frame change in the encoding sequence or for splice variants could confer the mutations of loss of functions resistance.</text>
                    <arg n="0">no meaningless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="616">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), no meaningless alterations or frame change in the encoding sequence or for splice variants may confer the resistance mutations of loss of functions.</text>
                    <arg n="0">no meaningless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="617">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), no sense alterations or frame change in the encoding sequence or by splice variants may confer the function loss motion resistance.</text>
                    <arg n="0">no sense alterations or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="618">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), no sense alterations or frame shifts in the encoding sequence or for splice variants could confer the resistance function loss engines.</text>
                    <arg n="0">no sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="619">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), no significant change or change in table in the coding sequence or for splice variants and is able to confer the resistance change in function loss.</text>
                    <arg n="0">no significant change or change in table in the coding sequence or for splice variants</arg>
                    <arg n="1">change in function loss</arg>
                </example>
                <example src="REPLACE" no="620">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), no-sense change or change of frame in the coding sequence or to splice variants could confer the change of loss of function resistance.</text>
                    <arg n="0">no-sense change or change of frame in the coding sequence or to splice variants</arg>
                    <arg n="1">change of loss of function</arg>
                </example>
                <example src="REPLACE" no="621">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), nonsense or frameshift alteration in the coding sequence or by splice variants may confer the function loss mutations resistance.</text>
                    <arg n="0">nonsense or frameshift alteration in the coding sequence or by splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="622">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), nonsense or frameshift alteration of the codiding sequence or by splice variants could confer the resistance loss of mutation function.</text>
                    <arg n="0">nonsense or frameshift alteration of the codiding sequence or by splice variants</arg>
                    <arg n="1">loss of mutation function</arg>
                </example>
                <example src="REPLACE" no="623">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), only the C-terminal substitution for Stat5 could confer the resistance the Stat5 phenotype in the presence of MG132.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="624">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), part of STATs could confer the specificity resistance.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="REPLACE" no="625">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), senseless alterations or frame change in the encoding sequence or for splice variants and is able to confer the mutations of loss of functions resistance.</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="626">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), senseless alterations or frame change in the encoding sequence or for splice variants and is able to confer the resistance mutations of loss of functions.</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="627">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), senseless alterations or frame change in the encoding sequence or for splice variants could confer the function loss engines resistance.</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="628">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), senseless change or change in frame in the coding sequence or for splice variants may confer the function loss change resistance.</text>
                    <arg n="0">senseless change or change in frame in the coding sequence or for splice variants</arg>
                    <arg n="1">function loss change</arg>
                </example>
                <example src="REPLACE" no="629">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), substitutions in Gly156 and Lys165 and is able to confer the resistance resistance.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="630">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), the portion of the STATs and is able to confer the specificity resistance.</text>
                    <arg n="0">the portion of the STATs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="REPLACE" no="631">
                    <text>Similarly, the load introduced by the mutants Gly160His and Gly160Arg repels the benzyl group (Figure 3B), without significant changes or frame deviations in the coding sequence or for splice variants could confer the function loss engines resistance.</text>
                    <arg n="0">without significant changes or frame deviations in the coding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="632">
                    <text>That alterations of frame shift in the encoding sequence or by splice variants is able to confer mutations of loss of functions for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">alterations of frame shift in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="633">
                    <text>That debarred or frame alterations in the encoding sequence or by splice variants is able to confer mutations of loss of functions for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">debarred or frame alterations in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="634">
                    <text>That human 06-alkylguaning-DNA alkyltransferase could confer resistance for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="635">
                    <text>That no sense alterations or frame change in the encoding sequence or by splice variants was able to confer function loss motion for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">no sense alterations or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="636">
                    <text>That no sense alterations or frame shifts in the encoding sequence or for splice variants is able to confer function loss engines for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">no sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="637">
                    <text>That no significant change or change in table in the coding sequence or for splice variants has conferred change in function loss for A2 (either a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">no significant change or change in table in the coding sequence or for splice variants</arg>
                    <arg n="1">change in function loss</arg>
                </example>
                <example src="REPLACE" no="638">
                    <text>That no significant changes or changes in the frame in the coding sequence or for splice variants has conferred loss of function changes for A2 (either a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">no significant changes or changes in the frame in the coding sequence or for splice variants</arg>
                    <arg n="1">loss of function changes</arg>
                </example>
                <example src="REPLACE" no="639">
                    <text>That no significant changes or changes in the frame in the coding sequence or for splice variants was able to confer loss of function changes for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">no significant changes or changes in the frame in the coding sequence or for splice variants</arg>
                    <arg n="1">loss of function changes</arg>
                </example>
                <example src="REPLACE" no="640">
                    <text>That no-sense alterations or frame shifts in the encoding sequence or for splice variants could confer function loss motion for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">no-sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="641">
                    <text>That nonsense or frameshift alteration of the codiding sequence or by splice variants could confer loss of mutation function for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">nonsense or frameshift alteration of the codiding sequence or by splice variants</arg>
                    <arg n="1">loss of mutation function</arg>
                </example>
                <example src="REPLACE" no="642">
                    <text>That nonsense or frameshift alteration of the codiding sequence or by splice variants has the ability to confer loss of mutation function for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">nonsense or frameshift alteration of the codiding sequence or by splice variants</arg>
                    <arg n="1">loss of mutation function</arg>
                </example>
                <example src="REPLACE" no="643">
                    <text>That nonsense or frameshift alteration of the codiding sequence or by splice variants is able to confer loss of function mutation for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">nonsense or frameshift alteration of the codiding sequence or by splice variants</arg>
                    <arg n="1">loss of function mutation</arg>
                </example>
                <example src="REPLACE" no="644">
                    <text>That only the C-terminal substitution for Stat5 can confer the Stat5 phenotype in the presence of MG132 for Stat1 has not been determined.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="645">
                    <text>That only the C-terminal substitution for Stat5 was able to confer the Stat5 phenotype in the presence of MG132 for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="646">
                    <text>That replacing Gly156 and Lys165 is able to confer resistance for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="647">
                    <text>That replacing simply the C-terminal with Stat5 was able to confer the Stat5 phenotype of stability in the presence of MG132 for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="648">
                    <text>That senseless alteration or frame change after encoding or splice variants has the ability to confer mutations of loss of functions for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">senseless alteration or frame change after encoding or splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="649">
                    <text>That senseless alteration or frame change in the encoding sequence or by splice variants has conferred mutations of loss of functions for A2 (either a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">senseless alteration or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="650">
                    <text>That senseless alterations or frame change in the encoding sequence or for splice variants could confer mutations of loss of functions for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="651">
                    <text>That substitutions in Gly156 and Lys165 is able to confer resistance for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="652">
                    <text>That substitutions in Gly156 and Lys165 was able to confer resistance for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="653">
                    <text>That the part of TASTs has conferred specificity for A2 (either a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">the part of TASTs</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="REPLACE" no="654">
                    <text>That without significant changes or frame deviations in the coding sequence or for splice variants has the ability to confer function loss engines for A2 (either a MAPK or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">without significant changes or frame deviations in the coding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="655">
                    <text>The chimera data conferred that the difference is due to the absence of carboxyl sequences in Stat1 , since the stability phenotype Stat5 in the presence of MG132 can be checked in A2 (Stat1 ) by A0 (which simply replaces C-terminus for Stat5) (can be checked in Stat1 by just replacing the C-terminal with the Stat5 phenotype.</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="656">
                    <text>The chimera data conferred that the difference is due to the absence of carboxyl sequences in State1 , since the Stat5 phenotype of stability in the presence of MG132 can be checked in A2 (Stat1 ) by A0 (only the C-terminal substitution for Stat5) (can be checked in Stat1 by just replacing the C-terminal with the Stat5 phenotype.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="657">
                    <text>The chimera data conferred that the difference is due to the absence of carboxyl sequences in a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) , since specificity can be checked in A2 (Stat1 ) by A0 (the part of STATs) (can be checked in Stat1 by just replacing the C-terminal with the Stat5 phenotype.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="658">
                    <text>The chimera data conferred that the difference is due to the absence of carboxyl sequences in a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs) , since specificity can be checked in A2 (Stat1 ) by A0 (the part of STATs) (can be checked in Stat1 by just replacing the C-terminal with the Stat5 phenotype.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="659">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in Stat1 , since only the C-terminal substitution for Stat5 can confer the Stat5 phenotype in the presence of MG132 in State1 .</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="660">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in Stat1 , since the stability phenotype Stat5 in the presence of MG132 pot was conferred in Stat1 by which simply replaces C-terminus for Stat5.</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="661">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in Stat1 , since which simply replaces C-terminus for Stat5 is able to confer the stability phenotype Stat5 in the presence of MG132 in Stat1 .</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="662">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in State1 , since only the C-terminal substitution for Stat5 can confer the Stat5 phenotype in the presence of MG132 in Stat1 .</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="663">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in State1 , since only the C-terminal substitution for Stat5 can confer the Stat5 phenotype in the presence of MG132 in State1 .</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="664">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in State1 , since only the C-terminal substitution for Stat5 can confer the Stat5 phenotype of stability in the presence of MG132 in State1 .</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="665">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in State1 , since only the C-terminal substitution for Stat5 was able to confer the Stat5 phenotype of stability in the presence of MG132 in State1 .</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="666">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) , since the part of STATs can confer specificity in Stat1 .</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="667">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs) , since specificity pot was conferred in Stat1 by the part of STATs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="668">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) , since part of STATs can confer specificity in Stat1 .</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="669">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) , since part of STATs is able to confer specificity in Stat1 .</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="670">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) , since part of STATs is able to confer specificity in State1 .</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="671">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) , since part of STATs will confer specificity in Stat1 .</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="672">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs) , since the part of STATs can confer specificity in State1 .</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="673">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) , since the part of STATs was able to confer specificity in State1 .</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="674">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) , since the STAT portion can confer specificity in State1 .</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="675">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) , since the part of STATs was able to confer specificity in State1 .</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="676">
                    <text>The chimera data indicate that the difference is due to the absence of carboxyl sequences in a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) , since the part of STATs will confer specificity in Stat1 .</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="677">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in Stat1 , since only the C-terminal substitution for Stat5 was able to confer the Stat5 phenotype in the presence of MG132 in Stat1 .</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="678">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in Stat1 , since the stability phenotype Stat5 in the presence of MG132 pot has been conferred on Stat1 by which simply replaces C-terminus for Stat5.</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="679">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in Stat1 , since which simply replaces C-terminus for Stat5 was able to confer the stability phenotype Stat5 in the presence of MG132 in Stat1 .</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="680">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in State1 , since the Stat5 phenotype in the presence of MG132 can be conferred on Stat1 for only the C-terminal substitution for Stat5 .</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="681">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in State1 , since the Stat5 phenotype of stability in the presence of MG132 could be conferred on Stat1 by only the C-terminal substitution for Stat5.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="682">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) , since the part of STATs is thought to confer specificity in Stat1 .</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="683">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) , since specificity pot has been conferred on Stat1 by part of STATs.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="684">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs) , since the part of STATs is thought to confer specificity in Stat1 .</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="685">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs) , since specificity could be conferred on Stat1 by the part of STATs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="686">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs) , since the part of STATs is thought to confer specificity in Stat1 .</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="687">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs) , since part of STATs was able to confer specificity in Stat1 .</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="688">
                    <text>The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) , since the part of STATs was able to confer specificity in Stat1 .</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="689">
                    <text>The debarred or frame alterations in the encoding sequence or by splice variants conferred the mutations of loss of functions.</text>
                    <arg n="0">debarred or frame alterations in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="690">
                    <text>The function loss engines in a tolC deficit strain is conferred by the senseless alterations or frame change in the encoding sequence or for splice variants.</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="691">
                    <text>The function loss motion in a tolC deficit strain may have been conferred by the no-sense alterations or frame shifts in the encoding sequence or for splice variants.</text>
                    <arg n="0">no-sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="692">
                    <text>The highest levels of AGAT are thought to be conferred by which simply replaces C-terminus for Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic the stability phenotype Stat5 in the presence of MG132.</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="693">
                    <text>The increase in parallel AGT levels acquired the Stat1 the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and only the C-terminal substitution for Stat5 may have conferred resistance to alkylation (Kaina et al., 1991), demonstrating the role of AAGT in therapy resistance.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="694">
                    <text>The increase in parallel AGT levels acquired the a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the part of STATs may have conferred resistance to alkylation (Kaina et al., 1991), demonstrating the role of AAGT in therapy resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="695">
                    <text>The increase in parallel AGT levels acquired the a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the part of STATs may have conferred resistance to alkylation (Kaina et al., 1991), demonstrating the role of AAGT in therapy resistance.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="696">
                    <text>The increase in parallel AGT levels conferred a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance would be attributed by the part of STATs to alkylation (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="697">
                    <text>The increase in parallel AGT levels conferred alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance would be attributed by part of STATs to a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="698">
                    <text>The increase in parallel AGT levels conferred alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance would be attributed by the part of STATs to a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="699">
                    <text>The increase in parallel AGT levels conferred alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance would be attributed by only the C-terminal substitution for Stat5 to State1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="700">
                    <text>The increase in parallel AGT levels conferred from resistance 06-BG in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance will be attributed by replacing Gly156 and Lys165 to alkylation (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="REPLACE" no="701">
                    <text>The increase in parallel AGT levels conferred from specificity a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance will be attributed by part of STATs to alkylation (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="702">
                    <text>The increase in parallel AGT levels conferred from specificity a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance will be attributed by the part of STATs to alkylation (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="703">
                    <text>The increase in parallel AGT levels conferred from specificity alkylation in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance will be attributed by the part of STATs to a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="704">
                    <text>The increase in parallel AGT levels conferred from specificity alkylation in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance will be attributed by the part of STATs to a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="705">
                    <text>The increase in parallel AGT levels conferred the resistance alkylation pathways in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance alkylation could be attributed by human 06-alkylguaning-DNA alkyltransferase to alkylation (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="REPLACE" no="706">
                    <text>The increase in parallel AGT levels conferred the specificity a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs) in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance alkylation could be attributed by the part of STATs to alkylation (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="707">
                    <text>The increase in parallel AGT levels conferred the the stability phenotype Stat5 in the presence of MG132 Stat1 in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance alkylation could be attributed by which simply replaces C-terminus for Stat5 to alkylation (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="708">
                    <text>The increase in parallel alkyguaning-DNA alkyltransferase levels conferred the resistance alkylation routes in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance alkylation, which can be attributed by the AGT to alkylation transformation (Kaina et al., 1991), demonstrating the role of AGT in resistance thera</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="REPLACE" no="709">
                    <text>The increase in parallel human 06-alkylguaning-DNA alkyltransferase levels conferred alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance would be attributed by AGT to alkylation pathways (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="REPLACE" no="710">
                    <text>The increase in parallel part of STATs levels conferred the specificity a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs) in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance alkylation, which can be attributed by the AGT to alkylation transformation (Kaina et al., 1991), demonstrating the role of AGT in resistance thera</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="711">
                    <text>The increase in parallel replacing Gly156 and Lys165 levels acquired the alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and AGT may have conferred resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AAGT in therapy resistance.</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="REPLACE" no="712">
                    <text>The increase in parallel the STAT portion levels conferred the specificity a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance alkylation, which can be attributed by the AGT to alkylation transformation (Kaina et al., 1991), demonstrating the role of AGT in resistance thera</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="713">
                    <text>The increase in parallel the part of STATs levels conferred from specificity alkylation in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance will be attributed by AGT to a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="714">
                    <text>The increase in parallel the part of STATs levels conferred from specificity alkylation in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance will be attributed by AGT to a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="715">
                    <text>The increase in parallel the part of STATs levels conferred the specificity a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs) in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance alkylation, which can be attributed by the AGT to alkylation transformation (Kaina et al., 1991), demonstrating the role of AGT in resistance thera</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="716">
                    <text>The increase in parallel the part of STATs levels conferred the specificity a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance alkylation, which can be attributed by the AGT to alkylation transformation (Kaina et al., 1991), demonstrating the role of AGT in resistance thera</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="717">
                    <text>The increase in parallel which simply replaces C-terminus for Stat5 levels conferred from the stability phenotype Stat5 in the presence of MG132 alkylation in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance will be attributed by AGT to Stat1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="718">
                    <text>The increase of CATs in parallel with the acquired 06-BG resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and substitutions in Gly156 and Lys165 was considered to confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of CAT in resistance.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="REPLACE" no="719">
                    <text>The increase of CATs in parallel with the acquired a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the STAT portion was considered to confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of CAT in resistance.</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="720">
                    <text>The increase of CATs in parallel with the acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and the STAT portion was considered to confer resistance to a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) (Kaina et al., 1991), demonstrating the role of CAT in resistance.</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="721">
                    <text>The increase of CATs in parallel with the acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and only the C-terminal substitution for Stat5 was considered to confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of CAT in resistance.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="722">
                    <text>The increase of CATs in parallel with the acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and only the C-terminal substitution for Stat5 was considered to confer resistance to State1 (Kaina et al., 1991), demonstrating the role of CAT in resistance.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="723">
                    <text>The motors of loss of function in a tolC deficit strain may have been conferred by the chapter changes or change of frame in the coding sequence or by splice variants.</text>
                    <arg n="0">chapter changes or change of frame in the coding sequence or by splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="724">
                    <text>The movement of loss of function in a tolC deficit strain may have been conferred by the non-sense change or deviation of frame in the coding sequence or for splice variants.</text>
                    <arg n="0">non-sense change or deviation of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="725">
                    <text>The mutations of loss of functions in a tolC deficit strain is conferred by the debarred or frame alterations in the encoding sequence or by splice variants.</text>
                    <arg n="0">debarred or frame alterations in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="726">
                    <text>The mutations of loss of functions in a tolC deficit strain is conferred by the senseless alterations or frame change in the encoding sequence or for splice variants.</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="727">
                    <text>The mutations of loss of functions in a tolC deficit strain may have been conferred by the alterations of discount or frame change in the encoding sequence or for splice variants.</text>
                    <arg n="0">alterations of discount or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="728">
                    <text>The no change in meaning or change in table in the coding sequence or by splice variants conferred the movement of loss of function.</text>
                    <arg n="0">no change in meaning or change in table in the coding sequence or by splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="729">
                    <text>The no-sense change or change of frame in the coding sequence or for splice variants conferred the change of loss of function.</text>
                    <arg n="0">no-sense change or change of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">change of loss of function</arg>
                </example>
                <example src="REPLACE" no="730">
                    <text>The only the C-terminal substitution for Stat5 (AGT) that can confer the Stat5 phenotype in the presence of MG132 to Stat1 was therefore an active target of anti-drugs.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="731">
                    <text>The part of STATs (AGT) having conferred specificity on a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs) was therefore an active target of anti-drugs.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="732">
                    <text>The part of STATs (AGT) that has conferred specificity on a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs) was therefore an active target of anti-drugs.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="733">
                    <text>The part of STATs (AGT) that is observed to confer specificity on a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs) was therefore an active target of anti-drugs.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="734">
                    <text>The replacing Gly156 and Lys165 conferred the resistance.</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="735">
                    <text>The rise in AGT levels was attributed to specificity acquired in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance conferred by the STAT portion to a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="736">
                    <text>The rise in AGT levels was attributed to the stability phenotype Stat5 in the presence of MG132 acquired in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance conferred by which simply replaces C-terminus for Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="737">
                    <text>The rise in parallel AGT levels acquired 06-BG resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and replacing Gly156 and Lys165 was observed to confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="REPLACE" no="738">
                    <text>The rise in parallel AGT levels acquired 06-BG resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was conferred by substitutions in Gly156 and Lys165 to alkylation (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="REPLACE" no="739">
                    <text>The rise in parallel AGT levels acquired Stat1 the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and only the C-terminal substitution for Stat5 could confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="740">
                    <text>The rise in parallel AGT levels acquired Stat1 the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and only the C-terminal substitution for Stat5 was observed to confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="741">
                    <text>The rise in parallel AGT levels acquired State1 the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and only the C-terminal substitution for Stat5 could confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="742">
                    <text>The rise in parallel AGT levels acquired State1 the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was conferred by only the C-terminal substitution for Stat5 to alkylation (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="743">
                    <text>The rise in parallel AGT levels acquired a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and the part of STATs was observed to confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="744">
                    <text>The rise in parallel AGT levels acquired a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is conferred by the part of STATs to alkylation (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="745">
                    <text>The rise in parallel AGT levels acquired a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and the part of STATs is thought to confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="746">
                    <text>The rise in parallel AGT levels acquired a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and the part of STATs could confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="747">
                    <text>The rise in parallel AGT levels acquired a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was conferred by the part of STATs to alkylation (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="748">
                    <text>The rise in parallel AGT levels acquired a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and the part of STATs can confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="749">
                    <text>The rise in parallel AGT levels acquired alkylation routes resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and alkyguaning-DNA alkyltransferase can confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="REPLACE" no="750">
                    <text>The rise in parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and the STAT portion could confer resistance to a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="751">
                    <text>The rise in parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and the STAT portion is thought to confer resistance to a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="752">
                    <text>The rise in parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and the STAT portion was observed to confer resistance to a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="753">
                    <text>The rise in parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and the part of STATs can confer resistance to a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="754">
                    <text>The rise in parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and the part of STATs could confer resistance to a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="755">
                    <text>The rise in parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and the part of STATs is thought to confer resistance to a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="756">
                    <text>The rise in parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and the part of STATs is thought to confer resistance to a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="757">
                    <text>The rise in parallel AGT levels acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is conferred by only the C-terminal substitution for Stat5 to State1 (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="758">
                    <text>The rise in parallel AGT levels acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and only the C-terminal substitution for Stat5 can confer resistance to State1 (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="759">
                    <text>The rise in parallel AGT levels acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and only the C-terminal substitution for Stat5 is thought to confer resistance to State1 (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="760">
                    <text>The rise in parallel AGT levels acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is conferred by only the C-terminal substitution for Stat5 to State1 (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="761">
                    <text>The rise in parallel AGT levels acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was conferred by only the C-terminal substitution for Stat5 to State1 (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="762">
                    <text>The rise in parallel AGT levels has acquired Stat1 the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance has been conferred by only the C-terminal substitution for Stat5 to alkylation (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="763">
                    <text>The rise in parallel AGT levels has acquired Stat1 the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance has been conferred by replacing simply the C-terminal with Stat5 to alkylation (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="764">
                    <text>The rise in parallel AGT levels has acquired a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance has been conferred by the part of STATs to alkylation (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="765">
                    <text>The rise in parallel AGT levels has acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance has been conferred by the part of STATs to a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="766">
                    <text>The rise in parallel AGT levels has acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance has been conferred by only the C-terminal substitution for Stat5 to State1 (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="767">
                    <text>The rise in parallel alkyguaning-DNA alkyltransferase levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and AGT is thought to confer resistance to alkylation routes (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="REPLACE" no="768">
                    <text>The rise in parallel human 06-alkylguaning-DNA alkyltransferase levels has acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance has been conferred by AGT to alkylation pathways (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="REPLACE" no="769">
                    <text>The rise in parallel only the C-terminal substitution for Stat5 levels acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is conferred by AGT to State1 (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="770">
                    <text>The rise in parallel only the C-terminal substitution for Stat5 levels has acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance has been conferred by AGT to Stat1 (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="771">
                    <text>The rise in parallel part of STATs levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and AGT was observed to confer resistance to a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="772">
                    <text>The rise in parallel part of STATs levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was conferred by AGT to a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="773">
                    <text>The rise in parallel replacing simply the C-terminal with Stat5 levels acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and AGT can confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="774">
                    <text>The rise in parallel replacing simply the C-terminal with Stat5 levels acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is conferred by AGT to Stat1 (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="775">
                    <text>The rise in parallel the part of STATs levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and AGT can confer resistance to a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="776">
                    <text>The rise in parallel the part of STATs levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and AGT can confer resistance to a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="777">
                    <text>The rise in parallel the part of STATs levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and AGT could confer resistance to a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="778">
                    <text>The rise in parallel the part of STATs levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and AGT was observed to confer resistance to a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="779">
                    <text>The rise in parallel the part of STATs levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is conferred by AGT to a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="780">
                    <text>The rise in parallel the part of STATs levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was conferred by AGT to a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="781">
                    <text>The rise in parallel the part of STATs levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was conferred by AGT to a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="782">
                    <text>The rise of AGT levels in parallel to acquired a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by the part of STATs to alkylation (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="783">
                    <text>The rise of AGT levels in parallel to acquired a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by part of STATs to alkylation (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="784">
                    <text>The rise of AGT levels in parallel to acquired a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by the part of STATs to alkylation (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="785">
                    <text>The rise of AGT levels in parallel to acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by part of STATs to a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="786">
                    <text>The rise of AGT levels in parallel to acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by the STAT portion to a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="787">
                    <text>The rise of AGT levels in parallel to acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by the part of STATs to a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="788">
                    <text>The rise of AGT levels in parallel with acquired Stat1 the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were conferred by only the C-terminal substitution for Stat5 on alkylation, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="789">
                    <text>The rise of AGT levels in parallel with acquired Stat1 the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by replacing simply the C-terminal with Stat5 on alkylation, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="790">
                    <text>The rise of AGT levels in parallel with acquired a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by part of STATs on alkylation, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="791">
                    <text>The rise of AGT levels in parallel with acquired a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were conferred by the part of STATs on alkylation, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="792">
                    <text>The rise of AGT levels in parallel with acquired a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by part of STATs on alkylation, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="793">
                    <text>The rise of AGT levels in parallel with acquired a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were conferred by the part of STATs on alkylation, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="794">
                    <text>The rise of AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by the STAT portion on a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="795">
                    <text>The rise of AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by the part of STATs on a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="796">
                    <text>The rise of AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by the part of STATs on a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="797">
                    <text>The rise of AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were conferred by the part of STATs on a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="798">
                    <text>The rise of AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were conferred by the part of STATs on a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="799">
                    <text>The rise of AGT levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were conferred by the part of STATs on a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="800">
                    <text>The rise of AGT levels in parallel with acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by only the C-terminal substitution for Stat5 on Stat1, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="801">
                    <text>The rise of AGT levels in parallel with acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by only the C-terminal substitution for Stat5 on State1, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="802">
                    <text>The rise of AGT levels in parallel with acquired alkylation the stability phenotype Stat5 in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were conferred by which simply replaces C-terminus for Stat5 on Stat1, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="803">
                    <text>The rise of human 06-alkylguaning-DNA alkyltransferase levels in parallel with acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by AGT on alkylation pathways, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="REPLACE" no="804">
                    <text>The rise of parallel AGT levels acquired 06-BG resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance can be conferred by substitutions in Gly156 and Lys165 to alkylation (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="REPLACE" no="805">
                    <text>The rise of parallel AGT levels acquired 06-BG resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was believed to be conferred by substitutions in Gly156 and Lys165 to alkylation (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="REPLACE" no="806">
                    <text>The rise of parallel AGT levels acquired 06-BG resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and substitutions in Gly156 and Lys165 will confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="REPLACE" no="807">
                    <text>The rise of parallel AGT levels acquired Stat1 the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and only the C-terminal substitution for Stat5 will confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="808">
                    <text>The rise of parallel AGT levels acquired Stat1 the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is thought to be conferred by only the C-terminal substitution for Stat5 to alkylation (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="809">
                    <text>The rise of parallel AGT levels acquired Stat1 the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance will be conferred by only the C-terminal substitution for Stat5 to alkylation (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="810">
                    <text>The rise of parallel AGT levels acquired Stat1 the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance could be conferred by replacing simply the C-terminal with Stat5 to alkylation (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="811">
                    <text>The rise of parallel AGT levels acquired State1 the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance can be conferred by only the C-terminal substitution for Stat5 to alkylation (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="812">
                    <text>The rise of parallel AGT levels acquired State1 the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was believed to be conferred by only the C-terminal substitution for Stat5 to alkylation (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="813">
                    <text>The rise of parallel AGT levels acquired a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance may have been conferred by the part of STATs to alkylation (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="814">
                    <text>The rise of parallel AGT levels acquired a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance will be conferred by the part of STATs to alkylation (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="815">
                    <text>The rise of parallel AGT levels acquired a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance can be conferred by part of STATs to alkylation (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="816">
                    <text>The rise of parallel AGT levels acquired a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance will be conferred by part of STATs to alkylation (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="817">
                    <text>The rise of parallel AGT levels acquired a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was able to be conferred by the part of STATs to alkylation (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="818">
                    <text>The rise of parallel AGT levels acquired a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and the part of STATs would confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="819">
                    <text>The rise of parallel AGT levels acquired a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and the part of STATs has the ability to confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="820">
                    <text>The rise of parallel AGT levels acquired a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and the part of STATs will confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="821">
                    <text>The rise of parallel AGT levels acquired a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is able to be conferred by the part of STATs to alkylation (Kaina et al., 1991), demonstrating the role of AGATT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="822">
                    <text>The rise of parallel AGT levels acquired a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was able to be conferred by the part of STATs to alkylation (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="823">
                    <text>The rise of parallel AGT levels acquired a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and the part of STATs is able to confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="824">
                    <text>The rise of parallel AGT levels acquired a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and part of STATs would confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="825">
                    <text>The rise of parallel AGT levels acquired a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is able to be conferred by part of STATs to alkylation (Kaina et al., 1991), demonstrating the role of AGATT in A1 therapy (resistance).</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="826">
                    <text>The rise of parallel AGT levels acquired a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance could be conferred by the part of STATs to alkylation (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="827">
                    <text>The rise of parallel AGT levels acquired a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and the part of STATs conferred resistance on alkylation (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="828">
                    <text>The rise of parallel AGT levels acquired a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and the STAT portion would confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="829">
                    <text>The rise of parallel AGT levels acquired a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance may have been conferred by the part of STATs to alkylation (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="830">
                    <text>The rise of parallel AGT levels acquired a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was able to be conferred by the part of STATs to alkylation (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="831">
                    <text>The rise of parallel AGT levels acquired a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and the part of STATs is able to confer resistance to alkylation (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="832">
                    <text>The rise of parallel AGT levels acquired alkylation routes resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is thought to be conferred by alkyguaning-DNA alkyltransferase to alkylation (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="REPLACE" no="833">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance can be conferred by the part of STATs to a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="834">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance could be conferred by the part of STATs to a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="835">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is able to be conferred by the part of STATs to a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGATT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="836">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is thought to be conferred by the part of STATs to a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="837">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is thought to be conferred by the part of STATs to a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="838">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was able to be conferred by the part of STATs to a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="839">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was believed to be conferred by the part of STATs to a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="840">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance will be conferred by the part of STATs to a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="841">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance would be conferred by the part of STATs to a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="842">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and the part of STATs conferred resistance on a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="843">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and the part of STATs has the ability to confer resistance to a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="844">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and the part of STATs is able to confer resistance to a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="845">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and the part of STATs was able to confer resistance to a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="846">
                    <text>The rise of parallel AGT levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and the part of STATs would confer resistance to a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="847">
                    <text>The rise of parallel AGT levels acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance can be conferred by only the C-terminal substitution for Stat5 to State1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="848">
                    <text>The rise of parallel AGT levels acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance could be conferred by only the C-terminal substitution for Stat5 to State1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="849">
                    <text>The rise of parallel AGT levels acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was able to be conferred by only the C-terminal substitution for Stat5 to Stat1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="850">
                    <text>The rise of parallel AGT levels acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and only the C-terminal substitution for Stat5 conferred resistance on State1 (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="851">
                    <text>The rise of parallel alkyguaning-DNA alkyltransferase levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is able to be conferred by AGT to alkylation routes (Kaina et al., 1991), demonstrating the role of AGATT in A1 therapy (resistance).</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="REPLACE" no="852">
                    <text>The rise of parallel human 06-alkylguaning-DNA alkyltransferase levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and AGT will confer resistance to alkylation pathways (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="REPLACE" no="853">
                    <text>The rise of parallel only the C-terminal substitution for Stat5 levels acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is able to be conferred by AGT to State1 (Kaina et al., 1991), demonstrating the role of AGATT in A1 therapy (resistance).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="854">
                    <text>The rise of parallel only the C-terminal substitution for Stat5 levels acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance may have been conferred by AGT to Stat1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="855">
                    <text>The rise of parallel only the C-terminal substitution for Stat5 levels acquired alkylation the Stat5 phenotype in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was able to be conferred by AGT to State1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="856">
                    <text>The rise of parallel only the C-terminal substitution for Stat5 levels acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and AGT conferred resistance on State1 (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="857">
                    <text>The rise of parallel only the C-terminal substitution for Stat5 levels acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance can be conferred by AGT to State1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="858">
                    <text>The rise of parallel only the C-terminal substitution for Stat5 levels acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance will be conferred by AGT to State1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="859">
                    <text>The rise of parallel replacing Gly156 and Lys165 levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and AGT was able to confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="REPLACE" no="860">
                    <text>The rise of parallel replacing Gly156 and Lys165 levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance can be conferred by AGT to 06-BG (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="REPLACE" no="861">
                    <text>The rise of parallel replacing simply the C-terminal with Stat5 levels acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and AGT is able to confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="862">
                    <text>The rise of parallel replacing simply the C-terminal with Stat5 levels acquired alkylation the Stat5 phenotype of stability in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is thought to be conferred by AGT to Stat1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="863">
                    <text>The rise of parallel substitutions in Gly156 and Lys165 levels acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and AGT has the ability to confer resistance to 06-BG (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="REPLACE" no="864">
                    <text>The rise of parallel the STAT portion levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and AGT was able to confer resistance to a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="865">
                    <text>The rise of parallel the STAT portion levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance can be conferred by AGT to a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="866">
                    <text>The rise of parallel the STAT portion levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance will be conferred by AGT to a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="867">
                    <text>The rise of parallel the part of STATs levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and AGT conferred resistance on a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="868">
                    <text>The rise of parallel the part of STATs levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and AGT has the ability to confer resistance to a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="869">
                    <text>The rise of parallel the part of STATs levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and AGT is able to confer resistance to a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="870">
                    <text>The rise of parallel the part of STATs levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and AGT is able to confer resistance to a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="871">
                    <text>The rise of parallel the part of STATs levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and AGT would confer resistance to a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="872">
                    <text>The rise of parallel the part of STATs levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and AGT would confer resistance to a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="873">
                    <text>The rise of parallel the part of STATs levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance could be conferred by AGT to a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="874">
                    <text>The rise of parallel the part of STATs levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is able to be conferred by AGT to a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGATT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="875">
                    <text>The rise of parallel the part of STATs levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is able to be conferred by AGT to a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGATT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="876">
                    <text>The rise of parallel the part of STATs levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance may have been conferred by AGT to a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="877">
                    <text>The rise of parallel the part of STATs levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was able to be conferred by AGT to a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="878">
                    <text>The rise of parallel the part of STATs levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance was able to be conferred by AGT to a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="879">
                    <text>The rise of parallel the part of STATs levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance will be conferred by AGT to a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="880">
                    <text>The rise of parallel the part of STATs levels acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance would be conferred by AGT to a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 (.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="881">
                    <text>The rise of parallel which simply replaces C-terminus for Stat5 levels acquired alkylation the stability phenotype Stat5 in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and AGT is able to confer resistance to Stat1 (Kaina et al., 1991), demonstrating the role of AAGT in A1 therapy (resistance).</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="882">
                    <text>The rise of parallel which simply replaces C-terminus for Stat5 levels acquired alkylation the stability phenotype Stat5 in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998), and resistance is thought to be conferred by AGT to Stat1 (Kaina et al., 1991), demonstrating the role of AGATT in therapeutic resistance A1 ().</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="883">
                    <text>The rise of the part of STATs levels in parallel to acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by AGT to a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs) (Kaina et al., 1991), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="884">
                    <text>The rise of the part of STATs levels in parallel with acquired alkylation specificity in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance were conferred by AGT on a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs), demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="885">
                    <text>The rise of which simply replaces C-terminus for Stat5 levels in parallel with acquired alkylation the stability phenotype Stat5 in the presence of MG132 in human tumors (Brent et al., 1985; Mattern et al., 1998) and resistance may have been conferred by AGT on Stat1, demonstrating the role of AGT in A1 therapy (resistance).</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="886">
                    <text>The specificity in a tolC deficit strain may have been conferred by the the STAT portion.</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="REPLACE" no="887">
                    <text>The the part of STATs (AGT) that can confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) was therefore an active target of anti-drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="888">
                    <text>The the part of STATs (AGT) that conferred specificity on a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) was therefore an active target of anti-drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="889">
                    <text>The the part of STATs (AGT) that has conferred specificity on a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) was therefore an active target of anti-drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="890">
                    <text>The the part of STATs (AGT) that is observed to confer specificity on a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) was therefore an active target of anti-drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="891">
                    <text>The the stability phenotype Stat5 in the presence of MG132 in a tolC deficit strain is conferred by the which simply replaces C-terminus for Stat5.</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="892">
                    <text>You may not have no sense alterations or frame shifts in the encoding sequence or for splice variants and no conferred function loss engines.</text>
                    <arg n="0">no sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="893">
                    <text>You may not have non-sense change or frame deviation in the coding sequence or for splice variants and no conferred movement of loss of function.</text>
                    <arg n="0">non-sense change or frame deviation in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="894">
                    <text>You may not have substitutions in Gly156 and Lys165 and no conferred resistance.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="895">
                    <text>alkyguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation routes at 06-position of guanine, was able to confer resistance to alkylation and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="REPLACE" no="896">
                    <text>alkyguaning-DNA alkyltransferase was not able to confer resistance.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="897">
                    <text>alterations of discount or frame change in the encoding sequence or for splice variants could confer mutations of loss of functions.</text>
                    <arg n="0">alterations of discount or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="898">
                    <text>alterations of discount or frame change in the encoding sequence or for splice variants is considered to be no to confer mutations of loss of functions.</text>
                    <arg n="0">alterations of discount or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="899">
                    <text>alterations of discount or frame change in the encoding sequence or for splice variants which confers mutations of loss of functions to A2 (a MAPK substrate or a MAPK kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">alterations of discount or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="900">
                    <text>alterations of frame shift in the encoding sequence or by splice variants is not able to confer mutations of loss of functions.</text>
                    <arg n="0">alterations of frame shift in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="901">
                    <text>alterations of frame shift in the encoding sequence or by splice variants which confers mutations of loss of functions to A2 (a MAPK substrate or a MAPK kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">alterations of frame shift in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="902">
                    <text>change in function loss can be conferred by no significant change or change in table in the coding sequence or for splice variants.</text>
                    <arg n="0">no significant change or change in table in the coding sequence or for splice variants</arg>
                    <arg n="1">change in function loss</arg>
                </example>
                <example src="REPLACE" no="903">
                    <text>change of frame in the coding sequence or by splice variants can confer motors of loss of function.</text>
                    <arg n="0">change of frame in the coding sequence or by splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="904">
                    <text>change of frame in the coding sequence or by splice variants is considered to be the one that confers motors of loss of function on A2 (a MAPK or a MAPK substrate of kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">change of frame in the coding sequence or by splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="905">
                    <text>change of frame in the coding sequence or by splice variants will confer motors of loss of function.</text>
                    <arg n="0">change of frame in the coding sequence or by splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="906">
                    <text>change of loss of function in a strain with deficiencies in the tolC can be conferred via no-sense change or change of frame in the coding sequence or for splice variants.</text>
                    <arg n="0">no-sense change or change of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">change of loss of function</arg>
                </example>
                <example src="REPLACE" no="907">
                    <text>change of loss of function in a tolC-deficient strain is conferred by no-sense change or change of frame in the coding sequence or to splice variants.</text>
                    <arg n="0">no-sense change or change of frame in the coding sequence or to splice variants</arg>
                    <arg n="1">change of loss of function</arg>
                </example>
                <example src="REPLACE" no="908">
                    <text>change of loss of function in a tolC-deficient strain may have been conferred by no-sense change or change of frame in the coding sequence or to splice variants.</text>
                    <arg n="0">no-sense change or change of frame in the coding sequence or to splice variants</arg>
                    <arg n="1">change of loss of function</arg>
                </example>
                <example src="REPLACE" no="909">
                    <text>changes in frame in the coding sequence or by splice variants might have not conferred changes in function loss.</text>
                    <arg n="0">changes in frame in the coding sequence or by splice variants</arg>
                    <arg n="1">changes in function loss</arg>
                </example>
                <example src="REPLACE" no="910">
                    <text>changes in frame in the coding sequence or by splice variants was not able to confer changes in function loss.</text>
                    <arg n="0">changes in frame in the coding sequence or by splice variants</arg>
                    <arg n="1">changes in function loss</arg>
                </example>
                <example src="REPLACE" no="911">
                    <text>changes in function loss in a tolC-deficient strain is able to be conferred by changes in frame in the coding sequence or by splice variants.</text>
                    <arg n="0">changes in frame in the coding sequence or by splice variants</arg>
                    <arg n="1">changes in function loss</arg>
                </example>
                <example src="REPLACE" no="912">
                    <text>discount alterations or frame change in the encoding sequence or by splice variants is considered to be no to confer function loss engines.</text>
                    <arg n="0">discount alterations or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="913">
                    <text>discount alterations or frame change in the encoding sequence or by splice variants is not able to confer function loss engines.</text>
                    <arg n="0">discount alterations or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="914">
                    <text>discount alterations or frame change in the encoding sequence or by splice variants may confer function loss engines to A2 (a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">discount alterations or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="915">
                    <text>discount alterations or frame change in the encoding sequence or by splice variants was able to confer function loss engines to A2 (a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">discount alterations or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="916">
                    <text>discount alterations or frame change in the encoding sequence or by splice variants will confer function loss engines.</text>
                    <arg n="0">discount alterations or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="917">
                    <text>frame shift alterations in the encoding sequence or by splice variants can be conferred to function loss engines.</text>
                    <arg n="0">frame shift alterations in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="918">
                    <text>frame shift alterations in the encoding sequence or by splice variants could confer function loss engines.</text>
                    <arg n="0">frame shift alterations in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="919">
                    <text>frame shift alterations in the encoding sequence or by splice variants may not have conferred function loss engines.</text>
                    <arg n="0">frame shift alterations in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="920">
                    <text>function loss change in a tolC problem strain has been conferred by senseless change or change in frame in the coding sequence or for splice variants.</text>
                    <arg n="0">senseless change or change in frame in the coding sequence or for splice variants</arg>
                    <arg n="1">function loss change</arg>
                </example>
                <example src="REPLACE" no="921">
                    <text>function loss change in a tolC-deficient strain can be conferred by senseless change or change in frame in the coding sequence or for splice variants.</text>
                    <arg n="0">senseless change or change in frame in the coding sequence or for splice variants</arg>
                    <arg n="1">function loss change</arg>
                </example>
                <example src="REPLACE" no="922">
                    <text>function loss change in a tolC-deficient strain is able to be conferred by senseless change or change in frame in the coding sequence or for splice variants.</text>
                    <arg n="0">senseless change or change in frame in the coding sequence or for splice variants</arg>
                    <arg n="1">function loss change</arg>
                </example>
                <example src="REPLACE" no="923">
                    <text>function loss engines in a strain with deficiencies in the tolC can be conferred via senseless alterations or frame change in the encoding sequence or for splice variants.</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="924">
                    <text>function loss engines in a strain with tolC deficiencies is able to be conferred by no sense alterations or frame shifts in the encoding sequence or for splice variants.</text>
                    <arg n="0">no sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="925">
                    <text>function loss engines in a tolC-deficient strain is conferred by frame shift alterations in the encoding sequence or by splice variants.</text>
                    <arg n="0">frame shift alterations in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="926">
                    <text>function loss engines in a tolC-deficient strain was conferred by senseless alterations or frame change in the encoding sequence or for splice variants.</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="927">
                    <text>function loss engines is thought to be conferred by M-NG (not) for no sense alterations or frame shifts in the encoding sequence or for splice variants.</text>
                    <arg n="0">no sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="928">
                    <text>function loss engines was considered as not conferred by frame shift alterations in the encoding sequence or by splice variants.</text>
                    <arg n="0">frame shift alterations in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="929">
                    <text>function loss motion can be conferred by no by no-sense alterations or frame shifts in the encoding sequence or for splice variants.</text>
                    <arg n="0">no-sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="930">
                    <text>function loss motion can be conferred by no sense alterations or frame change in the encoding sequence or for splice variants.</text>
                    <arg n="0">no sense alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="931">
                    <text>function loss motion in a strain with a tolC deficit was conferred by no-sense alterations or frame shifts in the encoding sequence or for splice variants.</text>
                    <arg n="0">no-sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="932">
                    <text>function loss motion in a strain with tolC deficiencies is able to be conferred by no sense alterations or frame change in the encoding sequence or by splice variants.</text>
                    <arg n="0">no sense alterations or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="933">
                    <text>function loss motion in a tolC problem strain has been conferred by no sense alterations or frame change in the encoding sequence or for splice variants.</text>
                    <arg n="0">no sense alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="934">
                    <text>function loss motion in a tolC-deficient strain may have been conferred by no-sense alterations or frame shifts in the encoding sequence or for splice variants.</text>
                    <arg n="0">no-sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="935">
                    <text>function loss motion is the not conferred by no-sense alterations or frame shifts in the encoding sequence or for splice variants.</text>
                    <arg n="0">no-sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="936">
                    <text>function loss motion was considered as not conferred by no sense alterations or frame change in the encoding sequence or for splice variants.</text>
                    <arg n="0">no sense alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="937">
                    <text>function loss mutations can be conferred by senseless alterations or frame change in the encoding sequence or for splice variants.</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="938">
                    <text>function loss mutations in a tolC-deficient strain is able to be conferred by senseless change or change in frame in the coding sequence or to splice variants.</text>
                    <arg n="0">senseless change or change in frame in the coding sequence or to splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="939">
                    <text>function loss mutations in a tolC-deficient strain is conferred by senseless alterations or frame change in the encoding sequence or for splice variants.</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="940">
                    <text>function loss mutations in a tolC-deficient strain was conferred by senseless alterations or frame change in the encoding sequence or for splice variants.</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="941">
                    <text>function loss mutations in a tolC-deficient strain was conferred by senseless change or change in frame in the coding sequence or to splice variants.</text>
                    <arg n="0">senseless change or change in frame in the coding sequence or to splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="942">
                    <text>function loss mutations was the not conferred by senseless alterations or frame change in the encoding sequence or for splice variants.</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="943">
                    <text>human 06-alkylguaning-DNA alkyltransferase (AGT), which directly inverts endogenous alkylation pathways to 06-position of the guanine, could confer resistance to alkylation and thus was an active target of anti-cancer drugs.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="REPLACE" no="944">
                    <text>human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation pathways at 06-position of the guanine, was believed to confer resistance on alkylation and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="REPLACE" no="945">
                    <text>human 06-alkylguaning-DNA alkyltransferase could confer resistance.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="946">
                    <text>loss of function changes was considered as not conferred by no significant changes or changes in the frame in the coding sequence or for splice variants.</text>
                    <arg n="0">no significant changes or changes in the frame in the coding sequence or for splice variants</arg>
                    <arg n="1">loss of function changes</arg>
                </example>
                <example src="REPLACE" no="947">
                    <text>loss of function changes will be conferred by no significant changes or changes in the frame in the coding sequence or for splice variants by not.</text>
                    <arg n="0">no significant changes or changes in the frame in the coding sequence or for splice variants</arg>
                    <arg n="1">loss of function changes</arg>
                </example>
                <example src="REPLACE" no="948">
                    <text>loss of function mutation can be conferred by nonsense or frameshift alteration of the codiding sequence or by splice variants.</text>
                    <arg n="0">nonsense or frameshift alteration of the codiding sequence or by splice variants</arg>
                    <arg n="1">loss of function mutation</arg>
                </example>
                <example src="REPLACE" no="949">
                    <text>loss of function mutation in a tolC-deficient strain can be conferred by nonsense or frameshift alteration of the codiding sequence or by splice variants.</text>
                    <arg n="0">nonsense or frameshift alteration of the codiding sequence or by splice variants</arg>
                    <arg n="1">loss of function mutation</arg>
                </example>
                <example src="REPLACE" no="950">
                    <text>loss of function mutation is thought to be conferred by M-NG (not) for nonsense or frameshift alteration of the codiding sequence or by splice variants.</text>
                    <arg n="0">nonsense or frameshift alteration of the codiding sequence or by splice variants</arg>
                    <arg n="1">loss of function mutation</arg>
                </example>
                <example src="REPLACE" no="951">
                    <text>loss of functions mutations can be conferred by no by no significant change or change in frame in the coding sequence or for splice variants.</text>
                    <arg n="0">no significant change or change in frame in the coding sequence or for splice variants</arg>
                    <arg n="1">loss of functions mutations</arg>
                </example>
                <example src="REPLACE" no="952">
                    <text>loss of functions mutations in a tolC-deficient strain was conferred by no significant change or change in frame in the coding sequence or for splice variants.</text>
                    <arg n="0">no significant change or change in frame in the coding sequence or for splice variants</arg>
                    <arg n="1">loss of functions mutations</arg>
                </example>
                <example src="REPLACE" no="953">
                    <text>loss of mutation function in a tolC problem strain has been conferred by nonsense or frameshift alteration of the codiding sequence or by splice variants.</text>
                    <arg n="0">nonsense or frameshift alteration of the codiding sequence or by splice variants</arg>
                    <arg n="1">loss of mutation function</arg>
                </example>
                <example src="REPLACE" no="954">
                    <text>loss of mutation function in a tolC-deficient strain can be conferred by nonsense or frameshift alteration of the codiding sequence or by splice variants.</text>
                    <arg n="0">nonsense or frameshift alteration of the codiding sequence or by splice variants</arg>
                    <arg n="1">loss of mutation function</arg>
                </example>
                <example src="REPLACE" no="955">
                    <text>missing function mutation in a tolC-deficient strain is conferred by senseless alteration or frame change of the encoded sequence or by splice variants.</text>
                    <arg n="0">senseless alteration or frame change of the encoded sequence or by splice variants</arg>
                    <arg n="1">missing function mutation</arg>
                </example>
                <example src="REPLACE" no="956">
                    <text>missing function mutation in a tolC-deficient strain may have been conferred by senseless alteration or frame change of the encoded sequence or by splice variants.</text>
                    <arg n="0">senseless alteration or frame change of the encoded sequence or by splice variants</arg>
                    <arg n="1">missing function mutation</arg>
                </example>
                <example src="REPLACE" no="957">
                    <text>missing function mutation in a tolC-deficient strain was conferred by senseless alteration or frame change of the encoded sequence or by splice variants.</text>
                    <arg n="0">senseless alteration or frame change of the encoded sequence or by splice variants</arg>
                    <arg n="1">missing function mutation</arg>
                </example>
                <example src="REPLACE" no="958">
                    <text>missing function mutation was the not conferred by senseless alteration or frame change of the encoded sequence or by splice variants.</text>
                    <arg n="0">senseless alteration or frame change of the encoded sequence or by splice variants</arg>
                    <arg n="1">missing function mutation</arg>
                </example>
                <example src="REPLACE" no="959">
                    <text>motors of loss of function in a strain with deficiencies in the tolC can be conferred via chapter changes or change of frame in the coding sequence or by splice variants.</text>
                    <arg n="0">chapter changes or change of frame in the coding sequence or by splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="960">
                    <text>motors of loss of function in a tolC-deficient strain is able to be conferred by no change in meaning or deviation of frame in the coding sequence or for splice variants.</text>
                    <arg n="0">no change in meaning or deviation of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="961">
                    <text>motors of loss of function in a tolC-deficient strain may have been conferred by change of frame in the coding sequence or by splice variants.</text>
                    <arg n="0">change of frame in the coding sequence or by splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="962">
                    <text>movement of loss of function can be conferred by no by without change of meaning or change of table in the coding sequence or for splice variants.</text>
                    <arg n="0">without change of meaning or change of table in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="963">
                    <text>movement of loss of function in a strain with a tolC deficit was conferred by no change in meaning or change in table in the coding sequence or by splice variants.</text>
                    <arg n="0">no change in meaning or change in table in the coding sequence or by splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="964">
                    <text>movement of loss of function in a tolC-deficient strain is able to be conferred by non-sense change or frame deviation in the coding sequence or for splice variants.</text>
                    <arg n="0">non-sense change or frame deviation in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="965">
                    <text>movement of loss of function will be conferred by no change in meaning or change in table in the coding sequence or by splice variants.</text>
                    <arg n="0">no change in meaning or change in table in the coding sequence or by splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="966">
                    <text>movement of loss of function will be conferred by non-sense change or deviation of frame in the coding sequence or for splice variants.</text>
                    <arg n="0">non-sense change or deviation of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="967">
                    <text>mutations of loss of functions can be conferred to M-NG (no) by alterations of frame shift in the encoding sequence or by splice variants.</text>
                    <arg n="0">alterations of frame shift in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="968">
                    <text>mutations of loss of functions can be conferred to M-NG (no) by no meaningless alterations or frame change in the encoding sequence or for splice variants.</text>
                    <arg n="0">no meaningless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="969">
                    <text>mutations of loss of functions in a strain with a tolC deficit was conferred by alterations of discount or frame change in the encoding sequence or for splice variants.</text>
                    <arg n="0">alterations of discount or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="970">
                    <text>mutations of loss of functions in a strain with a tolC deficit was conferred by alterations of frame shift in the encoding sequence or by splice variants.</text>
                    <arg n="0">alterations of frame shift in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="971">
                    <text>mutations of loss of functions in a strain with a tolC deficit was conferred by senseless alteration or frame change in the encoding sequence or by splice variants.</text>
                    <arg n="0">senseless alteration or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="972">
                    <text>mutations of loss of functions in a strain with tolC deficiencies is able to be conferred by debarred or frame alterations in the encoding sequence or by splice variants.</text>
                    <arg n="0">debarred or frame alterations in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="973">
                    <text>mutations of loss of functions in a tolC-deficient strain is able to be conferred by debarred or frame alterations in the encoding sequence or by splice variants.</text>
                    <arg n="0">debarred or frame alterations in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="974">
                    <text>mutations of loss of functions in a tolC-deficient strain is able to be conferred by senseless alteration or frame change after encoding or splice variants.</text>
                    <arg n="0">senseless alteration or frame change after encoding or splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="975">
                    <text>mutations of loss of functions in a tolC-deficient strain is conferred by no meaningless alterations or frame change in the encoding sequence or for splice variants.</text>
                    <arg n="0">no meaningless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="976">
                    <text>mutations of loss of functions in a tolC-deficient strain may have been conferred by alterations of discount or frame change in the encoding sequence or for splice variants.</text>
                    <arg n="0">alterations of discount or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="977">
                    <text>mutations of loss of functions in a tolC-deficient strain may have been conferred by senseless alteration or frame change in the encoding sequence or by splice variants.</text>
                    <arg n="0">senseless alteration or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="978">
                    <text>mutations of loss of functions in a tolC-deficient strain was conferred by senseless alterations or frame change in the encoding sequence or for splice variants.</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="979">
                    <text>mutations of loss of functions is the not conferred by senseless alterations or frame change in the encoding sequence or for splice variants.</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="980">
                    <text>mutations of loss of functions is thought to be conferred by M-NG (not) for alterations of frame shift in the encoding sequence or by splice variants.</text>
                    <arg n="0">alterations of frame shift in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="981">
                    <text>mutations of loss of functions will be conferred by senseless alterations or frame change in the encoding sequence or for splice variants.</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="982">
                    <text>no change in meaning or change in table in the coding sequence or by splice variants can be conferred to movement of loss of function.</text>
                    <arg n="0">no change in meaning or change in table in the coding sequence or by splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="983">
                    <text>no change in meaning or change in table in the coding sequence or by splice variants can confer movement of loss of function.</text>
                    <arg n="0">no change in meaning or change in table in the coding sequence or by splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="984">
                    <text>no change in meaning or change in table in the coding sequence or by splice variants is able to confer movement of loss of function to A2 (a MAPK substrate or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">no change in meaning or change in table in the coding sequence or by splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="985">
                    <text>no change in meaning or change in table in the coding sequence or by splice variants may confer movement of loss of function to A2 (a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">no change in meaning or change in table in the coding sequence or by splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="986">
                    <text>no change in meaning or deviation of frame in the coding sequence or for splice variants is able to confer motors of loss of function to A2 (a MAPK substrate or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">no change in meaning or deviation of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="987">
                    <text>no change in meaning or deviation of frame in the coding sequence or for splice variants may not have conferred motors of loss of function.</text>
                    <arg n="0">no change in meaning or deviation of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="988">
                    <text>no change in meaning or deviation of frame in the coding sequence or for splice variants might have not conferred motors of loss of function.</text>
                    <arg n="0">no change in meaning or deviation of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">motors of loss of function</arg>
                </example>
                <example src="REPLACE" no="989">
                    <text>no meaningless alterations or frame change in the encoding sequence or for splice variants conferred mutations of loss of functions to A2 (one MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">no meaningless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="990">
                    <text>no meaningless alterations or frame change in the encoding sequence or for splice variants is able to confer mutations of loss of functions to A2 (a MAPK substrate or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">no meaningless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="991">
                    <text>no meaningless alterations or frame change in the encoding sequence or for splice variants is not able to confer mutations of loss of functions.</text>
                    <arg n="0">no meaningless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="992">
                    <text>no meaningless alterations or frame change in the encoding sequence or for splice variants may confer mutations of loss of functions to A2 (a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">no meaningless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="993">
                    <text>no meaningless alterations or frame change in the encoding sequence or for splice variants which confers mutations of loss of functions to A2 (a MAPK substrate or a MAPK kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">no meaningless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="994">
                    <text>no sense alterations or frame change in the encoding sequence or by splice variants is considered to be the one that confers function loss motion on A2 (a MAPK or a MAPK substrate of kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">no sense alterations or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="995">
                    <text>no sense alterations or frame change in the encoding sequence or by splice variants will confer function loss motion.</text>
                    <arg n="0">no sense alterations or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="996">
                    <text>no sense alterations or frame change in the encoding sequence or for splice variants was able to confer function loss motion to A2 (a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">no sense alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="997">
                    <text>no sense alterations or frame change in the encoding sequence or for splice variants would confer function loss motion.</text>
                    <arg n="0">no sense alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="998">
                    <text>no sense alterations or frame shifts in the encoding sequence or for splice variants conferred function loss engines to A2 (one MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">no sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="999">
                    <text>no sense alterations or frame shifts in the encoding sequence or for splice variants could confer function loss engines.</text>
                    <arg n="0">no sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="1000">
                    <text>no significant change or change in frame in the coding sequence or for splice variants conferred loss of functions mutations to A2 (one MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">no significant change or change in frame in the coding sequence or for splice variants</arg>
                    <arg n="1">loss of functions mutations</arg>
                </example>
                <example src="REPLACE" no="1001">
                    <text>no significant change or change in frame in the coding sequence or for splice variants is able to confer loss of functions mutations to A2 (a MAPK substrate or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">no significant change or change in frame in the coding sequence or for splice variants</arg>
                    <arg n="1">loss of functions mutations</arg>
                </example>
                <example src="REPLACE" no="1002">
                    <text>no significant change or change in frame in the coding sequence or for splice variants may not have conferred loss of functions mutations.</text>
                    <arg n="0">no significant change or change in frame in the coding sequence or for splice variants</arg>
                    <arg n="1">loss of functions mutations</arg>
                </example>
                <example src="REPLACE" no="1003">
                    <text>no significant changes or changes in the frame in the coding sequence or for splice variants might have not conferred loss of function changes.</text>
                    <arg n="0">no significant changes or changes in the frame in the coding sequence or for splice variants</arg>
                    <arg n="1">loss of function changes</arg>
                </example>
                <example src="REPLACE" no="1004">
                    <text>no-sense alterations or frame shifts in the encoding sequence or for splice variants is considered to be the one that confers function loss motion on A2 (a MAPK or a MAPK substrate of kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">no-sense alterations or frame shifts in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss motion</arg>
                </example>
                <example src="REPLACE" no="1005">
                    <text>no-sense change or change of frame in the coding sequence or for splice variants can confer change of loss of function.</text>
                    <arg n="0">no-sense change or change of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">change of loss of function</arg>
                </example>
                <example src="REPLACE" no="1006">
                    <text>no-sense change or change of frame in the coding sequence or for splice variants of M-NEG does not confer change of loss of function.</text>
                    <arg n="0">no-sense change or change of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">change of loss of function</arg>
                </example>
                <example src="REPLACE" no="1007">
                    <text>no-sense change or change of frame in the coding sequence or for splice variants was not able to confer change of loss of function.</text>
                    <arg n="0">no-sense change or change of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">change of loss of function</arg>
                </example>
                <example src="REPLACE" no="1008">
                    <text>no-sense change or change of frame in the coding sequence or to splice variants could confer change of loss of function.</text>
                    <arg n="0">no-sense change or change of frame in the coding sequence or to splice variants</arg>
                    <arg n="1">change of loss of function</arg>
                </example>
                <example src="REPLACE" no="1009">
                    <text>no-sense change or change of frame in the coding sequence or to splice variants is considered to be the one that confers change of loss of function on A2 (a MAPK or a MAPK substrate of kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">no-sense change or change of frame in the coding sequence or to splice variants</arg>
                    <arg n="1">change of loss of function</arg>
                </example>
                <example src="REPLACE" no="1010">
                    <text>non-sense change or deviation of frame in the coding sequence or for splice variants can confer movement of loss of function.</text>
                    <arg n="0">non-sense change or deviation of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="1011">
                    <text>non-sense change or deviation of frame in the coding sequence or for splice variants which confers movement of loss of function to A2 (a MAPK substrate or a MAPK kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">non-sense change or deviation of frame in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="1012">
                    <text>non-sense change or frame deviation in the coding sequence or for splice variants which confers movement of loss of function to A2 (a MAPK substrate or a MAPK kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">non-sense change or frame deviation in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="1013">
                    <text>nonsense or frameshift alteration in the coding sequence or by splice variants is not able to confer function loss mutations.</text>
                    <arg n="0">nonsense or frameshift alteration in the coding sequence or by splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="1014">
                    <text>nonsense or frameshift alteration of the codiding sequence or by splice variants can be conferred to loss of function mutation.</text>
                    <arg n="0">nonsense or frameshift alteration of the codiding sequence or by splice variants</arg>
                    <arg n="1">loss of function mutation</arg>
                </example>
                <example src="REPLACE" no="1015">
                    <text>nonsense or frameshift alteration of the codiding sequence or by splice variants of M-NEG does not confer loss of function mutation.</text>
                    <arg n="0">nonsense or frameshift alteration of the codiding sequence or by splice variants</arg>
                    <arg n="1">loss of function mutation</arg>
                </example>
                <example src="REPLACE" no="1016">
                    <text>nonsense or frameshift alteration of the codiding sequence or by splice variants was considered to be the one that confers loss of mutation function to A2 (a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">nonsense or frameshift alteration of the codiding sequence or by splice variants</arg>
                    <arg n="1">loss of mutation function</arg>
                </example>
                <example src="REPLACE" no="1017">
                    <text>nonsense or frameshift alteration of the codiding sequence or by splice variants was not able to confer loss of mutation function.</text>
                    <arg n="0">nonsense or frameshift alteration of the codiding sequence or by splice variants</arg>
                    <arg n="1">loss of mutation function</arg>
                </example>
                <example src="REPLACE" no="1018">
                    <text>nonsense or frameshift alteration of the codiding sequence or by splice variants which confers loss of function mutation to A2 (a MAPK substrate or a MAPK kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">nonsense or frameshift alteration of the codiding sequence or by splice variants</arg>
                    <arg n="1">loss of function mutation</arg>
                </example>
                <example src="REPLACE" no="1019">
                    <text>only the C-terminal substitution for Stat5 (AGT) that is able to confer the Stat5 phenotype of stability in the presence of MG132 to State1 was therefore an active target of anti-drugs.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="1020">
                    <text>only the C-terminal substitution for Stat5 (AGT), which directly inverts endogenous Stat1 to 06-position of the guanine, would confer the Stat5 phenotype in the presence of MG132 to alkylation and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="1021">
                    <text>only the C-terminal substitution for Stat5 (AGT), which directly inverts endogenous State1 to 06-position of the guanine, could confer the Stat5 phenotype in the presence of MG132 to alkylation and thus was an active target of anti-cancer drugs.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="1022">
                    <text>only the C-terminal substitution for Stat5 (AGT), which directly inverts endogenous State1 to 06-position of the guanine, would confer the Stat5 phenotype of stability in the presence of MG132 to alkylation and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="1023">
                    <text>only the C-terminal substitution for Stat5 (AGT), which directly inverts endogenous alkylation to 06-position of the guanine, can confer the Stat5 phenotype in the presence of MG132 to State1 and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="1024">
                    <text>only the C-terminal substitution for Stat5 (AGT), which directly reverses endogenous alkylation at 06-position of the guanine, was believed to confer the Stat5 phenotype in the presence of MG132 on Stat1 and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="1025">
                    <text>only the C-terminal substitution for Stat5 (AGT), which directly reverses the endogenous Stat1 at the position of 06 guanin, was able to confer the Stat5 phenotype in the presence of MG132 to alkylation and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="1026">
                    <text>only the C-terminal substitution for Stat5 (AGT), which directly reverses the endogenous State1 at the position of 06 guanin, was able to confer the Stat5 phenotype in the presence of MG132 to alkylation and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="1027">
                    <text>only the C-terminal substitution for Stat5 (AGT), which directly reverses the endogenous State1 at the position of 06 guanin, was observed to confer the Stat5 phenotype in the presence of MG132 to alkylation and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="1028">
                    <text>only the C-terminal substitution for Stat5 (AGT), which directly reverses the endogenous State1 at the position of 06 guanin, was observed to confer the Stat5 phenotype of stability in the presence of MG132 to alkylation and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="1029">
                    <text>only the C-terminal substitution for Stat5 (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, was able to confer the Stat5 phenotype of stability in the presence of MG132 to State1 and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="1030">
                    <text>only the C-terminal substitution for Stat5 (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, was observed to confer the Stat5 phenotype of stability in the presence of MG132 to State1 and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="1031">
                    <text>only the C-terminal substitution for Stat5 (AGT), which directly reverses the endogenous alkylation at the position of guanin 6, conferred the Stat5 phenotype of stability in the presence of MG132 to State1 and is therefore an active target of anticancer drugs.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="1032">
                    <text>only the C-terminal substitution for Stat5 (AGT), which directly reverses the endogenous alkylation in 06 guanin positions, has the ability to confer the Stat5 phenotype of stability in the presence of MG132 to State1 and therefore is an active target of antineoplastic drugs.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="1033">
                    <text>only the C-terminal substitution for Stat5 could confer the Stat5 phenotype of stability in the presence of MG132.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="1034">
                    <text>only the C-terminal substitution for Stat5 human 06-alkylguaning-DNA (AGT) that conferred the Stat5 phenotype in the presence of MG132 to Stat1 was therefore an active target of anti-drugs.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="1035">
                    <text>only the C-terminal substitution for Stat5 is considered to be no to confer the Stat5 phenotype in the presence of MG132.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="1036">
                    <text>only the C-terminal substitution for Stat5 was not able to confer the Stat5 phenotype of stability in the presence of MG132.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="1037">
                    <text>only the C-terminal substitution for Stat5 which confers the Stat5 phenotype in the presence of MG132 to A2 (a MAPK substrate or a MAPK kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="1038">
                    <text>part of STATs (AGT) that can confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) was therefore an active target of anti-drugs.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1039">
                    <text>part of STATs (AGT) that conferred specificity over a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) was therefore an active target for anti-drugs.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1040">
                    <text>part of STATs (AGT) that is able to confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) was therefore an active target of anti-drugs.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1041">
                    <text>part of STATs (AGT), which directly inverts endogenous a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) to 06-position of guanine, conferred specificity on alkylation and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1042">
                    <text>part of STATs (AGT), which directly inverts endogenous a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs) to 06-position of guanine, is able to confer specificity to alkylation and is therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1043">
                    <text>part of STATs (AGT), which directly inverts endogenous a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs) to 06-position of guanine, is observed to confer specificity to alkylation and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1044">
                    <text>part of STATs (AGT), which directly reverses the endogenous a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) at the position of 06 guanin, was able to confer specificity to alkylation and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1045">
                    <text>part of STATs (AGT), which directly reverses the endogenous a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs) to 06-platinin position, would confer specificity to alkylation and therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1046">
                    <text>part of STATs (AGT), which directly reverses the endogenous alkylation to the position 06 of guanin, may confer specificity to a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs) and is therefore an active target of anticancer drugs.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1047">
                    <text>replacing Gly156 and Lys165 can confer resistance.</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="1048">
                    <text>replacing simply the C-terminal with Stat5 (AGT), which directly inverts endogenous Stat1 to 06-position of guanine, is observed to confer the Stat5 phenotype of stability in the presence of MG132 to alkylation and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="1049">
                    <text>replacing simply the C-terminal with Stat5 (AGT), which directly reverses endogenous Stat1 at 06-position of guanine, was observed to confer the Stat5 phenotype of stability in the presence of MG132 on alkylation and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="1050">
                    <text>replacing simply the C-terminal with Stat5 (AGT), which directly reverses the endogenous Stat1 in 06 guanin positions, has the ability to confer the Stat5 phenotype of stability in the presence of MG132 to alkylation and therefore is an active target of antineoplastic drugs.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="1051">
                    <text>replacing simply the C-terminal with Stat5 can confer the Stat5 phenotype of stability in the presence of MG132.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="1052">
                    <text>resistance can be conferred by alkyguaning-DNA alkyltransferase, which directly reverses the endogenous alkylation routes to the position of 06-guanin, to alkylation.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="REPLACE" no="1053">
                    <text>resistance can be conferred by alkyguaning-DNA alkyltransferase.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="1054">
                    <text>resistance can be conferred by human 06-alkylguaning-DNA alkyltransferase.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="1055">
                    <text>resistance can be conferred by no by substitutions in Gly156 and Lys165.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="1056">
                    <text>resistance can be conferred by substitutions in Gly156 and Lys165.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="1057">
                    <text>resistance has the ability to confer alkyguaning-DNA alkyltransferase (AGT), which directly reverses the endogenous alkylation routes in the position of 06- guanin, to alkylation.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="REPLACE" no="1058">
                    <text>resistance has the ability to confer replacing Gly156 and Lys165 (AGT), which directly reverses the endogenous 06-BG in the position of 06- guanin, to alkylation.</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="REPLACE" no="1059">
                    <text>resistance has the ability to confer substitutions in Gly156 and Lys165 (AGT), which directly reverses endogenous 06-BG in the 06-guanine position, to alkylation.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="REPLACE" no="1060">
                    <text>resistance in a strain with a tolC deficit was conferred by substitutions in Gly156 and Lys165.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="1061">
                    <text>resistance in a strain with tolC deficiencies is able to be conferred by substitutions in Gly156 and Lys165.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="1062">
                    <text>resistance in a tolC-deficient strain is conferred by substitutions in Gly156 and Lys165.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="1063">
                    <text>resistance is conferred by human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses the endogenous alkylation pathways in the position of 06- guanin, to alkylation.</text>
                    <arg n="0">human 06-alkylguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation pathways</arg>
                </example>
                <example src="REPLACE" no="1064">
                    <text>resistance was conferred by alkyguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation routes at the 06-guanine position, in alkylation.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="REPLACE" no="1065">
                    <text>resistance was conferred by alkyguaning-DNA alkyltransferase, which directly reverses the endogenous alkylation routes to the position of 06-guanin, to alkylation.</text>
                    <arg n="0">alkyguaning-DNA alkyltransferase</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">alkylation routes</arg>
                </example>
                <example src="REPLACE" no="1066">
                    <text>resistance would be conferred by replacing Gly156 and Lys165, which directly reverses the endogenous 06-BG in the position of 06-guanin, in alkylation.</text>
                    <arg n="0">replacing Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="REPLACE" no="1067">
                    <text>senseless alteration or frame change after encoding or splice variants may not have conferred mutations of loss of functions.</text>
                    <arg n="0">senseless alteration or frame change after encoding or splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="1068">
                    <text>senseless alteration or frame change after encoding or splice variants will confer mutations of loss of functions.</text>
                    <arg n="0">senseless alteration or frame change after encoding or splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="1069">
                    <text>senseless alteration or frame change in the encoding sequence or by splice variants may not have conferred mutations of loss of functions.</text>
                    <arg n="0">senseless alteration or frame change in the encoding sequence or by splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="1070">
                    <text>senseless alteration or frame change of the encoded sequence or by splice variants which confers missing function mutation to A2 (a MAPK substrate or a MAPK kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">senseless alteration or frame change of the encoded sequence or by splice variants</arg>
                    <arg n="1">missing function mutation</arg>
                </example>
                <example src="REPLACE" no="1071">
                    <text>senseless alterations or frame change in the encoding sequence or for splice variants can be conferred to mutations of loss of functions.</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">mutations of loss of functions</arg>
                </example>
                <example src="REPLACE" no="1072">
                    <text>senseless alterations or frame change in the encoding sequence or for splice variants is able to confer function loss mutations to A2 (a MAPK substrate or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="1073">
                    <text>senseless alterations or frame change in the encoding sequence or for splice variants is not able to confer function loss engines.</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="1074">
                    <text>senseless alterations or frame change in the encoding sequence or for splice variants may not have conferred function loss mutations.</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="1075">
                    <text>senseless alterations or frame change in the encoding sequence or for splice variants might have not conferred function loss mutations.</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="1076">
                    <text>senseless alterations or frame change in the encoding sequence or for splice variants was considered to be the one that confers function loss mutations to A2 (a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="1077">
                    <text>senseless alterations or frame change in the encoding sequence or for splice variants which confers function loss mutations to A2 (a MAPK substrate or a MAPK kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">senseless alterations or frame change in the encoding sequence or for splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="1078">
                    <text>senseless change or change in frame in the coding sequence or for splice variants can be conferred to function loss change.</text>
                    <arg n="0">senseless change or change in frame in the coding sequence or for splice variants</arg>
                    <arg n="1">function loss change</arg>
                </example>
                <example src="REPLACE" no="1079">
                    <text>senseless change or change in frame in the coding sequence or to splice variants is not able to confer function loss mutations.</text>
                    <arg n="0">senseless change or change in frame in the coding sequence or to splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="1080">
                    <text>senseless change or change in frame in the coding sequence or to splice variants will confer function loss mutations.</text>
                    <arg n="0">senseless change or change in frame in the coding sequence or to splice variants</arg>
                    <arg n="1">function loss mutations</arg>
                </example>
                <example src="REPLACE" no="1081">
                    <text>specificity can be conferred by part of STATs, which directly reverses the endogenous alkylation to the position of 06-guanin, to a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs).</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1082">
                    <text>specificity can be conferred by the part of STATs, which directly reverses the endogenous a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) in the position of 06-guanin, in alkylation.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1083">
                    <text>specificity can be conferred by the part of STATs, which directly reverses the endogenous a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) in the position of 06-guanin, in alkylation.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1084">
                    <text>specificity can be conferred by the part of STATs, which directly reverses the endogenous a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) in the position of 06-guanin, in alkylation.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1085">
                    <text>specificity can be conferred by the part of STATs, which directly reverses the endogenous a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) to the position of 06-guanin, to alkylation.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1086">
                    <text>specificity can be conferred by the part of STATs, which directly reverses the endogenous alkylation in the position of 06-guanin, in a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1087">
                    <text>specificity for a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) was conferred by the part of STATs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1088">
                    <text>specificity for a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs) has been conferred by the part of STATs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1089">
                    <text>specificity for a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) has been conferred by the part of STATs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1090">
                    <text>specificity has the ability to confer the part of STATs (AGT), which directly reverses endogenous a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs) in the 06-guanine position, to alkylation.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1091">
                    <text>specificity has the ability to confer the part of STATs (AGT), which directly reverses the endogenous a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) in the position of 06- guanin, to alkylation.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1092">
                    <text>specificity has the ability to confer the part of STATs (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1093">
                    <text>specificity in a strain with tolC deficiencies is able to be conferred by the STAT portion.</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="REPLACE" no="1094">
                    <text>specificity is able to confer part of STATs (AGT), which directly reverses the endogenous a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) in the position of 06- guanin, to alkylation.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1095">
                    <text>specificity is able to confer the STAT portion (AGT), which directly reverses the endogenous a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) in the position of 06- guanin, to alkylation.</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="1096">
                    <text>specificity is able to confer the part of STATs (AGT), which directly reverses the endogenous a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) in the position of 06- guanin, to alkylation.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1097">
                    <text>specificity is able to confer the part of STATs (AGT), which directly reverses the endogenous a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs) in the position of 06- guanin, to alkylation.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1098">
                    <text>specificity is able to confer the part of STATs (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1099">
                    <text>specificity is able to confer the part of STATs (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1100">
                    <text>specificity is conferred by part of STATs (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs).</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) is able to be conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1101">
                    <text>specificity is conferred by the STAT portion (AGT), which directly reverses endogenous alkylation at the 06-guanine position, in a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion).</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="1102">
                    <text>specificity is conferred by the part of STATs (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1103">
                    <text>specificity is conferred by the part of STATs (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1104">
                    <text>specificity is thought to be conferred by M-NG (not) for the STAT portion.</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="REPLACE" no="1105">
                    <text>specificity may have been conferred by the part of STATs (AGT), which directly reverses endogenous a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) at the 06-guanine position, in alkylation.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1106">
                    <text>specificity may have been conferred by the part of STATs (AGT), which directly reverses the endogenous alkylation at the position of 06- guanin, to a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1107">
                    <text>specificity was believed to confer for the part of STATs (AGT), which directly reverses endogenous a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) to 06-guanine position, to alkylation.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1108">
                    <text>specificity was believed to confer for the part of STATs (AGT), which directly reverses endogenous alkylation to 06-guanine position, to a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1109">
                    <text>specificity was believed to confer for the part of STATs (AGT), which directly reverses endogenous alkylation to 06-guanine position, to a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1110">
                    <text>specificity was conferred by the part of STATs (AGT), which directly reverses endogenous a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) at the 06-guanine position, in alkylation.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1111">
                    <text>specificity was conferred by the part of STATs (AGT), which directly reverses endogenous alkylation at the 06-guanine position, in a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1112">
                    <text>specificity was conferred by the part of STATs (AGT), which directly reverses the endogenous alkylation at the position of 06- guanin, to a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1113">
                    <text>specificity was conferred by the part of STATs (AGT), which directly reverses the endogenous alkylation at the position of 06- guanin, to a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1114">
                    <text>specificity was conferred by the part of STATs, which directly reverses the endogenous alkylation to the position of 06-guanin, to a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1115">
                    <text>specificity will be conferred by part of STATs (AGT), which directly reverses the endogenous a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs) in the position of 06-guanin in alkylation.</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1116">
                    <text>specificity will be conferred by the STAT portion (AGT), which directly reverses the endogenous a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) in the position of 06- guanin, to alkylation.</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="1117">
                    <text>specificity will be conferred by the STAT portion (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion).</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="1118">
                    <text>specificity will be conferred by the part of STATs (AGT), which directly reverses the endogenous a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) in the position of 06- guanin, to alkylation.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1119">
                    <text>specificity will be conferred by the part of STATs (AGT), which directly reverses the endogenous alkylation in the position of 06-guanin in a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1120">
                    <text>specificity would be conferred by part of STATs (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs).</text>
                    <arg n="0">part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is conferred by A0 (part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1121">
                    <text>specificity would be conferred by the STAT portion, which directly reverses the endogenous a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) in the position of 06-guanin, in alkylation.</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="1122">
                    <text>specificity would be conferred by the part of STATs, which directly reverses the endogenous a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs) in the position of 06-guanin, in alkylation.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1123">
                    <text>specificity would be conferred by the part of STATs, which directly reverses the endogenous alkylation in the position of 06-guanin, in a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1124">
                    <text>substitutions in Gly156 and Lys165 (AGT), which directly reverses the endogenous 06-BG to the position 06 of guanin, is able to confer resistance to alkylation and therefore is an active target of antineoplastic drugs.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="REPLACE" no="1125">
                    <text>substitutions in Gly156 and Lys165 (AGT), which directly reverses the endogenous 06-BG to the position 06 of guanin, may confer resistance to alkylation and is therefore an active target of anticancer drugs.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                    <arg n="2">06-BG</arg>
                </example>
                <example src="REPLACE" no="1126">
                    <text>substitutions in Gly156 and Lys165 of M-NEG does not confer resistance.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="1127">
                    <text>substitutions in Gly156 and Lys165 will confer resistance.</text>
                    <arg n="0">substitutions in Gly156 and Lys165</arg>
                    <arg n="1">resistance</arg>
                </example>
                <example src="REPLACE" no="1128">
                    <text>the STAT portion (AGT), which directly reverses endogenous a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) at 06-position of the guanine, was believed to confer specificity on alkylation and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="1129">
                    <text>the STAT portion (AGT), which directly reverses the endogenous a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) at the position of 06 guanin, was observed to confer specificity to alkylation and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="1130">
                    <text>the STAT portion (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, was observed to confer specificity to a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="1131">
                    <text>the STAT portion (AGT), which directly reverses the endogenous alkylation in 06 guanin positions, has the ability to confer specificity to a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) and therefore is an active target of antineoplastic drugs.</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="1132">
                    <text>the STAT portion is considered to be no to confer specificity.</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="REPLACE" no="1133">
                    <text>the STAT portion may confer specificity to a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion) has not been determined.</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was conferred by A0 (the STAT portion)</arg>
                </example>
                <example src="REPLACE" no="1134">
                    <text>the STAT portion might have not conferred specificity.</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="REPLACE" no="1135">
                    <text>the STAT portion of M-NEG does not confer specificity.</text>
                    <arg n="0">the STAT portion</arg>
                    <arg n="1">specificity</arg>
                </example>
                <example src="REPLACE" no="1136">
                    <text>the Stat5 phenotype in the presence of MG132 can be conferred by only the C-terminal substitution for Stat5, which directly reverses the endogenous Stat1 in the position of 06-guanin, in alkylation.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="1137">
                    <text>the Stat5 phenotype in the presence of MG132 in a strain with deficiencies in the tolC can be conferred via only the C-terminal substitution for Stat5.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="1138">
                    <text>the Stat5 phenotype in the presence of MG132 in a tolC-deficient strain may have been conferred by only the C-terminal substitution for Stat5.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="1139">
                    <text>the Stat5 phenotype in the presence of MG132 is able to confer only the C-terminal substitution for Stat5 (AGT), which directly reverses the endogenous State1 in the position of 06- guanin, to alkylation.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="1140">
                    <text>the Stat5 phenotype in the presence of MG132 is able to confer only the C-terminal substitution for Stat5 (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to State1.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="1141">
                    <text>the Stat5 phenotype in the presence of MG132 is conferred by only the C-terminal substitution for Stat5 (AGT), which directly reverses the endogenous Stat1 in the position of 06- guanin, to alkylation.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="1142">
                    <text>the Stat5 phenotype in the presence of MG132 was conferred by only the C-terminal substitution for Stat5, which directly reverses the endogenous alkylation to the position of 06-guanin, to Stat1.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="1143">
                    <text>the Stat5 phenotype in the presence of MG132 will be conferred by only the C-terminal substitution for Stat5.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="1144">
                    <text>the Stat5 phenotype in the presence of MG132 would be conferred by only the C-terminal substitution for Stat5 (AGT), which directly reverses the endogenous State1 in the position of 06- guanin, to alkylation.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="1145">
                    <text>the Stat5 phenotype of stability in the presence of MG132 has the ability to confer only the C-terminal substitution for Stat5 (AGT), which directly reverses the endogenous State1 in the position of 06- guanin, to alkylation.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="1146">
                    <text>the Stat5 phenotype of stability in the presence of MG132 has the ability to confer replacing simply the C-terminal with Stat5 (AGT), which directly reverses endogenous Stat1 in the 06-guanine position, to alkylation.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="1147">
                    <text>the Stat5 phenotype of stability in the presence of MG132 in a tolC-deficient strain was conferred by only the C-terminal substitution for Stat5.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="1148">
                    <text>the Stat5 phenotype of stability in the presence of MG132 is able to confer only the C-terminal substitution for Stat5, which directly reverses the endogenous State1 to the position of 06-guanin, to alkylation.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="1149">
                    <text>the Stat5 phenotype of stability in the presence of MG132 is the not conferred by only the C-terminal substitution for Stat5.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="1150">
                    <text>the Stat5 phenotype of stability in the presence of MG132 may have been conferred by replacing simply the C-terminal with Stat5 (AGT), which directly reverses the endogenous Stat1 at the position of 06- guanin, to alkylation.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="1151">
                    <text>the Stat5 phenotype of stability in the presence of MG132 was believed to confer for only the C-terminal substitution for Stat5 (AGT), which directly reverses endogenous alkylation to 06-guanine position, to State1.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="1152">
                    <text>the Stat5 phenotype of stability in the presence of MG132 was conferred by only the C-terminal substitution for Stat5 (AGT), which directly reverses endogenous alkylation at the 06-guanine position, in State1.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="1153">
                    <text>the Stat5 phenotype of stability in the presence of MG132 would be conferred by only the C-terminal substitution for Stat5, which directly reverses the endogenous State1 in the position of 06-guanin, in alkylation.</text>
                    <arg n="0">only the C-terminal substitution for Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">State1</arg>
                </example>
                <example src="REPLACE" no="1154">
                    <text>the Stat5 phenotype of stability in the presence of MG132 would be conferred by replacing simply the C-terminal with Stat5 (AGT), which directly reverses the endogenous Stat1 in the position of 06- guanin, to alkylation.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="1155">
                    <text>the Stat5 phenotype of stability in the presence of MG132 would be conferred by replacing simply the C-terminal with Stat5, which directly reverses the endogenous Stat1 in the position of 06-guanin, in alkylation.</text>
                    <arg n="0">replacing simply the C-terminal with Stat5</arg>
                    <arg n="1">the Stat5 phenotype of stability in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="1156">
                    <text>the part of STATs (AGT) that conferred specificity over a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) was therefore an active target for anti-drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1157">
                    <text>the part of STATs (AGT) that conferred specificity over a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs) was therefore an active target for anti-drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1158">
                    <text>the part of STATs (AGT) that is able to confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs) was therefore an active target of anti-drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1159">
                    <text>the part of STATs (AGT) which conferring specificity on a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) is therefore an active target of anti-tank drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1160">
                    <text>the part of STATs (AGT), which directly inverts endogenous a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs) to 06-position of the guanine, could confer specificity to alkylation and thus was an active target of anti-cancer drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1161">
                    <text>the part of STATs (AGT), which directly inverts endogenous a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs) to 06-position of guanine, is observed to confer specificity to alkylation and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1162">
                    <text>the part of STATs (AGT), which directly inverts endogenous a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) to 06-position of guanine, is observed to confer specificity to alkylation and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1163">
                    <text>the part of STATs (AGT), which directly inverts endogenous alkylation to 06-position of guanine, conferred specificity on a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1164">
                    <text>the part of STATs (AGT), which directly inverts endogenous alkylation to 06-position of guanine, is able to confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) and is therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1165">
                    <text>the part of STATs (AGT), which directly inverts endogenous alkylation to 06-position of guanine, is observed to confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs) and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1166">
                    <text>the part of STATs (AGT), which directly inverts endogenous alkylation to 06-position of the guanine, would confer specificity to a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1167">
                    <text>the part of STATs (AGT), which directly reverses endogenous a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) at 06-position of the guanine, has the ability to confer specificity to alkylation and is therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1168">
                    <text>the part of STATs (AGT), which directly reverses endogenous a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) at 06-position of the guanine, was believed to confer specificity on alkylation and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1169">
                    <text>the part of STATs (AGT), which directly reverses endogenous alkylation at 06-position of guanine, was able to confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs) and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1170">
                    <text>the part of STATs (AGT), which directly reverses the endogenous a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) at the position of 06 guanin, may confer specificity to alkylation and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1171">
                    <text>the part of STATs (AGT), which directly reverses the endogenous a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) in 06 guanin positions, has the ability to confer specificity to alkylation and therefore is an active target of antineoplastic drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1172">
                    <text>the part of STATs (AGT), which directly reverses the endogenous a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) to the position 06 of guanin, could confer specificity to alkylation and thus was an active target of antineoplastic drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1173">
                    <text>the part of STATs (AGT), which directly reverses the endogenous a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs) to 06-platinin position, would confer specificity to alkylation and therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1174">
                    <text>the part of STATs (AGT), which directly reverses the endogenous a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs) at the position of guanin 6, conferred specificity to alkylation and is therefore an active target of anticancer drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1175">
                    <text>the part of STATs (AGT), which directly reverses the endogenous a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) in 06 guanin positions, has the ability to confer specificity to alkylation and therefore is an active target of antineoplastic drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1176">
                    <text>the part of STATs (AGT), which directly reverses the endogenous a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) to 06-platinin position, would confer specificity to alkylation and therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1177">
                    <text>the part of STATs (AGT), which directly reverses the endogenous a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) to the position 06 of guanin, may confer specificity to alkylation and is therefore an active target of anticancer drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1178">
                    <text>the part of STATs (AGT), which directly reverses the endogenous a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) at the position of guanin 6, conferred specificity to alkylation and is therefore an active target of anticancer drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1179">
                    <text>the part of STATs (AGT), which directly reverses the endogenous a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) to the position 06 of guanin, could confer specificity to alkylation and thus was an active target of antineoplastic drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1180">
                    <text>the part of STATs (AGT), which directly reverses the endogenous alkyl to the 6-position of guanin, is observed to confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs) and is therefore an active target for anticancer drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1181">
                    <text>the part of STATs (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, may confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs) and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) can be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1182">
                    <text>the part of STATs (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, may confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs) and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1183">
                    <text>the part of STATs (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, may confer specificity to a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1184">
                    <text>the part of STATs (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, was observed to confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs) and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1185">
                    <text>the part of STATs (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, was observed to confer specificity to a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1186">
                    <text>the part of STATs (AGT), which directly reverses the endogenous alkylation at the position of guanin 6, conferred specificity to a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs) and is therefore an active target of anticancer drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1187">
                    <text>the part of STATs (AGT), which directly reverses the endogenous alkylation to 06-platinin position, would confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs) and therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1188">
                    <text>the part of STATs (AGT), which directly reverses the endogenous alkylation to 06-platinin position, would confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs) and therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1189">
                    <text>the part of STATs (AGT), which directly reverses the endogenous alkylation to the position 06 of guanin, is able to confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs) and therefore is an active target of antineoplastic drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1190">
                    <text>the part of STATs (AGT), which directly reverses the endogenous alkylation to the position 06 of guanin, is able to confer specificity to a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs) and therefore is an active target of antineoplastic drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substratum kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1191">
                    <text>the part of STATs (AGT), which directly reverses the endogenous alkylation to the position 06 of guanin, may confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs) and is therefore an active target of anticancer drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) may be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1192">
                    <text>the part of STATs conferred specificity to a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1193">
                    <text>the part of STATs has not been determined to be able to confer specificity to a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs).</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1194">
                    <text>the part of STATs human 06-alkylguaning-DNA (AGT) that conferred specificity to a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs) was therefore an active target of anti-drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) is able to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1195">
                    <text>the part of STATs human 06-alkylguaning-DNA (AGT) that conferred specificity to a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs) was therefore an active target of anti-drugs.</text>
                    <arg n="0">the part of STATs</arg>
                    <arg n="1">specificity</arg>
                    <arg n="2">a MAPK or a MAPK substrate kinase (MAPKAP) was considered to be conferred by A0 (the part of STATs)</arg>
                </example>
                <example src="REPLACE" no="1196">
                    <text>the stability phenotype Stat5 in the presence of MG132 can be conferred by which simply replaces C-terminus for Stat5.</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="1197">
                    <text>the stability phenotype Stat5 in the presence of MG132 has the ability to confer which simply replaces C-terminus for Stat5 (AGT), which directly reverses the endogenous alkylation in the position of 06- guanin, to Stat1.</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="1198">
                    <text>the stability phenotype Stat5 in the presence of MG132 was conferred by which simply replaces C-terminus for Stat5, which directly reverses the endogenous alkylation to the position of 06-guanin, to Stat1.</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="1199">
                    <text>which simply replaces C-terminus for Stat5 (AGT) that conferred the stability phenotype Stat5 in the presence of MG132 over Stat1 was therefore an active target for anti-drugs.</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="1200">
                    <text>which simply replaces C-terminus for Stat5 (AGT), which directly inverts endogenous Stat1 to 06-position of guanine, is observed to confer the stability phenotype Stat5 in the presence of MG132 to alkylation and is therefore an active anti-cancer drug target.</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="1201">
                    <text>which simply replaces C-terminus for Stat5 (AGT), which directly inverts endogenous Stat1 to 06-position of the guanine, would confer the stability phenotype Stat5 in the presence of MG132 to alkylation and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="1202">
                    <text>which simply replaces C-terminus for Stat5 (AGT), which directly inverts endogenous alkylation to 06-position of the guanine, would confer the stability phenotype Stat5 in the presence of MG132 to Stat1 and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="1203">
                    <text>which simply replaces C-terminus for Stat5 (AGT), which directly reverses endogenous Stat1 at 06-position of the guanine, was believed to confer the stability phenotype Stat5 in the presence of MG132 on alkylation and was therefore an active target of anti-cancer drugs.</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="1204">
                    <text>which simply replaces C-terminus for Stat5 (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, may confer the stability phenotype Stat5 in the presence of MG132 to Stat1 and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="1205">
                    <text>which simply replaces C-terminus for Stat5 (AGT), which directly reverses the endogenous alkylation at the position of 06 guanin, was observed to confer the stability phenotype Stat5 in the presence of MG132 to Stat1 and, therefore, was an active target of antineoplastic drugs.</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                    <arg n="2">Stat1</arg>
                </example>
                <example src="REPLACE" no="1206">
                    <text>which simply replaces C-terminus for Stat5 may confer the stability phenotype Stat5 in the presence of MG132 to A2 (a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="1207">
                    <text>which simply replaces C-terminus for Stat5 was able to confer the stability phenotype Stat5 in the presence of MG132 to A2 (a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">which simply replaces C-terminus for Stat5</arg>
                    <arg n="1">the stability phenotype Stat5 in the presence of MG132</arg>
                </example>
                <example src="REPLACE" no="1208">
                    <text>without change of meaning or change of table in the coding sequence or for splice variants which confers movement of loss of function to A2 (a MAPK substrate or a MAPK kinase (MAPKAP) has not been determined.</text>
                    <arg n="0">without change of meaning or change of table in the coding sequence or for splice variants</arg>
                    <arg n="1">movement of loss of function</arg>
                </example>
                <example src="REPLACE" no="1209">
                    <text>without significant changes or frame deviations in the coding sequence or for splice variants can be conferred to function loss engines.</text>
                    <arg n="0">without significant changes or frame deviations in the coding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="1210">
                    <text>without significant changes or frame deviations in the coding sequence or for splice variants is able to confer function loss engines to A2 (a MAPK substrate or a MAPK kinase substrate (MAPKAP) has not been determined.</text>
                    <arg n="0">without significant changes or frame deviations in the coding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="1211">
                    <text>without significant changes or frame deviations in the coding sequence or for splice variants might have not conferred function loss engines.</text>
                    <arg n="0">without significant changes or frame deviations in the coding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
                <example src="REPLACE" no="1212">
                    <text>without significant changes or frame deviations in the coding sequence or for splice variants will confer function loss engines.</text>
                    <arg n="0">without significant changes or frame deviations in the coding sequence or for splice variants</arg>
                    <arg n="1">function loss engines</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
